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Abstract
The aim of the work described in this thesis was to determine 
the mode of uptake of the tripeptide proteinase inhibitor leupeptin, 
in order to better interpret the effect of leupeptin on protein 
degradation within cells.
Different methods of leupeptin detection were developed to monitor 
various aspects of the accumulation and action of leupeptin within 
yolk-sac tissue. The rate of accumulation, intracellular fate, and degree 
of inhibition of intracellular proteinases afforded by leupeptin, were all 
determined.
The major route of entry of leupeptin into yolk sacs appeared to 
be fluid phase pinocytosis, though other modes, such as permeation, 
could not be entirely dismissed. Intracellular active leupeptin reached 
a steady state concentration that was capable of fully inhibiting lysosomal 
cathepsins B+L, though did not completely inhibit degradation of
125I-BSAfd‘ Leupeptin was able to permeate into isolated intact lysosomes.

1GENERAL INTRODUCTION
1.1. Protein Degradation
In mammals proteolysis occurs both intracellularly and 
extracellularly, and ranqes from the cleavage of a single peptide 
bond to the total hydrolysis of a protein.
The function of proteolysis varies greatly. Total hydrolysis of 
proteins is important in the degradation of dietary protein to 
provide nutrients for an organism, in turnover (ie synthesis and 
degradation) of essential endogenous proteins within an organism to 
maintain the integrity of such proteins (by removing damaged proteins 
or wrongly synthesised proteins), and in controlling the quantities 
of regulatory enzymes and of cell receptors through degradation. 
Limited proteolysis, involving cleavage of one or two peptide bonds 
is important in, for example, the activation of enzymes in enzyme 
cascade systems (eg in the clotting, and the complement systems of 
blood), and in the production of the active forms of peptide 
hormones and enzymes by proteolytic removal of an oligopeptide 
fragment from pro-hormones and zymogens. The functions of various 
types of hydrolysis are discussed by Barrett (1978), Dean (1980) and 
Hoizer & Heinrich (1980).
Proteinase enzymes have been purified and characterized from a 
wide variety of intracellular and extracellular sources (eg see 
Barrett 6 McDonald, 1980). They are generally classified according 
to their site of cleavage and mode of catalytic action:- 
a) Exoproteinases (or exopeptidases, depending on whether the 
substrate is a protein or peptide) cleave peptide bonds one or two 
residues away from the ends of a polypeptide chain.
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b) Endoproteinases (and endopeptidases) can cleave bonds distant 
from the ends of a polypeptide chain. Endoproteinases may be further 
classified, according to their mechanism of catalysis and active-site 
residues, into thiol, aspartate, serine and metalloendoproteinases. 
(This method of classification is discussed by Barrett, 1977.)
The various mechanisms and pathways of extracellular proteolysis 
have, in general, been well characterised. The proteinases involved 
are generally readily isolated, thus their specificity and kinetics 
can be determined. For example, the major enzymes responsible for 
proteolysis in the gut, le trypsin, chymotrypsin and pepsin, can be 
readily purified and their properties have been studied in detail.
The roles of endogenous inhibitors of proteolysis in controlling such 
processes as clotting and fibrinolysis are beginning to be 
understood.
Comparatively little is known about the mechanism(s) and 
pathway(s) of intracellular protein degradation. Many intracellular 
proteinases have been isolated (though purification is more difficult 
than for extracellular enzymes) and characterised (see Barratt S 
McDonald, 1980). They are often classified according to their 
location within the cell rather than by their catalytic action. Thus 
intracellular proteinases may be classified as 'lysosomal' or 
'non-lysosomal'. Lysosomes are membrane-bound vesicles containing, 
together with other hydrolytic enzymes, a wide variety and high 
concentration of proteinases collectively capable of hydrolysing 
virtually any protein presented to them. Lysosomal proteinases have 
pH optima that are slightly acidic (pH 4-5). 'Non-lysosomal' 
proteinases have been isolated from many sites in the cell, eg plasma 
membrane, mitochondria, ribosomes, peroxisomes, endoplasmic reticulum 
(Holzer & Heinrich, 1980). Many of these proteinases are highly 
specific for a particular cleavage site or protein. A pH optimum
^ ____________________________________
3near 7.0 is common to many non-lysosomal proteinases.
Proteins that are degraded intracellularly may be classified 
according to their origin and rate of turnover:-
a) Exogenous proteins are extracellular proteins that are taken 
into the cell by endocytosis before being degraded; such proteins 
include serum proteins, proteins derived from micro-organisms, and 
hormones. Exogenous protein uptake and degradation are important 
functions of certain cells such as mononuclear phagocytes, cells of 
the reticuloendothelial system, hepatocytes and renal cells.
b) Endogenous proteins are those of which the cell itself is 
composed. They are generally divided into three classes according to 
their rate of turnover (see Hershko & Ciechanover, 1982).
i) Long-lived proteins, which have a 'long' half-life (the actual 
half-life varies considerably), and are thought to include 
structural proteins and proteins of cell organelles.
ii) Short-lived proteins, which have shorter half-lives and include 
regulatory proteins (enzymes, receptors, etc.) and some soluble 
proteins.
iii) Abnormal proteins, which are produced by errors during 
synthesis, and possibly by damage to the protein during its 
lifetime in the cell. (It is not known whether the latter 
abnormal proteins are treated in the same way as those proteins 
with synthetic errors.) These proteins are thought to be 
degraded very rapidly.
A number of workers have postulated that intracellular protein 
degradation occurs via at least two pathways, either distinct from or 
interconnected to each other, and there is now much evidence to 
support this hypothesis, eg see reviews by Ballard (1978), Dean 
(1980) and Hershko & Ciechanover (1982). One pathway of degradation 
is known as the lysosomal pathway, in which proteins enter the
4lysosomes and are degraded by the lysosomal protelnases. It Is 
thought that all exogenous proteins, most long-lived endogenous 
proteins, some secretory proteins, and all proteins degraded during 
periods of enhanced proteolysis are degraded by the lysosomal 
pathway. The other pathway, generally known as the non-lysosomal 
pathway, is less well characterised. Proteinases specific for 
certain functions have been found throughout cells, but it is not 
clear how they might contribute to the overall degradation of cell 
proteins. It is thought that non-lysosomal proteolysis is important 
in the degradation of abnormal and short-lived proteins. Possibly 
only the initial, rate-limiting step in the degradation is 
non-lysosomal, with the final stages of proteolysis being completed 
within lysosomes.
Most of the investigations into mechanism(s) of intracellular 
proteolysis and types of protein degraded by them have been made 
using inhibitors of proteolysis. The use of these inhibitors is 
discussed in the next section.
1.2 Inhibitors of Protein Degradation
Inhibitors of protein degradation and of proteinases are used to 
determine which proteolytic pathway or individual proteinases are 
responsible for the degradation of specific proteins and classes of 
proteins eg Neff et al. (1979), Cockle & Dean, (1982) Grinde & Seglen 
(1980). The inhibitors used are chosen either to be specific for one 
particular type of proteinase (eg thiol endoproteinases) or to act 
generally on the entire lysosomal pathway. (No inhibitors that 
affect only non-lysosomal proteolysis have yet been identified.) 
Inhibitors are added to cell or tissue cultures, or administered to 
whole animals, and the rate of degradation of specific proteins or 
classes of protein monitored. Any decrease would suggest that
5degradation normally occurs via the inhibited pathway or involves a 
particular proteinase.
The most commonly used inhibitors in the study of intracellular 
proteolysis can be divided into two main groups namely the 
lysosomotropic amines and the 'peptide inhibitors'. An excellent 
review of both types is given by Seglen (1983).
Lysosomotropic amines are weak bases that are uncharged at 
neutral pH, but become protonated at acid pH. They accumulate within 
lysosomes since they permeate across the lysosomal (and plasma) 
membranes in their neutral form, become protonated in the acidic 
lysosomal lumen and are then unable to permeate back across the 
membrane in their charged forms. They act by buffering the lysosomal 
pH away from the optimum required by lysosomal proteinases, thus are 
thought to affect all lysosomal proteinases (de Duve et al., 1974; 
Poole S Ohkuma, 1981).
Peptide inhibitors include a wide range of natural and synthetic 
peptides that are thought to act as transition-state analogues. They 
generally contain modified or entirely novel amino acids. For 
example, the carboxylic acid group of the carboxy-terminal amino acid 
may be replaced by an aldehyde (eg leupeptin, antipain), a 
diazomethane (eg Z-Phe-Ala-CHNj), or a chloromethyl ketone group (eg 
Phe-Arg-CHjCl). The inhibitors pepstatin and E-64 contain the 
unusual residues 4-amino-3-hydroxy-6-methylheptanoic acid (AHMHA) and 
epoxysuccinyl-leucylamldo-(4-guanidino)butyrate, respectively.
Peptide inhibitors are usually specific for a particular class of 
proteinase.
In order for the results of inhibition studies to be interpreted 
unequivocally, a number of important factors must be considered:-
i) The specificity of the inhibitor must be known. If an inhibitor
is used to block a particular enzyme or pathway, it should not
6affect other proteinases or proteolytic pathway(s) within the 
cell. Ideally, it should also not affect any other process 
within the cell. Unfortunately, these requirements for 
specificity are not met by many of the commonly-used inhibitors. 
For example, lysosomotropic amines are known to cause 
non-specific toxic effects, affecting energy metabolism, protein 
synthesis, membrane fusion etc. (Dean et al., 1984? Seglen, 
1983). They are, however, thought to be specific for the 
lysosomal pathway of protein degradation, due to their mechanism 
of inhibition (ie increase of pH within lysosomes). Conversely, 
the majority of peptide inhibitors are non-toxic in vivo and in 
vitro (Umezawa & Aoyagi, 1977; Grinde S Seglen, 1980) and do not 
affect processes other than proteolysis. (An exception is the 
chloromethyl ketones, which are cytotoxic). However, peptide 
inhibitors are not necessarily specific to a particular 
proteinase or pathway. Depending on the access of the inhibitor 
to different intracellular sites, several or all proteinases of 
a particular class may be inhibited. It is therefore very 
important to know the sites to which peptide inhibitors have 
access within the cell, and the location of their possible 
target enzymes. Problems associated with this are discussed by 
Dean (1979); Cockle & Dean (1982); Hershko S Ciechanover (1982), 
and McGowan et al. (1976).
ii) The degree of inhibition afforded by the inhibitor should be 
assessed. If inhibition of a particular proteinase/pathway is 
incomplete, an estimate of the amount of protein degradation 
occurring via other route(s) will be too high because the 
inhibited pathway will continue to contribute to proteolysis. 
Lysosomotropic agents are generally assumed to inhibit lysosomal 
degradation totally, since all amines give about the same degree
7of inhibition of endogenous protein degradation and their 
effects are not additive when more than one amine is used 
(Grinde & Seglen, 1980; Seglen, 1983). This assumption can be 
challenged. For example, a constant percentage of proteolytic 
activity may remain within the lysosomes even at the increased 
pH; addition of more than one amine may not give rise to any 
further increase in lysosomal pH. The potency of the peptide 
inhibitors depends on a number of factors, such as the affinity 
(Kj) of the inhibitor for its target enzyme(s), and the 
intracellular concentration of the inhibitor (which itself 
depends on the rate of uptake and metabolic fate of the 
inhibitor). Complete inhibition of the lysosomal pathway is not 
expected to be achieved by any one peptide inhibitor, due to 
their specificity for particular classes of proteinases. 
Generally, a cocktail of inhibitors with different specificities 
is used to give more complete inhibition of the lysosomal 
cathepsins eg Grinde & Seglen (1980), McGowan et al. (1976). 
However, since peptide inhibitors may be capable of inhibiting 
non-lysosomal proteinases, such cocktails cannot be assumed to 
inhibit only lysosomal proteolysis.
Further knowledge of the sites of action and potency as 
inhibitors of proteolysis within intact cells would greatly enhance 
the interpretation of results obtained using peptide inhibitors, and 
may aid their use as therapeutic agents for the treatment of 
tissue-wasting diseases (in which the rate of intracellular 
proteolysis is increased and the rate of protein synthesis decreased; 
Griggs & Rennie, 1982). One peptide inhibitor that is commonly used 
in investigating tissue proteolysis, and which has been tested for 
therapeutic use in the tissue-wasting disease muscular dystrophy, is 
leupeptin. The main characteristics of this inhibitor are described
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8in the following section.
1.3 Leupeptin
Leupeptin is a tripeptide that is synthesised by various species 
of Streptomycetes. It is a mixture of propionyl- and acetyl- 
L-leucyl-L-leucyl-L-arginal; occasionally L-valine or L-isoleucine 
may be substituted for L-leucine (Kondo et al., 1969» Kawamura et 
al., 1969). Arginal is an arginine residue, but with an aldehyde 
group in place of the usual terminal carboxylic acid group.
Leupeptin exists predominantly in a cyclic or hydrated form (Maeda et 
al., 1971) but the active structure is probably the aldehyde (see 
Fig. 1.1). The aldehyde group acts as a transition-state analogue 
and the peptide moiety provides enzyme specificity. Leupeptin 
inhibits the major lysosomal thiol endoproteinases, cathepsins B and 
L, and several other lysosomal cathepsins eg H, N, S and T (Seglen, 
1983). It also inhibits non-lysosomal proteinases such as the thiol 
endoproteinases calpain, also known as calcium-activated neutral 
proteinase (Suzuki et al., 1981) and tissue kallikrein (Barrett & 
McDonald, 1980). Various extracellular enzymes are also inhibited by 
leupeptin, including papain (which is a thiol endoproteinase) 
trypsin, chymotrypsin, plasma kallikrein, and plasmin (which are all 
serine endoproteinases); see Umezawa & Aoyagi (1977). The precise 
mechanism of interaction of leupeptin with trypsin has been described 
(Kuramachi et al., 1979). Degradation of all exogenous proteins 
examined to date is quite strongly inhibited by leupeptin; eg see 
Dunn et al. (1979), Grinde & Seglen (1980), Neff et al. (1979); 
Knowles et al. (1981). Degradation of endogenous proteins is also 
inhibited, but the degree of inhibition observed varies considerably 
between different tissues and/or incubation regimes. Experiments in 
which the degradation of both long-lived and short-lived or abnormal
9proteins were investigated separately showed that leupeptin inhibited 
degradation of long-lived proteins but not short-lived or abnormal 
proteins (Neff et al., 1979).
In experiments designed to test its use as a therapeutic agent 
to treat muscular dystrophy, leupeptin has been added to various 
types of dystrophic and normal muscle tissue cultured in vitro, or 
administered L n _ vivo to genetically dystrophic chickens (which are 
used as a laboratory model of muscular dystrophy) and the degree of 
atrophy of the tissue monitored by electron microscopy. Most workers 
found the leupeptin provided protection against atrophy of dystrophic 
tissue in vitro, and found that the ultrastructure and integrity of 
normal tissue were maintained for longer than for controls incubated 
without leupeptin (Libby & Golberg, 1978; Libby et al., 1979; McGowan 
et al., 1976). In vivo results have been varied. Some workers claim 
leupeptin is able to delay or prevent the onset of muscular dystrophy 
if the inhibitor is administered before the onset of symptoms of the 
disease (Sher et al., 1981; Stracher et al., 1978). Other workers 
have found leupeptin to have little or no effect in vivo (Enomoto & 
Bradley, 1977).
Leupeptin has a number of limitations in its use. It does not 
totally inhibit the lysosomal pathway of degradation, since it does 
not inhibit cathepsin D, or exoproteinases. (It is occasionally used 
in conjunction with other inhibitors eg the cathepsin D inhibitor 
pepstatin, to give a greater degree of inhibition). It may also 
inhibit non-lysosomal enzymes, therefore it cannot automatically be 
used to distinguish lysosomal from non-lysosomal pathways of 
degradation. Its potency against each leupeptin-sensitive enzyme is 
not fully established _iii vivo. Only cathepsin B inhibition has been 
specifically measured (Neff et al., 1979); the degree of inhibition 
of other lysosomal or non-lysosomal enzymes has not been determined.
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Notably, the degree of inhibition of cathepsin L, which is the most 
powerful lysosomal proteinase (Barrett 6 Kirschke, 1981) has not been 
measured in vivo.
It is not fully established how leupeptin gains access to 
intracellular sites, or to which sites it has access (as noted by 
Libby s Goldberg, 1978; McGowan et al., 1976). (Some more recent 
studies suggest leupeptin is able to diffuse across membranes, but 
evidence for this is only circumstantial; see Section 1.4). There is 
some evidence that it can be degraded and/or inactivated by enzymes 
present in certain tissues (Beynon et al., 1981; Brown & Beynon,
1983) and it is not known whether the steady-state intracellular 
concentration of leupeptin is sufficient to give maximal inhibition 
of leupeptin-sensitive enzymes.
This thesis attempts to answer certain questions surrounding the 
intracellular site of action, potency, and intracellular fate of 
leupeptin. The mode of uptake of leupeptin was studied in order to 
predict likely site(s) of action, and the intracellular fate and 
potency were determined by monitoring the quantity of active 
leupeptin, and activity of cathepsin B + L within the tissue, 
respectively.
1.4 Possible Mechanisms of Uptake of Leupeptin into Tissues
It is important to investigate the mechanism of uptake of 
leupeptin not only because knowledge of this characteristic will 
provide information about the intracellular location(s) to which 
leupeptin has access but also because very little is known about the 
mechanism of uptake of small peptides by cells. There are two main 
routes by which small extracellular molecules may enter cells: namely 
pinocytosis and permeation across the plasma membrane.
Pinocytosis is the process of membrane invagination and
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'pinching-off' to form vesicles containing extracellular material (eg low mol. 
wt. solutes, soluble macromolecules, colloids). Substrates taken up by 
pinocytosis may be ingested entirely within the droplet of 
extracellular fluid (fluid—phase pinocytosis) or may become adsorbed 
to the plasma membrane (adsorptive pinocytosis). Characteristics of 
fluid-phase and adsorptive pinocytosis are given in reviews by 
Silverstein et al. (1977) and Pratten et al. (1980).
Uptake of macromolecular substrates by
pinocytosis leads to the material being enclosed in membrane-bound 
vesicles, which then fuse with lysosomes. The substrate remains 
trapped within the lysosomal system unless it can be degraded into 
smaller units (eg amino acids, monosaccharides, etc.) that are able 
to permeate through the lysosomal membrane (Lloyd, 1969; 1971).
Uptake by membrane permeation occurs by one or more of three 
possible mechanisms. Passive diffusion across the phospholipid 
bilayer of the plasma membrane, or possibly through small pores, may 
occur for small and/or lipophilic molecules. Alternatively, entry 
could occur by facilitated diffusion and/or active transport which 
involve specific carriers in the membrane. Active transport requires 
energy, and, unlike passive or facilitated diffusion, can transport 
substrates across the membrane aqainst a concentration gradient. 
Characteristics of membrane permeation mechanisms are described by 
West (1983). Uptake of substrates
by permeation across the plasma membrane would result in delivery of 
the substrate to the cytoffll. Permeation across the lysosomal 
membrane may then follow, provided the lysosomal membrane has similar 
permeability properties (transport systems, etc.) to the plasma 
membrane.
Thus; if leupeptin cannot cross the plasma or lysosomal membranes 
and is taken up by pinocytosis, it will become concentrated within
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lysosomes and inhihit lysosomal enzymes alone in a specific manner. 
However if leupeptin is taken up both by pinocytosis and by membrane 
permeation, it would have access to non-lysosomal and to lysosomal 
enzymes. In both cases, the location of leupeptin can only be 
predicted provided the permeability of lysosomal and plasma membranes 
are similar, as is suggested by Hales et al. (1984).
Methods are known that permit a distinction to be made between 
fluid and adsorptive pinocytosis (Pratten et al., 1980), and between 
passive, facilitated, or active membrane permeation (West, 1983). 
Unfortunately, it is difficult to distinguish between pinocytosis and 
membrane permeation since similar properties are observed for both 
modes of uptake. (For example, both pinocytosis and active transport 
have an energy requirement and saturation kinetics could apply to 
adsorptive pinocytosis and to facilitated or active transport.) 
Workers investigating pinocytosis generally use large macromolecules 
(eg proteins or synthetic polymers), colloids (eg colloidal gold) or 
molecules to which the plasma membrane is considered to be 
impermeable (eg sucrose, inulin). Workers in the field of membrane 
permeation generally study small molecules (eg amino acids, 
dipeptides, monosaccharides) or ions (eg Na+, K+, Ca2+) and incubate 
tissue or cells for short periods (eg 2 min) to preclude any major 
contribution towards uptake by pinocytosis.
Both pinocytosis and direct membrane permeation have been 
proposed by different workers to explain the uptake characteristics 
of tripeptides.
Pinocytosis was suggested by Ehrenreich & Cohn (1969) to be the 
mechanism of entry of (D-Ala)j into macrophages. Their conclusion 
that uptake was by pinocytosis was based on measurements of the 
lysosomal location of the tripeptide, and on the effects of 
inhibitors of pinocytosis (2,4 DNP and parafluorophenylalanine) on its
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uptake. Shaw & Dean (1980) suggested that uptake of the peptide 
proteinase inhibitor Z—Phe-Arg—CHNj was by adsorptive pinocytosis, on 
the basis of measurements both of the rate of uptake of a 
radiolabelled derivative, and of displacement of the labelled 
inhibitor from the cell membrane by unlabelled Z-Phe-Ala.
Although tripeptides are generally considered too large and 
hydrophilic to cross membranes by passive diffusion, several 
transport systems are known for small peptides in various mammalian 
tissues and in bacteria (Matthews, 1977). It is now well-established 
that gut mucosa contains fairly non-specific, active transport 
system(s) for dipeptides (Burston et al., 1977) that are distinct 
from amino acid carriers (Silk, 1977). Tripeptides (but not 
tetrapeptides or above) appear to be taken up by the dipeptide 
transport system; substitution of the terminal amine or carboxyl 
groups of the peptide abolishes affinity for transport. Transport of 
peptides has also been reported in kidney (Ganapathy, 1981), brain 
(eg Inoue et al., 1984), liver, skeletal muscle, erythrocytes, and 
tumour cells (Matthews & Payne, 1975). The specificity of transport 
in these tissues and cells is not well documented? often only 
specific, biologically-active peptides have been studied.
Uptake of peptide proteinase inhibitors has been investigated by 
a few workers, although conclusions tend to be based on the action of 
the inhibitor, which may not give a good indication of the rate or 
mode of uptake. Dean (1979) reported that pepstatin (isovaleric 
acid-L-Val-L-Val-AHMHA-L-Ala-AHMHA) entered macrophages via 
pinocytosis since it acts very slowly on intracellular proteolysis 
(similar results were observed in fibroblasts and hepatocytes). 
Z-Phe-Ala-CHNj also acts quite slowly and is thought to enter 
macrophages via adsorptive pinocytosis (Shaw & Dean, 1980). The 
inhibitor E-64 was found to become incorporated into the cytosolic
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fraction of liver before the lysosomal fraction (Hashida et al., 
1982), which was interpreted as uptake by permeation. Several 
reports suggest that leupeptin (Ac-Leu-Leu-Argal) may also enter by 
permeation (Cockle & Dean, 1984; Borin et al., 1981) since it is able 
to inhibit intracellular degradation very rapidly (Seglen et al., 
1979; Dean, 1979). However, no in-depth study of the mode of entry 
of this inhibitor has been made to date.
Uptake of leupeptin into rat visceral yolk sac (a mammalian 
tissue whose plnocytic behaviour is well characterised in vitro) is 
reported in the work described in this thesis.
1.5 Rat Visceral Yolk-Sac Tissue
The rat visceral yolk sac was used as a model tissue to study 
the uptake and intracellular fate of leupeptin. The rat yolk-sac 
incubation technique has several advantages over other commonly used 
methods of studying uptake (such as various routes of administration 
to living animals, organ perfusion, cell culture). It is easy to set 
up in vitro short-term incubation of the tissue and results are 
generally reproducible. Loss by filtration of low mol. mass 
molecules by the kidneys, that occurs in vivo, is avoided. Unlike in 
vivo studies only one type of endocytic cell, the yolk-sac epithelial 
cell, is involved. Also, previous investigations indicate that 
tissue integrity and cell structure are largely maintained. This 
contrasts with many cells isolated by methods involving exposure to 
proteolytic enzymes.
Another advantage in the use of yolk-sac tissue is that it is 
very active proteolytically. It has been suggested that one 
physiological role of the yolk-sac is to supply nutrients to the 
fetus via uptake and degradation of macromolecules (Freeman et^  al., 
1981). The degradation of endogenous and exogenous proteins have
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been studied previously in the yolk sac, using both peptide 
inhibitors and lysosomotropic amines as inhibitors (Livesey et al., 
1980; Knowles et al., 1981), Leupeptin was found to be quite 
effective, inhibiting the degradation of an exogenous protein 
(formaldehyde-denatured 125I-labelled albumin) by 80% and endogenous 
protein (mostly long-lived) by about 20% (Knowles et al., 1981).
The visceral yolk sac is one of the placental membranes that, in 
vivo, surround the developing fetus. It is comprised of three cell 
layers separated by two basal membranes. The outer cell layer, which 
after 16 days gestation is exposed to the uterine cavity, is known as 
the visceral endoderm. It is comprised of columnar vitelline 
epithelial cells, that are 'cemented together' by tight-junctions. 
They possess a highly microvillous apical surface, with calveoli 
extending into the cytoplasm, and are very pinocytically active. The 
cell membrane is coated with a mucopolysaccharide glycocalyx. The 
cells of the visceral endoderm are attached to the visceral basement 
membrane. The middle cell layer is known as the mesenchymal cell 
layer, through which run vitelline blood capillaries. Below the 
mesenchymal cells is the serosal basement membrane, to the lower side 
of which is attached the third, thin, layer of mesothelial cells. 
About one-third of the visceral yolk sac (nearest the chorioallantoic 
placenta) is highly folded (macrovillous); the cell layers are the 
same in both villous and non-villous regions (see Fig. 1.2).
1.6 Aims of the work described in this thesis.
It was hoped that the mode(s) of entry of leupeptin into cells 
could be determined in order to interpret more fully the action of 
this inhibitor on intracellular proteolysis. The mode of uptake of 
leupeptin was investigated to give an indication of the initial 
intracellular location, and the permeability of the lysosomal
16
membrane towards leupeptin monitored to determine whether leupeptin 
had free access to both lysosomal and non-lysosomal sites once within 
the cell. The optimum incubation period with leupeptin to achieve 
maximal inhibition of leupeptin-sensitive lysosomal enzymes was 
established. The intracellular fate of leupeptin was also assessed 
by measuring the amount of active inhibitor within the tissue.
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Fig. 1.1 Different Hydration States of Leupeptin
i) Hydrated form
ii) Aldehyde form
iii) Cyclic form
From Maeda et. al. (1971)
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Fig. 1.2 Transverse section through a highly folded region of the 
rat yolk sac
(From Ibbotson, G. Thesis, 1977)

GENERAI. MATERIALS AND METHODS
I. MATERIALS
Equipment
Gamma Counters
Beta Counter
Spectrophotometer
Water Baths
Centrifuoe
Homogenizers
5142 Selektronic Gamma Spectrometer.
Packard Instrument Ltd., Caversham, Berks., U.K
5136 Auto Gamma Scintillation Spectrometer. 
Packard Instument Ltd., Caversham, Berks., TI.K.
2425 Tri Carb Liquid Scintillation Spectrometer 
Packard Instruments Ltd., Caversham, Berks, U.K
CE373 Linear Readout Grating Spectrophotometer. 
Cecil Instruments Ltd., Cambridge, U.K.
Thermal Laboratory Eguipment.
A Searle Co., Oldham, U.K.
Mistral 4L.
M.S.E. , London, U.K.
Hand-held ground-glass; Jencons Scientific Ltd. 
Hemel Hempstead, Herts., U.K.
Potter Elvehjem-tvpe; Tri-R Instruments
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Rockville Instruments, N.Y., U.S.A.
LP3 tubes and L.I.P.
scintillation Shipley, W. Yorkshire, U.K.
vial inserts
Calculator TI 55. Texas Instruments.
Computer GEC 4080 Main-frame computer.
Chemicals
Medium 199 Powdered medium 199, with Earl's Salts and 
L-glutamine; containing 100,000 units 
Penicillin-Streptomycin.
Gibco Europe Ltd., Uxbridge, Middlesex, U.K.
95% 02 ;5% cc>2 British Oxygen Co. Ltd., Medical Gases Division.
Gas London, U.K.
Calf Serum Calf Serum 1, Heat Inactivated. Wellcome Reagents 
Ltd., Beckenham, U.K.
125i- Code IMS.30. Sodium iodide in dilute sodium
hydroxide, pH 7-11 (free from reducing agents), 
approximately 1mCi per 10pl.
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125I-PVP
Amersham International PLC, Bucks, IJ.K.
Code IM.3 3P. 125I-PolyvinylpyrrbLidone in 
succinate buffer solution. Concentration 2-4mg/ml. 
[The solution as supplied was generally diluted to 
20-40ug/ml in medium 199 before addition to flasks 
to give a final concentration of 2-4ijg/ml.] 
Amersham International PLC, Bucks, U.K.
Leupeptin Ac~L-Leu-L—Leu-Arglnal.0.5H2so4 . H2 0
Peptide Institute Inc., Minoh-shi, Osaka 562,
Japan.
Trypsin Type IX (code T-0134), from porcine pancreas. 
Sigma Chemical Company, Poole, Dorset, U.K.
Bovine Serum Code A-7906
Albumin Sigma Chemical Co., Poole, Dorset, U.K.
All other chemicals were of analytical grade and were generally
obtained from Sigma Chemical Company, Poole, Dorset, U.K. or from BDH 
Chemicals Ltd., Poole, Dorset, U.K.
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II. METHODS
2* 1 • Preparation of Formaldehyde-Denatured 125I-Labelled 
Bovine Serum Albimin (125I-BSA. .)
2.1a. Iodination Procedure Bovine serum albumin (BSA) was 
iodinated usinq the chloramine-T method adapted from the method 
described by Williams et aU  (1971) which, in turn, was based on the 
method of Bocci (1969). Albumin (20mq) was dissolved in 0.05M
Na2H-KH2 phosphate buffer, pH 8.0, (9ml), and cooled on ice. A 
solution of 125I-iodide (1mCi in 10pl) was then added. After 
thorough mixing, a solution of choramine-T (4ml, 1mg/ml solution in 
buffer) was added and the reaction mixture stirred for exactly 8 min. 
The reaction was then stopped by the addition of sodium 
metabisulphite solution (3ml, 2mg/ml in buffer). Excess iodide (in 
the form of solid KI, approximately 500mg) was then added to aid 
displacement of unreacted 125I-iodide during subsequent dialysis.
2.1b Denaturation Procedure. A formaldehyde solution (10%, w/v) 
was prepared by mixinq 5ml formalin (ie 40% formaldehyde) with 15ml 
of 0.5M sodium carbonate buffer (pH10). The iodination reaction 
mixture (undialysed) was mixed with an equal volume of 10% 
formaldehyde, and stirred at room temperture for approximately 70h. 
The solution was then transferred to Visking tubing (leaving 
approximately 50 pi for analysis of labelling efficiency) and 
dialysed against at least three changes of 1% sodium chloride 
solution (51), until the dialysis solution showed background 
radioactivity. The contents of the Visking tubinq were then 
transferred into bottles in 5 ml aliquots and stored at -20°C.
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2.1c Labelling Efficiency. The labelling efficiency was determined 
using the reserved undialysed reaction mixture.
The solution (approximately 50U1) was made up to approximately 
5ml with distilled water and samples (1ml) assayed for radioactivity. 
Serum (0.1ml) and TCA (0.5ml, 20%w/v solution) were added to 
precipitate the protein-bound 125^ thig precipitate was spun down at 
1OOOg for 20 rain. The TCA-soluble fraction (mostly 125I-iodide) was
transferred to another tube for counting. The labelling efficiency 
was calculated:-
Labelling Efficiency = (T-S) x 100
Where T = Total radioactivity in 1ml sample, (c.p.m.,
corrected for background).
and S = TCA-soluble radioactivity (c.p.m. in the
same sample, corrected for background and 
counting geometry - see p25).
After dialysis the amount of TCA-soluble material in the 
preparation was determined by treating a small (50ul) sample of 
dialysed solution in the same way as described above. The 
percentage of TCA solubles was calculated:-
TCA-soluble c.p.m. (corrected)
% sols x 100
Total c.p.m.
This value was typically 0.4-0.6% at the time of bottling.
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2*2* Method for Incubation of Rat Yolk-Sac Tissue
The method was based on that of Williams et al. (1975a,b); 
modifications of this method will be described in Sections 2.2b. and 
2.6.
Pairs of Wistar rats from an inbred colony were mated overnight 
in grid cages. If a sperm-plug was detected beneath the cage the 
next morning, pregnancy was timed from midnight on the night of 
mating. At 17.5 days of gestation, the pregnant females were 
sacrificed by asphixiation in carbon dioxide, then the uterus was 
removed and placed in warm (370C) medium 199 in a petri-dish. A 
longitudinal cut was made in the uterus wall, and each conceptus 
removed. For each conceptus, the placental cap and foetus were 
dissected from the yolk sac. The yolk sacs were then placed in fresh 
medium in a clean petri-dish and each gently separated from the 
under-lying amnion. The yolk sacs were then placed in sterile, 50ml 
Erlenmeyer flasks (cleaned by sonication in Na2 C(>3 solution) 
containing medium 199 (with or without 10% calf serum) under a 95% 
oxygen 5% carbon dioxide atmosphere, each sealed with a sterile 
silicone rubber bung. The flasks and yolk sacs were maintained at 
37°C in a shaking water-bath for at least 10 minutes before addition 
of substrate. An aliguot (10% v/v of total volume of medium in 
flask) of substrate dissolved in medium was added to each flask, the 
flasks regassed with 95% 02: 5% C02, and the yolk sacs incubated for 
up to 9h in the water bath. After various incubation periods, yolk 
sacs were removed from the flasks and washed in three changes of ice 
cold 1% saline (approximately 20ml, 3 x 2mln). A sample of 
incubation medium was removed from the flask at the same time as the 
yolk sac. The precise method of analysing these samples depended on 
the experiment and type of substrate used, see Sections 2.4 and 2.5,
below
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2.2a. Standard Volume Incubation Method The followinq details of 
the general incubation technique apply to the standard volume method. 
As described in Williams et ah  (1975a,b), yolk sacs were incubated 
sinqly in separate flasks, in a total volume of 1 0ml medium.
The yolk sacs were added to flasks containing 9ml 
substrate-free, gassed medium, then 1ml of a solution of substrate in 
medium 199 added to initiate the time-course of incubation. At each 
sample time (1-9h) two flasks were removed from the water-bath, the 
yolk sacs rinsed and duplicate 1 ml samples of medium taken from each 
flask.
2.2b Reduced Volume Incubation Method This method was developed to 
conserve scarce/expensive materials. It is suitable for substrates 
that are not captured rapidly from the medium and are thus not 
markedly depleted from the medium during the course of an experiment. 
Yolk sacs were incubated together (3 per flask) in a final volume of 
7ml medium.
The three yolk sacs were added to a flask containing 6.3ml 
substrate-free, gassed medium then substrate dissolved in medium 
(0.7ml) was added. At each sample time the shaking mechanism on the 
water bath was stopped, and one yolk sac removed from each of two 
different flasks, together with 1ml medium from each flask; the 
flasks remaining in the water-bath throughout. The flasks were then 
regassed, re-stoppered, and incubation continued. The yolk sacs were 
rinsed, then the tissue and medium processed as described in Section
2.5. Alternate duplicate flasks were opened at each sample time.
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2« 3 • Method of Protein Determination
The Folin method of protein assay (Lowry et al., 1951) was used 
to determine the protein content of tissue samples throughout the 
project. The tissues were prepared either as soluble digests in I0M 
sodium hydroxide (containing protein at a concentration of about 
1mg/ml), or as homogenates in water (containing protein at about 
4mg/ml). Duplicate samples of the tissue preparation containing 
about O.lmg protein (ie 0.1ml NaOH digest or 20yl homogenate) were 
made up to a total volume of 0.5ml NaOH, then 0.5ml H2o added. 
Standards were prepared over the range 0.0-0.2mg protein using bovine 
serum albumin. (BSA was dissolved in water at a concentration of 
1mg/ml and triplicate sample volumes, of 0 -0 .2ml, were made up to
0.5ml H 2 O , then 0.5mlfy|g0|^  was added.) Folin A solution (5ml) was 
added to both tissue samples and standards, then, after at least 2 0  
F°lin B solution (0.5 ml) was added and the reaction mixture 
vortexed thoroughly. Colour was allowed to develop for a minimum of 
45 min, then the absorbance at 750nm was read against a water blank. 
The values for the standards were fed into a linear regression 
program on a calculator from which the line of best fit was 
determined, and the mg-eguivalents of BSA could be calculated for 
each tissue sample. The correlation coefficient (which can be used 
as a crude measure of linearity) was always greater than 0.98 in this 
range of protein concentration.
2.4. Methods of Preparation of Tissue and Medium for Assay: 
Degradable and Non-degradable substrates
2.4a. Non-Degradable: 125j_pvp
The non-degradable 1 2 ®I-labelled substrate used throughout this 
project was 1 2 5 I-polyvinylpyrrolidone (125i_pvp) at a final 
concentration of 2—4yg/ml (depending on the batch). Each rinsed yolk
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sac was digested in a total volume of 5ml sodium hydroxide (1M) until 
totally solubilized. (This usually took 1h at 37°C.) Duplicate 1ml 
samples of the digest were dispensed into disposable 3ml tubes and 
assayed for radioactivity in a crystal scintillation gamma counter. 
Samples of incubation medium (2 x 1ml) were assayed for radioactivity 
in the same counter. The yolk-sac digest was assayed for protein 
content as described in Section 2.3.
2.4b. Degradable Substrate: 125I-BSA_.fa
125T nc. wag used at a concentration of approximately 1 pg/ml.
The yolk-sac tissue was treated as described in Section 2.4a. The
medium samples contained both macromolecular ^Sl-BSA.,, andfa
125I-labelled degradation products of 125I-BSAfd that had been
released from the yolk sac. The total radioactivity of the sample
(volume 1ml) was measured, then the intact 1 2 5 I-BSAfd precipitated by
the addition of 0.5ml trichloroacetic acid (TCA), 20% w/v, (for
medium containing 1 0 % serum), or 0 .1ml serum followed by 0 .5 ml 2 0 %
TCA (for serum-free medium). The resulting precipitate was spun
down (1 0 0 0 g, 2 0 min), then the soluble fraction decanted into another
tube and assayed for radioactivity. The observed counts in the
acid-soluble inaction were corrected for the change in counting
volume (which increased from 1.0 to 1.5ml) and for occlusion of
acid-soluble material in the pelleted precipitate as described below.
Determination of Correction Factor: A solution of 1 2 5 I-Tyrosine
(labelled by essentially the same method as described for 125I-BSA_.fa
in Section 2.1.) was treated as described above. The carrier protein 
precipitate was spun down and the TCA-soluble fraction decanted into 
fresh counting vials and assayed for radioactivity. (This fraction 
should contain all the radioactivity originally present, except for 
any which became trapped within the pellet.) The correction factor
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was calculated as follows
Total counts (corrected for background) 
in 1ml solution of 1 2 5 I-Tyr
Correction factor » —________________.____ _______________________
TCA-soluble counts (corrected for background)
2>5* Methods of Preparation of Tissue and Medium for Assay;
3H - or 1 4C-Lahelled Substrates 
The substrates used were 3 H-inulin, 1 4C-sucrose, and 
3 H-leupeptin.
Medium samples (0.5ml) were placed in scintillation vial inserts 
(total capacity 5ml) and 4ml of scintillation fluid added. The
contents of the inserts were mixed thoroughly and allowed to stand 
overnight before assaying for radioactivity in a liquid scintillation 
counter. Medium 199 contains phenol red which gives it a pink colour. 
This caused colour quenching of the observed counts in each sample. 
The counting efficiency of medium relative to distilled water was 
therefore found, by adding a "spike" (1 0 yl, more than 2 0 0 0 c.p.m.) of 
tritiated water (for experiments using 3H-labelled substrates) or
14 ..
C-sucrose (for those using 1 4C-sucrose as a substrate) to samples 
(0.5ml) of distilled water and fresh medium. Scintillation fluid 
(4ml) was added and the tubes counted at the same time as the 
experimental samples. The relative counting efficiency was 
calculated as follows
Counts (cpm corrected for background) 
observed in medium
Relative counting efficiency
of medium with respect to —
water ( % ) Counts (cpm corrected for background)
observed in water
xlOO
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The observed counts in incubation medium were then corrected for 
quenching by multiplying by a quench correction factor (ie 
1 0 0 /relative counting efficiency, %).
Several different methods of solubilizing yolk-sac tissue for 
counting were tested for reproducibility and to minimize quenching. 
These are described in Appendix 3. The most commonly used method 
was that of homogenization in a ground-glass homogenizer, which gave 
good tissue disruption. The relative counting efficiency of samples 
prepared by this method was determined using an homogenate of 
un-incubated tissue spiked with 3 H2o or 1 4C-sucrose. The counting 
efficiency was reproducible both between samples and stable over 
prolonged periods of time (when samples were re-counted up to 9 days 
after addition to scintillation fluid)• The counts observed in the 
experimental yolk-sac samples were corrected for quenching as 
described above.
2.6. Uptake of Non-Radiolabelled Leupeptin
For these experiments, it was necessary to sample a larger 
quantity of tissue at each time-point in order to obtain sufficient 
leupeptin from the tissue to analyse. A modification of the reduced 
volume method (see Section 2.2b) was therefore used. Since the 
leupeptin was not labelled, it was possible to introduce a control by 
measuring the uptake of 1 2 5 I-PVP into the same yolk sacs as used to 
monitor leupeptin accumulation.
After dissection, yolk sacs were placed in flasks containing 
medium 199 (5.6ml, 3 yolk sacs per flask) and allowed to equilibrate 
for at least 10 min. A solution of leupeptin in distilled water 
(0.7ml, generally Img/ml, except where the effect of different 
concentrations of leupeptin were studied) and of PVP in medium
(0.7ml,20-40iig/ml) were then added to each flask to initiate uptake.
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In some experiments, a sample of medium (50pl) was immediately 
removed for leupeptin assay, to find out whether depletion of 
leupeotin from the medium occurred durinq incubation. At intervals 
between 1 and 8 h, all three yolk sacs were removed from a flask, 
toqether with samples of medium (3 x 1ml). The yolk sacs were 
rinsed ( 3 x 2  min) in ice cold 1% saline then either stored at -20°C 
or immediately prepared for assay of leupeptin and radioactivity 
content (see Sections 4.2.4, and 5.2.3). One sample of medium was 
stored at -20°C for assay of leupeptin content, the remaininq two 
samples were counted for ^^I-radioactivity.
2.7. Quantitation of Uptake
The quantity of substrate accumulated within yolk sacs by a 
given time was expressed as the volume of incubation medium (ul) 
whose contained substrate was captured by a unit quanity (mq) of 
yolk-sac tissue (see Williams et al., 1975a,b). This method of 
expression allowed direct comparisons of results obtained from 
different yolk sacs incubated on different days and with different 
substrates. The value is independent of the quantity of yolk-sac 
tissue and method of quantitation used for the substrate (eg beta or 
gamma radioactivity counting for labelled substrates or assays to 
detect the mass of inhibitory leupeptin).
For substrates that are neither degraded within nor released from 
the tissue, the amount of substrate within the tissue at a given time 
is equal to the total uptake. However if a substrate is released 
from the tissue (either intact or following degradation), the amount 
of substrate within the tissue at a given time is not equal to the 
amount that entered the tissue over that period. Provided the amount 
of intact/degraded substrate released over a particular period can be 
measured, the total uptake can be calculated. However, if
quantitation of the amount released is not possible, only the rate of 
tissue-accumulation (rather than uptake) can be monitored.
The rate of uptake (not accumulation) is termed the Endocytic 
Index (E.I.), and has the units pi incubation medium per mg yolk-sac 
protein per hour (pl/mg yolk-sac protein/h). When uptake is 
substantially linear with time the line of best fit through a plot of 
uptake values (yl/mg) against time (h) can be found using a linear 
regression calculator program. The gradient (which is equal to the 
E.I.), and correlation coefficient (which was used as a crude measure 
of the degree of scatter of the points) of the line of best fit could 
both be calculated usinq this program.
Because the E.I. could only be meaningfully calculated from 
uptake plots which were linear, all plots were examined by eye to 
ensure that there was no curvature in the time-course of uptake.
2.7a. 125I-Labelled Non-Degradable Substrate: IZ^I-PVP Because 
this substrate was not degraded or released from yolk-sac tissue 
(Williams et al., 1975a) the rate of uptake could be calculated 
directly from the amount of radioactivity within the tissue, as 
follows
Where : - U 
Y
M
P
M x P
Uptake (pl/mg yolk-sac protein)
Total radioactivity in the yolk sac (c.p.m., 
corrected for background)
Total radioactivity per ill incubation medium 
(c.p.m., corrected for background)
Protein content of the yolk sac
(mg equivalents of BSA)
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quantitation of the amount released is not possible, only the rate of 
tissue-accumulation (rather than uptake) can be monitored.
The rate of uptake (not accumulation) is termed the Endocytic 
Index (E.I.), and has the units pi incubation medium per mg yolk-sac 
protein per hour (pl/mg yolk-sac protein/h). When uptake is 
substantially linear with time the line of best fit through a plot of 
uptake values (pl/mg) against time (h) can be found using a linear 
regression calculator program. The gradient (which is equal to the 
E.I.), and correlation coefficient (which was used as a crude measure 
of the degree of scatter of the points) of the line of best fit could 
both be calculated using this program.
Because the E.I. could only be meaningfully calculated from 
uptake plots which were linear, all plots were examined by eye to 
ensure that there was no curvature in the time-course of uptake.
2.7a. 125I-Iw»belled Non-Degradable Substrate: 125I-PVP Because 
this substrate was not degraded or released from yolk-sac tissue 
(Williams et al., 1975a) the rate of uptake could be calculated 
directly from the amount of radioactivity within the tissue, as 
follows:-
Where:- U 
Y
M
P
M x P
Uptake (pl/mg yolk-sac protein)
Total radioactivity in the yolk sac (c.p.m., 
corrected for background)
Total radioactivity per pi incubation medium 
(c.p.m., corrected for background)
Protein content of the yolk sac
'
I
f
i
!
'
3
;
I
(mg equivalents of BSA)
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The computer program given in Appendix 1.1 was routinely used to 
calculate the uptake of 1 2 5 I-PVP.
2.7b. 125I-Ijibelled Degradable Substrate: 125I-BSAf(J The total 
amount of a ^2 5l-labelled protein taken up is not equivalent to the 
amount present within the tissue at any one time because the protein 
is degraded within the tissue to low molecular weight 2^ 5l-labelled 
degradation products, mostly ^^I-Tyr (see Williams et al., 1975b)( 
which are released back into the medium. However, it is possible to 
quantitate the amount of TCA-soluble degradation products in the 
medium (see Section 2.4b), therefore this quantity can be added to 
the amount of substrate in the yolk sac, to calculate the total 
uptake at each time-point.
The rate of uptake of 1 2 5 I-BSAfd is very hiqh due to its 
adsorption onto the plasma membrane; this results in significant 
depletion of substrate from the medium during the incubation period. 
The mean quantity of substrate present in the medium during each 
incubation period was therefore used to calculate each value of
uptake over a given interval
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Uptake was calculated as follows:-
Y + 10 (S - F)
u - -----------------------  X 103
M’ x P
Where:- U = Total uptake (pi of incubation medium/mg yolk-sac 
protein).
Y = Total radioactivity in the yolk-sac (c.p.m., 
corrected for background)
S = TCA-soluble radioactivity per ml incubation medium at 
the end of the incubation period (c.p.m., 
corrected for background and for counting 
geometry and occlusion, 
see Section 2.4b).
F = Quantity of TCA-soluble radioactivity per ml of medium 
that had been incubated at 37°C in the absence 
of a yolk sac (corrected for background, 
counting geometry, and occlusion)
M' = Mean quantity of TCA-insoluble radioactivity per ml 
incubation medium over the particular incubation 
period.
P = Protein content of yolk sac (mg).
F allows TCA-soluble material (eg 2^ 3 I-iodide or ^25j_tyrosin e ) f  
either present in the ^^i-BSA^ stock solution at the start of the 
experiment or generated spontaneously from the 1 2 5 I-BSAJ.(J during the 
incubation, to be distinguished from that generated by yolk 
sac-associated degradation. The value M' was calculated from the 
total radioactivity observed in the medium sample and the TCA-soluble
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Uptake was calculated as follows:-
Y + 10 (S - F)
U = --------------  x 103
M* x P
Where:- U = Total uptake (ul of incubation medium/mg yolk-sac 
protein).
Y = Total radioactivity in the yolk-sac (c.p.m., 
corrected for background)
S = TCA-soluble radioactivity per ml incubation medium at 
the end of the incubation period (c.p.m., 
corrected for background and for counting 
geometry and occlusion, 
see Section 2.4b).
F = Quantity of TCA-soluble radioactivity per ml of medium 
that had been incubated at 37°C in the absence 
of a yolk sac (corrected for background, 
counting geometry, and occlusion)
M' = Mean quantity of TCA-insoluble radioactivity per ml 
incubation medium over the particular incubation 
period.
P = Protein content of yolk sac (mg).
F allows TCA-soluble material (eg ^^j-iodide or 125i_tyrosine), 
either present in the ^^I-BSA^ stock solution at the start of the 
experiment or generated spontaneously from the  ^^ I-BSA^ ,juring the 
incubation, to be distinguished from that generated by yolk 
sac-associated degradation. The value M* was calculated from the 
total radioactivity observed in the medium sample and the TCA-soluble
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radioactivity in that sample as follows:-
M' = [M—(S+F)] + s-F
2
Where M' and F are as defined above, and M is the total 
radioactivity observed in the medium sample (c.p.m., corrected for 
background).
The computer program detailed in Appendix 1,2 was routinely 
used to calculate the uptake values of
2,7c 14c- and ^H-Labelled Substrates For these substrates, the
'
radioactivity detected in the yolk sacs and medium could not be 
compared directly. Beta radioactivity is measured by mixing 
scintillator with the sample to be counted. Often the sample itself
I
will interfere with the process of energy-transfer between the beta 
emissions and scintillator, giving rise to quenching. The amount of 
quenching that occurs depends on factors such as the intensity of 
colour and protein content of the sample, and the degree of mixing 
between sample and scintillation fluid. Medium 199 (which is 
coloured) and solubilized yolk sacs (which contain protein) each 
produce a different amount of quenching. In order to compare the 
radioactivity content of the medium with that of yolk sacs to 
calculate uptake, it was necessary to 'normalize* the observed counts 
to correct for the different counting efficiency of each. The 
observed count from a "spike" of radioactivity added to a sample of 
medium or yolk-sac solution was compared with that from an identical 
"spike" added to water to find the relative counting efficiency, as 
described in Section 2.5. The observed counts in samples of medium 
and yolk sacs derived from uptake experiments could then be
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normalized by multiplying by the appropriate relative counting 
efficiency correction factor. The normalized counts could be 
directly compared in the numerator and denominator of the 'uptake' 
equation. Uptake was therefore calculated as follows:-
Y x c.f.(yolk-sac) x V (yolk-sac)
0  = ----------------------------------------
M x V(medium) x c"^ * (medium) x P
Where:-
U = 
Y =
c,f,(yolk sac)
v (yolk sac)
v (medium)
M =
c*^*(medium) ~
Uptake (yl/mg)
Yolk-sac associated radioactivity 
(c.p.m. per yolk sac sample)
Correction factor for relative counting 
efficiency of the yolk-sac sample 
Constant to convert normalized c.p.m. in sample 
volume assayed, to total normalized c.p.m. for 
whole yolk sac.
Constant to convert normalized c.p.m. in medium 
sample assayed, to normalized c.p.m. 
per yl medium
Observed c.p.m. in sample of medium assayed. 
Correction factor for relative 
counting efficiency of the medium.
2.7d. Non-Radiolabelled Leupeptin
Detection of non-radiolabelled leupeptin depended on the 
leupeptin being in an active, inhibitory form. Any inactive 
molecules or degradation products could not be detected. Calculations 
were thus limited to determining the amount of active,
tissue-associated leupeptin. [If no inactivation or loss of leupeptin 
occurred, this tissue-associated leupeptin would be equivalent to the 
total uptake. If inactivation or loss did occur, total uptake and 
thus E.I. could not be calculated.] The amount of active 
tissue-associated leupeptin was calculated in terms of ill incubation 
medium per mq yolk-sac protein as follows:-
Total active leupeptin associated 
with the yolk-sac (yg)
Tissue-associated leupeptin =
(yl/mq) Active leupeptin in medium (yg/ul)
x mq yolk-sac protein
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3. 1 IWTRODOCTION
Many studies have been made of the effects of leupeptin as an 
inhibitor of proteolysis within intact cells. However, little has 
been established concerning the effects of time of exposure to 
leupeptin and of the concentration of leupeptin in the extracellular 
fluid on the results of such experiments.
Seglen et al. (1979) reported that, in hepatocytes, the 
inclusion of a 2 0min pre-incubation period with leupeptin (1 2 0yg/ml) 
had no effect on results relative to equivalent experiments with no 
pre-incubation. Similarly, Dean (1979) detected no increase in the 
degree of inhibition of proteolysis in macrophages over an incubation 
period of 2-48h in the presence of leupeptin (50yg/ml). Such results 
are compatible with an immediate and maximal effect of leupeptin on 
exposure of cells to this inhibitor. Conversely, Tanaka et al. (1979) 
found that maximal inhibition of BANA-hydrolase activity in 
hepatocytes did not occur until after 1 0h incubation with leupeptin 
(50pg/ml). Some investigators have included, for poorly defined 
reasons, a pre-incubation period in their experimental designs. Thus, 
Knowles et al. (1981) included a 30min pre-incubation period in a 
study of exogenous protein degradation, and Libby and Goldberg 
(1978) pre-incubated muscle tissue with leupeptin for 90min before 
measuring degradation.
No systematic investigation of the effect of pre-incubation 
conditions (time and leupeptin concentration) on the inhibition of 
proteolysis has been reported. However, unless it can be demonstrated 
that the observed degree of inhibition of proteolysis is neither a 
function of an arbitrarily-chosen leupeptin concentration nor of an 
arbitrarily chosen pre-incubation time, any observed inhibition of 
proteolysis will be incapable of unequivocal interpretation.
On exposure of cells to leupeptin, the amount of leupeptin that
enters the cells will determine the degree of inhibition of 
proteolysis. If the rate of penetration of the inhibitor is high 
(because cellular membranes are freely permeable and the 
extracellular concentration is high) the agent may rapidly induce a 
maximal inhibition of proteolysis, providing leupeptin-sensitive 
proteinases are involved in the rate-limiting steps of proteolysis. 
(Leupeptin would be expected to act rapidly on reaching its target 
enzymes, since the affinity of leupeptin for these enzymes is high, 
Barrett & Kirschke, 1981.) Conversely, if permeation of leupeptin to 
its site of action is slow, a lag period may be anticipated as the 
concentration of leupeptin within the intracellular compartments 
where proteolysis occurs builds up to a level that induces maximal 
inhibition.
The work described in this chapter therefore investigated the 
effects of varying both the leupeptin concentration in the medium 
and the duration of the pre-incuhation period, on the observed rates 
of proteolysis of an exogenous protein. The protein chosen for this 
study was formaldehyde-denatured ^25x_iaheiie<3 bSA because it has 
been shown to be degraded solely within lysosomes following its 
association with yolk-sac tissue (Livesey & Williams, 1979).
Measuring the degree of inhibition of the degradation of this protein 
thus gives a relative measure of the quantity of active (inhibitory) 
leupeptin within lysosomes in situ. (Without further knowledge of 
the permeability properties of the lysosomal membrane towards intact 
leupeptin, it is impossible to say whether or not this is a 
concentration that exceeds that present in the cytosol.)
In an attempt to establish whether leupeptin was entering the 
yolk-sac tissue entirely by pinocytosis, several known inhibitors of 
pinocytosis were used to try to block the uptake of leupeptin. 
(Possible effects of leupeptin on pinocytosis had to be investigated
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as part of the related series of control experiments.) In other 
experiments a study was made of the regain of proteolytic capacity by 
tissue that has previously been exposed to leupeptin.
In summary, the experiments reported in this chapter aimed to 
establish:-
i) The effects of pre-incubatinq yolk sacs for different periods of 
time on the degree of inhibition of proteolysis of 1 2 5 I-BSAfd 
induced by a given concentration of leupeptin.
ii) The effect of varying the leupeptin concentration during the 
pre-incubation period on the resulting degree of inhibition of 
proteolysis.
iii) The mode of uptake of leupeptin by the tissue, (fey attempting to 
block its uptake using known inhibitors of pinocytosis.)
iv) The time-course of regain of proteolytic capacity by tissues 
previously exposed to leupeptin.
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3.2. MATERIALS AND METHODS
I. MATERIALS
All equipment and chemicals are as described in Chapter 2.
II. METHODS
3.2.1 General Methods
The incubation of yolk sacs was divided into three different 
periods, termed the pre-incubation, wash, and degradation phases. 
During the pre-incubation phase, yolk sacs were incubated in the 
presence of various concentrations of leupeptln, with or without 
inhibitors of pinocytosis, for various periods of time. A control, in 
which no leupeptin was present, was also included. The yolk sacs were 
then rinsed in fresh medium (wash phase), and re-incubated in medium 
199 containing 1 2 5 I-BSAf(J for the degradation phase, during which 
period the release of TCA-soluble ^^I-BSA^ degradation products
into the medium was monitored. The general experimental details 
were as follows.
After dissection, yolk sacs were placed in flasks containing 
substrate—free, gassed medium 199 (3 yolk sacs in 6.3ml of medium
per flask, see Section 2.2b.). The pre-incubation phase was initiated 
by the addition of leupeptin (0.7ml stock solution, 1mg/ml in water, 
diluted if necessary with medium to give a final concentration in the 
flask of 25-100 ug/ml) or, for the control, medium 199 (0.7ml).
After pre-incubation for a set time, each group of three yolk 
sacs was transferred, together, to flasks containing warm gassed 
medium 199 (approximately 20ml) and rinsed for 2 min. Two further 
such rinses in fresh medium were made. The yolk sacs were then 
transferred singly to 3 separate flasks containing warm gassed medium
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125I-BSA^d (approx. 10pg/ml, 10ml). Samples of medium (1ml)
were removed from each flask at 15 or 30min intervals over a period 
of 150min: the volume of medium in the flask was kept constant by 
replenishing with fresh medium. The amount of TCA-soluble
1975b; Livesey & Williams, 1979) was estimated by adding 0.1ml serum 
(as a carrier protein) followed by 0.5ml TCA (20% w/v) to each
down (1 0 0 0 g, 2 0min) and the soluble fraction transferred to new 
counting vials for assay of radioactivity. In some experiments 
leupeptin was also present in the wash and degradation phases. The 
experiment was performed as above except the concentration of 
leupeptin was the same as that in the pre-incubation phase throughout 
the experiment.
3*2.2. Calculation and Expression of Results
The total amount (in c.p.m.) of TCA-soluble radioactivity 
released into the medium after each sample time was calculated as 
follows:-
i= 0
where Tn = Total radioactivity released into the medium 
(c.p.m.) up to the time of removal of the nth 
sample (c.p.m. per mg yolk-sac protein)
P = Protein content of the yolk sac (mg)
= Radioactivity per ml medium in the ith sample 
(c.p.m. corrected for background) 
f * Counting geometry correction factor
125 I_BSAfd de9 ra<Jation product (mainly 1 2 5 I-Tyr; Williams et al.,
sample to precipitate intact 1 2 5 I-BSAfd. The precipitate was spun
i=n-l
Tn 10 Ci(i=n)’f - P
(see Section 2.4b)
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Data were routinely processed using the computer program given in 
Appendix 1.3.
The mean value of Tn for the 3 yolk sacs that underwent 
identical pre-incubation phases was calculated and the results 
plotted as a graph of mean c.p.m. released (Tn) against degradation 
phase incubation period. The slope of the graph between 60-150 mins 
of incubation was determined as a measure of the rate of degradation 
of 1 2 5 I-BSAfd by the tissue. The rate observed in leupeptin-treated 
tissue was expressed as a percentage of that observed in control 
tissue.
I
3.2.3. Recovery of the Proteolytic Capacity of Tissue
after Exposure to Leupeptin I
The reversibility of the leupeptin-induced inhibition of
1 25 'l-BSAfd degradation was measured by determining the time-course
and extent of regain of proteolytic capacity by the tissue. After
Pre-incubation with leupeptin (100pg/ml for 45mins) the tissues were ,
rinsed in three changes of fresh medium (generally 3 x 4min) then
transferred, together, to substrate-free medium 199 (approximately
10ml per flask) for recovery periods of 60-180 min. (A recovery
period of 6min was obtained by reducing the wash period to 3 x 2min.)
The yolk sacs were then transferred singly to separate flasks
containing medium 199 plus BSA^d and the degradation phase of
the experiment continued as described in Section 3.2.1.
3.2.4. Variation of Duration of the Pre-incubation Phase and 
of the Leupeptin Concentrations 
The method was essentially as described in Section 3.2.1. The 
pre-incubation period was varied from 10-180min, with leupeptin at 
concentrations of 25, 50 and 100yg/ml medium.
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Data were routinely processed using the computer program given in 
Appendix 1.3.
The mean value of T„ for the 3 yolk sacs that underwent 
identical pre-incubation phases was calculated and the results 
plotted as a graph of mean c.p.m. released (Tn ) against degradation 
phase incubation period. The slope of the graph between 60-150 mins 
of incubation was determined as a measure of the rate of degradation 
of I by the tissue. The rate observed in leupeptin-treated
tissue was expressed as a percentage of that observed in control 
tissue.
3.2.3» Recovery of the Proteolytic Capacity of Tissue 
after Exposure to Leupeptin
The reversibility of the leupeptin-induced inhibition of
125
i-BSAfd degradation was measured by determining the time-course 
and extent of regain of proteolytic capacity by the tissue. After 
pre-incubation with leupeptin (100yg/ml for 45mins) the tissues were 
rinsed in three changes of fresh medium (generally 3 x 4min) then 
transferred, together, to substrate-free medium 199 (approximately 
10ml per flask) for recovery periods of 60-180 min. (A recovery 
period of 6min was obtained by reducing the wash period to 3 x 2mln.)
The yolk sacs were then transferred singly to separate flasks 
containing medium 199 plus 1 2 5 I-BSA(. <1 and the degradation phase of 
the experiment continued as described in Section 3.2.1.
3*2-4- Variation of Duration of the Pre-incubation Phase and 
of the Leupeptin Concentrations
The method was essentially as described in Section 3.2.1. The 
pre-incubation period was varied from 10-180min, with leupeptin at 
concentrations of 25, 50 and 100pg/ml medium.
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3*2.5. Effect of Inhibitors of Pinocytosis on the Uptake 
of teupeptln during Pre-incubation 
The inhibitors used in this study were ammonium chloride (20mM) 
and low temperature (6 , 15 and 20°C), as these were shown to be more 
readily reversible than other conditions that inhibit pinocytosis 
(see Section 3.3.4). Before addition of leupeptin to initiate the 
45min pre-incubation phase, yolk sacs were allowed to equilibrate in 
either medium 199 containing ammonium chloride (20mM, 6.3ml) or in 
medium 199 (6.3ml) maintained at 6 , 15 or 20°C. Control experiments 
were carried out in which yolk sacs were exposed to no inhibitor (ie 
maintained at 37°C in medium 199 alone), leupeptin only (ie no 
exposure to ammonium chloride or low temperatures), or pinocytic 
inhibitor only (ie equilibrated with ammonium chloride without 
leupeptin: no equivalent low temperature treatment was carried out),
before transfer to medium containing 1 2 5 I-BSAf(J. The rate of 
production of TCA-soluble material by tissue that had been exposed to 
both leupeptin and an inhibitor of pinocytosis was expressed as a 
percentage of that by tissue exposed to the pinocytic inhibitor 
alone. The rate observed in tissue that had been exposed only to 
leupeptin was expressed as a percentage of the control rate, for 
tissue that had been pre-incubated in medium 199 alone.
3.2.6. Reversibility and Effectiveness of Inhibitors of 
Pinocytosis in the Rat Yolk Sac 
For the experiments described in Section 3.2.5., it was 
important that the effects of any inhibitor used to block pinocytosis 
during the pre-incubation phase were rapidly and fully reversible, so 
that its effects did not continue during the degradation phase.
Continued inhibition of either uptake or degradation of the 
125I-BSAf^ by the inhibitor of pinocytosis used would lead to
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confusion in the interpretation of results. It was also important 
that any such inhibitor should totally block pinocytosis, since any 
small residual entry of leupeptin into the tissue by pinocytosis 
would affect the subsequent rate of 1 2 5 I-BSAfd degradation and could 
be misinterpreted as signifying non-pinocytic uptake of some of the 
leupeptin. The degree of inhibition of pinocytosis and the 
reversibility of several inhibitors were tested as described below.
3.2.6a Degree of Inhibition of Pinocytosis The degree of 
inhibition of degradation of 2^ ^I—BSA^d was taken as a measure of the 
effectiveness of the putative inhibitors of pinocytosis.
Yolk sacs were pre-incubated separately in the presence of the
inhibitor for 10—60min, then 2^ ^I-BSA^d was added to the medium. The
release of TCA-soluble radioactivity was monitored as described in
Section 3.2.1.; the medium used to replenish the sample volumes
contained inhibitor at the same concentration as the sample. For
some experiments, the Endocytic Index rather than rate of 1 2 5 I-BSA,.fa
degradation was determined, by assaying medium and yolk-sac tissue at 
various intervals (as described in Section 2.2a, 2.4b and 2.7b). 
Inhibitors tested were rotenone (10_5M), monensin (50mM), high K+:Na+ 
concentration (1M solutions of NaH2po4 and K2HPO4 titrated together 
to pH 7.3, then 0.5ml buffer added to 9.5ml medium), EGTA (5mM and 
1mM), fluoride (20 pg/ml), ammonium chloride (20mM), and low 
temperature (6-20°C). The more suitable inhibitors were further 
tested for their ability to inhibit uptake of 1 2 5 I-PVP, using the 
method described in Section 2.2a and 2.4a. The inhibitor was 
included in the medium in which the yolk sacs were incubated, and 
tissue was allowed to equilibrate for 30 minutes before addition of
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3.2.6b Reversibility of Effects of Inhibitors: Regain of Pinocytic
and Proteolytic Capacity Tissue was incubated in the presence of
various compounds reported to inhibit pinocytosis in the yolk sac.
In most cases the experiments were performed in a similar fashion to
that described in Section 3.2.1. except that tissue was pre-incubated
for 1 hour in the presence of an inhibitor of pinocytosis, rather
than with leupeptin. The tissue was rinsed (x3) in changes of
substrate-free medium for up to 30min, to allow time for recovery to
occur, then transferred to medium containing 1 2 5 I-BSAfd an<j the rate
of production of TCA-soluble material monitored as described in
Sections 3.2.1. and 3.2.2. [In some experiments, ^^I-BSA wasr a
(
present at the same time as the inhibitor, since the same tissue was I
used for investigation of both effectiveness and reversibility of an j
inhibitor. After monitoring the production of TCA-solubles in the 
presence of inhibitor as described in Section 3.2.6a the tissue was 
rinsed in fresh medium as described above then transferred to fresh 
inhibitor-free medium containing 1 2 5 I-BSAfd#] Controls were treated
t
in the same way as experimental tissue except that no inhibitor was
present during any part of the incubation. ;
Inhibitors tested for reversibility were rotenone (10-5M), EGTA 
(5mM, with or without 5mM CaClj supplement in the degradation phase 
medium), methylamine (2 0mM), ammonium chloride (2 0 mM), and low 
temperatures (6,15 and 20°C).
3.2.7. Effect of Pre-incubation with Leupeptin on the 
Subsequent Rate of Pinocytosis 
Yolk sacs were pre-incubated in the presence or absence of 
leupeptin (100yg/ml) as described in Section 3.2.1. Tissue was then 
washed in three changes of fresh medium ( 1 2  min) and transferred to 
flasks containing ^®I-PVP in medium 199 (approximately 3pg/ml,
10ml). The uptake of 1 2 5 I-PVP over a period of 120min was monitored 
as described in Sections 2.2 and 2.4a, and the Endocytic Indices of 
leupeptin-treated and control tissues were determined as described in
Section 2.7a.
3.3 RESULTS
3 » 3 * 1 Effect of Pre-Incubation of Yolk-Sac Tissue with Leupeptin, 
on the Subsequent Uptake of 1 2 5 I-PVP 
The Endocytic Index of 1 2 5 I-PVP for tissue that had been 
pre-incubated with leupeptin was determined, to establish whether 
pinocytosis was affected during the subsequent degradation phase in
corresponding experiments with 1 2 5 I-BSA__ as substrate.fa
The E.I. (mean ± standard deviation) of leupeptin-treated and of 
control tissues was 3.35 ± 0.47 and 3.64 ± 0.40 respectively. There
was no marked difference between the two mean E.I.'s, indicating that 
the pinocytic capacity of the tissue was unaffected by pre-incubation 
with leupeptin.
3* 3 »2. Recovery of the Proteolytic Capacity of Tissue after 
Exposure to Leupeptin
3.3.2a. Effect of Pre—incubation of Tissue with Leupeptin on 
aibsequent Degradation of 125I-BSAfd Pre-incubation of tissue with
leupeptin greatly affected the ability of the tissue to degrade 
125I-BSAjd. Fig. 3.1 shows a typical plot of the time-course of 
release of TCA-soluble 2^ ^I-BSA^d degradation products from tissue 
that had been pre-incubated without leupeptin (control), 
pre-incubated for 1 hour with leupeptin (1OOyg/ml), or incubated with 
leupeptin (1OOpg/ml) throughout the pre-incubation, wash and 
degradation phases.
In control tissue the TCA-soluble radioactivity was released 
into the medium at a constant rate, with no lag phase over the 
initial period. The rate of release of TCA-soluble radioactivity was 
much greater than that in tissues that had been exposed to leupeptin. 
Tissue that had been exposed to leupeptin for one hour showed a 
pattern of release of TCA-solubles similar to that observed for
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tissue that had been exposed to leupeptin continuously, although in 
tissue exposed for 1h the increase in rate after 60 minutes 
degradation phase was more marked, and release of TCA-solubles was 
greater than for tissue continuously exposed to leupeptin. The 
time-course of release of TCA-solubles between 60-150 minutes of 
degradation phase was approximately linear in all cases; the rate in 
these linear regions was calculated and the inhibited rate expressed 
as a percentage of the rate in control yolk sacs to determine the 
percentage remaining degradative capacity (as described in Section
3.2.2. ). Results for several determinations following one hour 
exposure to leupeptin (100pg/ml) are shown in Table 3.1. The value 
of c.p.m./mg yolk-sac protein/min varied from day to day according to 
the specific radioactivity of the 1 2 5 I-BSAf ( 1 preparation and the 
gamma-counter efficiency. This variation was normalized by 
expressing the rate as a percentage of the matched control. The 
mean percentage remaining degradative capacity for this 
pre-incubation regime was 33.7%. (The eguivalent value for tissues 
continually exposed to leupeptin was 18.0%.)
A lag in onset of degradation was observed for all tissues that 
had been exposed to leupeptin. Further investigations into^cause of 
the observed lag period were made by varying the recovery time 
between the pre-incubation phase, with leupeptin, and the degradation 
phase. This also gave an indication of the time course of any 
recovery of the capacity to degrade 1 2 5 I-BSAf ( 5 after leupeptin 
exposure.
3.3.2. b Effect of Variation of Recovery Periods The tissue was
incubated as described in Section 3.2.3. Pre-incubated tissue was
allowed to recover in medium containing neither leupeptin nor 
125I-BSAfjj for 6 , 1 2 , 60, 1 2 0 and 180 minutes, before transfer to 
medium containing ^2 ®I-BSA^^ for the degradation phase. Fig 3.2 shows
the time-course of recovery by the tissue, expressed in terms of the 
percentage residual degradative capacity. Although this value 
varied somewhat between experiments there was no overall increase in 
the capacity of the tissue to degrade 1 2 5 I-BSAfd throughout the 
recovery period.
The effect of the recovery period on the observed delay in onset
of release of TCA-solubles is shown in Fig 3.3, which is a typical
plot of the quantity of 125I-BSAfd degraded (c.p.m. released/mg
protein) against degradation-phase time. A lag phase of
approximately 60min was apparent in all cases, even after 180min
recovery. This indicates that the delay in onset of 1 2 5 I-BSA.f <3
degradation was not dependent on the period between the 
pre-incubation and degradation phases but rather on the period of 
exposure to 1 2 5 I-BSAf(J, and/or to leupeptin.
3.3.3. Variation of Pre-incubation Phase Conditions; Effects of 
Leupeptin Concentration and Exposure Time.
These experiments were conducted in order to obtain some 
indication of the rate of action (and hence uptake) of leupeptin at 
various concentrations. The experiments were carried out as 
described in Section 3.2.1. The final leupeptin concentration was 
25, 50 or 100pg/ml and the pre-incubation periods were 10, 20, 30,
45, 60, 120 and 180min. Typical plots of the TCA-solubles released 
(c.p.m. per mg yolk-sac protein) aqainst degradation-phase time, for 
25, 50 and 100ug/ml are shown in Figs 3.4, 3.5 and 3.6 respectively.
The degree of inhibition observed rose with increasing 
pre-incubation time. For leupeptin at a concentration of 100yg/ml, 
a maximum inhibition was reached after approximately 60min; no 
further inhibition was observed after longer pre-incubation times.
It was noteworthy that the magnitude of the lag period, described in
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the time-course of recovery by the tissue, expressed in terms of the 
percentage residual degradative capacity. Although this value 
varied somewhat between experiments there was no overall increase in 
the capacity of the tissue to degrade 1 2 5 I-BSAfd throughout the 
recovery period.
The effect of the recovery period on the observed delay in onset
of release of TCA—solubles is shown in Fig 3*3* which is a typical
plot of the quantity of 125I-BSAfd degraded (c.p.m. released/mg
protein) against degradation-phase time. A lag phase of
approximately 60min was apparent in all cases, even after 180min
recovery. This indicates that the delay in onset of 1 2 5 I-BSA.f d
degradation was not dependent on the period between the 
pre-incubation and degradation phases but rather on the period of 
exposure to 1 2 5 I-BSAf<J, and/or to leupeptin.
3*3.3. Variation of Pre-incubation Phase Conditions: Effects of 
Leupeptin Concentration and Exposure Time.
These experiments were conducted in order to obtain some 
indication of the rate of action (and hence uptake) of leupeptin at 
various concentrations. The experiments were carried out as 
described in Section 3.2.1. The final leupeptin concentration was 
25, 50 or 100|jg/ml and the pre-incubation periods were 10, 20, 30,
45, 60, 120 and 180min. Typical plots of the TCA-solubles released 
(c.p.m. per mg yolk-sac protein) against degradation-phase time, for 
25, 50 and 100pg/ml are shown in Pigs 3.4, 3.5 and 3.6 respectively.
The degree of inhibition observed rose with increasing 
pre-incubation time. For leupeptin at a concentration of 100pg/ml, 
a maximum inhibition was reached after approximately 60min; no 
further inhibition was observed after longer pre-incubation times.
It was noteworthy that the magnitude of the lag period, described in
Section 3.3.2, seemed to depend on the pre-incubation period with
leupeptin (being less apparent for short pre-incubation periods).
Figs. 3.7 a,b,c,d,e show a comparison of the rate of degradation of 
125I-BSAf(1, in matched experiments, in tissue exposed to 50 and 
1OOpg/ml leupeptin for various periods. Initially, the degree of 
inhibition was greater in those tissues exposed to the higher 
concentration of leupeptin, however after 180 minutes the degree of 
inhibition was the same for both concentrations. This degree of 
inhibition was the maximum observed for leupeptin at 100yg/ml. Fig.
3.8 shows this effect more clearly, by expressing the rate of 
degradation as the percentage residual degradatlve capacity. The 
residual degradatlve capacity in tissue exposed to leupeptin at 
100yg/ml decreased fairly rapidly (approximately 15% inhibition was 
apparent after only 1 0min) up to 60min exposure time, after which it 
was more or less constant up to 240min. For leupeptin at 50yg/ml, 
the residual degradative capacity decreased more slowly over 
10-180min pre-incubation time, but eventually reached the same 
maximal inhibition observed with leupeptin at lOOyg/ml. Leupeptin 
at a concentration of 25yg/ml gave the slowest decrease in residual 
proteolytic capacity, and the maximum degree of inhibition reached 
was never as great as for concentrations of 50 or 100yg/ml.
The maximum inhibition achieved was never total; approximately 
20% of the degradation of 1 2 5 I-BSAf(J continued to occur.
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3.3.4 Effectiveness and Reversibility of Inhibitors of Plnocytosls
3.3.4a Effectiveness of Inhibitors The rate of degradation of 
125
l”BSAfd the presence of different inhibitors of pinocytosis was 
monitored in an initial assessment of the degree of inhibition of 
pinocytosis and/or degradation. The results are shown in Table 
3.2a. Sodium fluoride (20pg/ml) and EGTA (1mM) were found to have 
no effect on the rate of degradation of 125I-BSAf(J, indicating that 
uptake was not inhibited, and rotenone (10-5M) gave only partial 
inhibition. The most effective inhibitors were ammonium chloride at 
20mM (lower concentrations gave partial inhibition) and low 
temperature (B^C), (both of which inhibited virtually all release of 
TCA-soluble material), and methylamine, (which inhibited the majority 
of TCA-soluble release). Monensin (50mM) and high K+:Na+ 
concentration were tested for effectiveness by monitoring the 
Endocytic Index of 125I-BSAf(J in treated tissue, rather than the rate 
of release of TCA-soluble material alone. Table 3.2b shows these 
results. Monensin gave approximatly 75% inhibition of uptake and 
degradation, and a high K+ :Na+ concentration gave almost total 
inhibition. For monensin, the total amount of radioactivity 
associated with the tissue remained fairly high, suggesting that 
pinocytosis occurred to some extent, but degradation was inhibited. A 
high K+:Na+ concentration decreased the amount of radioactivity 
within the yolk-sac, suggesting that pinocytosis was the inhibited 
step.
3.3.4b Reversibility of Effects of Inhibitors Tissue was 
incubated in the presence of the inhibitor for 1h then rinsed and 
either transferred immediately to flasks containing 125I-BSAfd or 
allowed to recover for up to 30min in the final wash flask, before 
transfer to I-BSAf<J-containing flasks. The rate of release of
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TCA-solubles radioactivity was then monitored to determine whether
full proteolytic capacity of the tissue towards 125I-BSA_ wasfd
recovered. This required regain of both pinocytic and proteolyic 
activity, since pinocytosis is normally rate-limiting in the process. 
The results are given in Table 3.3. The values shown are typical for 
each inhibitor. (It was not possible to take mean values of the rate 
of release of TCA-solubles (c.p.m./mg/min) because of the variation 
in this value from day to day.)
Methylamine and rotenone were shown to be not reversible, 
although some recovery did occur after 30min. EGTA was also not 
reversible, particularly so if Ca2+ was included in the medium in an 
attempt to counter-act the sequestration of Ca2+ions. Exposure of 
the tissue to temperatures below 37°C appeared to enhance the 
subsequent rate of degradation of 125I-BSAf(i, lower temperatures 
producing greater enhancement. This experiment did not distinguish 
whether this was caused by an increase in the rate of pinocytosis or 
of proteolysis. (A similar effect was observed with ethanol-exposed 
yolk sacs; the rate of uptake of ^2^I-PVP was increased, suggesting 
pinocytosis rather than proteolysis was stimulated. G.Steventon, 
unpublished data.) The effects of ammonium chloride were readily 
reversible, even after only nine minutes rinse/recovery period. The 
degree of recovery was somewhat variable, a mean percentage recovery 
value for all such experiments (with different wash times) was 90.4%, 
standard deviation 25.2
Since ammonium chloride gave a high degree of inhibition of 
release of TCA-solubles together with a rapid and comparatively 
complete recovery it was considered suitable for use in attempts to 
inhibit any pinocytic uptake of leupeptin. However, ammonium 
chloride is a potent inhibitor of proteolysis, therefore it was 
necessary to check that the inhibition of release of TCA-solubles was
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caused by an inhibition of pinocytosis, rather than just proteolysis. 
Uptake of 125I-PVP in the presence of ammonium chloride (20mM) was 
therefore monitored as described in Section 3.2.6a. The mean E.I. was 
0.16, whereas that for control tissue was 1.6. Pinocytosis was thus 
inhibited 90% by ammonium chloride at this concentration.
3.3.5 Effect of Inhibitors of Pinocytosis on Entry of 
Leupeptin into Yolk-Sac Tissue 
The method used in these experiments is described in Section
3.2.5. As shown in Section 3.3.4a,b., ammonium chloride and low 
temperature are potent, rapidly-reversible inhibitors of pinocytosis, 
therefore their inclusion in the pre-incubation phase with leupeptin 
should prevent any pinocytic uptake of leupeptin. Their effects 
should then be reversed during the standard wash phase so that 
pinocytosis and degradation of I-BSA^ would occur normally. 
Typical plots of release of TCA-solubles (c.p.m./mg yolk-sac protein) 
against degradation phase time, after pre-incubation with leupeptin 
in the presence of ammonium chloride (20mM), are shown in Figs 3.9 
a,b,c,and d. The same data are also expressed as a percentage of 
the matched control in Table 3.4. The figures clearly show that 
release of TCA-soluble radioactivity was inhibited in
leupeptin-treated tissue, whether or not NH^Cl was present during the 
leupeptin exposure period. Hence, it would appear ammonium chloride 
did not fully prevent entry of some leupeptin into the lysosomes, 
suggesting that uptake of leupeptin was not entirely dependent on 
pinocytosis. However, residual proteolytic activity within the 
lysosomes was greater in tissue that had been incubated in the 
presence of leupeptin and ammonium chloride, than in that exposed to 
leupeptin alone. This indicates that the amount of leupeptin 
present within the lysosomes was greater when ammonium chloride was
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absent. This observation suqgests either a reduced uptake of 
leupeptin in the presence of the inhibitor or an increased rate of 
loss of leupeptin from lysosomes containing ammonium chloride.
The results obtained using low temperature as an inhibitor of 
pinocytosis in the pre-incubation phase are shown in Fig.3.10. The 
rate of degradation of ^^I-BSA^ after treatment with leupeptin at a 
low temperature was calculated as a percentage of that measured in 
yolk-sacs that had been pre-incubated at 37°C in the absence of
inhibitor. Results given in Section 3.3.4b suggested that 
125I-BSAjj degradation (at 37°C) was enhanced after pre-incubation 
at a lower temperature. This suggestion is further supported by the
results in Fig. 3.10, since in many cases the rate of degradation of 
125I-BSAf<j was greater in low temperature/leupeptin-treated tissue 
than in the controls maintained at 37°C throughout. These data do not 
allow clear conclusions to be drawn as to whether leupeptin uptake 
was abolished at low temperatures. However, the amount of leupeptin 
within the tissue (as determined by the residual degradatlve 
capacity) did appear to be temperature dependent, since the degree of 
inhibition given by leupeptin increased as the temperature of 
pre—incubation increased from 6 — 20°C, even though at these 
temperatures the control rate (37°C) was less than or equal to the
inhibited rate
3.4 DISCUSSION
3.4.1. General features of — BSAf^ degradation as a probe for 
leupeptin
The method of estimating the amount of leupeptin associated with 
yolk-sac tissue described in this chapter has a number of 
advantages
i) The method relies on inhibition of lysosomal function in intact, 
living tissue and therefore relates to normal lysosomes situ 
(rather than to, for example, diluted lysosomal extract under 
arbitary conditions).
ii) The method circumvents any problems that might be associated 
with obtaining leupeptin from tissue in an extract suitable for 
the measurement of leupeptin content.
iii) The substrate was a protein, rather than a low molecular mass 
chromogenic or fluorogenic substrate, hence any observed 
inhibition is likely to be more representative of the effects of 
leupeptin on proteolysis in general.
iv) The assay detects intralysosomal leupeptin only. Any leupeptin 
bound to the external cell surface, rather than being 
internalized, would not be detected. (In contrast, such 
non-internalized substrate may be included in the value for 
total uptake when using other methods to measure uptake.)
v) The assay was found to be sensitive to small amounts of 
leupeptin. (For example a decrease in rate of degradation of 
125I-BSAfd could be detected after only ten minutes exposure of 
tissue to leupeptin at a concentration of 100yg/ml.)
The success of the method depended on certain factors described 
below.
The protein substrate must be degraded intracellularly. If anyi)
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degradation occurred at the surface of the plasma membrane, or 
by free proteinases released into the bulk medium,
Interpretation of the observations would be difficult. However 
it has been established that degradation of ^2^I—BSAjd by yolk 
sacs is entirely intralysosomal (Livesey & Williams, 1979), so 
any observed effects of leupeptin must relate to an inhibition 
of lysosomal function.
ii) Leupeptin must not affect the rate of pinocytosis by the tissue. 
Any inhibition of pinocytosis caused by leupeptin would affect 
the rate of degradation of 125I-BSAfd, since pinocytic capture 
of a protein is the rate-limiting step in its degradation within 
yolk sacs (Williams et al., 1975b). Thus, in the assay, any 
such inhibition of pinocytosis would cause an inhibition of 
degradation. This in turn would be mistakenly equated with 
inhibition of lysosomal enzymes.
iii) For those experiments in which leupeptin was present in the 
pre-incubation phase only, the inhibition of lysosomal enzymes 
caused by leupeptin must not be rapidly reversible, otherwise 
little or no effect would be present during degradation phase.
If the effects of leupeptin are rapidly reversible and/or some 
or all of the leupeptin is lost from the tissue during the wash 
phase, the amount of leupeptin that enters the tissue during the 
pre-incubation phase could not be assessed by measuring 
inhibition of degradation of 125I-BSAfd during the 
leupeptin-free degradation phase. To detect different amounts 
of tissue-associated leupeptin, either the duration of the 
period of inhibition or the degree of inhibition (or both) must 
differ during the degradation phase after exposure of the tissue 
to different incubation regimes with leupeptin.
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The method was not without disadvantages. The main disadvantage 
of the method was that the absolute quantity of leupeptin within the 
lysosomes could not be calculated, since the relationship between
intralysosomal concentration of intact leupeptin and the rate of 
125degradation of I-BSA^ was not known. Another disadvantage was 
that only leupeptin within the lysosomal system was detected, so the 
leupeptin content of the entire tissue could not be assessed. The 
relative proportion of leupeptin in lysosomal or non-lysosomal 
compartments would depend on the permeability of the plasma and 
lysosomal membranes toward leupeptin, therefore measurements of the 
lysosomal content of leupeptin may not reflect the total tissue 
content of leupeptin.
Overall, this method of detecting leupeptin permits a semi- 
quantitative estimate of the amount of active leupeptin within the 
lysosomal system of intact tissue to be made.
3.4.2. Discussion of Results Obtained Using This Method
The main findings of this chapter are interesting when compared 
with the literature on the degree of inhibition of degradation caused 
by leupeptin for different classes of proteins (eg short-lived, 
long-lived, abnormal, endogenous or exogenous) in different cell 
types (see reviews by Seglen, 1983; Dean, 1980). Experiments show 
that the degree of inhibition varies a great deal, from no inhibition 
of degradation of abnormal endogenous proteins in hepatocytes (Neff
et al., 1979) to 80% inhibition of degradation of exogenous 
125I-BSAfj in the yolk sac (Knowles et al., 1981). The differences 
were assumed to indicate differences in the contribution of 
leupeptln-sensitive thiol proteases towards degradation of proteins 
of different half-lives and in different cell types. However care 
should be exercised when comparing these results, since not only did
the type of cell and class of protein studied differ between 
experiments, but also the concentration of leupeptin used, the 
pre-incubation period with leupeptin, and the period over which 
degradation was studied. Changes in any of these factors could lead 
to differences in the observed degree of leupeptin-induced 
inhibition. Indeed, results described in this chapter show that the 
degree of inhibition of degradation of 125I-BSAfd in rat yolk sacs 
was dependent on both the period of exposure to, and concentration 
of, leupeptin during the pre-incubation phase.
Onset of inhibition occurred after only ten minutes exposure to 
leupeptin, suggesting fairly rapid entry of leupeptin into the 
tissue. The degree of inhibition observed rose progressively with 
time, maximal inhibition was not achieved until after one hour 
exposure to leupeptin (100 pg/ml). Lower concentrations of 
leupeptin in the pre-incubation medium required longer periods of 
exposure to achieve the same degree of inhibition. These observations 
indicate that, for a given leupeptin concentration, the amount of 
leupeptin within the lysosomal system increased gradually with 
increasing time of exposure to leupeptin, at least up to the time 
when maximum inhibition was observed.
Several explanations could be put forward to account for the 
constant maximum degree of inhibition of 125I-BSAfd degradation, and 
why this was not equal to 100%. The most likely is that the 
remaining 20% of degradation was mediated by leupeptin-insensitive 
enzymes in the lysosome, such as cathepsins D and possibly H (which 
is not very sensitive to leupeptin). The relative contribution of 
various lysosomal proteinases towards the degradation of I-BSAfd 
in vivo is unknown, though purified cathepsins B, D, H, and L are all 
capable of hydrolysing 125I-BSAfd (Kooistra et al., 1982). Any 
degradation mediated by leupeptin-insensitive enzyme(s) would still
■
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take place if leupeptin-sensitive enzymes were fully inhibited, and 
may even occur to a greater extent when the leupeptin-sensitive 
pathways become blocked (Tanaka et al., 1981). Further increases in 
the leupeptin content of the lysosomes would not lead to any further 
inhibition of degradation of 125i-BSAfd.
Other explanations can be dismissed on consideration of
experimental evidence. 125I-BSAfd has been shown to be degraded
entirely within lysosomes (Livesey and Williams, 1979) so the
residual degradation could not be attributed to a
leupeptin-insensitive, non-lysosomal pathway. Degradation of 
125I-BSAfd via a population of lysosomes that did not contain 
leupeptin was considered unlikely. (The only source of such 
lysosomes would be a new population of primary lysosomes, and these 
would only remain leupeptin-free if the lysosomal membrane is not 
permeable to leupeptin and if they did not fuse with existing 
lysosomes that contained leupeptin. Also, turnover of lysosomes 
during the experimental period would not be expected to occur to any 
great extent; lysosomal components are reported to have a half-life 
of about 30h (Dean, 1977).
An alternative explanation is that leupeptin itself was degraded 
within the lysosomes to reach a steady-state concentration (when the 
rate of degradation was equal to the rate of uptake), this
concentration giving rise to an 80% inhibition of degradation of 
125I-BSAf(j. However, if leupeptin is inactivated, the tissue could be 
expected to regain its proteolytic activity after exposure to 
leupeptin; no such recovery was observed, even after a 3h recovery 
period.
The rate of degradation of 125I-BSAfd in the continuous presence 
of leupeptin was lower than that in tissues that had only been 
exposed to the inhibitor for one hour. This may have been due to
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partial recovery of the tissue on removal of leupeptin.
Alternatively, the increased leupeptin exposure time of the 
continuously-exposed tissue may have led to the increased inhibition 
observed (indeed degrees of inhibition similar to that observed for 
continuous presence, ie 18%, were observed in some of the experiments 
in which tissue was pre-incubated for 180 minutes with leupeptin 
100ug ml, then re-incubated over the degradation phase without 
leupeptin) .
Leupeptin is a competitive inhibitor (Umezawa and Aoyagi, 1977) 
and is therefore theoretically reversible. Previous studies using rat 
yolk sacs demonstrated that inhibition of exogenous (though not 
endogenous) protein degradation by leupeptin was indeed partially 
reversible after a two hour recovery period (Knowles et al., 1981). 
However, Seglen et al. (1979) found leupeptin to be irreversible in 
practice when working with hepatocytes, and Kirschke et al. (1977) 
found that leupeptin acted as a pseudo-irreversible inhibitor towards 
purified cathepsin L. In the experiments reported in this chapter, a 
decreased rate of degradation of I-BSAf(j was observed after 
incubation with leupeptin, even though leupeptin was not present 
during the period when the rate of degradation was measured. Indeed 
the rate of degradation was inhibited to a similar extent in tissue
that had been allowed to recover in medium free from both leupeptin 
125and I-BSAfj for up to 180 minutes before monitoring the 
degradation. This continued inhibition must have been caused by a 
continuous presence of leupeptin within the lysosomes (at least up to 
the maximum period monitored, which was 5.5 hours).
There are several mechanisms by which leupeptin might become 
trapped in lysosomes. First, if lysosomal and plasma membranes were 
impermeable towards leupeptin, the only route of entry of leupeptin 
into the tissue would be via pinocytosis, leading to delivery to the
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partial recovery of the tissue on removal of leupeptin.
Alternatively, the increased leupeptin exposure time of the 
continuously-exposed tissue may have led to the increased inhibition 
observed (indeed degrees of inhibition similar to that observed for 
continuous presence, ie 18%, were observed in some of the experiments 
in which tissue was pre-incubated for 180 minutes with leupeptin 
100(jg ml, then re-incubated over the degradation phase without 
leupeptin).
Leupeptin is a competitive inhibitor (Umezawa and Aoyagi, 1977) 
and is therefore theoretically reversible. Previous studies using rat 
yolk sacs demonstrated that inhibition of exogenous (though not 
endogenous) protein degradation by leupeptin was indeed partially 
reversible after a two hour recovery period (Knowles et al., 1981). 
However, Seglen et al. (1979) found leupeptin to be irreversible in 
practice when working with hepatocytes, and Kirschke et al. (1977) 
found that leupeptin acted as a pseudo-irreversible inhibitor towards
purified cathepsin L. In the experiments reported in this chapter, a
125decreased rate of degradation of I-BSAfd was observed after 
incubation with leupeptin, even though leupeptin was not present 
during the period when the rate of degradation was measured. Indeed 
the rate of degradation was inhibited to a similar extent in tissue
that had been allowed to recover in medium free from both leupeptin 
125and I-BSAfj for up to 180 minutes before monitoring the 
degradation. This continued inhibition must have been caused by a 
continuous presence of leupeptin within the lysosomes (at least up to 
the maximum period monitored, which was 5.5 hours).
There are several mechanisms by which leupeptin might become 
trapped in lysosomes. First, if lysosomal and plasma membranes were 
impermeable towards leupeptin, the only route of entry of leupeptin 
into the tissue would be via pinocytosis, leading to delivery to the
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lysosomal system. Leupeptin would then remain trapped within 
lysosomes and loss could only occur via exocytosis or degradation of 
leupeptin. Second, even if the membranes were permeable to 
leupeptin, the leupeptin may still become trapped within lysosomes by 
virtue of its binding to lysosomal enzymes. (Leupeptin is a 
tight-binding inhibitor with a fairly low for lysosomal enzymes?
(apparent) values of 7 x 10 for cathepsin B, approximately 3.7 
x 10 M for cathepsin L, but only about 5 x 10-oM for cathepsin H, 
were reported by Barrett & Kirschke, 1981), hence it may remain bound 
to the enzymes even if the concentration of leupeptin in the tissue 
was low, giving rise to the continued inhibition. Third, the 
leupeptin molecule has a positively charged arginal group which may 
possibly act in a lysosomotropic manner. (Lysosomotropic agents are 
normally molecules that are uncharged at neutral pH, and therefore 
able to permeate the lysosomal membranes freely, but become 
protonated within the lower pH of lysosomes so cannot pass out 
through the membrane. The pKfl of the guanidinyl group of arginine is 
12.48 therefore it would be expected to be charged even at neutral 
pH, which may render the molecule resistant to membrane permeation. 
However, the molecule can cyclize (see Fig.1.1), and the cyclized 
form may have an altered pKa and behave as a conventional weak base.)
The lack of recovery of proteolysis also suggests either that no 
new population of primary lysosomes was synthesised during the 
experimental period (as suspected from previous results) or that such 
lysosomes were rapidly inhibited to the same extend as pre-existinq 
lysosomes by excess leupeptin within the tissue.
The release of TCA-soluble radioactivity in control tissue (ie 
that which had not been exposed to leupeptin) was linear over the 
entire degradation phase. However, tissue that had been exposed to 
leupeptin showed a lag phase of up to 60 minutes during which
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degradation was either very slow or did not occur. After this 
period, the degradation of ^2^I-BSA^d increased to a constant rate 
which was used to calculate the degree of inhibition of proteolysis.
The length of the lag period seemed to depend on both the 
concentration of leupeptin to which the tissue had been exposed and 
the duration of such exposure. Shorter lag periods were observed in 
tissue that has been exposed to leupeptin for a shorter period of 
time and/or to lower concentration of leupeptin.
Several possible causes may be put forward to explain the lag 
phase; some of these could be ruled out on the basis of further 
investigations. A study of the time-course of recovery of 
proteolysis in the yolk sac showed that lag periods were observed in 
tissue that had been allowed to recover for 180 minutes, and were of 
a similar duration to those observed in tissue that had not undergone 
a recovery period. Hence a rapid partial loss of leupeptin over the 
first 60min after pre-incubation could be rejected as an explanation of 
the lag period. Likewise, a partial inhibition or delay in onset of
pinocytosis in tissue that had been exposed to leupeptin, (which
1 o 5would cause a delayed delivery of I-BSAjd to the lysosomes, so 
delay degradation and give rise to the lag phase), can be dismissed
because pre-incubation of tissue with leupeptin did not affect the
125uptake of the pinocytic marker I-PVP. Lysosomal turnover during 
the lag phase was considered unlikely during the period involved, as 
discussed above.
The observed lag followed by an increased rate of degradation 
could be explained by displacement of leupeptin from its site of 
action, (ie the active site of cysteine cathepsins) by incoming 
125I-BSAfd, once the 125I-BSAfd reached a sufficiently high
concentration within lysosomes. The ability of a substrate to 
displace an inhibitor is characteristic of competitive inhibitors and
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would depend on the dissociation constants of ^^I-BSA- andf d
leupeptin for lysosomal enzymes. However, since the concentrations
125of I-BSAfd and leupeptin within the lysosomes are not known, the 
likelihood of displacement of leupeptin from the lysosomal enzymes 
cannot be predicted.
An alternative explanation, which is well supported by evidence
from the literature, is that a delay in fusion between lysosomes and
pinosomes was induced by leupeptin. This would cause a delay in the 
125delivery of I-BSAf(J to lysosomes, and hence a delay in onset of 
degradation would occur. This would not be detectable when ^^I-PVP 
uptake was studied since accumulation of this marker could occur in 
either pinosomes or secondary lysosomes. Delayed fusion between 
endosomes and lysosomes has been proposed as the cause of the 
observed accumulation of autophagosomes in leupeptin-treated cells. 
Leupeptin causes an accumulation of undegraded proteins within the 
lysosomes. Fusion between the distended lysosomes/autophagolysosomes 
that are caused by this massive protein accumulation and other 
vesicles is then inhibited, hence giving rise to the observed 
accumulation of autophajpsomes (Korvacs et_ al., 1982; Furono et^  al., 
1982 a,b). The process of accumulation of proteins and inhibition 
of fusion is reported to take at least 30 minutes after onset of 
inhibition of degradation (Tolleshaug & Berg, 1981).
Inhibition of fusion can explain many of the characteristics of 
the lag period. The amount of material that accumulated in 
lysosomes would depend on the amount of leupeptin present, and on the 
period of accumulation. This is dictated by the pre-incubation 
regi~me and by the period of 'recovery' allowed. Hence the lag 
period would be expected to depend on the pre-incubation regi^me, and 
would not he prevented by a recovery period.
The studies with inhibitors of pinocytosis were carried out to
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assess what proportion of leupeptin was taken up by pinocytosis.
Many inhibitors cited in the literature as inhibiting pinocytosis 
were unsuitable for use, since they were either insufficiently potent 
or their effects were not reversible. It was important that any 
inhibitor used should have both these properties. (An incomplete 
inhibition of pinocytosis would lead to an underestimate of the 
amount of leupeptin entering the tissue via this route, and
incomplete recovery of pinocytosis would lead to an over-estimation
125of the inhibition of degradation of I-BSA^ by leupeptin.)
Although many data are available on the effectiveness of pinocytic 
inhibitors little has been reported on the reversibility of their 
effects. The inhibitors tested in this study are described below.
Sodium fluoride is reported to inhibit pinocytosis in 
macrophages by 70% at a concentration of 1mM (Cohn, 1966) by acting 
as an inhibitor of glycolysis. However, it did not affect 
pinocytosis in the rat yolk sac at the concentration tested,
(20(jg/ml). EGTA (1mM) was also without effect. It has been shown
2+to inhibit pinocytosis in the yolk sac by sequestration of Ca ions, 
its effect being reversed when an equal concentration of CaCl2 was 
included during incubation (Duncan fi Lloyd, 1978). Possibly the 
lack of inhibition observed was due to an excess of Ca in medium 
199 (Ca2+ concentration reported to be 1.8mM.) At 5mM, inhibition of 
pinocytosis occurred, but recovery was poor. The reason for total 
lack of recovery in the presence of excess Ca (added to replace any 
sequestered by EGTA) is unknown. Rotenone acts as an inhibitor of 
the electron transport chain and therefore effects the energy balance 
of the cell. It has been used in the past to inhibit pinocytosis in 
rat yolk sac tissue. However, it only induced a 70% inhibition of 
pinocytosis, and only 50% of this inhibition was reversible. 
Methylamine (20mM), reported to inhibit pinocytosis by about 90%
H
M
H
Q
n 
3~
13
3>
63
(Livesey et al., 1980), blocked the release of TCA soluble 
radioactivity. However, high levels of radioactivity within the 
tissue were observed, suggesting that proteolysis rather than 
pinocytosis was inhibited (as might be expected with this 
lysosomotropic agent.) Its effects were only partially reversible, 
even after a prolonged recovery period. (Lack of reversibility of 
this inhibitor was also observed by Seqlen et al., 1979.) Monensin, 
which acts as a Na+:K+ ionophore (Uchida et al., 1980) is reported to 
affect endocytosis, however there is some conflict in the literature 
about the inhibited step. In rat embryo fibroblasts, fluid-phase 
pinocytosis was inhibited by 90% after 24 hour exposure to monensin 
(1 viM), but fusion between lysosomes and pinosomes was unaffected 
(Wilcox et al., 1982). Conversly, Harford et al. (1983) found that 
uptake of an asialoglycoprotein was not inhibited, but subsequent 
fusion between pinosomes and lysosomes was inhibited by monensin 
(1OpM) in rat hepatocytes. In yolk sacs, monensin (50mM) was shown 
to decrease the E.I. of 125I-BSAf(J by approximately 75%, however the 
final concentration of 0.1% ethanol in the medium, necessary to 
solubilize the monensin, was found to adversly affect control tissue. 
(Such effects have recently been characterised in more detail by 
G.Steventon? unpublished data). High potassium: low sodium ratios 
were reported to inhibit endosome-lysosome fusion but not pinocytosis 
(Baeniziger & Fiete, 1982) However, it appeared to be a very 
effective inhibitor of uptake of 125I-BSAf(l in this system, 
decreasing the Endocytic Index by approximately 95%. Unfortunately, 
no study was made on the reversibility of this inhibitor.
Low temperatures have been shown to inhibit pinocytosis in the 
volk sac (Duncan fi Lloyd, 1978) and in other cells eg perfused liver 
(Dunn et at;, 1980), macrophages (Cohn 1966). In the perfused liver, 
temperatures below 10*C inhibited endocytosis» between 10 to 20°C
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endocytosis occurred slowly, but fusion between pinosomes and 
lysosomes was prevented. Between 20 to 37°C both pinocytosis and 
degradation occurred at increasing rates. In yolk sac, pinocytosis 
was found to be inhibited completely below 20°C. Temperatures of 6, 
15, and 20°C were tested for reversibility of their effects and 
complete inhibition of pinocytosis at 6°C was verified. Proteolytic
activity was rapidly regained in all cold-treated tissue.
125Surprisingly, degradation of I-BSAf<1 appeared to be stimulated by
125pre-treatment at a low tempterature. Since uptake of I-BSAf(J is 
the rate-limiting step in its degradation, this suggests that the 
rate of pinocytosis may have ben stimulated by the cold treatment. 
Ammonium chloride at a concentration of 20mM was found to fully
inhibit proteolysis and pinocytosis. Inhibition was readily
12 5reversible, with uptake and proteolysis of I-BSAj^ returning to 
approximately 90% of the control value within 9 minutes. This rapid 
recovery after inhibition was also reported by Livesey et al.(1980) 
and Seglen et al. (1979) in hepatocytes.
The properties of low temperature and NH^Cl (20mM) fulfilled the 
necessary requirements for this study, therefore these were employed 
to inhibit pinocytosis during the pre-incubation phase with 
leupeptin, their effects being reversed during the wash period before 
incubation with 125I-BSAf(J. However, the results obtained with low 
temperature were ambiguous since, in many cases, the rate of 
degradation of 12^I-BSAf(3 in the tissue incubated with leupeptin at 
low temperature was stimulated above that of the control tissue. 
Although no conclusion could be reached on the proportion of uptake 
of leupeptin occurring via pinocytosis, the mechanism of uptake of 
leupeptin did appear to be temperature dependent. Results obtained 
using ammonium chloride were more conclusive. Although in several 
experiments, the effects of NH^Cl proved to be not totally
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reversible, by expressing the rate of degradation of 125I-BSA,. as af d
percentage of that in the matched control tissue (incubated with or 
without NH^Cl in the absence of leupeptin) it was possible to assess 
the degree of inhibition given by the leupeptin in tissue incubated 
with both ammonium chloride and leupeptin or just leupeptin. The 
mean values of percentage residual degradative capacity for tissue 
treated with leupeptin alone was 57.7%, this increased to 73.4% for 
tissue incubated with leupeptin in the presence of NH^Cl. This 
sigjests that less leupeptin was able to enter the tissue to cause 
inhibition of proteolysis in the presence of the inhibitor of 
pinocytosls. However the specificity of action of both NH^Cl and 
low temperature towards pinocytosis as opposed to other possible 
membrane transport systems is not known. Low temperature reduces 
the fluidity of the membrane (which may affect entry of leupeptin by 
diffusion) and would affect any energy-requiring membrane transport 
such as active transport via a carrier. The mechanism of action of 
NH4C1 in the inhibition of pinocytosis is not known, but it is 
reported to affect cells in many ways (eg see Livesey et^  al., 1980? 
Seglen, 1983; Dean et al., 1984). It could therefore inhibit other 
membrane transport systems or affect the degree of inhibition given 
by leupeptin by causing it to be lost more rapidly from the tissue 
after uptake.
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Fig. 3.1 Effect of Leupeptin on the Time-Course of Release of TCA-soluble 
12SI-BSAfd Degradation Products
Tissue was pre-incubated with or without leupeptin for lh then 
rinsed and transferred to medium containing a trace quantity of 
125I-BSAf(J, with or without leupeptin as described in Section 3.2.1. 
The release of TCA-soluble radioactivity was monitored as described 
in Sections 3.2.1 and 3.2.2. The graph shows typical results.
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2 Recovery of Degradative Capacity Towards 
Following Exposure to Leupeptin
125I-BSAfd
After incubation with leupeptin (100 yg/ml, 45 min) tissue was
rinsed and incubated in substrate-free medium for various periods.
. . 125Tissue was then transferred to medium containing i-b s a ^,
and production of TCA-soluble radioactivity monitored as
described in Section 3.2.1 . Results are expressed as the
125I-BSA„ degradation ± standard deviation, fdmean rate of
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Fig. 3.3 Typical Time-Course of Release of TCA-soluble Radioactivity from 
Leupeptin-Treated Yolk Sacs Following Various Periods of Recovery
Yolk sacs were treated as described for Fig. 3.2. Results shown 
are typical time-courses of release of TCA-soluble radioactivity, 
from which the duration of the lag period (before onset of 
125I-BSAfd degradation) and the rate of I-BSAfd degradation 
could be determined.
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Fig. 3.4 Time-Course of Release of TCA-soluble Radioactivity from
Tissue Pre-incubated in Leupeptin at 25 ug/tnl for Various Periods
Tissue was pre-incubated with leupeptin (25 yg/ml) for various 
periods, then rinsed and transferred to leupeptin-free medium 
containing 125I-BSAfd. The release of TCA-soluble radioactivity 
was monitored as described in Section 3.2.1. Typical results
are shown.
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. 3..5 Time Course of Release of TCA-soluble Radioactivity from
Tissue Pre-Incubated in Leupeptin at 50 yg/ml for Various Periods
Details as for Fig. 3.4, except that leupeptin was present at 
a concentration of 50 ug/ml during pre-incubation.
___________________ Control (no leupeptin present during pre incubatic
j___________   | 10 min pre-incubation
__________________ a 20 min pre-incubation
_^________________ $ 30 min pre-incubation
„______________  h 120 min pre-incubation
_____ , 60 min pre-incubation
Fig. 3.6 Time-Course of Release of TCA-soluble R a d io a c t iv i t y  from_
Prp-Incubated in Leupeptin at 100 ug/ml for Various Periods
Details as for Fig. 3.4 except that leupeptin was present at a 
concentration of 100 ug/ml during pre-incubation
TC
A-
so
lu
bl
e 
ra
di
oa
ct
iv
it
y 
re
le
as
ed
 (
c.
p.
m.
/m
g 
pr
ot
ei
n)
• Control (no leupeptin)
U  Leupeptin (50 yg/ml)
^ Leupeptin (100 ug/ml)
Fig. 3.7a Comparison of the Time-Course of Release of TCA-soluble Radioactivity 
from Yolk Pre-Inoubated for lOmin with Leupeptin at
50 and 100 ug/ml
Tissue was pre-incubated for the given time with leupeptin at 
50 and 100 yg/ml, then rinsed and re-incubated in leupeptin-free 
medium containing 125I-BSAf<J. Release of TCA-soluble radioactivity 
was monitored as described in Section 3.2.1. Typical results are
shown.
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Fig. 3.7b Comparison of the Time-Course of Release of TCA-soluble
Radioactivity from Yolk Sacs Pre-Incubated for 30 min with 
Leupeptin at 50 and 100 yg/rol
Details as for Fig. 3.7a
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Fig. 3.7c Comparison of the Time-Course of Release of TCA-soluble
Radioactivity from Yolk Sacs Pre-incuhated for 60 min with 
Leupeptin at 50 and 100 yg/ml
Details as for Fig. 3.7a
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Fig. 3.7d Comparison of the Time-Course of Release of TCA-soluble
Radioactivity from  Yolk Sac P r e - I n cuba ted  f o r  120 min wi t h  
L e u p e p t in  a t  50 and 100 ug/wl
Details as for Fig. 3.7a
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Fig. 3.7e Comparison of the Time-Course of Release of TCA-soluble
Radioactivity from Yolk Sacs Pre-Incubated for 180 min with 
Leupeptin at 50 and 100 ug/ml
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X Leupeptin at 25 pg/ml present during pre-incubation
A  Leupeptin at 50 pg/ml present during pre-incubation
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The rate of release of TCA-soluble radioactivity from tissue 
treated with leupeptin as described in Fig. 3.4, 3.5 and 3.6 was 
determined, and expressed as a percentage of that of control 
tissue that had not been exposed to leupeptin. The mean (* standard 
deviation) percentage inhibition of release is given for each 
concentration of leupeptin for various pre-incubation periods.
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o Ammonium chloride (20mM) present during pre-incubation 
0 Ammonium chloride (20mM) and Leupeptin (100 ug/ml) present
■ Leupeptin (100 ug/ml) present during pre-incubation 
Fig. 3.9a,b Time-Course of Release of TCA-soluble Radioactivity from Tissue 
Pre-incubated with Leupeptin in the Presence and Absence 
of Ammonium Chloride
Yolk sacs were pre-incubated for 45min with leupeptin in the 
presence and absence of ammonium chloride. The tissues were then 
rinsed and re-incubated with 125I-BSAfd, and the release of TCA- 
soluble material monitored as described in Section 3.2.1. Each 
diagram represents results from a single experiment.
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■ Leupeptin (100 yg/ml) present during pre-incubation
Fig. 3.9c,d Time-Course of Release of TCA-soluble Radioactivity from
Tissue after Pre-Incubation with Leupeptin in the Presence 
and Absence of Aminoniuin Chloride
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Details as for Fig. 3.9a,b
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on the Subsequent Rate of Degradation of I-BSAfd
Yolk sacs were pre-incubated with leupeptin for 60 min
at the temperatures indicated. A control, in which no^leupeptin
was present during preincubation, was maintained at 37°C.
The tissues were rinsed and reincubated with I“88* «  at 
The rate of release of TCA-soluble radioactivity from 
leupeptin-treated tissue was determined, and calculated as 
a percentage of that from control tissue. The points 
represent the mean values ± standard deviation at each
temperature.
Table 3.1
Degradation of 125I-BSAi;J after lh Pre-incubation With or Without 
Leupeptin (100 yg/ml)
Tissue was incubated as described in Section 3.2.1. The rate of
125I-BSA degradation was determined from the slope of the linear 
fd
portion of the time-course of release of TCA-soluble radioactivity.
Experiment Rate of 125I-BSAf(J Degradation 
(cpm/min/mg yolk-sac protein)
' Pre-incubated with ^ Pre-incubated without'
leupeptin (100 ug/ml) leupeptin
i 25.8 56.7
ii 12.4 53.2
iii 16.2 67.5
iv 14.2 77.2
V 21.1 47.7
vi 40.9 86.7
vii 19.2 58.0
viii 13.2 39.9
Residual
Degradative
Capacity
45.5
23.3
24.0
18.4
44.2
47.2
33.1
33.1
Table 3.2
Effectiveness of Inhibitors of Pinocytosis in the Rat Yolk Sac
Table 3.2a
The effect of inhibitors on the rate of uptake and degradation of
125I-BSA_, was fa monitored by measuring the rate of
release of
TCA-soluble 125I-BSAfd degradation products, as described in
Section 3.2.6a. Results are from typical experiments.
Rate of 125I-BSA,. Degradation Remaining
Inhibitor Concentration Pinocytic/(cpm/min/mg yolk-sac protein) Degradative
Inhibitor present Control Capacity (%)
Ammonium 20mM 0.0 21.0 0.0
Chloride
Low 6°C 0.87 86.7 1.0
Temperature
Methylamine 20mM 1.4 21.4 6.5
Rotenone io-5m 23.2 86.7 26.8
Ammonium lOmM 14.9 32.8 45.5
Chloride
EGTA ImM 40.1 39.9 100.5
Sodium 20 ug/ml 24.1 21.4 112.6
Fluoride
Table 3.2b
The effect of inhibitors on the Endocytic Index of JV5I-BSAf(J was
determined as described in Section 3.2.6a.
125KT of I-BSA-, Remaining
Inhibitor Concentration
fd Pinocytic Activity
Inhibitor present Control
Monensin 50mM 67.7 262.4 25.8
High K*Na+ 10.9 288.3 3.8
Table 3.3
Reversibility of Inhibitors of Pinocytosis in the Rat Yolk Sac
Tissue was incubated in the presence of inhibitors of pinocytosis for Ih 
then rinsed and/or allowed to recover in the absence of inhibitor, and 
re-incubated in medium containing 125I-BSAf(J, as described in 
Section 3.2.6b. Typical rates of release of TCA-soluble radioactivity 
from inhibitor-treated and control tissue are given together with the 
percentage recovery.
Inhibitor Cone. Rinse/Recovery 
Period (min)
Rate of Release of TCA-Soluble 
Radioactivity (cpm/min/mg protein)
Recovery
(%)
Inhibitor-treated Control
Ammonium Q 53.9
56.4 95.6
20mM 7 35.9 73.0Chloride 12 28.5
30 14.6 14.9
98.0
6°C 4 121.0
86. 7 140.5
Low
Temperature 15°C
20°C
4
4
41.5
36.4
44.2
44.2
93.9
82.4
Methylamine 20mM 12 0.0
26.9 0.0
Rotenone io-5m 30 44.3
86.7 51.1
EGTA* 5mM 12 0.0
44.2 0.0
EGTA 5mM 12 28.3
80.7 35.1
*Calcium chloride (5mM) present during re-incubation period
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4.1. INTRODUCTION
The rate of uptake of a substrate can give a good indication of 
the mode of entry of the substrate into cells. If the uptake 
kinetics of the test substrate are similar to those of a standard 
marker substrate, whose uptake kinetics and mode of uptake are 
established in the same cell type, uptake of the test substrate is 
probably, but not definitely, by the same mechanism (Roberts et al., 
1977; Shaw & Dean, 1980). In some cases, competition between 
substrates and saturability characteristics can also be used to 
identify the mode of uptake, eg amino acid active transport systems
(reviewed by Christensen, 1984).
In the previous chapter inhibition of Intra-lysosomal 
proteolysis was used as the basis of a semi-quantitative method of 
estimating the rate of entry of leupeptin into the lysosomal system 
of yolk-sac cells. However, a number of assumptions and problems 
are encountered in trying to derive a rate of uptake of leupeptin 
from such data (see Chapter 3 for further discussion).
An established method of comparing the rates of uptake of 
different substrates that are captured by pinocytosis is to compare 
values of the Endocytic Index (E.I.), which is equivalent to the 
volume of external fluid (yl) whose substrate content has been 
internalized by unit quantity of tissue (mg protein) per unit time 
(h); Williams et a h  (1975a). Rates of uptake expressed in this way 
may be compared regardless of differences in day-to-day specific 
radioactivity or method of detection of the substrate (eg Roberts et 
al., 1977, compared 125I-, 14C- and 198Au-labelled substrates).
The basal rate of uptake is given by the rate of capture of a 
marker that enters entirely by fluid phase pinocytosis. If the E.I. 
of a substrate is greater than that of markers for fluid-phase 
pinocytosis, the substrate may have an affinity for the plasma
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membrane (via binding to specific receptors or to non-specific 
adsorption sites) so that it is taken up both in the fluid-phase and 
bound to the internalized membrane (ie. adsorptive pinocytosis). An 
alternative possibility, available for small or lipophilic molecules, 
is that the substrate enters by passive diffusion or facil^itated or 
active transport. The net rate of uptake would then be a composite of 
the rate of pinocytosis and the rates of accumulation via other 
membrane transport systems. [A rate of uptake lower than that of 
fluid phase pinocytosis would not be expected because in yolk-sac 
tissue pinocytosis occurs continuously, thus substrate present in the 
extracellular fluid must enter the cell at the rate of fluid-phase 
pinocytosis (unless the agent modifies the rate of pinocytosis at 
tracer concentrations).)
Comparison of the uptake of leupeptin with that of markers of 
fluid pinocytosis would thus indicate whether uptake occurred at the 
same rate as fluid-phase pinocytosis or was accelerated as a result 
of either adsorption to the plasma membrane or uptake via additional 
membrane transport systems. Several such markers for fluid phase and 
adsorptive pinocytosis are known. These are all molecules that enter 
the cell by pinocytosis alone because they are either too large 
and/or too polar to enter by membrane permeation. In rat yolk sacs, 
125I-PVP has been used extensively? 14C-sucrose and certain 
preparations of colloidal (198Au) gold are also taken up in the fluid 
phase (Roberts et al., 1977).
Values of the rate of uptake obtained by measuring the substrate 
content of the tissue will not automatically give a true indicatio 
of the rate of entry of the substrate. Non-degradable macromolecular 
substrates entering the tissue by pinocytosis will remain trapped 
within lysosomes, therefore the rate of accumulation in the tissue 
of such a substrate is equivalent to the rates of capture by
pinocytoais (provided there us no appreciable loss via exocytosis). 
However, when degradable substrates enter lysosomes, they yield 
fragments that are able to pass out of the tissue (eg amino acids, 
mono-saccharides). The amount of substrate remaining within the 
tissue at any time will be less than the total amount that has been 
captured, as a result of loss by degradation. If the rates of 
uptake and degradation are equal (as would be the case when entry is 
the rate-limiting step) the net rate of accummulation will fall to 
zero and a steady-state concentration of substrate within the tissue 
will be observed (Williams et al., 1975b» Livesey & Williams, 1979).
A steady-state concentration could also be observed if the intact 
substrate was rapidly lost from the tissue by diffusion or membrane 
transport. Hence a linear time-course of accumulation of leupeptin 
would only be expected if inactivation, degradation or loss from the 
tissue occurred at rates far lower than the rate of uptake. If a 
steady-state concentration was observed, uptake followed by 
inactivation and/or loss by membrane permeation, may be 
responsible.
In this and subsequent chapters, attempts were made to determine 
the rate of accumulation of leupeptin in order to gain insight into 
its mode of uptake and intracellular fate.
The method used to detect leupeptin throughout this chapter is 
based on the original assay technique developed by Umezawa and 
co-workers (eg Aoyagi & Umezawa, 1975; Umezawa 6 Aoyagi, 1977), and 
has been successfully modified by others (eg Beynon al., 1981).
It relies on the ability of leupeptin to inhibit the proteinase 
trypsin. To estimate leupeptin concentrations, the rate of hydrolysis 
of the trypsin substrate benzoyl-arginine-p-nitroanilide (BAPNA) was
determined in the presence and absence of a sample of leupeptin.
The percentage inhibition observed could be used to estimate the
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amount of leupeptin present by comparison with a standard curve (see 
Beynon et al., 1981). The leupeptin content of tissue that had been 
incubated with leupeptin, and the medium in which the tissue was 
incubated, can both be analysed by this method; hence uptake could be 
calculated in terms of yl/mg protein. The assay detected the content 
of active leupeptin in the whole tissue, (not just that within 
secondary lysosomes, c.f. Chapter 3). Inactivated or fully degraded 
leupeptin would not be detected by this method.
The method of assay was also used to follow the fate of 
leupeptin in yolk-sac tissue. There are many reports in the 
literature that suggest leupeptin may be inactivated within tissue 
(see Section 4.4.5. for further comment), therefore leupeptin was 
incubated with a yolk-sac homogenate in an attempt to characterise 
its inactivation.
Rapid inactivation of leupeptin (in the incubation medium) by 
proteolytic enzymes released from the yolk sac could cause a rapid 
depletion in the concentration of leupeptin to which the yolk-sacs 
were exposed. The stability of leupeptin in "conditioned" medium (ie 
medium in which tissue had been incubated) was therefore also 
investigated.
In summary the main aims of the experiments reported in this 
chapter were to investigates-
i) The rate of accumulation of active leupeptin by yolk-sac tissue.
ii) The rate and pH optimum of degradation of leupeptin by yolk-sac
homogenates.
iii) The stability of leupeptin in "conditioned" medium.
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4.2. MATERIALS AMD METHODS
I. MATERIALS
Equipment
Spe ctrophotomete r 550 S UV/VIS Spectrophotometer.
Perkin Elmer, Beaconsfield, Bucks U.K. 
Sample chamber thermostatted to 25°C.
Chart Recorder Hitachi Ltd. Model 056-1002. 
Tokyo, Japan.
All other equipment as described in Chapter 2 
Reagents
BAPNA N-Benzoyl-DL-Arqinyl-4-Nitroanilide,
Sigma Chemical Co., Poole, Dorset, U.K.
1mq/ml solution, dissolved in hot (approximatly 
90°C) distilled water.
Triethanolamine Triethanolamine hydrochloride (0.2M), adjusted
buffers to pH 7.8 with sodium hydroxide, containing 
calcium chloride (20mM).
Trypsins 50pg/ml solution,dissolved in HC1 acidified water,
pH 3.
All other reagents as described in Chapter 2
II. METHODS
4,2.1. Leupeptln Assay: Inhibition of Trysln-Mediated
Hydrolysis of N-Benzoyl-DL-Arginyl-4-Nitroanillde (BAPNA)
The method used was developed from that of Beynon et al. (1981), 
which was itself based on a general trypsin inhibitor assay described 
by Fritz et al. (1974). The rate of hydrolysis of BAPNA was measured 
by following the increase in extinction at 405nm caused by the 
release of p-nitroaniline. By determining the degree of inhibition 
of this reaction by known amounts of leupeptin, a standard curve 
relating percentage remaining activity to the amount of leupeptin 
present in the assay mixture could be constructed, and unknown 
concentrations determined. Maximal inhibition of trypsin occurred 
within 3 min therefore it was possible to use the same reaction 
mixture to measure the rate of hydrolysis both before and after 
addition of leupeptin. The reaction was performed as follows.
A freshly-prepared solution of BAPNA (0.5ml) was mixed with 
triethanolamine buffer (1.9ml) in a cuvette, and allowed to 
equilibrate to 25°C in a water-bath. Trypsin solution (0.1ml) was 
added to initiate hydrolysis and the increase in extinction at 405nm 
followed for about one minute using a thermostatted spectrophotometer 
coupled to a chart recorder. An aqueous solution (10pl) containing 
leupeptin was then added to the cuvette with mixing, and the new, 
inhibited rate of reaction monitored, after about 5min, for a further 
5min. The slopes of the chart recorder traces were determined to find 
the rates of the uninhibited and inhibited reactions, and the 
percentage residual activity in the presence of leupeptin calculated.
A standard curve was prepared by using the data obtained on 
adding known concentrations of leupeptin to the assay mixture. A p 
of percentage residual activity against amount of leupeptin added (pg
per 1Opl) was non-linear. A good straight-line transformation of the 
data was obtained when the probit value of the percentage residual 
activity was plotted against the log of the amount of leupeptin 
present. (A discussion on the use of probit plots and probit analysis 
can be found in Beynon et a U ,  1981 and in Colquhoun 1971.) The 
probit value of the percentage residual activity was found from 
appropriate tables.
4.2.2. Accumulation of Leupeptin
The method used to incubate the tissue was similar to that 
described in Section 2.6., except separate yolk sacs were used to 
determine the uptake of 125I-PVP. Hence, two sets of flasks were set 
up, each flask containing three yolk sacs. One set of flasks 
contained medium (6.3ml) and leupeptin (0.7ml, 0.5 or 1.0mg/ml) and 
the other set contained medium (6.3ml) and I PVP (0.7ml,
20-40(jg/ml). In some experiments, the medium contained 10% calf 
serum. At intervals over 3 to 9h, one flask from each set was 
removed from the water bath. Tissue and medium from the leupeptin 
incubation were prepared for assay as described in Section 4.2.4. 
Tissue and medium from the 125I-PVP uptake experiment were assayed as 
described in Section 2.4a. The quartlty of tissue-associated leupeptin 
was calculated as described in Section 2.7d., and the quantity of 
tissue-associated 125I-PVP was calculated as described in Section
2.7a.
4.2.3. inactivation of Leupeptin by a Yolk-Sac Homogenate
A yolk-sac homogenate was prepared as follows. Yolk sacs were 
dissected as described in Section 2.2., then rinsed immediately in 
ice-cold saline (1%). The tissue was then homogenized in ice-cold 
distilled water (usually 0.5ml per yolk sac) using a Potter
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Elvehjem-type Teflon-on-qlass homogenizer. The homogenate was then 
centrifuged at 1000g for 10 mins to pellet any cellular debris, and 
the supernatant used for the inactivation investigations.
In experiments in which the effect of pH on leupeptin 
inactivation was studied the buffers used were:-
pH 3.5 and 4.5 0.01M Acetic acid/NaOH
pH 5.5 and 6.5 0.01M Maleic acid/NaOH
pH 7.5 0.01M Na2HP04/NaH2PO4
pH 8.5 and 9.5 0.01M Glycine/NaOH
All buffers were made up to an ionic strength of 0.15M with sodium 
chloride. For these experiments equal volumes (0.5ml) of homogenate- 
supernatant and buffer were mixed in a 3ml disposable tube, then a 
sample of leupeptin (50pg) added. The tubes were kept at 37°C
for 15-5 then any reaction stopped by the addition of TCA (5% w/v 
solution, 1ml) to precipitate the homogenate protein. The 
TCA-soluble fraction (obtained by spinning down the precipitate at 
1000g, 20min) was assayed for active leupeptin. In control 
experiments the stability of leupeptin in the various buffers was 
examined by using the same method except distilled water replaced the 
homogenate.
In one experiment to determine the optimum pH of degradation, 
mercaptoethanol was included in the incubation mixture. Homogenate 
(0.5ml), buffer (0.4ml) and mercaptoethanol (20mM, 0.1ml) were mixed, 
then the experiment continued as described above. Control incubations 
to find the stability of leupeptin over the pH range also included 
mercapethanol. An additional control, to assess whether the buffers 
gave sufficient buffering capacity to maintain the desired pH, was 
also carried out. Because of the low volumes involved, a pH meter 
could not be used, therefore the pH profile of ^^I-BSA^ degradation 
was monitored. Incubations were carried out as for the leupeptin
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incubations, except 125I-BSAf(J (0.5ml) was added instead of 
leupeptin. The percentage of TCA-soluble material generated after 
incubation was then determined.
In experiments to determine the time-course of leupeptin 
inactivation, buffer at pH 7.5 was used for all incubations» the 
reaction was stopped after periods of incubation between 2-30h.
4.2.4. Preparation of Samples for Leupeptin Assay
4.2.4a Incubated Yolk Sacs Yolk sacs that had been incubated
with leupeptin and rinsed were homogenised in 1.5ml distilled water 
in a Teflon-on-glass Potter-Elvehjem type homogeniser. The 
homogenate was then sonicated (30sec) to disrupt any vesicles and 
centrifuged at 1000g for 20min, to remove cellular and tissue debris. 
The supernatant was used directly in the leupeptin assay. Samples 
(2 x 0.1ml) were removed for protein assay. The remaining supernatant 
and pellet were digested in sodium hydroxide (1M, 5ml) and also 
assayed for protein content as described in Section 2.3, using 0.05ml 
digest per assay.
4.2.4b Incubation Mediun Medium containing leupeptin was diluted 
with distilled water to give a leupeptin concentration of about 
25pg/ml before assay.
4.2.4c Honogenate In experiments in which the degradation of 
leupeptin by yolk-sac homogenate was measured, the incubation was 
terminated by precipitating the homogenate proteins with an equal 
volume of aqueous TCA (5% w/v). The TCA-soluble fraction was assayed 
for leupeptin. The effect of addition of a sample of leupeptin-free 
TCA (10yl, 2.5%w/v) to the leupeptin assay reaction mixture was 
determined as a necessary control.
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4.2.5. Stability of Leupeptin In Conditioned Medium
In some experiments, flasks in which yolk sacs had been 
incubated, and from which the yolk sacs and a sample of medium had 
been removed, were returned to the water bath and incubated for the 
remainder of the experiment. A further sample of medium was then 
removed, for assay of its leupeptin content. Any difference between 
this value and the leupeptin content of the medium sampled at the 
time of removal of the yolk sacs would be attributable to 
inactivation by enzymes released from the yolk sacs into the 
incubation medium, ie by "conditioned" medium.
4.2.6 Recovery of Leupeptin from Yolk Sac
Known ¿mounts of leupeptin (5-30yg) were added to aliquots 
(1.5ml) of a yolk-sac homogenate (one freshly-dissected yolk sac per 
1.5ml of distilled water). The homogenate was then prepared for 
assay as described in Section 4.2.4a and 4.2.4c, ie either the 
homogenate was centrifuged at 1000g for 20min and the supernatant 
assayed for leupeptin immediately, or aqueous TCA (0.5ml, 10%w/v) was 
added to the whole homogenate and the TCA-soluble fraction assayed 
after pelleting the precipitated protein. The results were plotted 
as u g  leupeptin detected against u g  leupeptin added.
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4.3. RESULTS
4.3.1. Standard Curve for BAPNA-Based Leupeptln Assay
The standard curve covered a ranqe of leupeptin concentrations 
from 1-100pg/ml (ie the amount of leupeptin added in the 10pl sample 
ranged from 0.01 to 1.0|jg.) The plot of percentage inhibition of 
trypsin against amount of leupeptin present (vig) is given in 
Fig. 4.1. The plot was approximately linear for additions of up to 
0.2pg leupeptin (equivalent to 75% inhibition) then became very 
curved at higher inhibitor concentrations. However, when a plot of 
the probit value of the percentage residual activity against the log 
of the amount of leupeptin present was used as the standard curve, 
the plot was substantially linear (Fig.4.2). Linear regression 
analysis gave a correlation co-efficient of -0.997.
Although it was possible to detect inhibition of trypsin by very 
small amounts of leupeptin (ie below 0.02pg), results were not very 
reproducible at these concentrations. Large differences in degree of 
inhibition were produced by only very slightly different 
concentrations of leupeptin. (This could be anticipated from the 
steep slope of the inhibition curve. Fig. 4.1., at low leupeptin 
concentrations.) Conversely, at high concentrations of leupeptin 
(above 0.2yg in 10yl) only small differences in the deqree of 
inhibition occurred even with fairly large changes in the amount of 
leupeptin present. (A change from 0.5 to 1.0jig gave a difference of 
only 5.4% inhibition, compared with a change from 0.01 to 0.5yg which 
gave a difference of 76.3%.)
Whenever possible, assays were carried out using 0.02-0.2pg 
leupeptin in the 10pl sample (ie 2-20pg/ml). This corresponds to a 
range of percentage inhibition from 20-80% (compared with 0.01-1.0pg 
which corresponds to 10-95% inhibition). Samples below 2pg/ml (0.02ug
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in 10uX) were assayed at least three times in an attempt to minimize 
experimental error.
Possible sources of error in the assay method include:-
i) Errors in dispensing small volumes of reagents, especially the 
10yl sample of leupeptin solution.
ii) Errors in the measurement of the rate of reaction from the 
chart recorder trace. Error in measurement of the gradient (in terms 
of mm increase along the absorbance axis per unit time) was greatest 
when extreme (ie very fast or very slow) rates were observed. (This 
occurred particularly at high concentrations of leupeptin for which 
the absorbance increased very little with time.) Error may also 
arise during estimation of the slope. Although reaction conditions 
were optimized to give linearity, some curvature was apparent in the 
uninhibited reaction, and curvature was a feature of the trace 
immediately after the addition of leupeptin, before enzyme-inhibitor 
association was complete. This effect led to a slightly subjective 
choice of the portion of the time-course from which the gradient was 
derived.
iii) Formation of small crystals of the BAPNA substrate on the 
sides of the plastic cuvette during the reaction. (This occurs 
particularly if the cuvette is scratched or unclean? Fritz et^  al., 
1974). BAPNA is not very soluble in water (the substrate stock 
solution required warming to 90°C to dissolve the BAPNA) and crystals 
readily formed on rough surfaces, causing erratic noise in the 
trace. The same type of interference would be caused by cloudy 
reaction mixtures (caused by, for example, dust within the cuvette). 
Precautions were therefore taken to keep reactants and cuvettes as 
dust-free and as clean as possible by passing solutions through 
filter paper and regularly cleaning cuvettes in detergent.
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4 .3 .2 . Effect of Trichloroacetic Acid (TCA) on Rate of Hydrolysis 
of BAPNA
The standard curve was determined using leupeptin solutions in 
water, but many of the samples assayed for leupeptin content were 
solutions in 2.5% TCA. The activity of trypsin has a strong 
dependence on pH, therefore it was necessary to establish whether the 
addition of 2.5% TCA alone would affect the pH of the assay buffer 
and hence decrease the rate of the reaction. When 10yl of the 
solution of 2.5% TCA was added to the reaction mixture in place of a 
leupeptin sample, the rate observed did not differ from the initial 
rate, before the sample was added. In ten observations, the mean 
rate in the presence of TCA was 100.1 i 5% (S.D.), relative to the 
initial rate.
4.3.3. Stability of Leupeptin Solutions on Storage
A preliminary investigation was carried out to determine whether 
samples of leupeptin dissolved in medium 199 and 2.5% TCA were stable 
on storage. No detectable loss of leupeptin occurred over a period of 
2Oh at 4°C for a solution of leupeptin in medium 199 containing 10% 
serum and little loss occurred for a solution of leupeptin in 2.5%
TCA (the amount of leupeptin decreased by 0.02yg, from 0.18 to 
0.16(jg, over the 20h period). It was therefore considered acceptable 
to store experimental samples at -20°C before assay. After storage 
at -20°C for several days, no decrease in leupeptin content was 
detectable.
4.3.4. Recovery of Leupeptin From Yolk-Sac Tissue
In order to determine the total amount of active leupeptin 
present within the yolk-sac or in a yolk-sac homogenate, it was 
necessary to establish how much of the leupeptin present was
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detectable by the trypsin-based assay. The method is given in 
Section 4.2.6. Fig. 4.3. shows results obtained when either 
homogenate supernatants or the TCA-soluble fraction of a homogenate 
which contained a known quantity of leupeptin was added to the assay 
reaction mixture. TCA-precipitation gave complete recovery over the 
range of leupeptin concentrations used. However, recovery of
leupeptin from the homogenate supernatant was dependent on the concentration of
leupeptin added to the homogenate. At low concentrations recovery was
rather poor, at about 0.64pq leupeptin/mq yolk-sac protein only 35%
of the added leupeptin could be detected. The percentage recovery
increased with increasing concentration, reaching 65% for leupeptin
added at a concentration of about 2pg/mg (see Fig. 4.3). In
experiments in which homogenate supernatants were used to find the
leupeptin content of the tissue, it was therefore necessary to use
the recovery curve (Fig. 4.3) to convert the observed leupeptin
content of the sample to the actual leupeptin content.
4.3.5 Accumulation of Active Leupeptin
Only active leupeptin could be detected by the 
trypsin-inhibition method, therefore these results gave values of 
tissue-associated leupeptin rather than uptake.
Several different incubation conditions were investiged to try 
to find optimal conditions for uptake so that the amount of leupeptin 
in the tissue would be within the detection limits of the assay 
method. These were with leupeptin at 50(jg/ml in medium with or 
without 10% calf serum, and at 100yg/ml in medium without serum.
Incubation periods were up to nine hours, to allow maximal 
tissue-association of leupeptin. The results are given in Table 4.1.
For each experiment a matched control was performed, in which the 
uptake of 125I-PVP was measured. Uptake of 125l-PVP was linear
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throughout the 9h incubation period, with a mean Endocytic Index of 
2.65ul/mg/h in the absence of serum. Tissue levels of leupeptin did 
not increase progressively over the 9h period. The results from each 
experiment were very scattered. No real differences were apparent in 
the net uptake (pl/mg) after incubation under the different 
conditions of serum and leupeptin concentration. The amount of 
leupeptin detected in the 1Opl sample of homogenate varied between 
0.012 to 0.029pg (ie approximately 1-3gg/ml). These values were at 
the lower limit of detection, where the amount of error was greatest, 
(see Section 4.3.1). The values of tissue-associated leupeptin so 
determined are therefore not necessarily accurate.
4.3.6. Depletion of Leupeptin from the Medium
4.3.6a During Incubation The concentration of leupeptin in the 
medium at the start of an uptake experiment was compared with that 
after various periods of incubation with yolk sacs. No general trend 
of loss of leupeptin with increased incubation time was apparent. 
Likewise, little change was observed in the concentration of 
radioactivity (c.p.m.) in the 125I-PVP control medium over the same 
incubation period, indicating that medium depletion through uptake 
and retention within the yolk sac would not be detectable if uptake 
of leupeptin occurred by fluid-phase pinocytosis alone. (A rate of 
uptake of 2.§pg/mg/h, as observed for 125I-PVP, would lead to a loss 
of 4% of the substrate from the medium via uptake and retention in 
the yolk sac. If uptake of leupeptin occurred at the same rate as 
fluid-phase pinocytosis, a loss of only 2 or 4ug leupeptin ie 
0.3-0.6ijg/ml, for medium concentrations of 50 and 100pg/ml 
respectively, would be expected. This would not be detectable by the
assay.)
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4.3.6. b In Conditioned Medium The stability of leupeptin in 
conditioned medium at 37°C was measured by comparing the amount of 
leupeptin in the medium at the time of removal of the yolk sacs with 
that observed up to 7h later. If any loss of activity occurred 
leupeptin may have been partially/fully degraded and/or inactivated 
by enzymes that had been released from the yolk-sac tissue. However, 
no such loss of leupeptin was observed. (Indeed in many samples the 
amount of inhibitory activity in the medium appeared to increase with 
time. This must reflect error in the assay.)
4 .3 .7 . Optimal pH for Inactivation of Leupeptin by Yolk-Sac 
Homogenate
The amount of leupeptin detectable after incubation at various 
pH's with a yolk-sac homogenate was compared with that remaining 
after incubation at the same pH for the same period, but in buffer 
alone. TCA was added to both homogenate and buffer incubation 
mixtures before assay of the remaining leupeptin content. The 
difference between these values was a measure of the amount of 
homogenate-mediated leupeptin inactivation that occurred at each 
particular pH. The amount of leupeptin remaining at each pH in the 
absence of homogenate was a measure of the stability of leupeptin at 
that pH and formed a necessary control experiment.
Figure 4.4. shows the stability of leupeptin over the pH range
3.5 to 9.7 in homogenate-free buffer solutions. The amount of 
leupeptin remaining decreased gradually on increasing the pH from
3.5 to 8.5, by which pH only about 70% of the leupeptin added 
remained after incubation. After incubation at pH 9.5 the activity 
of leupeptin was greatly reduced, therefore homogenate-mediated 
inactivation at this pH was not investigated.
The amount of homogenate-mediated inactivation at each pH#
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expressed as yg leupeptln inactivated per mg homogenate-protein per 
hour, is shown in Fig. 4.5. The rate of inactivation at each pH for 
the different experiments varied considerably. This may have been 
caused by differences in the activity of enzymes in each individual 
homogenate. In one experiment, mercaptoethanol was included in the 
incubation mixture. Mercaptoethanol provides free thiol groups, which 
are essential for the activity of cysteine proteinases, therefore it 
was thought that the presence of excess of this cofactor may lead to 
an increased enzyme activity and possibly increased leupeptin 
inactivation. However, results show that less inactivation occurred 
compared with results obtained using a similar concentration of 
homogenate protein, suggesting that free thiol groups are not an 
essential cofactor and may even prevent leupeptin inactivation. In 
most experiments, the amount of leupeptin inactivated did not change 
much with pH, which suggests that leupeptin inactivation occurred 
over a wide range of pH. Either the enzyme responsible had a very 
broad pH optimum or a number of enzymes, with different pH optima but 
similar kinetic characteristics, were responsible for inactivation.
An alternative possibility was that the buffering capacity of 
the dilute buffers used was insufficient to maintain the desired pH 
over the incubation period. The pH profile of degradation of 
125I-BSAfd was measured to check for differences in proteolytic 
enzyme activity in buffers of different pH. Degradation of 
125I-BSAfd is known to have a sharp pH optimum at pH 4 (Livesey & 
Williams, 1979). The pH profile of 125I-BSAfd degradation togothor 
with matohod loupcptin inaefeivatien rooulto, ohtainod uuing »hn nnmo 
eondltlono of huffee, hemegewate and lwoubatien is shown in
Fig 4.6. The degradation of 125I-BSAfd showed a pH optimum at 4.5, 
even though inactivation of leupeptin in the same buffers did not
This suggests that the buffershave any obvious pH dependence.
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maintained the expected pH throughout the experiment, and that the 
yolk-sac enzymes were still active on homogenization and incubation 
at 37®C.
4 .3 .8 . Time-Course of Inactivation of Leupeptin by Yolk-Sac 
Homogenate
Aliquots of homogenate in phosphate buffer, pH 7.4, were 
incubated with either 20 or 50pg leupeptin. At various intervals 
between 2 and 30h, TCA was added to one aliquot and the TCA-soluble 
fraction assayed for leupeptin. The amount of leupeptin remaining was 
subtracted from that added to find the amount of leupeptin 
inactivated. This was expressed as ug/mg yolk-sac protein. Fig. 4.7 
shows a graph of the pg leupeptin inactivated per mg yolk-sac protein 
against time (h).
Homogenate-mediated inactivation of leupeptin occurred in all 
experiments. However, the rate of inactivation differed greatly 
between experiments. Several differences in experimental conditions 
were used. The homogenate preparations were different for each 
experiments the homogenate in experiment 1 was used fresh, whereas 
those used for experiment 2 and 3 had been stored at -20 C for 5 and 
1 week(s) respectively. Also 50ug of leupeptin was added to the 
homogenate in experiment 1, compared with 20pg in experiments 2 and 
3. The maximum rate of inactivation, observed in experiment 1, was 
approximately 0.2pg/mg protein/h. Only comparatively slight 
increases in the amount of leupeptin inactivated were observed over 
the 22h incubation period in experiments 2 and 3.
The effect of variation of protein concentration on the rate of 
inactivation was determined. The same homogenate was used for all 
incubations, so that the effects of inter-homogenate variation were 
avoided. Different concentrations were achieved by diluting the
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homogenate with distilled water. 50yg of leupeptin was added to each 
aliquot of diluted homogenate, and the reaction stopped after 20h 
incubation at 37°C. The results, expressed as ug leupeptin 
inactivated per h against mg yolk-sac protein per h are shown in Fig.
4.8. The increase in inactivation with increasing protein 
concentration indicates that inactivation was homogenate-mediated.
The graph is non-linear, which suggests that the rates of 
inactivation observed in the previous experiment, in which different 
homogenate protein concentrations were used, cannot be compared.
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4.4. DISCUSSION
Inhibition of Trypsin Catalysed Hydrolysis of BAPNA as a
Method of Detection of Leupeptln
Enzyme inhibition assays have been used for many years to 
estimate the amount of inhibitor in a system. Several important 
conditions must be met if such assays are to be strictly 
quantitative. Many of these relate to the stability of the 
enzyme-inhibitor complex.
The interaction between leupeptin and trypsin is reversiblef 
even though a covalent bond forms between the two. Kuramochi et al. 
(1979) propsed a mechanism in which the association of leupeptin with 
trypsin occurs in two steps; first a non-covalent Michaelis complex 
forms, then a hemiacetal adduct
The dissociation constant for the formation of the Michaelis complex 
(K1 ) was 1.24 x 10-3M which implies a fairly low affinity between 
inhibitor and enzyme. The overall dissociation constant (Kp) for the
Conditions necessary for the quantitative analysis of inhibitors
Ideally a linear relationship should exist between the degree of 
inhibition observed and the amount of inhibitor added. (This re 
a stoichiometric interaction between enzyme and inhibitor.) However, 
all enzyme-inhibitor interactions are non-linear at high inhib
OH
Trypsin-O-i-Leupeptin
H
Hemiacetal Adduct
association of leupeptin with trypsin was found to be about 2 x 10 ®M
at pH 8.2.
have been described by Bergmeyer (1984), and are briefly summarized
below.
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concentrations; linearity may cease anywhere between 70 and 95% 
inhibition. Preferably only the linear part of an enzyme-inhibitor 
interaction curve is used for calculation of the amount of inhibitor 
present. A linear relationship is not so important when an 
experimentally-determined standard curve is used for the calculation 
of the amount (jig) of inhibitor present. Any non-linearity in the 
interaction is apparent in the standard curve and is therefore taken 
into account when calculating the amount of inhibitor present. For 
the interaction between leupeptin and trypsin, the inhibition curve 
was non-linear beyond 75% inhibition, but the probit transformation 
of the standard curve was essentially linear over the whole range.
Another important consideration in any inhibitor assay is 
competition between the inhibitor and substrate for the active site 
of the enzyme. The interaction between inhibitor and enzyme should 
have a very much lower than the Kn, for the interaction between 
substrate and enzyme. If the is 103 to 10^-fold smaller than the 
competition can be ignored as effectively all the inhibitor will 
be bound to the enzyme. (An alternative means of overcoming any 
competition would be to set the enzyme concentration 10^  to 10^-fold 
higher than the of the inhibitor. However, this would have the 
attendant disadvantage of making the assay less sensitive to changes 
in inhibitor concentration.) The dissociation constant of the 
leupeptin-trypsin complex is 2 x 10“®M (Kuramachi et al.,1979) 
whereas the substrate BAPNA has a 1^ of 4.3x10 (Fritz et al.,
1974), therefore the difference in affinity for the enzyme should 
overcome competition. (The initial association reaction of leupeptin 
with trypsin has a K1 of 1.24 x 10-3M, therefore competition may 
occur initially, but the subsequent reaction of leupeptin to form a 
covalently-linked complex should ensure all inhibitor becomes bound 
to the enzyme.)
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The spectrophotometrlc method of leupeptin detection obeyed all 
the necessary conditions for inhibitor assays, therefore this assay 
was considered to be a potential method of determining quantitatively 
the leupeptin content of samples.
4.4.2. Estimation of Leupeptin Content of Media, Homogenates, etc 
The standard curve was determined using leupeptin dissolved in 
distilled water, therefore any change in sample composition had to be 
checked for its effects on the enzyme assay.
4.4.2a. TCA Results in Section 4.3.2. showed no change in the 
rate of BAPNA hydrolysis,- the triethanolamine buffer used for the 
assay appeared to maintain the optimum pH even after addition of the 
small volume of TCA solution.
4.4.2b. Medium 199 Phenol red, which is present in medium 199, 
has an absorbance peak at 557nm for pH qreater than 7• Addition of 
10yl of leupeptln-free, diluted medium 199 to the assay mixture did 
not affect the observed absorbance (at 405nm), or the rate of 
reaction.
4.4.2c Homogenate Addition of tissue homogenate (centrifuged to 
remove cell debris) was found to slightly decrease the observed rate 
of BAPNA hydrolysis. The rate was decreased to about 91% ± 3 
relative to the rate before any addition, corresponding to about 0.01 
Ug of leupeptin. This value was subtracted from any results from 
experiments in which homogenate that contained leupeptin was added to 
the assay system. The apparent decrease in rate of hydrolysis of 
BAPNA may have been caused by an increased turbidity of the assay 
solution (Fritz et al., 1974) or could have been caused by the 
presence of trypsin inhibitors within yolk-sac tissue. (To date no 
such inhibitors have been reported. )
Because the substrate BAPNA is not specific for trypsin, and can
3~
i3T
3>
i
88
be hydrolsed by enzymes likely to be present in the homogenate (eg 
cathepsin B), an increased rate of reaction after addition of the 
homogenate to the assay might be expected. However, no such increase 
was observed, either because the amount of homogenate enzymes was 
small in comparison to the amount of trypsin present in the reaction 
mixture (5pg) or because their pH optima were far lower than the 
assay pH of 7.8.
The recovery of leupeptin from a yolk-sac homogenate depended on 
how the homogenate was prepared for assay. Addition of the 
centrifuged homogenate directly to the assay reaction mixture 
resulted in a low recovery of leupeptin. However, when the homogente 
was precipitated with TCA total recovery was achieved; all leupeptin 
that had been added to the homogenate was detected in the TCA-soluble 
fraction. Clearly the untreated homogenate caused loss of leupeptin, 
by a mechanism which was not active in the presence of TCA. Possible 
mechanisms are described below.
i) Leupeptin binds tightly to its 'target' enzymes, some of which 
would be present in the homogenate (eg cathepsins B,(H), and L). 
Leupeptin bound to homogenate enzymes would not be detected in the 
assay, since leupeptin must bind to trypsin to be detectable. The 
proportion of leupeptin bound to homogenate enzymes or trypsin would 
depend on the of leupeptin for each enzyme at a pH of 7.8.
ii) Another possible sequestor of leupeptin could be the pelleted 
cell debris, which was not assayed. Leupeptin could become occluded 
by mechanical trapping within the pellet, or by binding to membranes, 
connective tissue, and other pelleted material. Since 
TCA-precipitation gave complete recovery, leupeptin must not become 
trapped in a pellet of denatured proteins, therefore mechanical 
trapping would probably not account for all of the sequestration of 
leupeptin.
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4.4.3. Tissue Accumulation of Leupeptln
The amount of leupeptin associated with the tissue was barely 
detectable by the BAPNA assay. The experimental values fell in the 
region of the standard curve that corresponds to high probit values, 
for which errors were relatively large. The incomplete recovery of 
leupeptin from the yolk-sac homogenate introduced additional sources 
of error, both in the conversion of the amount of leupeptin observed 
to the amount estimated to be present in the yolk sac, and by further 
lowering the amount of leupeptin available for detection. Thus only 
overall trends in the results rather than reliable quantitative data 
are available for discussion.
Firstly, there was no detectable progressive increase in the 
quantity of leupeptin that became associated with tissue on 
incubation with leupeptin. This lack of accumulation could suggest 
that there is loss of leupeptin from the tissue after uptake, since 
uptake of 125I-PVP continued progressively over the 9h incubation 
period. (Loss of leupeptin from the tissue could be caused either by 
inactivation of the inhibitor within yolk sacs, or by release of 
intact leupeptin from yolk sacs.)
Secondly, there was no detectable difference in the quantity of 
leupeptin associated with yolk-sac tissue that had been incubated 
with or without serum or at a leupeptin concentration of 50 or 
100ug/ml of medium (Table 4.1). However, the degree of scatter of 
results was such that no definite conclusions could be drawn.
The minimal rate of uptake of leupeptin would be that of 
fluid-phase pinocytosis. Lfctake via this route would be greatest at 
the higher concentration of leupeptin (100pg/ml) when serum was 
absent (since the rate of pinocytosis of 125I-PVP has been shown to 
he decreased in the presence of 10% serum; Forster S Williams, 1984). 
The rate of fluid-phase pinocytosis, given by the rate of uptake of
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the marker 125I-PVP, is about about 3(jl/mg/h in serum-free medium. 
Hence, assuming no loss from the tissue after uptake, a typical 
yolk-sac sample of 12mg protein would take up about 3yg of leupeptin 
by fluid-phase pinocytosis after 8h incubation in serum-free medium 
with leupeptin at a concentration of 100 ug/ml. This should give a 
concentration of leupeptin in the tissue homogenate of about 2yg/ml, 
which is only just within the detection limit. Hence, if uptake of 
leupeptin occurred only by fluid-phase pinocytosis, the time-course 
of accumulation over 3-9h would be very difficult to quantitate.
Overall, the results suggest that leupeptin associated with the 
tissue only slowly, and is possibly lost from the tissue after 
uptake.
4.4.4. Loss of Leupeptin from the Incubation Medium
Any progressive decrease in the amount of leupeptin in the 
incubation medium during incubation with yolk sacs would have serious 
implications on any attempts to quantitate accumulation by the 
tissue.
However, no overall decrease in the amount of leupeptin in the 
medium (either in the presence or absence of yolk-sac tissue) was 
observed. The lack of depletion from the medium indicates that 
leupeptin is stable at 37°C in medium 199 for up to 9h, and that it 
is not taken up rapidly and retained or degraded within the tissue 
(c.f. 125I-BSAf<J, williams et al., 1975b). Leupeptin must be resistant 
to inactivation by enzymes associated with the outer face of the 
plasma-membrane and by enzymes released into the bulk medium, (unlike 
the longer peptides: calcitonin, glucagon, insulin, and insulin 
B-chain; Livesey, 1978). Protection from degradation may be due to 
its action as an inhibitor of any such enzymes (in which case 
leupeptin would show an affinity for cell membranes) or because the
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blocked amino end and the aldehyde moiety at the carboxyl end lead to 
little affinity for such enzymes, and hence make it a poor substrate.
4 .4 .5 , Inactivation of Leupeptin by a Yolk-Sac Homegenate
The experiments described in Sections 4.3.7. and 4.3.8 show that 
enzymes present in a yolk-sac homogenate are capable of inactivating 
leupeptin. The mechanism of inactivation (eg t£*al degradation, 
oxidation/reduction of the essential aldehyde group) and the enzyme 
or enzymes responsible could not be identified from these results.
Many reports suggest circumstanial evidence to indicate that 
leupeptin may become inactivated , in vitro and in vivo. Effects on 
intact cells tend to be reversible over 24h after removal of 
leupeptin from the system, suggesting slow inactivation of leupeptin 
may occur within cells (although slow leakage from the cell or 
re-synthesis of inhibited proteases could also account for such 
observations). For example, autophagolysosomes, which accumulate in 
liver cells after administration of leupeptin, do not persist for 
longer than 24h (Furuno et al., 1982a; Henell & Glaumann, 1984; 
Ishikawa et al., 1983). Also Dunn & Aronson (1977) found that protein 
degradation was not inhibited when leupeptin was administered 24h 
before measurement of degradation began, and Knowles et al.(1981) 
suggested that the lack of progressive increase in degree of 
inhibition of proteolysis caused by leupeptin in yolk-sac tissue may 
be due to lack of accumulation of the inhibitor as a result of 
inactivation.
More direct evidence of inactivation of leupeptin is given by 
the work of R.J. Beynon and co-workers. Beynon et al. (1981) showed 
that leupeptin and chymostatln (another proteinase inhibitor derived 
from Streptomyces) were inactivated by mouse-liver homogenates. Some
of the characterisics of the enzyme or enzymes responsible were
established by carrying out inhibitor studies and by determining the 
pH profile of inactivation. Later (Brown & Beynon, 1983) it was 
shown that homogenates of many other tissues were capable of 
inactivating leupeptin. In order of decreasing ’leupeptinase' 
activity, tissues tested were:- gut mucosa, spleen, gut smooth 
muscle, lung, kidney, brain, heart, liver and skeletal muscle. For 
mice, the total body capacity for inactivation was calculated as 
750yg/24h. The subcellular distribution showed maximum activity in 
the cytosol, but high levels of activity were apparent in the 
microsomal and heavy particulate fractions. Place et al. (poster 
communication) isolated from rat liver two enzymes capable of 
inactivating leupeptin, and characterized one of these. This enzyme 
appeared to be a metallo-enzyme, that hydrolysed the Leu-Arginal 
bond. A total liver capacity for inactivation was propsed to be 8mg 
leupeptin per hour at 37°C, pH 7.5. Other evidence of inactivation 
is given by Tanaka (1983), who showed that leupeptin was metabolized 
after administration to rats either orally or intraveneously.
The finding that leupeptin was inactivated by a yolk-sac 
homogenate was therefore not unexpected. Attempts to further 
characterize the conditions that gave optimal inactivation proved 
inconclusive. The rate of inactivation differed greatly between 
experiments in which different homogenates were used, even though the 
method of preparation of the homogenate was similar. The amount of 
inactivation that occurred was shown to depend in a non linear 
fashion on the ¿mount of homogenate protein present, so preventing 
comparison of rates of inactivation in homogenates of different 
protein content. Furthermore, the rate of inactivation appeared to 
depend on the amount of leupeptin added initially, being greater 
50ug than for 20pg of leupeptin (Fig. 4.7).
Large differences in the rate of inactivation were also apparent
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in experiments in which the pH profile of inactivation was studied.
The low activity of the homogenate containing mercaptoethanol 
supports the results of Beynon et al. (1981), who also found that 
'leupeptinase' activity was inhibited by thiol agents. However, 
unlike the results reported in that paper, no pH optimum was observed 
for Inactivation of leupeptin by a yolk-sac homogenate. Possibly 
more than one enzyme in the yolk-sac homogenate was capable of 
inactivating leupeptin, each having a maximum rate at a different pH, 
or the enzyme capable of leupeptin inactivation was active over a 
broad pH range. 125I-BSAf(J was degraded, as expected, with a pH 
optimum of about 4, indicating degradation of this substrate was 
brought about by lysosomal enzymes, which were active under the 
conditions of assay.
Leupeptin was shown to lose activity on incubation in buffers of 
different pH, the rate of inactivation being greatest at pH 9.5. 
Possibly part of the structure essential for activity, namely the L 
configuration and aldehyde moiety of arginal, became changed at high 
pH. Racemization of the chiral centre of arginal was reported to 
occur slowly at room temperature at pH 8.0; 50% activity, ie total 
racemization, being achieved after 4 days (Umezawa S Aoyagi; 1977). 
Aldehyde groups are highly reactive and can undergo a variety of acid 
or base-catalysed reactions, eg. aldol condensation.
To summarise
This method of leupeptin assay was useful in obtaining a 
general impression of the uptake characterstics of leupeptin into 
yolk-sac tissue, but was insufficiently sensitive to permit 
quantitation of the small amounts of leupeptin associated with the 
tissue. The fact that only small amounts were observed within the 
tissue suggests slow uptake and/or rapid loss of leupeptin.
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Inactivation of leupeptin by yolk-sac homogenates also occurred, 
but no details of rate could be measured due to large variations 
between experiments. None of the homogenates showed any marked pH 
optimum for leupeptin degradation.
m
Fm
e
z
. :
t n
3
r
a
Pe
rc
en
ta
ge
 I
nh
ib
it
io
n 
of
 T
ry
ps
in
100
80
60
60
20
0 2 0.6 0.6 0.8 1-0
Amount of leupeptin added to assay (yg)
The percentage of enzyme activity that remained when various 
amounts of leupeptin were added to a fixed amount of trypsin 
was determined as described in Section 4.2.1. The points
iThe percentage of trypsin activity that remained in the presence 
of various amounts of leupeptin (determined as described in 
Section 4.2.2) was converted to its probit value using tables.
The mean probit values <± standard deviation) then plotted against 
the logarithm of each amount of leupeptin present to obtain a 
linear standard curve
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4.3 Recovery of Leupeptin from Yolk Sacs
Yolk sacs were prepared for assay of leupeptin content as 
described in Section 4.2.6. The graph shows the mean quantity of 
leupeptin detected in the homogenate and TCA-solubles against the 
amount added to the yolk-sac tissue
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Fig. 4.4 Stability of Leupeptin in Buffers of pH 3.5-9.5
for 15-5 h
Leupeptin (50 yg) was incubated with buffer^as described
in Section 4.2.3. The amount of leupeptin that remained after 
incubation was determined as described in Section 4.2.1. The 
graph shows mean values ± standard deviation at each pH.
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Fig. 4.
^  Protein concentration 2.7 mg/ml 
O  Protein concentration 2.8 mg/ml 
A  Protein concentration 4.77 mg/ml
A  Protein concentration 2.46 mg/ml, mercaptoethanol (2mM) presen
Leupeptin ( 5 0  ug> was added to yolk sac homogenate mixed
with buffers, as described in Section 4.2.3. The amount of leupeptin 
that remained after incubation was determined as described in Section 
4.2.1. The amount of homogenate-mediated leupeptin inactivat' 
calculated from the difference between the amount of leupeptin 
remaining after incubation in the presence and absence of homogenate 
protein, and expressed as yg inactivated per mg protein per hour.
Each plot represents results from a single experiment, carried out 
under similar conditions.
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Fig. 4.6 Degradation of 125I-BSA by Yolk Sac Homogenate over the 
pH range 3.5-9.7
125I-BSAfd (approx. 50 yg) was incubated with yolk-sac homogenate
mixed with the buffers described in Section 4.2.3 and incubated
125at 37°C for 15-16h. The percentage of I-BSAf(J that was 
degraded at each pH was determined from the percentage of 
TCA-soluble radioactivity present at the end of incubation.
100'
Fig.
9 0
6 0
US
a
2-0'
3 .
TO 7 0  ‘3 0
Time (h)
• Exp. 1. Protein 4.2 mg/ml; Leupeptin 50 yg; fresh tissue
a Exp. 2. Protein 20 mg/ml; Leupeptin 20 yg; tissue frozen 5 week
^ Exp. 3. Protein 9.7 mg/ml; Leupeptin 20 yg; tissue frozen 1 wee.
.7 Time-Course of Inactivation of Leupeptin by Yolk-Sac Homogenates,
Leupeptin was incubated with yolk-sac homogenates as indicated. At 
various intervals TCA was added and the samples assayed for leupeptin 
as described in Section 4.2.1. The amount inactivated was calculated 
from the difference between the amount detected and the amount added, 
and expressed as yg leupeptin inactivated per mg protein. Each plot 
represents a separate experiment using slightly different incubation 
conditions.
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Fig. 4.8 Inactivation of Leupeptin by Different Concentrations of 
Yolk-Sac Homogenate Protein
A yolk-sac homogenate was diluted with phosphate buffer pH 7.5 
Leupeptin (50 vg) was incubated with samples of the diluted 
homogenate for 15.5h, then TCA (final concentration 2.5% w/v) 
added. The amount of leupeptin inactivated, calculated from 
the difference between the amount detected after incubation 
and the amount added was expressed as ug leupeptin inactivated 
per h, and plotted against mg protein present.
Table 4.1
125,Accumulation of active leupeptin and I-PVP
The accumulation of active leupeptin under various incubation conditions
125was determined as described in Section 4.2.2. Uptake of I-PVP was 
monitored under the same conditions, as a control. Results shown are 
from individual experiments.
Experiment I II
Incubation 10% calf serum 0% calf serum
Conditions Leupeptin at Leupeptin at
50 vig/ml 50 yg/ml
Substrate Leupeptin 125I-PVP Leupeptin 125I-PVP
Accumulation 3h 3.3 6.0 3.1 8.4
(ul/mg protein) 
after
incubation 5h 5.3 11.7 3.5 11.3
period
7h 3.6 15.7 3.9 14.7
9h 2.9 26.7 3.6 18.5
Endocytic
Index
3.25 1.69
Ill
0% calf serum 
Leupeptin at 
100 yg/ml
, 125,Leupeptin I-PVP
3.7 17.5
1.7 26.9
2.48
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5.1. INTRODUCTION
The main aims of the experiments described in this chapter were 
essentially the same as those of Chapter 4, ie to compare the 
accumulation kinetics of leupeptin with those of markers, whose mode 
of uptake and intracellular fate are known, in order to establish the 
mechanism of uptake and the intracellular fate of leupeptin.
The results obtained usinq the BAPNA-based assay described in 
Chapter 4 sugqested that the quantity of active leupeptin within the 
tissue was low and did not increase over a 3-9h incubation period.
The small amounts of leupeptin within the tissue were impossible to 
assay accurately because the assay was not sufficiently sensitive. 
Thus little information could be obtained regarding the kinetics of 
leupeptin accumulation, preventing the suggestion of a possible mode 
of uptake of leupeptin.
The work reported in the present chapter used a more sensitive, 
method of leupeptin detection for which a fluorogenic substrate, 
carbobenzoxy-phenylalanyl-arginyl-7-aminomethylcoumarin 
(Z-Phe-Arg-AMC), was used instead of BAPNA as the trypsin substrate.
A maior advantage of fluorogenic substrates over chromogenic 
substrates is that, in general, it is possible to determine 
fluorescence with greater sensitivity than absorbance. [In 
fluorimet^jry the signal measured is a increase from zero intensity, 
when light is emitted during excitation, whereas for chromogenic 
measurements the absorbance signal is related to the ratio of 
intensity of incident and transmitted light (Allinger et al., 1976). 
This change in intensity will be small relative to the overall 
intensity of incident and transmitted light. For any measurement a 
small increase from zero is generally determined more accurately than 
a small decrease from a large 'standing' values.]
For trypsin assays, the AMC leaving group has an added advantage
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over the commonly-used chromophore benzoyl-Arg-nitroanilide (BAPNA) 
because it has been shown by Kanaoka et^  al^ ( 1977) that the amide 
link in benzoyl-Arg-aminomethylcoumarin is more susceptible to 
cleavage by trypsin than is that of BAPNA.
AmincCmethylcoumarin substrates also have many advantages over 
traditional fluorogenic substrates such as naphChylamides. 
7-Amino-4-methylcoumarin (AMC) is very highly fluorescent and can 
be detected at very low concentrations. (The maximum fluorescence 
intensity of AMC is approximately 14 times greater than that of 
naphthylamine). The fluorescence intensity of AMC does not change 
with pH over the range 4 to 7, whereas that of naphlhylamine shows a 
strong pH dependence. No toxic effects have been reported for AMC, 
unlike naphlhylamine which is classed as a potent carcinogen.
Although amincQnethylcoumarin substrates are, at present, more 
expensive than corresponding naphlhylamine or chromogenic substrates, 
the high cost is offset by the very small amounts required for 
detection in each assay.
Because very low concentrations of AMC can be measured, less 
trypsin was required in each assay to produce detectable amounts of 
AMC from Z-Phe-Arg—AMC. Hence the amount of leupeptin required to 
produce a measurable inhibition of the enzyme was also lowered (Fritz 
et al., 1974).
It was hoped that the decreased detection limit for leupeptin 
would enable the small amounts of leupeptin within tissue to be 
measured accurately. The amount of leupeptin within yolk-sac tissue 
after shorter periods of incubation with leupeptin could then be 
measured, to determine the initial rate of accumulation of intact 
leupeptin. The rate of accumulation was compared with the rate of 
uptake of 125I-PVP to assess whether uptake occurred by fluid-phase 
Pinocytosis. Further evidence was obtained by using an inhibitor of
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pinocytosis (ammonium chloride, 20mM) to establish whether 
accumulation of leupeptin was blocked.
Possible intracellular fate(s) of leupeptin were followed by 
measuring the loss of leupeptin from yolk sacs using a modification 
of the method originally described by Williams et al. (1975a). The 
standard method of measuring loss of a substrate from pre-loaded 
tissue is to monitor the appearance of the substrate in fresh 
suhstrate-free medium. However, in such experiments, only release of 
intact leupeptin would be detected; it would not be possible to 
monitor inactivation within the tissue followed by release of 
degradation products. Consequently, loss was followed by monitoring 
the amount of active leupeptin remaining within tissue that had been 
loaded with leupeptin, after various periods of re-incubation.
It was hoped to distinguish between loss of leupeptin activity 
occurring via lysosomal inactivation and via release of intact 
leupeptin, by assaying the re-incubation medium for leupeptin, and by 
using ammonium chloride (10mM) to inhibit proteolysis within the yolk 
sac. The effect of ammonium chloride on the loss of inhibitory
leupejtin from yolk sacs was therefore determined, and compared with
125its effect on both the release of I-PVP (which only occurs via 
exocytosis or cell death, Williams et al., 1975a) and the degradation
of 125I-BSAfd-
To summarise, the following were investigated using the 
Z-Phe-Arg-AMC-based leupeptin assay:-
i) The rate of accumulation of active leupeptin in yolk-sac tissue
125was compared with the rate of uptake of I-PVP.
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ii) The effect of ammonium chloride (20mM) on the accumulation of
125leupeptin (and I-PVP) was investigated.
iii) The rates of loss of leupeptin, 125I-BSAf(j, and 125I-PVP were 
measured, and compared with the rate of loss determined in the 
presence of ammonium chloride.
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5.2.
I. MATERIALS
Equipment
Fluorimeter
Chart Recorder
Reagents
Z-Phe-Arg-7-ÄMC
HEPPS Buffer
Trypsin
Leupeptin
MATERIALS AND METHODS
Model 3000 Fluorescence Spectrophotometer. 
Perkin-Elmer, Beaconsfield, Berks, U.K. Excitation 
wavelength 360 nm, emission wavelength 460 nm. 
Model 056-1002 Hitachi Ltd. Tokyo, Japan.
Code PB 13520.
Cambridge Research Biochemicals Ltd., Cambridge. 
Z-Phe-Arg-7-AMC was dissolved in DMSO (3mg/ml, 
4.75mM) to produce a stock solution, stored at 
-20°C. Stock solution was diluted 10p 1:2.5ml (to 
12pg/ml, 19)iM) in HEPPS buffer before use.
0.1M HEPPS, dissolved in distilled water, 
adjusted to pH 8.0 with NaOH (1M).
0.1mg/ml, dissolved in HC1 acidified water (pH 
3).
1mg/ml stock solution, dissolved in water. Added 
to yolk-sac incubations or diluted as necessary 
for use as standards in assay.
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125I-BSAfd Prepared as described in Section 2.1. A stock
solution of about 100ug/ml in medium 199 was 
prepared.
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II. METHODS
5.2.1. Carbobenzoxy-Phenylalanyl-Arginyl-7-Aminomethylcoumarin-Based 
Assay for Leupeptin
The method of assay was similar to that of the BAPNA-based assay 
and was suggested by Dr. R. Beynon, University of Liverpool 
(personal communication). The rate of trypsin-mediated hydrolysis of 
Z-Phe-Arg-AMC was monitored in the presence and absence of an aliquot 
of test solution containing leupeptin of unknown concentration. The 
percentage inhibition given by the leupeptin was then calculated and 
the corresponding concentration of leupeptin found from a standard 
curve of the probit of the percentage residual activity against the 
natural logarithm of the leupeptin concentration.
Experimental details differed slightly from the BAPNA-based 
assay. The amount of trypsin present in the assay was decreased by a 
factor of 10. Separate assay reaction mixtures were used to measure 
the inhibited and uninhibited rates. Trypsin and leupeptin were 
allowed to equilibrate together for at least two minutes before 
addition of the substrate, to allow complete association between the 
enzyme and inhibitor before initiating the reaction by addition of 
substrate. (This was necessary because association between enzyme 
and inhibitor was likely to be slower at the low concentrations used 
and because the hydrolysis reaction was measured over a shorter 
period. ) The uninhibited rate was measured after a similar 
'equilibration' period in the absence of leupeptini a number of these 
uninhibited reaction rates were determined throughout the 
experimental session.
Thus the assay was executed as follows:-
HEPPS buffer (1.5ml), trypsin (10|jl), and when appropriate the 
sample solution of leupeptin (20pl), were pipetted into a cuvette and
KEFA F UNlNP-r-cH-Y \ ir‘>r
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;
allowed to equilibrate for at least 2min at 25°C in a water bath. 
(Longer periods of equilibration did not affect the rate of 
reaction.) The substrate, Z-Phe-Arg-7-AMC (0.5ml), was then added, 
and the rate of hydrolysis monitored using the fluorimeter described 
in the Materials section. The rate of reaction was measured between 
20 and 80 percent deflection on the chart recorder, to standardize 
the choice of the portion of time-course used. (Standard curve 
assays for leupeptin concentrations above 1ug/ml were monitored 
between 20 and 50* deflection only.) The percentage residual activity 
for each sample was calculated from the mean of the inhibited rates 
(experimental samples were assayed at least in duplicate; standard 
curve samples were assayed from 3 to 10 times) and the mean of 
uninhibited rates determined at the same time as inhibited samples 
(generally assayed about 4 times per period). The appropriate probit 
value of this percentage was found from tables. The concentration of 
leupeptin corresponding to the percentage residual activity observed 
for the samples of unknown leupeptin concentration was then 
calculated. [In later assays the amount of reactants used were 
decreased by half to conserve substrate, so that the volumes used 
were:- buffer, 0.75ml; substrate, 0.25ml; leupeptin, 10pl; and 
trypsin, 10pl of a 0.05mg/ml solution. The decrease in volume did 
not affect the standard curve.]
Other ways of plotting the standard curve data, such as 
computer-fitted curves, were also assessed for convenience of use.
5-2.2. Accumulation of Active Leupeptin
The method used to study the accumulation of active leupeptin 
was as described in Section 2.6. It was necessary to check whether 
the presence of leupeptin affected uptake of 125I-PVP when uptake of 
both substrates into the same yolk sac was measured. A control in
¡CEELE UNIVERSITY UE/J-r
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which accumulation of leupeptin and uptake of 125I-PVP was determined 
in separate yolk-sac incubations was performed as described in 
Section 4.2.2. The effect of an inhibitor of pinocytosis (ammonium 
chloride, 20mM) on accumulation of leupeptin was determined.
Ammonium chloride (0.7ml, 200mM in distilled water) was added to 
medium (4.9ml) and yolk sacs incubated in this medium for at least 
15min before the addition of leupeptin (0.7ml) and ^2^I-PVP (0.7ml) 
to initiate the incubation. The experiment was then continued as 
described in Section 2.6. In one experiment, low temperature was 
used to inhibit pinocytosis. The experiment was performed as 
described in Section 2.6 except the yolk sacs were incubated at 5°C.
5.2.3. Preparation of Samples for Leupeptin Assay 
5.2.3a. Yolk-Sac Tissue Many different methods of preparing 
tissue for assay of leupeptin content were tested for suitability (eg 
efficiency of disruption of tissue, recovery of leupeptin and 
technical ease of execution). These methods are described in 
Appendix 2. The following method of tissue preparation was used for 
all experiments reported in this chapter. Yolk sacs (3 per sample) 
were homogenised in 0.1% Triton X-100 (1ml), in a hand-held 
ground-glass-on-ground-glass homogenizer. (Similar results were 
obtained when yolk sacs were homogenised in distilled water then the 
homogenate sonicated for 30sec.) The total volume of homogenate was 
noted. A sample of homogenate (0.5ml) was mixed with an equal volume 
of TCA (5% w/v), the precipitated protein separated by centrifugation 
( lOOOg, 20min), and the volume of the TCA-soluble fraction noted.
This TCA-soluble fraction was used in the assay of the leupeptin 
content of the tissue. The remaining tissue homogenate was made up 
to 5ml with NaOH(1M) and assayed for protein content and for
radioactivity as described in Sections 2.3. and 2.4a.
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5.2.3b Medium Two of the aliquots of medium that were removed 
from the incubation flask (see Section 2.6.) were assayed for
aliquot was diluted with distilled water so that the leupeptin 
concentration fell within the range of the standard curve, and assayed 
for active leupeptin.
The amount of leupeptin recovered from incubated yolk-sac tissue 
was estimated by adding a known amount of leupeptin to intact, 
unincubated tissue then preparing the tissue for assay as described 
in Section 5.2.3a. The leupeptin content of the tissue was
a solution of 10% calf serum (heat inactivated) was also measured. 
In some recovery experiments a solution of a mixture of peptides
the yolk sac instead of Triton x-100 (0.1%), before addition of leupeptin 
and homogenization, in order to try to displace leupeptin from any 
non-specific peptide-binding sites in the homogenate.
5*2.5. Loss of Leupeptin from Pre-Loaded Yolk-Sac Tissue
Yolk sacs were incubated for 3h with leupeptin (10Opg/ml) and 
125I-PVP (2-4yg/ml) to load the tissue with these substrates. All 
tissue was then removed from the flasks and rinsed in three changes 
of fresh, gassed, warm medium (approximately 10ml each). Samples (3 
x 1ml) of the loading medium were reserved for assay of leupeptin and 
radioactivity content, as described in Section 5.2.3b. The rinsed 
yolk sacs were transfered to flasks containing fresh, gassed, warm 
medium (7ml) (keeping together throughout the procedure the sets of 
three yolk sacs that were incubated in the same flask during the
125I-PVP radioactivity as described in Section 2.4a. The remaining
5.2.4. Recovery of Leupeptin
expressed as a percentage of that added. Recovery of leupeptin from
determined using the Z-Phe-Arg-AMC-based assay and the observed value
(Gly-Tyr and Tyr-Arg, each at a concentration of 1mg/ml) was added to O
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loading phase of the experiment) and re-incubated for up to 5h.
After re-incubation for a set period, the yolk sacs (three per flask) 
were removed and rinsed in cold 1% saline, then stored together at 
-20°C prior to preparation for assay of leupeptin and 125I-PVP 
content, as described in Section 5.2«3a. One set of three yolk sacs 
was not re-incuhated, but instead was used (after rinsing) to 
determine the initial leupeptin content of the tissue after loading. 
In some experiments samples of re-incubation medium (3 x 1ml) were 
also reserved for assay of 125I-PVP radioactivity. The amount of 
active leupeptin remaining within the yolk sac after re-incubation 
was calculated in terms of pi of medium whose contained leupeptin had 
been captured per mg protein and compared with that present in yolk 
sacs that had not been re-incubated. The difference betwen the two 
was expressed as a percentage of leupeptin lost:-
%Leupeptin
lost
Amount present (pl/mg) _ Amount present (ul/mg) 
after loading after re-incubation
Amount present (pl/mg) after loading
The amount of ^2^I-PVP released into the re-incubation medium was 
also expressed in terms of pl/mg, and checked for correlation with 
the amount lost from the tissue.
The effect of an inhibitor of lysosomal proteolysis, ammonium 
chloride (10mM), on the loss of leupeptin and ^^I-PVP from yolk sacs 
was determined. The experimental procedure was as described above 
except that ammonium chloride was added to the re-incubation medium 
ah a final concentration of 10mM.
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5.2.6. Loss of ^^I-BSA^ from Yolk-Sac Tissue
In the experiment described in Section 5.2.6., loss of leupeptin 
was compared with the loss of a non-degradable substrate, I-PVP, 
which can only be lost from the tissue by exocytosis and/or cell 
death. It was considered necessary to compare the loss of leupeptin
< ncwith that of a degradable substrate, I-BSAf(j. Tissue was loaded 
with 125I-BSAf(J by a method similar to that used in Section 5.2.6.
Yolk sacs were incubated (2 per flask) in medium 199(6.0ml) and 
125I-BSAf(1 stock solution( 1.0ml) for 3h then rinsed in three changes 
of warm medium and re-incubated in flasks containing fresh, warm, 
gassed medium 199 (7ml). At intervals up to 5h, duplicate samples 
were taken by removing the 2 yolk sacs from a flask, rinsing them in 
three changes of cold 1% saline and digesting them separately in NaOH 
(1M, 5ml). Aliguots of the digest were analysed for radioactivity 
and for protein content. The effect of ammonium chloride (10mM) on 
the loss of ^^I-BSA^ from yolk-sac tissue was determined by 
including ammonium chloride in the re-incubation medium.
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5.3. RESULTS
5.3.1. Standard Curve for Z-Phe-Arg-7-AMC-Based Leupeptln ftssay 
The standard curve for this assay covered a range of leupeptin 
concentrations between 0.1 and 50yg/ml (ie 0.001 to 0.5yg leupeptin 
per assay). This corresponded to approximately 10% to 99% 
inhibition. The concentration of leupeptin in the yolk-sac samples was 
usually between 0.1-2.0yg/ml, any samples found to be above this 
range were diluted with distilled water to approximately 1.0yg/ml and 
re-assayed. (Incubation medium was routinely diluted 100-fold before 
assay.) This allowed the middle portion of the standard curve to be 
used, corresponding to 10 to 70% inhibition. A plot of 'percentage 
inhibition' against 'concentration of leupeptin in the test solution 
added to the assay (yg/ml) is shown in Fig. 5.1. The graph is 
non-linear, suggesting that association between leupeptin and trypsin 
was non-stoichiometric at these low concentrations (Bergmeyer, 1984, 
see also Chapter 4).
The standard curve was transformed into a linear form by 
plotting the probit of the percentage residual activity against the 
natural log of the concentration of leupeptin in the test solution.
This plot is shown in Fig.5.2. The degree of scatter about the mean 
value of probit percentage residual activity for each concentration 
of leupeptin was generally greatest at the higher and lower 
concentrations. [Probit values give the best linear transformation 
when the percentage values are close to 50% (Colquhoun, 1971), hence 
the very high and low percentage residual activity given by the 
extreme concentrations of leupeptin would not necessarily be expected 
to fall exactly on the line of best fit.]
An attempt was made to fit a curve to the non-probit-transformed data using 
curve-fitting programs in a package written for the GEC 4080 computer 
at Keele, and a curve-fitting program written for use on the
KEELE U
N
N
ERSiTY U
B
ilK
r
108
1906A/7600 computer at Manchester. The standard curve data were 
plotted in terms of percentage residual activity against either 
leupeptin concentration (pg/ml) or natural log of the leupeptin 
concentration. The computer-fitted curves that most closely fitted 
the data are shown in Figs. 5.3, and 5.4. A major disadvantage of 
the computer-fitted curves was the difficulty in converting observed 
percentage residual activities to the corresponding values of 
leupeptin concentration. No convenient means of determining values 
from such curves was available (other than estimation by eye, which 
would be both inaccurate and time-consuming). Since the 'fit* of the 
computer-fitted curves did not differ greatly from that of the 
probit-transformed straight-line plot, it was decided to use the 
linearized standard curve to calculate the leupeptin content of the 
experimentally derived samples.
For reasons that are not understood, the uninhibited rate of 
reaction tended to increase over each experimental session. Measured 
in terms of centimeters deflection across the chart recorder per 
minute, the rate would increase by up to 10% over the entire session 
(lasting up to 8 hours). It was therefore necessary to monitor the 
uninhibited rate several times throughout the session, and use a mean 
value of those uninhibited rates determined at approximately the same 
time as the assays containing leupeptin, when calculating the 
percentage residual activity.
Although the uninhibited reaction proceeded linearly over the 
period of monitoring, the assays containing leupeptin tended to give 
a non-linear trace. The rate of reaction slowed slightly with 
increasing time. The decrease in reaction rate over the period of 
monitoring may have been partly attributable to a decrease in 
temperature during the reaction. [The assay mixtures in the cuvettes 
were equilibrated together in a water-bath at 25°C, and the substrate
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and buffer solutions were stored at this temperature also. However, 
the fluorimeter was not thermostatted, therefore the temperature of 
the assay mixture may have dropped over the period of monitoring, 
particularly since small assay volumes were used. The ambient 
temperature of the room in which the fluorimeter was housed differed 
over the entire series of experiments, from about 15°C to 22°C.]
5.3.2. Recovery of Leupeptin
The chosen method of preparation of yolk-sac tissue for use in 
these experiments gave better recovery of leupeptin than other 
methods tested. However, the recoveries obtained using the 
homogenization and TCA precipitation method as described in Section 
5.2.3a, were not ideal. Unlike the corresponding results in the 
BAPNA-based method, full recovery was never achieved and the amounts 
recovered (expressed as a percentage of the amount added) were very 
variable. A plot of percentage recovery against amount of leupeptin 
added to the tissue is shown in Fig.5.5. The amount recovered when 
5pg of leupeptin was added varied between 1.3pg to 3.4pg, 
corresponding to 26 to 68% recovery.
The percentage recovered did not seem to depend either on the 
amount of leupeptin added to the tissue (mean percentage recovery on 
addition of 5pg leupeptin was 47.6% (n=12) whereas on addition of 
20)ig and 30yg leupeptin, recovery was 56.8% and 38.8%, respectively), 
or on the concentration of homogenate protein present before TCA 
precipitation. When leupeptin was added to a 10% solution of 
heat-inactivated calf-serum the percentage recovery was greatly 
increased, possibly as a result of a glycoprotein trypsin inhibitor 
present in the serum, which may be incompletely precipitated by TCA. 
It was hoped that addition of an excess of other small peptides might 
increase the recovery of leupeptin by displacing leupeptin from any
110 ;
non-specific binding sites on the homogenate macromolecules before 
precipitation. However, the presence of Gly-Tyr and Tyr-Arg had no 
effect on the observed recoveries. Manipulation of the tissue and 
homogenate (eg transfer of small volumes of homogenate from 
homogenizing vessel to the vial to which the TCA was added and 
measurement of small volumes of homogenate and TCA-solubles) 
producing incomplete recovery of the total volumes involved may have 
contributed to the poor recovery.
The results were too scattered to construct a calibration curve 
from which the amount of leupeptin likely to be present within yolk 
sacs incubated with leupeptin could be determined from the amount 
detected in such yolk sacs (c.f. Chapter 4 results). It was 
therefore decided to use the overall mean value of the percentage 
recovery to give a correction factor. The percentage recovery did 
not vary greatly with the amount of leupeptin added, so the 
correction factor should be applicable to the entire range of amounts 
of leupeptin detected. The mean percentage recovery was 48.7% (n = 
30, standard deviation = 3.0) hence the correction factor used to 
adjust the leupeptin content of all yolk sacs in subsequent 
experiments was 2.05.
Addition of 10pl of TCA (2.5% w/v solution) or medium (diluted 
100-fold) to the assay did not affect the rate of the reaction.
5*3.3. Uptake of Leupeptin and 125I-PVP
Leupeptin accumulation was monitored in yolk sacs that were
incubated in medium containing leupeptin at concentration of 100 and
200pg/ml. in experiments performed at a leupeptin concentration of
100pg/ml, ^25j_pyp wag aig0 present in the medium, and uptake of 
125_I-PVP was monitored simultaneously in these yolk sacs to determine 
the rate of fluid-phase pinocytosis. Uptake of ^2^I-PVP and
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accumulation of leupeptin (at an extracellular concentration of 
100pg/ml) is shown in Fig. 5.6 and accumulation of leupeptin at 
200pg/ml is shown in Fig. 5.7. Results (corrected for recovery) are 
expressed as the mean ± S.D.
5.3.3a. Uptake of ^25I-PVP Since the experimental design 
involved incubating the yolk sacs with both leupeptin and 125I-PVP it 
was necessary to check whether the presence of leupeptin had any 
effect on the rate of uptake of 125I-PVP. [The presence of 12^I-PVP 
does not affect the rate of uptake of other molecules taken up by 
pinocytosis (Roberts et al., 1974), and is unlikely to affect any 
other membrane transport process since it does not bind to the cell 
membrane and is non-toxic. It was therefore considered unlikely that 
uptake of leupeptin would be affected by the presence of 125I-PVP.] 
Little difference was observed between the rate of uptake of 125I-PVP 
measured in the presence and absence of leupeptin (100yg/ml). The 
Endocytic Index in matched experiments was 3.51pl/h/mg yolk-sac 
protein in the absence of leupeptin and 3.44pl/h/mg in the presence 
of leupeptin.
5.3.3b Accumulation of Leupeptin After the tissue had been 
incubated with leupeptin (100pg/ml) for 1h the observed concentration 
of leupeptin in the TCA-soluble fraction of the homogenized yolk sac 
(uncorrected for recovery) was about 1 yg/ml, which was within the 
detection limit. The results obtained using leupeptin at a 
concentration of 200yg/ml were very scattered hence results can only 
be interpreted partially. Results obtained using leupeptin at a 
concentration of lOOpg/ml were considerably less scattered, the 
standard deviation ranging from 0.86 to 2.23 at each point.
At both concentrations, the amount of leupeptin within the 
tissue reached a steady-state, when no further accumulation of the 
active inhibitor occurred. This steady-state was reached after about
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3h with leupeptin at lOOyg/ml. The tissue was still pinocytically, 
and hence metabolically, active after these times (as shown by the 
continued linear uptake of 125I-PVP up to 8h) indicating that the 
lack of accumulation was unlikely to be caused by the cessation of 
pinocytosis or active transport. The most likely explanation is that 
uptake of leupeptin continued throughout the incubation period, but, 
as time progressed, the leupeptin was lost from the tissue at the 
same rate as its entry. (Further experiments were carried out to 
investigate loss of leupeptin from yolk sacs loaded with leupeptin.) 
The steady-state concentration (corrected for recovery) of active 
leupeptin within the tissue was about 1.25 and 2.0pg/mg yolk-sac 
protein for leupeptin at concentrations of 100 and 200gg/ml medium, 
respectively.
The initial rate of accumulation of leupeptin at 100pg/ml (over 
the first 3h) can be compared with that of the fluid-phase pinocytic 
marker 125I-PVP. These rates were very similar, suggesting that 
leupeptin may possibly enter the tissue by pinocytosis, like
125i-p v p.
The effect of an inhibitor of pinocytosis on accumulation of 
leupeptin was determined. A plot of uptake of leupeptin (100pg/ml)
IOCand JI-PVP in the presence of ammonium chloride (20mM) is shown in 
Fig 5.8. Uptake of 2^^I-PVP was strongly inhibited, indicating that 
pinocytosis had been abolished by the ammonium choride. No 
accumulation of leupeptin within the tissue occurred, suggesting that 
uptake of leupeptin was also inhibited. The degree of inhibition was 
similar to that observed for 125I-PVP. Since ammonium chloride is 
thought to affect tissue-processes other than pinocytosis, an attempt 
was made to monitor accumulation of leupeptin using an alternative 
inhibitor, low temperature. No leupeptin was detected in the tissue 
(by this method of assay) after incubation for up to 8h at this
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temperature. Uptake of 125I-PVP was also very strongly Inhibited. 
(Tissue levels were only just detectable by y-counting; results not 
shown).
5.3.4. Loss of Active Leupeptln from Pre-Loaded Yolk-Sac Tissue
Tissue was loaded by incubating with leupeptin (lOOpg/ml) and
125I-PVP for 3h, (thus achieving the maximum, steady-state 
concentration of leupeptin within the tissue) then re-incubated in
substrate-free medium for up to 5h. The amounts of leupeptin and 
125I-PVP lost from yolk sacs, expressed as a percentage of that 
present in yolk sacs immediately after loading, are shown in Fig.
5.9. [The percentage of ^2®I-PVP lost from yolk sacs correlated well 
with the percentage detected in the medium, therefore only loss from
the tissue will be discussed here.] For most experiments, the loss of 
125I-PVP was only monitored in yolk sacs that had been loaded with 
both leupeptin and 12®I-PVP (ie loss of both substrates was monitored
40Csimultaneously) but in one experiment loss of I-PVP was also 
monitored in separate yolk sacs that had not ben exposed to 
leupeptin, to check whether the presence of leupeptin within the 
tissue affected the rate of loss of ^2^I-PVP. No difference was 
observed between loss of 12^I-PVP in the presence and absence of 
leupeptin.
Very little 12^I-PVP was lost from the tissue during 
reincubation (approximately 5%). Since 125I-PVP can only be released 
from the tissue by exocytosis and/or cell lysis (Williams et^  al., 
1975a) the results indicate that these processes did not occur to any 
great extent during the 5h re-incubation period. In contrast, 90% of 
the active leupeptin was lost from the tissue after about 3h 
reincubation, hence 85% of the loss must have been caused either by 
inactivation of leupeptin within the tissue or by release of intact
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leupeptin by a mechanism other than exocytosis/cell lysis.
The steady-state concentration of leupeptin after the 3h loading 
incubation period was about 1.25yg/mg yolk-sac protein (see Section
5.3.3.). Hence, assuming a total of about 12mg protein per yolk-sac 
sample (which is a typical mass for a set of three yolk sacs), the 
90% loss of leupeptin corresponds to 13.5pg leupeptin. An 
approximate rate of loss of leupeptin over the first 3h of 
re-incubation can thus be calculated as 0.375jig leupeptin/mg yolk sac 
protein/h.
If the loss of leupeptin activity from the tissue was caused 
only by release of intact leupeptin from the tissue, the final 
concentration of active leupeptin in the re-incubation medium would 
have been about 2yg/ml, which is well within the detection limits of 
the assay. However, when an attempt was made to assay the 
re-incubation medium, little or no active leupeptin was detected.
5.3.5. Effect of Ammonium Chloride (IQmM) on Loss of ^^I-BSAPt,, 
125I-PVP and Active Leupeptin from Pre-loaded Yolk-Sacs
Ammonium chloride (10mM) was included in the re-incubation 
medium to inhibit lysosomal proteolysis, and hence inhibit the 
hydrolysis of degradable substrates within the lysosomes of the 
pre-loaded yolk sacs. This would inhibit loss of such a substrate 
from the tissue.
The results obtained when the tissue was loaded with I-BSA^ 
and re-incubated in the presence and absence of ammonium chloride 
(10mM) are shown in Fig. 5.10; these are typical of results for 
proteins. In the absence of ammonium chloride, ^ 5 i_bsAj^ is rapidly 
lost from the tissue over the first hour of re-incubation. Only 
about 65% of the ^^I-BSA^ was lost, no further loss occurred over 
the remainder of the 5h re-incubation period. (Similar results were
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also observed by Livesey (1978) and may possibly be caused by
125I-BSAf(j remaining associated with the yolk sac in the 
intercellular spaces, where it is not degraded.) When ammonium 
chloride was present in the re-incubation medium both the rate and 
amount of '“ I-BSAfd loss were lowered. A maximum of about 45% was 
lost from the tissue, and the steady-state was only reached after a 
2h re-incubation period. These results indicate that the presence of 
10mM ammonium chloride in the re-incubation medium was sufficient to 
inhibit hydrolysis of ^^I-BSA^^; the undegraded protein remained 
trapped within the yolk-sac lysosomes.
The effects of ammonium chloride on the loss of both leupeptin
and 125I-PVP (measured simultaneously) are shown in Fig. 5.11.
Ammonium chloride had no effect on the amount of I-PVP lost from 
the tissue, indicating that exocytosis and cell death were unaffected 
by the inhibitor. (It also suggests that the permeability of the 
cell membranes towards this large substrate, mean mol. mass = 40,000, 
was unchanged.) The observed effect of ammonium chloride on the loss 
of leupeptin from the yolk sacs was unexpected. Loss of leupeptin 
was accelerated, virtually all leupeptin was lost from the tissue 
within one hour. The rate of loss was calculated to be about 1.25pg 
leupeptin/mg yolk sac protein/h. This increase in the rate of loss 
could not be attributed to increased exocytosis or cell death, and it 
occurred even though proteolysis was inhibited under the same 
conditions.
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5.4. DISCUSSION
5.4.1. Trypsin-Mediated Hydrolysis of Z-Phe-Arg-7-AMC 
as a Method for Assay of Leupeptln
In this assay the detection limit for leupeptin was lowered by 
decreasing the amount of trypsin in the reaction mixture, so that 
less leupeptin was required to achieve an observable inhibition. The 
readily-hydrolysed substrate and the highly fluorescent reaction 
product allowed the reaction to be monitored using this lower enzyme 
concentration. The major advantage of the assay was that it enabled 
the very small amounts of leupeptin present within the yolk-sac 
tissue to be detected quantitatively. Accumulation of leupeptin 
could therefore be monitored and compared with the uptake of a marker 
molecule.
However, a number of problems were encountered when using this 
assay method. (Some of the practical problems and means of 
overcoming themwere discussed in the results section). An important 
drawback was that of incomplete recovery of leupeptin from yolk-sac 
tissue. Several different methods of preparing tissue for assay were 
tested in an attempt to improve the recovery (see Appendix 2). 
However, even using the method that gave the best recovery (ie TCA 
precipitation), only about 50% of leupeptin added to the tissue in 
control experiments was detected, and this value was variable. The 
reason for the poor recovery was not identified. Possibly leupeptin 
became bound to proteins in the yolk-sac homogenate and was 
co-precipitated with them on addition of TCA. Since addition of 
dipeptides did not improve recovery, any such putative binding sites 
must be fairly specific for leupeptin. (Experiments conducted to 
test whether leupeptin became appreciably bound to a yolk-sac 
homogenate are discussed in Chapter 6).
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Another potential problem associated with the method was that 
the Kjh for the association of trypsin with Z-Phe-Arg-7-AMC was not 
known, hence it was not possible to predict whether competition 
between the substrate and leupeptin would occur. (Ideally the for 
the interaction between an inhibitor and enzyme should be 10^- to 
1 0^-fold smaller than the for the substrate-enzyme interaction, 
see Section 4.4.1). The standard curve was non-linear, suggesting 
that the interaction between leupeptin and trypsin was 
non-stoichiometric, as would be expected if competition did occur. 
However, the inhibition observed in samples of unknown leupeptin 
concentration were compared with those observed in a standard curve 
for which the concentrations of leupeptin were known. Any 
competition between substrate and inhibitor would occur in both 
standard curve and experimental sample, and would thus not affect the 
conversion of the observed percentage inhibition to a quantity (nq) 
of leupeptin.
5.4.2. Discussion of Experimental Results Obtained Using 
the Z-Phe-Arg-7-AMC Based Leupeptin Assay
Only intact leupeptin can be detected by this enzyme assay, 
therefore the observed rate of entry of leupeptin corresponds to the 
rate of accumulation of intact, active leupeptin, rather than the 
total rate of uptake.
The results in Fig.5.6 show that accumulation of leupeptin 
occurred at approximately the same rate as fluid-phase pinocytosis, 
suggesting that this is probably the main route of entry. However, 
as it was possible that the net rate of accumulation observed was 
less than the true rate of uptake, additional routes of entry could 
not be entirely ruled out.
Further evidence for fluid-phase pinocytosis being an important
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mode of entry was given by the results from experiments in which 
pinocytosis was inhibited by ammonium chloride or low temperature.
In such experiments, tissue accumulation of leupeptin was inhibited 
to the same extend as fluid-phase pinocytosis. However, the mechanism 
of action of ammonium chloride as an inhibitor of pinocytosis is not 
established and several additional effects in yolk sacs are well 
documented (Livesey et al., 1980). It is therefore possible that the 
inhibition of leupeptin accumulation in the presence of ammonium 
chloride may not have been caused entirely by an inhibition of 
pinocytosis. Likewise, the total inhibition of accumulation observed 
for tissue incubated at 5°C could have been attributed both to 
inhibition of pinocytosis and/or to other membrane immobilizing 
effects. Nevertheless, ammonium chloride and low temperature would 
not be expected to totally inhibit any passive diffusion across the 
cell membrane, therefore the strong inhibition of accumulation of 
leupeptin afforded by these agents suggests that passive diffusion is 
not a major route of entry for leupeptin into yolk-sac tissue.
After 3h incubation with leupeptin (1OOpg/ml) (and about the 
same period with leupeptin at 200pg/ml) the amount of active 
leupeptin in the tissue reached a constant value of approximately 12 
or 10pl/mg yolk-sac protein for leupeptin at an extracellular 
concentration of 100 and 200pg/ral respectively. This corresponded to 
about 1.25 and 2.0pg leupeptin per mg of tissue protein.
The generation of a steady-state in which the quantity of 
leupeptin associated with the tissue remains constant in spite of 
continuing pinocytic capture, requires loss of active leupeptin from 
the tissue. This could arise either by inactivation and/or 
degradation within the tissue or by release of intact leupeptin from 
the tissue. The rate of loss must equal the rate of entry. This 
would occur if the rate of inactivation was not rate-limiting or if
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leupeptin left the tissue at the same rate as entry (as would he 
expected for non-concentrative passive or facilitated diffusion).
Loss of leupeptin activity from tissue that had been loaded with 
leupeptin (100ug ml) was monitored in an attempt to identify the mode 
of loss. The maximum rate of loss was calculated to be about 
0.37(yjg/mg yolk-sac protein/h, which is equivalent to 3.75gl/mg 
yolk-sac protein/h. This is similar to the rate of accumulation of 
leupeptin observed over the first three hours during the uptake 
experiment (ie about 3.44 pl/mg/h).
Leupeptin could not be detected in the re-incubation medium, 
which suggested that some or all of the leupeptin must have been 
inactivated rather than released from the tissue. [Only 5% of loss 
of substrate can be attributed to exocytosis and/or cell death, as 
indicated by the 125I-PVP results. This corresponds to 0.7ijpg 
leupeptin, giving a concentration in the re-incubation medium of 
0.1yg/ml, which would be only just detectable using this assay.]
The inclusion of ammonium chloride (10mM) in the re-incubation
4 hCmedium was shown to inhibit lysosomal proteolysis of ,,i3I-BSAf(j, as 
less radioactivity was lost from the tissue in the form of the 
membrane-permeable degradation products of 12-il-BSAf(J. Ammonium
chloride did not appear to greatly affect the rate of release of
125I-PVP, suggesting that exocytosis, membrane permeability to 
towards large molecules, and cell lysis were not affected. However, 
in the presence of ammonium chloride the rate of loss of leupeptin 
from the tissue was increased three-fold and the extent of loss 
increased from 90% (observed in the absence of ammonium chloride) to 
100%.
At least two possible explanations can be forwarded to explain
the enhanced loss of leupeptins
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a) Leupeptin may have been inactivated and/or degraded more 
rapidly in the presence of ammonium chloride.
If leupeptin inactivation/degradation was entirely lysosomal, 
stimulation in the presence of a lysosomotropic agent would suggest 
that the enzyme(s) responsible must be maximally active near neutral 
pH. Several such enzymes that may be capable of cleaving the peptide 
bonds of leupeptin exist, eg lysosomal aminopeptidase, lysosomal 
carboxypeptidase B, dipeptidylpeptidase I, (Barrett, 1977).
Alternatively, ammonium chloride may act by increasing the 
permeability of the lysosomal membrane, allowing access of leupeptin 
to sites and enzymes not normally available. [Small changes in the 
lysosomal membrane permeability are feasible because ammonium 
chloride causes vacuolation of lysosomes, and the distended membrane 
may become more 'leaky' towards small molecules.] It is known that 
leupeptin normally has access to lysosomal sites (because it inhibits 
lysosomal proteolysis), therefore any change in membrane permeability 
is most likely to affect movement of leupeptin from lysosomes to the 
cytoplasm. Cytosolic peptidases could then inactivate/degrade the 
leupeptin. This possible explanation of the effect of ammonium 
chloride would only hold if leupeptin did not normally have access to 
the cytoplasm.
b) Leupeptin may have been released (intact) from the tissue 
more rapidly in the presence of ammonium chloride.
The rate of release of leupeptin may increase if the ammonium 
chloride increased plasma membrane permeability and/or stimulated 
membrane transport systems, and if the rate of exocytosis or 
diacytosis of vesicles containing leupeptin was enhanced. This 
possibility was further investigated in Chapter 6.
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To summarize, the assay gave clear results with good 
reproducibility. It was possible to detect the total tissue content 
of active leupeptin. The experiments described in this Chapter 
suggest that:-
i) Accumulation of leupeptin occurs at a rate similar to that of 
fluid phase pinocytosis.
ii) Accumulation of leupeptin appeared to be inhibited by ammonium 
chloride (20mM) and low temperature.
in) Leupeptin activity was lost from the tissue, so that a
steady-state concentration was reached after about 3 hours.
iv) Loss of leupeptin activity (but not 125I-PVP or 125I-BSAfdj was 
enhanced in the presence of ammonium chloride (10mM).
Since it was necessary to apply a mean correction factor to all 
amounts of leupeptin measured in the TCA-soluble fraction of yolk 
sacs (to correct for poor recovery of leupeptin) the precise quantity 
of leupeptin within the yolk sacs may not correspond exactly to that 
shown in the results. However, the general pattern was quite clear, 
and since the correction factor was a constant, it should not alter 
the slope of the graph of accumulation of leupeptin against time 
(ie the rate of accumulation), when accumulation is expressed as pi 
of medium whose substrate content has been captured.
Amount of leupeptin added (vg)
Fig. 5.1 Inhibition Curve for Trypsin and Leupeptin Using 
Z-Phe-Arq-AMC as the Substrate
The percentage of enzyme activity that remained when various 
amounts of leupeptin were added to a fixed amount of trypsin 
was determined by the enzyme assay described in Section 5.2.1. 
Each point represents a single determination.
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In concentration (yg/ml) of leupeptin added 
Fig. 5.2 Probit Transformation of the Inhibition Curve: Linearization to 
give Standard Curve
The probit value of the percentage residual activity of trypsin in 
the presence of various amounts of leupeptin (determined as 
described for Fig 5.1) was plotted against the natural logarithm 
of the concentration (yg/ml) of leupeptin added to the assay.
Each point represents a single determination. The graph also shows 
a regression analysis giving the line of best fit and 95%
confidence limits.
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Fig. 5.3 Computer-Fitted Line of Best Fit Through Standard Curve Data:
Percent Residual Activity against natural log. Leupeptin Concentration
The data given in Fig. 5.1 were plotted as percentage residual 
activity against the natural log of the concentration of leupeptin 
added, and the curve of best-fit calculated by computer.
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• Recovery of leupeptin from yolk sac homogenate 
q Recovery of leupeptin homogenates in the presence of peptides
0 Recovery of leupeptin from calf serum
5.5 Recovery of Leupeptin from the TCA-soluble Fraction of 
a Yolk-Sac Homogenate
Yolk sacs were homogenized and known amounts of leupeptin 
added, as described in Section 5.2.4. The amount of 
leupeptin detected in the TCA-soluble fraction of the homogenate, 
measured as described in Section 5.2.1, was calculated as a 
percentage of that added. Peptides were added to some 
homogenates before TCA-precipitation. Recovery of leupeptin 
from calf serum, rather than yolk sac homogenate, was also 
measured. The plot shows results for individual determinations 
using different homogenates.
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Active leupeptin
125I-PVP
Fig. 5.6 Accumulation of 
Sacs
125 I-PVP and Active Leupeptin Within Yolk
Yolk sacs were incubated with both leupeptin and 
125I-PVP, as described in Section 2.6. Tissue and medium 
were assayed for leupeptin and radioactivity as described 
in Section 5.2.3. The amount of tissue-associated leupeptin 
was corrected for recovery, then substrate accumulation 
calculated as described in Sections 2.7a and 2./d.
The graph shows mean accumulation (± S.D.),
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Fig. 5.7 Accumulation of Active Leupeptin Within Yolk Sacs with Leupeptin 
at a Medium concentration of 200 pg/ml
Yolk sacs were incubated with leupeptin (200 ug/ml) as described 
in Section 2.6, except that 125I-PVP was not present. Yolk sacs 
and medium were assayed for active leupeptin, and tissue 
associated leupeptin corrected for recovery. Accumulation 
of leupeptin within the tissue was calculated as described in 
Section 2 . 1 A .  The graph shows the mean results (± standard 
deviation).
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A  Leupeptin in the presence of ammonium chloride 
a 125i-PVP in the presence of ammonium chloride
Fig. 5.8 Accumulation of 125I-PVP and Active Leupeptin Within Yolk Sacs 
Incubated in the Presence of Ammonium Chloride
Yolk sacs were incubated with both 125I-PVP (2-4 ug/nl) and leupeptin 
(100 yg/ml) in medium containing ammonium chloride (20 mM). I-PVP 
accumulation was also measured in the absence of ammonium chloride 
as a matched control. Tissue and medium were assayed for leupeptin 
and for radioactivity, then accumulation of substrates was 
calculated as described Fig. 5.6. The mean accumulation (± standard 
deviation for control) is shown.
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O 125i-b sa in the absence of ammonium chloride 
125■ I-BSA in the presence of ammonium chloride
Fig. 5.10 Loss of 125I-BSAfJ from Pre-Loaded Yolk Sacs in the Presence 
and Absence of Ammonium Chloride
125Tissue was incubated with I-BSA^ then rinsed and 
re-incubated with and without ammonium chloride (10 mM) .
The amount of radioactivity that remained within the tissue 
after reincubation (calculated in terms of yl/mg protein) 
was expressed as a percentage of that present in tissue that 
had not been reincubated, as described in Section 5.2.6.
The mean percentage ± standard deviation is shown in the diagram.
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O Leupeptin in the presence of ammonium chloride
• Leupeptin in the absence of ammonium chloride
12S •A I-PVP in the presence of ammonium chloride
IOC
k  I-PVP in the absence of ammonium chloride
Fig. 5.11 Loss of 125I-PVP and Active Leupeptin from Pre-Loaded Yolk Sacs 
in the Presence and Absence of Ammonium Chloride
Tissue was treated as described in Fig. 5.9, except that ammonium 
chloride (lOmM) was present during re-incubation. The percentage 
of substrate lost in the presence of ammonium chloride (mean ± S.D.) 
was plotted together with the data from Fig. 5.9 in order to
illustrate the effect of ammonium chloride on the loss of active 
125leupeptin and I—PVP from yolk sacs.
CHAPTER 6
RADIOMETRIC (^H-MONITORING) METHOD OF LEUPEPTIN DETECTION
6.1. IHTWDDPCTION
The most frequently utilized method of quantitating uptake (or 
accumulation) is to use a substrate that has been radio-labelled. 
Uptake can then be monitored by counting the amount of radioactivity 
within the cells or tissue after incubation with tracer quantities of 
the radiolabelled substrate. Uptake is either expressed as c.p.m. 
per unit cell mass or number of cells (eg Ose et al., 1980;
Besterman et ah, 1981), or, by using the specific radioactivity of 
the substrate, c.p.m. can be converted to the amount of substrate 
captured (pmol or pg). Alternatively, uptake can be expressed as the 
volume of incubation medium (pi) whose contained substrate has been 
captured by the cells or tissue (eg Williams et al., 1975a; Bowers & 
Olszewski, 1972).
The radioisotopes most commonly used in biochemical 
investigations are 125I, 14C and 3«. The first of these is a 
y-emitter and hence is detected by using a crystal scintillation 
counter; 14C and 3H are 0-emitters whose emissions are less 
penetrating hence they are detected by liquid scintillation counting. 
The isotopes 3H and 14C are usually incorporated into the normal 
molecular structure of a compound, so the labelled and non labelled 
molecules are structurally indistinguishable. 1 generally 
covalently attached to molecules to form an iodinated derivative, 
hence the properties of the molecule may be affected.
In the work described in this chapter, the accumulation and 
release of leupeptin were investigated using a sample of tritiated 
leupeptin. (This substrate is not commercially available in a 
labelled form and the unlabelled molecule cannot be iodinated because 
the molecule does not contain tyrosine. The sample of H leupeptin 
used was synthesized by Dr. J. Powers using a method of 
isotope-exchange (Bush et al., 1981), and was kindly donated by Dr.
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r. Beynon, University of Liverpool.]
The many advantages and disadvantages inherent in using 
radiolabelled substrates will be considered in detail in the 
discussion section of this chapter. Briefly, the main advantage of 
using a radiolabelled substrate is the low detection limit that is 
possible if the substrate is available at high specific 
radioactivity. It was hoped that the lower detection limit for 
3H-leupeptin would permit accumulation of leupeptin to be measured 
with greater sensitivity. If so, accumulation could be monitored over 
a wider concentration range, and small amounts of leupeptin 
associated with the tissue, either at early times during a 
time-course of accumulation or during inhibition studies, could be 
accurately quantified.
Many criteria have been used in the past to differentiate 
between the various modes of uptake of extracellular material into 
cells (ie passive diffusion, facilitated or active transport, fluid 
or adsorptive pinocytosis). However, similar criteria may be used to 
demonstrate different modes of uptake (see Chapter 1), therefore a 
combination of criteria must be used in order to decide on the 
mechanism of uptake. In this chapter, the effects of leupeptin 
concentration, temperature of incubation, and metabolic inhibitors on 
the rate of accumulation of 3H-leuneptln were all monitored in an 
attempt to distinguish between the various modes of uptake. Also the 
rate of accumulation of 3H-leupeptin was compared with the rate of 
uptake of a 3H-labelled marker for fluid-phase pinocytosis,
3H-labelled inulin (mol.wt.5,250).
3H-Inulin has been used by Bowers & Olszewski (1972) to study 
fluid-phase pinocytosis in the Acanthamoeba. In the Acanthamoeba 
3H-inulin obeyed all the requirements for a marker of fluid phase 
pinocytosis (discussed further in Section 6.4.3). It could not pass
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through the cell membrane rapidly via diffusion or permeation; it was 
not metabolized; and it was taken up at the same minimal rate as 
other fluid pinocytosis markers, hence it does not appear to adsorb 
to the plasma membrane. Equivalent checks were made in the yolk-sac 
system before using 3H-inulin as a marker to compare the rate of 
accumulation of 3H-leupeptin with the rate of fluid-phase 
pinocytosis.
Release of radiolabelled material, from tissue or cells that 
have been preloaded with a radio-labelled substrate, can be monitored 
by measuring the appearance of the label in the re-incubation medium 
(Besterman et al., 1981; Dean 6 Jessup, 1982; Williams et ah,
1975a). Ideally the nature of the released radiolabelled material 
should be known, so that the possibility of intracellular degradation 
of the substance can be assessed. (Unlike the enzyme assay based 
methods of detection, any inactivated 3H-leupeptin and/or 3H-labelled 
degradation products are detected.) Several attempts were made to 
find a convenient method for the separation of intact leupeptin from 
any degradation products (see Appendix 4).
The total amount of radioactivity released may give an 
indication of the mode of release. The time-course of release of 
3H-leupeptin-derived radioactivity was compared with that of markers 
of pinocytosis that are released by exocytosis/cell death alone. If 
either leupeptin itself or leupeptin degradation products were 
released by a mechanism other than exocytosis/cell death, the 
kinetics of release would be expected to differ from those of these 
markers.
In results described in Section 5.3.6 it was observed that 
ammonium chloride enhanced the loss of leupeptin activity from yolk 
sacs. Several possible explanations were put forward: an Increased 
rate of lysosomal inactivation or degradation; increased permeability
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of the lysosomal membrane (leading to release of leupeptin from 
lysosomes followed by possible degradation by cytosolic peptidases); 
increased permeability or stimulation of transport through the plasma 
membrane (leading to release of leupeptin from the tissue). In the 
experiments reported in this chapter, the effect of ammonium chloride 
on the release of label derived from 3H-leupeptin (ie intact and/or 
degraded material) and of two non-degradable radiolabelled markers of 
fluid-phase pinocytosis was determined, to try to distinguish between 
these possibilities. The markers used were of different molecular 
sizes. It was thus hoped to detect any small changes in membrane 
permeability, as well as any changes in the extent of exocytosis/cell 
death, that may occur in the presence of ammonium chloride.
It was also noted in Chapter 5 that when leupeptin was added to 
a yolk-sac homogenate and the homogenate proteins precipitated with 
TCA, recovery of the leupeptin from the soluble fraction was poor. 
Possible explanations of this were discussed; one of these was that 
leupeptin bound to some of the homogenate proteins and was 
co-precipitated. This possibility was investigated using 
3H-leupeptin. A mixture of 3H-leupeptin and homogenate protein was 
passed down a column of Sephadex G—25 and the elution pattern 
compared with the elution positions of 3H-leupeptin and homogenate 
protein. Any shift in the elution profile of 3H-leupeptin towards the 
protein elution position in the mixture would indicate that leupeptin 
had become associated with the homogenate protein. The percentage of 
3H-leupeptin that was spun down, with either cell debris or the 
TCA-precipitated fraction of a yolk-sac homogenate, was also
determined.
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To summarise, the following were investigated using 3H-labelled
substrates:-
i) The uptake characteristics of 3H-leupeptin were compared
with those of 3H-inulin (which was shown to be a suitable marker 
for fluid-phase pinocytosis). The effects of variation of 
leupeptin concentration (over the range 10y g-100ug/ml), of 
lowering the temperature of incubation (4°C - 37°C), and of a 
metabolic inhibitor on the rate of accumulation of 
3H-leupeptin, were determined.
ii) Release of 3H—leupeptin and fluid—phase markers of different 
molecular mass was monitored in the presence and absence of 
ammonium chloride.
iii) Possible association between macromolecular components of the 
yolk-sac homogenate and 3H-leupeptin was investigated.
iv) Attempts were made to separate intact leupeptin from its 
putative degradation products (Appendix 4).
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6 .2 . MATERIALS AND METHODS
T. MATERIALS
Equipment
PD-10 Columns Pre-ftiled with Sephadex-G25. Bed volume 8.5ml 
Pharmacia Ltd., Milton Keynes, Bucks., U.K.
Reagents
3H-Leupeptin The material used was synthesized by Dr.J. Powers 
and kindly donated to the author by Dr.R. Beynon, 
Dept. Biochemistry, University of Liverpool. It 
consisted of a total mass of 4mg, with an 
activity of 62yCi. A stock solution (1mg/ml in 
distilled water) was prepared and dispensed as 
0.5ml aliquots for storage at -20°C. As required, 
this solution was diluted to give a 'working' 
stock solution (usually 25yg/ml), which was 
diluted 10-fold on addition to incubation flasks.
^H-Inulin Code TRA.324. Amersham International PLC, Bucks. 
The solid was dissolved in distilled water to 
give a 0.14mg/ml stock solution, which was stored 
in sealed ampoules at -20°C. This solution was 
generally diluted in medium 199 to 3.5yg/ml, 
before addition to incubation flasks to give a 
final concentration of 0.35yg/ml.
TT 14u C-Sucrose Code CFB.146. Amersham International PLC, Bucks. 
Diluted in water to give a 20yg/ml stock
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solution, stored at-20°C. Stock solution 
generally diluted in medium, to 0,4pg/ml, before 
addition to flasks to give a final concentration 
of 0,04yg/ml.
Scintillation Optiphase 'MP'. LKB, South Croyden, Surrey, U.K.
Fluid
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IX. METHODS
g.2.1. Uptake of Radio-Labelled Markers 
6.2.1a. Uptake of 3H-Inulin
Since the uptake of 3H-inulin had not previously been studied in 
the yolk-sac system, it was necessary to verify that the molecule was 
suitable for use as a marker of fluid-phase pinocytosis.
The methods of incubation of yolk sacs and of preparation of 
samples of medium and tissue for assay are described in full in 
Sections 2.2, 2.5, and 2.7c. Uptake was monitored both in the 
presence and the absence of 10% calf-serum in the medium. Uptake of 
125j_pyp wag monitored in matched control experiments (as described 
in Sections 2.2, 2.4a, and 2.7a) to ascertain the rate of fluid-phase 
pinocytosis.
Possible degradation of 3H-inulin was investigated by column 
chromatography. Yolk sacs (3) were incubated for 3h in medium 199 
(7ml) containing 3H-inulin (0.7ijg/ml) as described in Section 2.2, 
then rinsed in three changes of fresh warm medium. The yolk sacs 
were then re-incubated in fresh medium for 3h. Samples of the 
re-incubation medium, which would contain any degradation products, 
were loaded onto a gel chromatography column (PD-10) and eluted with 
water. A sample of inulin stock solution, that had not been incubated 
with yolk sacs, was passed down the same column, and the elution 
profiles compared.
The time-course of release of 3H-inulin-derlved radioactivity 
from pre-loaded yolk sacs was also monitored, and compared with 
release of 125I-PVP. The experiment was carried out as described in 
Section 6.2.2. except yolk sacs were re-incubated in ammonium 
chloride-free medium only. The following modifications were 
necessary for the ^2^I—labelled substrate.
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125, -PVP was present in the loading medium at a concentration of 
about 35vig/ml. Yolk sacs were digested in NaOH (1M, 5ml/yolk sac) 
before assaying for radioactivity and protein, as described in 
Section 2.4a and 2.3. Samples (1.0ml) of medium were also assayed for 
radioactivity, as described in Section 2.4a. Quantitation of release 
of 125j_pvp Was as described in Section 6.2.2., except correction for 
relative counting efficiency was unnecessary. ,Once these 
preliminary experiments comparing the characterisics of 3H-inulin 
uptake had been completed, 3H-inulin was used as a marker with which 
to compare accumulation of 3H-leupeptin.
6.2.1b. Accumulation of 3H-Leup>eptin
Accumulation of 3H-leupeptin was monitored as described in 
Sections 2.2b and 2.5, and calculated as described in Section 2.7c. 
Uptake of 3H-inulin was monitored in matched experiments to indicate 
the rate of fluid-phase pinocytosis.
1) Concentration Dependence: The effect of leupeptin
concentration on the rate of accumulation was determined over 
the range 3-100pg/ml. In experiments in which leupeptin was 
used at a concentration of 3, 5 or 10ug/ml, only H leupeptin 
was added to the medium. In experiments with leupeptin at a 
concentration of 50 and 100pg/ml, 3H-leupeptin was at a final 
concentration of 10pg/ml, and unlabelled leupeptin at 
concentrations of 40 and 90pg/ml. 
ii) Temperature Dependence: Accumulation of leupeptin was
monitored at 4°C, 25°C, 30°C, 34°C and 37»C. (Uptake of 
3H-inulin was monitored in matched experiments at the same 
temperature.) The experiments were performed as described in 
Chapter 2, except that the water bath in which the incubation 
flasks were placed was maintained at the above temperatures.
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The normal equilibration period of approximately 10min was 
considered sufficient to permit the tissue to adjust to the 
lower temperature. For these experiments, 3H-leupeptin was used 
at a final concentration of 2.5yg/ml, and unlabelled leupeptin 
at 10Opg/ml.
iii) Effects of a Metabolic Inhibitor s The rates of accumulation
of 3H_ieupeptin and 3H-inulin were monitored in the presence of 
rotenone (10-5M). Experiments were carried out as described in 
Section 2.2b, except that rotenone was present in the incubation 
medium. 3H-Leupeptin or 3H-inulin was added to give final 
concentrations of 5 and 0.35pg/ml, respectively.
6.2.2. Release of Radiolabelled Substrates
6.2.2a. Incubation Method. Release of radioactivity derived from 
ingested 3H-inulin, 14C-sucrose, and 3H-leupeptin was monitored in 
the presence and absence of ammonium chloride (10mM).
Yolk sacs were loaded with substrate by incubating for 2-3 hours 
in flasks containing 3-5 yolk sacs in a final volume of 10ml medium. 
The final substrate concentrations during this period were:
3H-inulin, 1.4pg/ml; 14C-sucrose, 0.25pg/ml; and 3H-leupeptin,
5iig/ml. (Experimental details of yolk-sac incubation are given in 
Section 2.2.). After loading, the yolk sacs were rinsed in three 
changes of warm (37°C) fresh medium (approximately 20ml, 3 x 2min). 
The yolk sacs were then transferred to flasks containing warm, fresh, 
gassed, substrate-free medium (7-10ml) with or without ammonium 
chloride (10mM), and were re-incubated for a further 4 hours,
(keeping the same 3-5 yolk sacs together throughout). After 
re-incubation the yolk sacs were rinsed in ice-cold saline, 
homogenized in water (1ml per yolk sac), and assayed for 
radioactivity and protein content as described in Sections 2.5 and
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2.3. At Intervals during the re-incubation, samples of medium 
(0.5ml) were removed from the flask for assay of radioactivity (as 
described in Section 2.5.) and the medium in the flask replenished 
with fresh warm medium, with or without ammonium chloride. The 
flasks were gassed (95%02t 5%C02> before commencement of the loading 
and re-incubation and after removal of each medium sample.
In one experiment, the amount of leupeptin-derived radioactivity 
released during each saline rinse was assayed in the presence and 
absence of cold leupeptin (50)jg/ml), to determine whether 
^H-leupeptin was displaced from cell-surface binding sites.
6.2.2b. Quantitation of Release. The amount of radioactivity 
(c.p.m.) released from the yolk-sac tissue was expressed in the same 
units as uptake (ie ul of medium per mg yolk-sac protein). This was 
then expressed as a percentage of the amount present in the yolk sac 
at the start of re-incubation.
The total amount of radioactivity released after a particular 
re-incubation period was calculated using the following equation 
(modified from Williams et al., 1975a):-
i=n-l
i=0
if'Ctri C 
i r-Rr.
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where Tn = Total radioactivity (c.p.m.) released during 
the re-incubation period up to the time of 
the n*"*1 sample.
V = Volume (ml) of medium during the re-incubation.
C ± = Radioactivity (c.p.m) per ml re-incubation
medium the ith sample, corrected for 
background and relative counting efficiency 
(see Section 2.5).
X  = Total volume removed during sampling (generally 
2 x 0 . 5ml).
The total radioactivity released (Tn) was then expressed in
terms of yl medium released per mg yolk-sac protein as follows:-
r = Tn
M.P
Where Rn — Total volume (yl) of medium whose contained 
substrate was released from the yolk sac 
during the re-incubation period up to the 
time of the n^ *1 sample.
M = Radioactivity per yl loading medium (c.p.m.
corrected for background and relative counting 
efficiency).
p = Protein content of the yolk sac (mg).
The accumulation (yl/mg) into the yolk sacs at the start of 
re-incubation was calculated as described in Section 2.7c, except the 
total radioactivity released from the yolk sac (ie Tn where n = final 
sample) was added to the total radioactivity observed in the yolk sac 
after re-incubation. The amount of substrate released (ie Rj,) was
y frcri C MNIVrDCW
V i 1RR
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then expressed as a percentage of the total accumulation.
6,2.3. Binding of 3H-Leupeptin to Yolk-Sac Homogenate Proteins 
An investigation was made to determine whether or not 
3H-leupeptin became bound to yolk-sac homogenate proteins. A yolk-sac 
homogenate was mixed with 3H-leupeptin and passed down a PD-10 
gel-chromatography column. The elution profile was compared with that 
of homogenate protein and 3H-leupeptin. The experiment was carried 
out as follows.
A solution of leupeptin was prepared by adding 10pl of 
3H-leupeptin solution (1mg/ml) to 1ml unlabelled leupeptin (50pg/ml).
A sample (0.1ml) of this solution was added to 0.4ml distilled water, 
loaded onto the column and eluted with water, as described below. 
Yolk-sacs (3) were homogenized in 0.1% Triton X-100 (0.75ml) in a 
hand-held ground-glass-on-ground-glass homogenizer. Aliquots (0.5ml) 
of this homogenate were treated as follows:—
i) Duplicate samples were centrifuged (1000g, 20 min) and the 
supernatant decanted from the pelleted cell debris. The above 
leupeptin solution (0.1ml) was added to each supernatant, and 
the volume of each noted. An aliquot of this
supernatant/leupeptin mixture (0.1ml) was taken for assay of 
total radioactivity, and the remaining volume adjusted to 0.5ml 
before loading onto the column. The sample was eluted with 
distilled water; 25 x 0.5ml fractions of eluant were collected. 
These were assayed for radioactivity#
ii) Leupeptin solution (0.1ml) was added to each of duplicate 
aliquots of homogenate, then the mixture centrifuged at 1000g 
for 20 minutes. The pelleted cell debris was resuspended in 
0.5ml distilled water and assayed for radioactivity. The volume 
of the supernatant was noted, and a 0.1ml sample removed for
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assay of total radioactivity. The remaining volume was adjusted 
to 0.5ml and the sample loaded onto the column and eluted as 
described above.
iii) 0.1ml of the leupeptin solution was added to duplicate aliquots 
of homogenate, then 0.5ml TCA (5%w/v) was added. The resulting 
precipitate was spun down (1000g, 20 min). The pelleted 
precipitate was re-suspended in 0.5ml distilled water and 
assayed for radioactivity. The volume of the soluble fraction 
was noted; 0.1ml of this solution was reserved for assay of 
radioactivity and 0.5ml was loaded onto the column and eluted as 
described above.
iv) One aliquot of the homogenate was centrifuged (1000g, 20min) and 
the volume of supernatant adjusted to 0.5ml. This was loaded 
onto the column and eluted as above, except that the eluant 
fractions were assayed for protein content (by the Folin assay) 
rather than for radioactivity.
The results were plotted as observed counts (c.p.m. per fraction) 
against fraction number. For the experiments described in parts (ii) 
and (iii), the percentage of leupeptin pelleted with the cell 
debris and TCA-precipitate during centrifugation was determined. The 
counts observed in the pellet and samples of supernatant assayed for 
radioactivity as described above, were normalized to correct for 
differences in counting efficiency. [The relative counting efficiency 
(with respect to water) of each sample was determined by comparing 
the observed counts in a "spike" of tritiated water added to samples 
of 3H-leupeptin-free pellet, supernatant and distilled water, as 
described in Section 2.5.] The amount pelleted was then calculated:-
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Percentage Pelleted “
Counts in pellet (c.p.m., normalized) 
-----------------------— -------------  xlOO
Counts in pellet (c.p.m., normalized)
+ counts in total volume of supernatant 
(c.p.m., normalized)
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g RESULTS
6t3.1. Uptake of 3H-Inulln: Assessment of Suitability for U3e 
as a Marker of Fluid-phase Pinocytosis.
The results in this section are those obtained when comparing 
uptake of 3H-inulin with that of the known fluid-phase marker of 
pinocytosis, 125I-PVP. In the absence of serum the mean Endocytic 
Indices (± S.D.) of 3H-inulin and of 125I-PVP were 3.53 (± 1.5 ) and 
3.89 (± 1.8)pl/mg/h respectively. In the presence of 10% calf-serum 
the E.I.'s decreased to 3.18 and 2.81pl/mg/h respectively. Thus the 
Endocytic Indices of 3H-inulin and 125I-PVP were very similar, 
suggesting that uptake of 3H-inulin was by fluid-phase pinocytosis.
Both the standard volume and reduced volume methods of 
incubation were used in the absence of serum to monitor H—inulin 
uptake. In matched experiments, virtually no difference was observed 
in the mean E.I. of 3H-inulin using the different methods
(2.39)i 1/mg/h for reduced volume? 2.33pl/mg/h for standard volume).
The mean uptake value at each time point was calculated from a number 
of reduced volume uptake experiments, and the plot of mean uptake 
against time (Fig. 6.1) inspected for linearity. The plot is 
essentially linear, with an E.I. of 2.53jig/mg/h, (correlation 
coefficient 0.997). The standard deviation of points beyond 5h is 
high. (This was also observed for 125I-PVP uptake beyond 6h, in 
results described in Chapter 5.) Possible explanations for this are 
given in Section 6.4.2.
The possibility of intracellular degradation of H-inulln was 
investigated by column chromatography. The elution profile of 
3H-inulin that had been released from loaded yolk-sacs (Fig. 6.2) can 
be compared with that of 3H-inulin that had not been incubated, (Fig. 
6.3). The elution profiles are very similar, the majority of the
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3H - in u l in  passing down the co lum n in  the v o id  vo lum e, 
i  1 2 5The release of H-inulin and I-PVP from pre-loaded yolk-sacs 
was monitored in the presence and absence of serum (Fig. 6.4). 
Different batches of 3H-inulin were used in the presence and absence 
of serum. These results show several characteristic features.
i) The total amount of substrate released by 4.0 hours was greater 
in the absence of serum. This was particularly noticable for 
3H-inulin.
ii) The total amount of 3H-inulin released by 4.0 hours was always 
greater than that of 125I-PVP, in matched experiments.
iii) over the period 0.25-4h, the rate of release of 3H-inulin was 
greater than that of 125I-PVP in the absence of serum, but about 
the same in the presence of 10% serum*
6.3.2. Accumulation of 3H-Leupeptin
The rate of accumulation of 3H-leupeptin was compared with that 
of 3H-inulin, under various incubation conditions. The time-course of 
the uptake/accumulation (± standard deviation) for all 3H-inulin and 
all 3H-leupeptin experiments carried out at 37°C in the absence of 
serum (ie at various substrate concentrations, experiments not 
necessarily matched) is given in Fig. 6.5. The plot of uptake of 
3H-inulin was approximately linear and, although the mean value of 
3H-leupeptin accumulation gave a curved plot, the standard deviation 
about the mean was such that the time course of accumulation of 
3H-inulin and 3H-leupeptin were indistinguishable.
6.3.2a. Effect of Extracellular Leupeptin Concentration on the 
Rate of Accuulation of 3H-leupeptin. Uptake of a substrate by a 
mechanism such as adsorptive pinocytosis or facilitated membrane 
transport increases with increasing substrate concentration up to a
v'ctri r
 M
M
iw
cn
cw
rv ; 
\
n
o
r
139 )
mm
maximum rate, when the transport system becomes saturated. No further 
increase then occurs. If the concentration of labelled substrate is 
constant and only the unlabelled substrate concentration increases 
(as is often the case in experimental design) the E.I. of the 
substrate would appear to decrease with increasing concentration, as 
competition between labelled marker and unlabelled molecule occurs.
For non-saturable uptake mechanisms, eg fluid-phase pinocytosis 
or passive diffusion, the amount of substrate taken up (yg/ml tissue 
protein/h) will increase linearly with increasing concentration, thus 
the E.I. (v 1/mg/h) will remain constant.
Table 6.1 reports the rate of accumulation and correlation 
coefficients calculated from the mean time-courses of accumulation of 
3H-leupeptin at concentrations of 3, 5, 10, 50, and 100pg 
leupeptin/ml together with the Endocytic Indicies and correlation 
co-efficients of 3H-inulin (concentration 0.35 yg/ml) determined in
)
matched experiments.
The rate of accumulation of leupeptin was typical of that of 
fluid-phase pinocytosis. There was no systematic change in the rate 
of accumulation with increasing concentration of leupeptin.
The time—course of accumulation of H—leupeptin at 
concentrations of 10yg/ml and 100yg/ml together with matched 
3H-inulin controls, are shown in Figs. 6.6 and 6.7 respectively. The 
time-course of accumulation of each substrate in the matched 
experiments was virtually identical, further supporting the evidence 
for a lack of change in rate of accumulation with leupeptin
concentration.
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6.3.2b. Effect of Temperature on the Rate of Accumulation of 
^H-Imupeptin and 3H-Inulin. The rates of accumulation of 
3H-leupeptin (lOOpg/ml) and 3H-inulin (0.35yg/ml) were monitored at 
4, 25, 30, 34 and 37°C. Figs. 6.8 and 6.9 show the time-courses of 
accumulation at each of these temperatures for 3H-leupeptin and 
3H-inulin respectively. These plots indicate that the rates of 
accumulation of both 3H-inulin and of 3H-leupeptin were strongly 
temperature-dependent.
At 4°C, accumulation of both substrates was completely 
inhibited. Between 25 and 34°C, the rate of accumulation increased 
markedly. Accumulation at 34°C appeared to be indistinguishable from 
that at 37°C (the standard deviation at most points overlapped ).
The degree of scatter about the mean value of uptake was high, 
especially for incubation periods of 6 - 8 hours. For both 
substrates, the time-course of uptake started to level off at 37°C 
after 6h. Possible reasons for non-linear time-courses of 
accumulation are discussed in Section 6.4.2.
Because of this curvature, it was decided to calculate the rates 
of uptake/accumulation of the substrates over the initial 4h period 
of incubation only. These rates were determined for each individual 
uptake experiment, then the mean rate and standard deviation 
calculated for each temperature. The results are summarized in Fig.
6.10. Over the temperature range 25 - 37°C the mean rate of 
accumulation of each substrate increased in direct proportion to the 
temperature.
The temperature coefficient (Q10) calculated from the gradient 
of the straight line drawn between the points was 1.92 for 
3H-leupeptin and 2.59 for 3H-inulin. These are fairly typical of 
values for metabolic reactions, which generally have a Q^q of 
about 2. An Arrhenius-type plot, of 1/TOO against the mean natural
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log of the rate of uptake/accumulation was non-linear for both 
3H-leupeptin and 3H-inulin (see Fig. 6.11).
6.3.2c. Effect of Pinocytic Inhibitors on 3H-Leupeptin and
^H-Inulin Accunalation. Experiments were carried out 
using rotenone (10-5M) as an inhibitor of pinocytosis. Accumulation 
of both 3H-inulin and 3H-leupeptin were strongly inhibited, see Fig. 
6 . 12.
6.3.3. Release of Radiolabelled Substrates from Loaded 
Yolk Sacs; Effect of Ammonium Chloride
Release of the fluid-phase pinocytic markers 3H-inulin (mol. 
mass 5,200) and 14C-sucrose (mol. mass 342) from loaded yolk sacs was 
monitored in the presence and absence of ammonium chloride (10mM). 
Release of radiolabel from yolk sacs loaded with H—leupeptin (ie 
release of radiolabelled intact leupeptin and/or degradation 
products) was also monitored, for comparison with both the rate of 
release of fluid-phase markers and the rate of loss of leupeptin from 
yolk-sacs observed in Section 5.3.4 and 5.3.5.
In preliminary experiments the rate of uptake of c-sucrose was 
determined, to confirm the previously reported rate and mode of 
uptake of this marker in yolk sacs (Roberts et al., 1977). The 
time-course of uptake is shown in Fig. 6.13. The plot was linear 
over the first 4h of incubation, then a slight decrease in the 
rate of accumulation occurred. (Possible explanations for this 
observation are given in Section 6.4.2.)
The time-courses of release of  ^C-sucrose, H-inulin and 
3H-leupeptin (and/or degradation products) are shown in Figs. 6.14, 
6.15 and 6.16 respectively.
The total percentage of substrate released by 4h, when the
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tissue was incubated in serum-free medium, varied greatly between 
markers: 14C-sucrose (25%), 3H-inulin (15%), and 125I-PVP (5%).
[Release of 3H-leupeptin should not be compared directly with these 
results because it was not established whether the material released 
was intact leupeptin or degradation products (in which case the 
amount released would not depend on the membrane permeability towards 
leupeptin). The total quantity of 3H-leupeptin-derived radiolabel 
released after 4h was about 28%.]
Release of 14C-sucrose (Fig. 6.14) proceeded rapidly over the 
first hour and release was slightly more rapid in the presence of 
ammonium chloride. The rate of release then slowed considerably: 
after about 2.5h no further substrate was released. The amount of 
radioactivity that had been released after this period in the 
presence of ammonium chloride was virtually the same as that released 
in its absence.
The pattern of release of 3H-inulin was slightly different (Fig. 
6.15). The percentage released over the first hour of re-incubation 
rose only slightly (from about 8 to 13%) and no marked difference was 
apparent between yolk sacs re-incubated with or without ammonium 
chloride. The rate of release between 1-4h was very slow (about 0.9%/ 
h), but the amount released did not reach a constant value (c.f.
14results for C-sucrose).
Release of 2^^I-PVP in the presence and absence of ammonium 
chloride was investigated in Chapter 5 (results in Section 5.3.4b; 
see Fig 5.11) and results were found to be similar whether the 
increase in radioactivity in the medium or the decrease in 
radioactivity in the tissue was monitored. No large initial release 
of this marker was observed, only about 5% of the tissue-associated 
125I-PVP was released by the end of the re-incubation period. No 
difference was observed in results obtained in the presence or
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absence of ammonium chloride.
Fig. 6.16 shows the release of radiolabel from yolk sacs loaded 
with 3H-leupeptin. Unlike the results observed in Section 5.3.4 (in 
which loss of active leupeptin was monitored) the release pattern of 
3H-label was the same whether or not ammonium chloride was present. A 
rapid initial release (over the first hour of reincubation) was 
followed by a slightly slower rate of release that continued over the 
entire reincubation period. (A constant plateau was never reached.) 
The rate between 1-4h (about 3.5% per h) was greater than that 
observed for any of the other substrates.
6.3.4. Binding of 3H-Leupeptin to Yolk-Sac Homogenate Proteins
In Section 5.4.2. it was suggested that a possible explanation 
for the poor recovery of leupeptin from yolk-sac homogenates was that 
the leupeptin became bound to yolk-sac protein(s) (eg cathepsins B 
and L, to which it binds tightly) and was co-precipitated with them 
on addition of TCA. In this chapter it was hoped to detect any such 
protein-bound leupeptin by differentiating between protein-bound and 
free 3H-leupeptin in a yolk-sac homogenate/3H-leupeptin mixture, 
using a gel-chromatography column. The TCA-soluble fraction of 
homogenate/3H-leupeptin was also eluted from the column to determine 
whether any changes in the elution characteristics of 3H-leupeptin 
occurred after treatment with TCA.
Gel-chromatography on Sephadex separates molecules chiefly 
according to molecular size, although ionic charge and hydrophobicity 
may also affect the elution position, particularly if water is used 
as the eluant. (Aromatic and positively-charged molecules are 
retained on the gel, negatively-charged molecules are excluded.) The 
column used for these experiments contained Sephadex G25, which has a 
fractionation range of about 1,000 - 5,000 for peptides and globular
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proteins. Free ^H-leupeptin, since it is below this fractionation 
range, would therefore be expected to elute with an elution volume 
approximately equal to the bed volume. Cell proteins would be 
expected to elute in the void volume, provided their molecular mass 
was greater than 5,000. Small polypeptides may elute anywhere 
between the void volume and the bed volume.
The eluant collected during sample loading was termed the first 
fraction, and each fraction volume was 0.5ml. Dextran-blue (a high 
mol. mass dye) was eluted in fractions 8 to 10 indicating that the 
void volume of the column was about 4ml. The bed volume of the 
column was reported to be 8.0ml.
Fig. 6.17 shows a typical elution profile of a sample of 
3H-leupeptin that had not been mixed with a yolk-sac homogenate. An 
elution peak occurred at a volume of 8ml, (ie equal to the bed 
volume). A slight 'shoulder' was observed before the main peak, at 
an elution volume of about 5ml. This could represent higher - 
molecular-mass impurities or possibly forms of leupeptin with 
different hydration (eg cylic form or alcohol form — see Fig 1.1). 
The nature of the material in this subsiduary peak was not 
determined.
Fig. 6.18 shows a typical elution profile of yolk-sac proteins, 
as determined by the Folin assay. [Colour development with the 
Folin-Ciocalteu's phenol reagent is greatest for proteins, but 
peptides and aromatic amino acids will also react, Lowry et al., 
1951.] Two major peaks occurred, at elution volumes of 4.5 and 10ml, 
corresponding approximately to the void volume and a volume greater 
than the bed volume. Some Folin-posltive material also eluted in 
volumes between these peaks. The elution profile indicates that the 
yolk-sac homogenate contained a range of proteins with different 
molecular mass. Those with a molecular mass over 5,000 (which
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includes cathepsin B and L, mol. mass 25,000 and 24,000 respectively; 
Barrett S McDonald, 1980) should have eluted in the void volume. 
Proteins and polypeptides with a molecular mass between 1,000 - 5,000 
eluted between the void and bed volume. (The resolution of the PD-10 
columns was insufficient to distinguish individual proteins over this 
fractionation range.) Folin-positive amino acids and peptides with a 
molecular mass less than 1,000 generally elute either with or after 
the bed volume, depending on the gel-solute interactions, and must 
have given rise to the second observed peak. Comparatively few 
Folin-positive compounds eluted in the same position as 3H-leupeptin, 
ie with an elution volume of 5 to 8ml.
For experiments in which 3H-leupeptin was added to a whole 
yolk-sac homogenate that was then centrifuged to remove cell debris, 
a typical elution profile of the supernatant was as shown in Fig. 
6.19. The main peak occurred at an elution volume of 7.0ml, with a 
small subsiduary peak at 4.5ml. This elution profile is similar to 
that of 'pure' 3H-leupeptin, except that the position of the peaks 
was shifted, by about 1ml, towards that expected for larger/more 
positively-charged molecules. The elution bands did not 
correspond to either of the main protein elution bands, therefore it 
seems unlikely that the shift in the leupeptin elution position was 
caused by leupeptin becoming bound to a homogenate protein. (In 
particular, these results indicate that leupeptin did not elute with 
cathepsins B and L in the void volume.)
The percentage of 3H-leupeptin that became trapped within the 
pelleted cell debris could be determined by counting samples of the 
supernatant and pellet for radioactivity. (It was necessary to 
correct the observed count for background and relative counting 
efficiency). About 10% of the added radioactivity became associated 
with the pelleted cell debris.
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A typical profile of 3H-leupeptin that was added to the 
supernatant of a yolk-sac homogenate (after cell debris had been 
centrifuged down) is shown in Fig* 6.20* The elution pattern was 
virtually identical to that shown in Fig.6.19 (for which 3H-leupeptin 
was added before centrifugation).
Fig. 6.21 shows the elution profile for the TCA-soluble fraction 
of a yolk-sac homogenate to which 3H-leupeptin had been added. A 
single elution peak occurred at a volume of 7ml, which is at a 
similar position to that of the main elution peak observed in Figs. 
6.19 and 6.20. However in the presence of TCA there was no 
subsiduary peak. This suggests that the material that gave rise to 
the subsidiary peak was precipitated, or co-precipitated, by TCA. 
Since the nature of the material was unknown, no definite correlation 
could be made between loss of this material and poor recovery of 
leupeptin activity after treatment with TCA, but it seems unlikely 
that loss of the quantity of material present in the subsidiary peak 
could account for the observed loss of about 50% of leupeptin 
activity. (The material may have been a tritiated impurity that was 
precipitated by TCA.)
The percentage of radioactivity that became associated with the 
pelleted TCA precipitate was about 20%, which although fairly high, 
does not account for all of the loss of leupeptin activity.
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6.4. DISCPSSION
6.4.1. Use of Radiotracers to Monitor Endocytosls
The widespread use of radiolabelled substrates in the study of 
endocytosis results from the many advantages inherent in their use. 
Some of these are briefly listed below.
Firstly, detection of the radiolabel is a rapid and 
experimentally easy method, and the counting process is generally
automated. This is a major advantage when monitoring a large number
of samples.
Secondly, it is usually possible to detect very small quantities 
of radiolabelled substrate, especially if both the specific 
radioactivity (ie d.p.m. per unit quantity of substrate) and the 
efficiency of detecting the emitted radiation are high. Only tracer
quantities of radiolabelled substrate need be used, therefore uptake
of low concentrations of substrates can be monitored.
Thirdly, the radiolabel remains detectable even if the substrate 
becomes degraded within the cell. The amount of radioactivity within 
a tissue/cell incubation system will not change, but the distribution 
between tissue and medium or between different subcellular 
compartments may do so. The proportion of intact to degraded 
molecules may well differ throughout the course of an experiment, and 
with suitable analytical methods it is possible to monitor such 
changes, and hence follow the intracellular fate of a substrate. 
However if no convienient method exists to separate the intact 
compound from its metabolites, problems may arise in interpretation 
of data.
Fourthly, use of radiolabelled tracers has advantages over 
methods of quantitating endocytosis based on morphometric analysis. 
The advantages and disadvantages of the use of radiolabelled markers
14R ;
as opposed to morphometric techniques are discussed by Pratten et al.
(1980) and Silverstein et al. (1977).
Disadvantages inherent in the use of radiolabelled markers 
depend to a large extent on the type of radioisotope used.
125I-labelled compounds have been used in the work reported in 
the earlier chapters of this thesis; some problems associated with 
their use are discussed below.
i) There is a possibility of a difference in biological behaviour 
between labelled and non-labelled material, arising as a result 
both of incorporating a "foreign" iodine atom, and of 
oxidation/reduction reactions that may occur during labelling.
ii) Iodinated compounds have limited 'shelf-life'• has a
half-life of sixty days, and loss of radioiodide from the 
labelled molecule, or dénaturation, or aggregation of material 
during storage may cause problems•)
5
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These problems are offset by the ease of sample preparation for 
gamma-counting, and the greater count rate produced by 125I compared 
with equal gram-quantities of 3H and 14C. A further advantage in 
some experiments using 125I-labelled proteins, is the lack of 
re-incorportation of the labelled degradation product I Tyr#
Advantages and disadvantages inherent in the use of 125I-labelled 
products are reviewed by Bolton (1977).
Beta-emitting radioisotopes were used extensively in the work 
reported in this chapter. Several problems are associated with their 
use:-
i) 3H may dissociate from the labelled molecule; the likelihood of 
dissociation depends on the position of the labelled atom.
Generally labile 3H-hydrogen atoms are removed from the parent 
molecule immediately after synthesis. However, slow exchange of
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non-labile 3H-hydrogen atoms with hydrogen atoms from the 
solvent may occur during storage, producing 3H2o as an impurity. 
This problem does not arise with 14C-labelled compounds, as 
carbon atoms do not exchange with the solvent.
3jj_ or 14c-labelled components of a degradable biopolymer are 
likely to become utilized by the cell in biosynthetic pathways, 
due to their being structurally identical to unlabelled 
components. [This problem may be overcome by ensuring that a 
large excess of unlabelled component(s) are present during a 
'chase' period.]
iii) Beta radiation (and, in particular, 3H-beta-emissions) are not 
very penetrating, therefore the isotope must be in close contact 
with the scintillator for transmission of radiation energy. 
Ideally the sample to be counted should be dispersed evenly 
throughout the scintillation fluid as a homogeneous solution or 
heterogeneous suspension or emulsion. This may require careful 
and time-consuming sample preparation.
iv) Beta radiation is susceptible to quenching, in which energy is 
absorbed by non-scintillant components in the sample mixture. 
Colour quenching occurs in samples containing chromophores, and 
chemical quenching occurs in samples containing, for example, 
proteins.
The latter two factors may give rise to a poor counting 
efficiency for beta radiation. Many methods have been developed to 
maximize the detection efficiency and/or correct for quenching (eg 
see Peng, 1977). Those relevant to the yolk-sac system are discussed 
below.
Several methods of preparation of yolk-sac tissue were assessed 
for reproducibility and recovery, the results are given in Appendix
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3. None of the methods used was ideal. Homogenization in water was 
used for experimental tissue because this gave the most reproducible 
results. Preparation of tissue for radioassay is discussed by 
Silverman et al. (1985).
As pointed out in Section 2.7c, the number of counts observed in 
samples of medium 199 and of yolk-sac tissue are not immediately 
comparable, because the counting efficiency of each type of sample is 
different. The counts observed in a ‘spike' of radiolabelled compound 
in both medium 199 and tissue homogenate was compared with that 
observed in water, and the counting efficiency of each type of sample 
relative to water determined. The observed counts were then 
normalized using this relative counting efficiency. These normalized 
counts could be compared directly to calculate the volume of 
incubation medium whose contained substrate was associated with the 
tissue, (ie p1/mg yolk-sac protein). \
The use of 3H-labelled leupeptin enabled the peptide to be 
detected reliably at very low concentrations, such as those present 
in yolk sacs when using low concentrations of substrate in the 
medium, or short incubation times, or when inhibitors of uptake were 
present. Also, less tissue was required at each time point to obtain 
sufficient 3H- leupeptin to assay.
6.4.2. Linearity of Accumulation
Many of the time-courses of accumulation determined during 
experiments reported in this chapter showed a tendency towards 
non-linearity. The rate of accumulation decreased with time, 
suggesting the approach of an intracellular steady-state. Such 
non-linearity was observed when accumulation of 3H-leupeptln,
14C-sucrose, and in some experiments, 3H-inulin, was monitored.
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To avoid repetition in the various sections of this chapter, 
Dossible general causes of such non-linearity will be discussed 
below, together with the most likely explanation for each particular 
substrate. There are three main causes possible:-
i) The tissue viability may decrease during the incubation period, 
giving rise to a decreased rate of uptake and possibly an 
increased rate of release (due to increased cell lysis). Tissue 
was incubated in a small volume of serum-free medium for long 
periods of time, hence viability of the tissue may have been 
lowered towards the end of the incubation period. A high 
standard deviation about the mean accumulation value suggests 
reduced viability since individual tissues may well have 
different survival times. Such variability was observed for all 
substrates (ie 3H-leupeptin, 3H-inulin, 14C-sucrose and
125i-p v p).
ii) Release of intact substrate may occur during the incubation 
period, either by rapid exocytosis or by direct membrane 
permeation. The only mechanism of release for markers of 
plnocytosis such as 125I-PVP and 14C-sucrose (other than during 
cell lysis), is by exocytosis. Rates of exocytosis reported in 
the literature vary considerably. Some, but not all reports 
suggest that exocytosis is quantitatively significant during 
short-term tissue incubations and is sufficient to give rise to 
non-linearity in the time-course of accumulation (eg Besterman 
et al., 1981). However, in yolk sacs, the rate of exocytosis 
(as determined by release of 125J-PVP) appears to be slow, and 
is not sufficient to cause non-linearity of the time-course of 
accumulation in standard volume cultures (eg Ibbotson fi 
Williams, 1979). The membrane permeability of yolk-sac membranes 
towards 3H-leupeptin and 3H-inulin was not known, therefore
release by direct membrane permeation of the intact molecule 
could not be dismissed as a possible cause of any non-linearity 
in the plot of accumulation against time. However, it was 
considered unlikely that 3H-inulin could pass through membranes 
intact, due to it large size and on consideration of the results 
of Bowers & Olszewski (1972), who found that 3H-inulin did not 
permeate through the plasma membrane of Acanthamoeba.
iii) Intracellular degradation of the substrate to yield
membrane-permeable degradation products that are released from 
the tissue. Intracellular degradation of a substrate followed by 
release of membrane-permeable degradation products is often 
observed to give rise to an intracellular steady-state 
concentration of intact substrate plus degradation products.
This occurs within 1-2h for protein substrates in rat yolk sacs 
(eg Williams et al., 1975b> Livesey & Williams, 1981). 
Intracellular degradation of 3H-leupeptin was considered to be 
quite probable (yolk-sac homogenate mediated loss of leupeptin 
activity was noted in Chapter 4, and degradation of leupeptin 
was reported by Beynon et alj., 1981). 3H-Inulin and ^C-sucrose 
are not generally considered to be degradable intracellularly, 
hence were not expected to be released by this mechanism. 
However, release from yolk-sac tissue of radiolabel derived from 
these markers was found to occur at a greater rate than release 
of 125i_pvp (which is thought to occur by cell death alone). 
This suggests that either limited intracellular hydrolysis of 
3H-inulin and 14C-sucrose occurs within yolk sacs, or the 
substrate preparations used contained readily hydrolysable 
radiolabelled contaminants, or the substrates stimulated the 
rate of exocytosis. Any one of these effects could lead to an 
increased rate of release and hence a non-linear time—course of
A
153 }
accumulation. Isolation and identification of the released 
radiolabelled products would be necessary to distinguish between 
these possibilities.
Hence for each substrate the following possible explanations for 
non-linarity of accumulation by the tissue could apply?-
*^I-PVP. The only likely reason for any non-linearity is reduced 
viability of the tissue, since abundant evidence exists to indicate 
that 125j_pvp ig not rapidly released from yolk sacs and is not 
degraded within them. The time-course of uptake of 125I-PVP showed 
little tendency towards non-linearity, although the standard 
deviations about the mean for time points above 4h were large.
^H-Inulin and 14C-Sucrose. In addition to reduced viability other 
explanations of the observed non-linearity are plausible. Radiolabel 
was released into the medium more rapidly for these substrates than 
for 125I-PVP, suggesting either stimulation of exocytosis or 
intracellular degradation of the substrate and/or radiolabelled 
contaminants to produce and to release degradation products.
Substrate degradation would be expected to be limited in extent, 
since both markers are reported to be non-degradable. Release of 
either marker by direct membrane permeation was not expected, on 
consideration of previous reports (eg Bowers & Olszewski, 1972? 
Besterman £t al., 1981).
3H-Leupeptin. Non-lineariy in the time course of accumulation of 
this substrate could have been caused by any of the above
explanations.
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6.4.3. 3H-Inulln
The uptake kinetics of 3H-inulin were investigated to confirm 
whether this marker behaved in the same way as established markers of 
fluid-phase pinocytosis in the rat yolk-sac system.
Many criteria must be met before the mode of uptake of a 
molecule can be attributed to fluid-phase pinocytosis, eg see Pratten 
et al. (1980); Ose et al^ (1980); Steinman 6 Cohn (1972); Steinman et 
al. (1974); Besterman et a h  (1981). Briefly the various requirements 
of fluid-phase (as opposed to adsorptive) pinocytic markers are:- 
i) Uptake should occur at the same minimum rate observed for other 
fluid-phase markers in that cell system, 
li) The rate of uptake (pg/h per mg tissue) should increase in a 
direct proportion to the extracellular concentration of 
substrate. (The E.I. expressed in terms of pl/mq/h, should 
remain constant.)
iii) The rate of loss of the substrate should be low, with no 
substantial, readily releasable component.
iv) The substrate should not associate with the cell/tissue at low 
temperatures or in the presence of pinocytic inhibitors.
Ideally, all these criteria should be established before uptake of 
a macromolecular substrate is claimed to occur via fluid-phase 
pinocytosis. Experiments in this section were therefore designed to 
assess whether they applied to the behavior of H inulin in rat 
yolk-sac tissue.
The rate of accumulation of 3H-inulln was virtually identical to 
that of 125I-PVP, an established fluid-phase marker in the yolk-sac 
system. The time-course of accumulation was approximately linear, at 
least over the initial six hours of incubation. Only a very small 
concentration range of 3H-inulin was tested, so nothing conclusive
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can be reported on the concentration dependence of the rate of 
accumulation.
The time-course of release of 3H—inulin was difficult to 
interpret. Both the amount and the rate of release of 3H-inulin were 
greater than that of 125I_pVP, the difference was particularly 
noticable in the absence of serum. [The effect of serum on release 
of substrates is not well documented, although some reports mention 
that the presence of serum (Ibboson 6 Williams, 1979) or 
concentration of serum (Dean S Jessup, 1982) has no effect on 
exocytosis.] A slight increase in the amount of substrate released 
in the absence of serum might be expected, since cell viability is 
slightly lowered, therefore cell death with consequent release of all 
cell contents, might occur to a greater extent. It is possible that 
the greater release of 3H-inulin compared with 125x_pVp was due to 
limited intracellular degradation of that molecule or of 
radiolabelled contaminants, which would also explain the tendency 
towards a decrease in the rate of accumulation on prolonged
1
incubation, see Section 6.4.2. (Thus a greater amount of 
impurities in the different batch of 3H-inulin used in the absence of 
serum would explain the increased rate of release.) However, no 
impurities or lower molecular mass degradation products were observed 
when unincubated 3H-inulin and radiolabel released from yolk sacs 
loaded with 3H-inulin were passed down a Sephadex G-25 column.
The evidence presented in this section, coupled with the 
previously reported data on 3H-inulin (Bowers S Olszewski, 1972) 
strongly suggests that uptake of 3H-inulin by rat yolk sacs is via
fluid-phase pinocytosis.
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6.4.4. Accumulation of 3H-Leupeptln
The results discussed in this section refer only to the net 
accumulation of radiolabel within tissue, which does not necessarily 
correspond to the total uptake of leupeptin. However the rate of 
tissue accumulation of radioactivity is a good approximation to the 
total rate of uptake, provided the rate of release is not too great. 
(Release of leupeptin-derived radioactivity from yolk sacs is 
discussed in Section 6*4.5).
Experiments were designed to distinguish between possible routes 
of entry of leupeptin into the cell, ie passive diffusion, 
facilitated transport, active transport, fluid-phase pinocytosis, and 
adsorptive pinocytosis.
Measuring the rate of accumulation for increasing substrate 
concentrations should allow distinction between facilitated 
transport, active transport, or adsorptive pinocytosis (which are all 
saturable), and passive diffusion, or fluid-phase pinocytosis (which 
are not saturable). Accumulation of 3H-leupeptin over the 
concentration range 3-100pg/ml did not appear to show saturation 
kinetics. (No systematic change in the rate of accumulation of 
3H-leupeptin with increasing concentration occurred). The 
time-course of accumulation at each concentration of leupeptin was 
indistinguishable from that of matched 3H-inulin controls.
In principle, metabolic inhibitors should permit differentiation 
between passive diffusion or facilitated transport (which do not 
require energy and are thus not inhibited) and active transport or 
pinocytosis (which are energy dependent, and are thus inhibited by 
metabolic inhibitors). However some metabolic inhibitors may have 
unwanted side effects; any changes in either the cell membrane or the 
substrate itself in the presence of inhibitor may affect both passive 
and facilitated transport. The metabolic inhibitor rotenone (which
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inhibits the electron transport chain thus lowering cellular ATP 
levels) strongly inhibited 3H-leupeptin accumulation (Fig. 6.12).
This inhibitor is not reported to affect energy-independent processes 
suggesting that accumulation of leupeptin requires energy.
The temperature dependence of a metabolic reaction is often 
given in terms of the temperature co-efficient (Q10), which is the 
relative increase/decrease in the rate on raising/lowering the 
temperature by 10°C. The Q10 value gives an indication of the 
activation energy of the transport mechanism (processes with a high 
activation energy will have a high Q-jo value). It was hoped that the 
temperature dependence of the rate of accumulation might allow 
differentiation between uptake via permeation and pinocytosis.
The Q10 of permeation of different substrates across a specific 
plasma membrane will depend on the oil/water partition coefficient, 
molecular size, degree of hydration etc. of the substrate.
Facilitated and active transport usually have a Q10 greater than that 
which might be expected from the characteristics of the substrate if 
passive diffusion were the method of uptake, but this is not 
sufficiently reliable to be a diagnostic test. Membrane transport 
processes and permeability are generally affected by the transition 
temperature of the membrane (ie the temperature at which the lipids 
in the membrane start to crystallize, which depends on the lipid 
composition). The Q^q values (and activation energy) of transport 
differ above and below this temperature, and membrane permeability 
shows a maximum at this temperature (Bach, 1983). Some exceptions 
are known, eg Racker & Hinkle (1974) suggest that transport by 
membrane pores may not change at the transition temperature.
Several reports have been made on the temperature dependence of 
pinocytosis, though some observations differ in detail. Most workers 
have found that pinocytosis is inhibited at and below about 15 C,
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which corresponds roughly to the transition temperature of many 
membranes (eg Dunn et aU, 1980; Shirazi et al^, 1982; Duncans 
Lloyd, 1978; Mahoney et al., 1977). However, Silverstein et ab^
(1977) and Ose et al. (1980) found no critical thermal transition 
point, pinocytosis continued at a rate directly proportional to 
temperature over the range 2-38°C. In general, above about 15 C the 
Q10 and activation energy of fluid-phase pinocytosis is constant up 
to 38°C; the Q10 is in the region of 2.8 (Shirazi et al., 1982; 
Pratten S Lloyd, 1979; Mahoney et al., 1977). The Q1Q of receptor
mediated pinocytosis is often reported to show an inflection point at 
about 20°C, below which the Q10 and activation energy of uptake is 
considerably increased (eg Weigel & Oka, 1981).
In yolk sacs, pinocytosis was totally inhibited at 20°C (Duncan 6 
Lloyd, 1978). Unlike the results of Shirazi et al. (1982) an 
inflection point was observed at 30 °C for fluid-phase pinocytosis, 
using 125I-PVP as a marker. The activation energy (and hence 01Q) 
above this temperature was greater than that below it (Duncan, 1978). 
Above 30°C, the Q10 was 7.05, which is considerably higher than those 
reported for pinocytosis and other membrane transport mechanisms in 
other cells and tissues at temperatures between 30-37°C. Hence in 
rat yolk sacs it was just possible that the temperature dependence of 
uptake could be used to distinguish between pinocytosis and other 
mechanisms of transport.
However, temperature dependence of accumulation of neither 
Vleupeptin nor 3H-inulin concurred with that reported by Duncan 
(1978). The rate of uptake of the marker 3H-inulin decreased in 
direct proportion to temperature (with no discontinuity at 30 C).
The Q10 was 2.59, which is similar to those reported in other 
systems. The temperature dependence of 3H-leupeptin was similar to 
that of 3H-inulin except that the Q 10 was 1.92 which is slightly
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lower than most reported values for pinocytic markers. Temperatures 
between 4-25°C were not tested therefore it is not possible to 
determine whether a transition temperature was apparent between these 
temperatures. It is likely that a transition occurred at or around 
25°C, since uptake was almost fully inhibited at this temperature.
Arrhenius plots are frequently used to calculate the activation 
energy of transport processes. A discontinuity in the Arrhenius plot 
signifies a change in the activation energy and is observed, for 
example, when diferent processes become rate-limiting in pinocytosis 
(eg Wiegel R Oka, 1981) and/or at the membrane transition temperature 
(Bach, 1983). Although no clear discontinuity was observed between 
25-37°C for the uptake of 3H-inulin and 3H-leupeptin the Arrhenius 
plot between these temperatures was not linear. A more informative 
plot may have been obtained if a greater range and larger number of 
temperatures had been used.
6.4.5. Release of Radiolabelled Substrates from Yolk-sac Tissue 
It was hoped that the results from these experiments would 
provide information on the following points.
i) The mode(s) of release of 3H-leupeptin-derived radioactivity 
(by comparison with the release of pinocytic markers that are 
thought to be released only by exocytosis or cell death).
ii) The effect of NH4cl on the release of 3H-leupeptin-derived 
radioactivity and pinocytic markers of various sizes, in order 
to further investigate the effect of NH4cl on loss of leupeptin 
activity observed in Section 5.3.5.
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6.4.5a. Mode of Release of ^H-Leupeptin
There are several ways by which an internalized substrate can be 
released from cells, depending on the nature of the substrate. 
Non-degradable molecules that are incapable of crossing cell 
membranes are released only by exocytosis and/or cell death.
Substrates that are able to cross cell membranes are also released by 
direct permeation across the plasma membrane. Degradable molecules, 
even if incapable of crossing membranes intact, may be broken down 
into fragments that can be released by permeation. Different 
kinetics of release would be expected for these different types of 
substrate.
Markers of pinocytosis such as 3H-inulin, 14C-sucrose and 
125j_pvp are thought to be released from cells via cell death or 
exocytosis alone. If the rate of release of 3H-leupeptin-derived 
radioactivity was found to be greater than the rate of release of 
these markers, 3H-leupeptin-derived label must be released by 
permeation, either as intact leupeptin or following degradation to 
membrane-permeable fragments.
Before discussing the patterns of release observed for the above 
substrates, it is pertinent to review some of the current literature 
on the expected kinetics of exocytosis of non-membrane-permeable, 
non-degradable substrates. Such substrates are generally released in 
a rapid initial burst followed by a slower constant rate of release.
In yolk sacs, Williams et al^ (1975a) and Roberts et al^ (1977) 
proposed that the initial burst of release was caused by dissociation 
of substrates trapped in extracellular sites such as the microvillus 
surface, open pinocytic channels and possibly intercellular spaces. 
The percentage of substrate released during this phase was not 
reproducible, the duration of which was about 1h. The slower, linear 
release phase was attributed to release of intracellular substrate by
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cell lysis and possibly exocytosis.
However, other workers have proposed alternative mechanisms to 
account for the different release phases. Besterman et al, (1981) 
monitored the release of 14C-sucrose from macrophages and fibroblasts 
over a period of two hours. They proposed that the observed rapid 
initial release was caused by release of substrate from a small 
intracellular compartment with a short half-life, and the subsequent 
slower release phase by turnover of a larger compartment with a long 
half-life. The duration of each phase and percentage of substrate 
released depended on the loading period. Dean & Jessup (1982) 
characterised a linear release phase of 14C-sucrose from fibroblasts 
that occurred after 4h, and suggested that this release may reflect 
membrane recycling.
In the work reported in this thesis the release patterns of 
3H-inulin and 125I-PVP (Sections 5.3.4, 6.3.1, and 6.3.3) were as 
expected for non-degradable pinocytic markers, ie an initial rapid 
release was followed by a slower, approximately linear, release. The 
percentage of 3H-inulin released during the initial phase was much 
higher than that of 125I-PVP. This may have been caused by the 
smaller 3H-inulin molecules becoming more readily trapped at 
extracellular sites. (3H-Inulin is known to pass through tight 
junctions in liver cells, Lowe et al., 1985, thus may have greater 
access to intercellular spaces.) Possible causes for the slightly 
greater rate of release of 3H—inulin compared with ^23I—PVP during 
the linear release phase are discussed in Section 6.4.2.
The release pattern of 14C-sucrose differed from that expected 
for non-degradable pinocytic markers and from that previously 
reported for 14C-sucrose in yolk-sac tissue (Roberts et al., 1977). 
The reason for this anomaly was not investigated, though it may have 
been caused by release of intact 14C-sucrose or degradation products
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of 14c-sucrose (or 14C-sucrose contaminants) via membrane permeation.
The release pattern of radiolabel from 3H-leupeptin-loaded 
tissue was similar to that of 125I-PVP and 3H-inulin (a rapid initial 
burst was followed by a slower linear rate of release), except that 
the percentage of radioactivity released during the burst and the 
rate of release during the linear phase were greater than those of 
3H-inulin and 125I-PVP. The initial burst of release may have been 
caused by the release of leupeptin that had become trapped at 
extracellular sites of the yolk sacs. (Adsorbtion of leupeptin to the 
plasma membrane was not thought likely because 3H-leupeptin was not 
displaced from the yolk sac during a 3x2 min rinse period in the 
presence of cold leupeptin.) The greater rate of release of 3H-label 
during the linear release phase could be caused by a slow release of 
intact leupeptin or leupeptin degradation products from the tissue by 
membrane permeation in addition to release by cell lysis or 
exocytosis. However, further evidence is required on the nature of 
the 3H-label released during the different phases before making any 
firm conclusions on the mechanism(s) of release of leupeptin.
6.4.5b Effect of Ammonium Chloride on the Release of ^-Leupeptin 
Derived Radioactivity: Comparison with Pinocytic Markers
In the experiments reported in this section, the effect of 
ammonium chloride on the release of pinocytic markers of various 
molecular sizes and on the release of ^H—leupeptin—derived label from 
loaded yolk sacs was determined to try to explain the increased loss 
of active leupeptin discussed in Section 5.4.2«
The effect of ammonium chloride on the vacuolar system of cells 
is well documented. Cells become highly vacuolated (Seglen & Reith, 
1976; Ohkuma & Poole, 1981). Many membrane fusion processes are 
inhibited, eg endocytosis, vesicle-lysosome fusion. Exocytosis is
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also Inhibited by up to 25%; the dose-response curve is biphasic, 
with maximal inhibition occurring at lower concentrations (Dean & 
Jessup, 1982). A review of the effect of amines on mammalian cells 
is given by Dean et al. (1984).
Unfortunately, little is known about the effects of ammonium 
chloride on membrane permeability or on membrane transport systems. 
The lysosomal membrane must expand to accommodate the increased 
lysosomal volume, which may result in the membrane becoming more 
porous. Also, it is possible that lysosomal membrane transport 
mechanisms may rely on the maintanance of a particular pH within the 
lvsosome and thus would not operate normally in the presence of 
ammonium chloride.
Release of 125I-PVP and 3H-inulin were unaffected by ammonium 
chloride (10mM), (which suggests that either exocytosis was not 
inhibited in the yolk sac or the substrates were not released by 
exocytosis). No increase in cell lysis or in plasma membrane 
permeability, to molecules with a mol. mass >5,000 (detectable as an 
increased rate of substrate release) was thus apparent. The initial 
rate of release of 14C-sucrose was slightly increased, but because 
this substrate behaved anomolously in the absence of ammonium 
chloride, no conclusions can be drawn on the effect of ammonium 
chloride on its release.
Ammonium chloride did not increase the release of 3H-leupeptin. 
This suggests that the enhanced loss of leupeptin activity 
discussed in Section 5.4.2. was not due to release of intact 
leupeptin from the tissues. The loss may have been caused by 
leupeptin inactivation, but any such inactivation must not have given 
rise to membrane-permeable degradation products. No information was 
available on the effect of ammonium chloride on lysosomal membrane 
permeability, therefore the mechanism of enhanced intracellular
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inactivation could not be identified.
To summarise, uptake of 3H-leupeptin did not appear to be 
saturable but was energy dependent. The temperature dependence of 
uptake was marked but could not be used as a basis to distinguish 
between pinocytic and other modes of uptake. The rapid rate of 
release of radiolabel from 3H-leupeptin loaded yolk-sacs suggested 
that either degradation of leupeptin occurred, or that both the 
lysosomal and plasma membranes were more permeable towards leupeptin 
than towards pinocytic markers. The lack of effect of ammonium 
chloride indicates that the increased loss of leupeptin activity 
observed in the presence of ammonium chloride (Section 5.3.5) was not 
due to an increase in the amount released from the tissue (either 
intact or following degradation).
Fig. 6.1 Uptake of 3H-Inulin by Rat Yolk Sacs
Yolk sacs were incubated with 3H-inulin using the reduced volume 
method described in Section 2.2b. The amount of substrate within 
the tissue was calculated in terms of yl/mg yolk-sac protein as 
described in Section 2.7c. The graph shows the mean uptake values.
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Fig. 6.2 Elution Profile of 3H-Radioactivity Released from Yolk Sacs
3Loaded with H-Inulin
Yolk sacs were incubated with 3H-inulin to load the tissue with 
substrate, then reincubated in fresh medium. Samples (1ml) of 
reincubation medium were loaded onto a small chromatography 
column containing Sephadex G25 (PD-10 column) and eluted with 
water. The eluant (collected in 1ml fractions) was assayed for 
radioactivity.
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Fig. 6.3 Elution Profile of H-Inulin
3H-inulin stock solution was diluted in distilled water.
The diluted solution (1ml) was loaded onto a small chromatography 
column containing Sephadex G25 (PD-10 column) and eluted with 
water. The eluant (collected in 1ml fractions) was assayed for 
radioactivity.
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Fig. 6.4 Release of ~":-?VP and 3H-Inulin from Loaded Yolk Sacs 
in the Presence and Absence of Calf Serum
Yolk sacs were incubated in serum—free medium containing 
either 125I-PVP or 3H-inulin. The yolk sacs were then 
rinsed and re-incubated in substrate-free medium containing 
either no serum or 10% serum. Samples of re-incubation medium 
were removed for assay of radioactivity, as described in 
Section 6.2.2.
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fig. 6.5 Time-Course of Accumulation of H-Leupeptin Compared With
Uptake of 3H-Inulin
Accumulation of substrate within yolk sacs was determined as detailed 
in Section 6.2.1b. Each point represents the mean accumulation 
(± S.D.), as described in Section 6.3.2.
Ac
cu
mu
la
ti
on
 o
f 
su
bs
tr
at
e 
(y
l/
mg
 y
ol
k 
sa
c 
pr
ot
ei
n)
20 /
Fig. 6.
15
1 0 -
5-
I
I
0 1 2  3
Time (h)
^  3H-Leupeptin (10 pg/ml)
3O H-Inulin
Time-Course of Accumulation of H-Leupeptin at 10 yg/ntl
Yolk sacs were incubated in medium containing H-leupeptin 
(10 yg/ml) and accumulation of radioactivity within the tissue 
measured as described in Section 6.2.1b. Uptake of H-inulin was 
determined In a matched control.
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Time Course of Accumulation of H-Leupeptin at 100 yg/ml
Yolk sacs were incubated in medium containing H-Leupeptin 
(10 yg/ml) and unlabelled leupeptin (90 yg/ml), and accumulation of 
radioactivity within the tissue measured as described in 
Section 6.2.1b. Uptake of 3H-inulin was determined in a matched
control.
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Effect of Incubation Temperature on the Time-Course of Accumulation 
of 3H-leupeptin.
3
Yolk sacs were incubated in medium containing a trace of H-leupeptin 
(total leupeptin concentration 102.5 yg/ml) at the temperatures 
indicated. Accumulation of radioactivity was determined as detailed 
in Section 6.2.1b. Each point represents the mean accumulation 
(± S.D.) from at least 3 experiments.
;□ 37°C « 25°C
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Fig. 6.9 Effect of Incubation Temperature on the Time-Course of 
Accumulation of ^H-Inulin
Uptake of 3H-inulin was monitored as matched controls to the 
experiments described in Fig. 6.8. Accumulation of H-inulin was 
determined as detailed in Section 6.2.1b. Each point represents 
the mean ( ±S.D.) from at least 3 experiments.
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Fig. 6.10 Summary of the Effect of Temperature on the Rate of Accumulation 
of 3H-Leupeptin and 3H-Inulin
The rate of accumulation of substrate during the initial 4h 
incubation period was determined for each individual experiment 
described in Section 6.2.1. The mean rate of accumulation 
(± s.D.) was then plotted against the temperature of incubation.
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The natural log of the rates of accumulation of substrate determined 
for Fig. 6.10 were found, and the mean value (± S.D.) plotted 
against 1/T(K) for each substrate.
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3 . 3Fig. 6.12 Effect of Rotenone on the Accumulation of H-Leupeptin and__H
Yolk sacs were incubated with substrate in medium containing 
rotenone (10_5M) as described in Section 6.2.1b. Uptake of 
3H-inulin was also monitored in the absence of rotenone to 
indicate the rate of fluid-phase pinocytosis.
a  ;
-Inulin

Su
bs
tr
at
e 
re
le
as
ed
 (
% 
pr
es
en
t 
in
it
ia
ll
y)
A  Ammonium chloride (lOmM) present during re-incubation 
• Ammonium chloride absent during re-incubation
Fig. 6.14 Time-Course of Release of l4C-Sucrose from Loaded Yolk Sacs 
in the Presence and Absence of Ammonium Chloride
Tissue was incubated with C—sucrose then re—incubated in
substrate-free medium in the presence and absence of ammonium 
chloride. The re-incubation medium was assayed for radioactivity 
as described in Section 6.2.2a,b. Results shown are the 
mean (± S.D.) from 3 experiments.
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Fig. 6.15 Time-Course of Release of ^H-Inulin from Loaded Yolk
Sacs, in the Presence and Absence of Ammonium Chloride
Tissue was incubated as described in Section 6.2.2a and the 
results calculated as described in Section 6.2.2b.
Results shown are the mean (± S.D.) from 3 experiments.
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Fig. 6.16
Ammonium chloride absent during pre-incubation
Time-Course of Release of 3H-Leupeptin from Loaded Yolk 
Sacs, in the Presence and Absence of Ammonium Chloride
Tissue was incubated as described in Section 6.2.2a and the 
results calculated as described in Section 6.2.2b. Results 
shown are the mean (± S.D.) from 3 experiments.
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3 V° '.17 Elution Profile of H-Leupeptin on Sephadex G25
A solution of 3H-leupeptin (0.5ml) was loaded onto a PD 10 
column and eluted with water. The eluant (0.5ml fractions) 
was assayed for radioactivity, as described in Section 6.2.3.
A cell-free yolk-sac homogenate (0.5ml) was loaded onto a 
PD-10 column and eluted with water. The eluant (0.5ml fractions) 
was assayed for protein by the Folin assay as described
in Section 6.2.3.
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Fraction number!Vo t VeElution Profile of H-Leupeptin mixed with Whole Yolk-Sac
Homogenate on Sephadex G25
A solution of 3H-leupeptin was added to a whole yolk-sac homogenate 
then the mixture centrifuged to remove tissue debris. The 
supernatant (0.5ml) was loaded onto aPD-10 column and eluted 
with water. Fractions (0.5ml) of the eluant were assayed 
for radioactivity, as described in Section 6.2.3.
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A solution of 3H-leupeptin was added to the supernatant 
of a yolk-sac homogenate that had been centrifuged to remove 
tissue debris. The mixture (0.5ml) was loaded onto a 
PD-10 column and eluted with water. Fractions (0.5ml) of 
the eluant were assayed for radioactivity as described 
in Section 6.2.3.
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^H-leupeptin was added to a whole yolk-sac homogenate then the 
yolk-sac proteins precipiated with TCA. A sample (0.5ml) 
of the TCA soluble fraction was loaded onto a PD-10column 
and eluted with water. Fractions (0.5ml) of the eluant 
were assayed for radioactivity, as described in Section 6.2.3,
/Table 6.1
Effect of Concentration on the Rate of Accumulation of Leupeptin
Yolk sacs were incubated with 3H-Leupeptin (or a mixture of 3H-leupeptin 
and unlabelled leupeptin) as described in Section 6.2.1b. The rate of 
accumulation was calculated from the mean value of accumulation at each 
time point for at least 2 experiments. The rate of uptake of 
3H-inulin was determined in the same way as matched controls.
Leupeptin
Cone.
3H-Leupeptin
Rate of Accumulation
(yl/h/mg protein)
Correlation
Coefficient
H-Inulin 
Rate of Uptake 
(yl/h/mg protein)
Correlation
Coefficient
3 2.58 0.97 2.50 0.98
5 2.45 0.99 2.49 0.98
10 3.17 0.99 3.57 0.99
50 2.98 0.97 3.63 0.99
100 2.71 0.96 3.87 0.99
Mean Rate 
of
Accumulation 2.78 (±0.29)
over
concentration 
range (±S.D.)
3.39 (±0.61)
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7.1 IHTRODUCTION
Although many reports indicate that leupeptin is able to inhibit 
lysosomal enzymes in situ (eg Knowles et al., 1981; Seglen et al., 
1979), thus must be able to enter lysosomes, the possibility of 
leupeptin acting at other intracellular sites cannot be eliminated 
since it is capable of inhibiting both lysosomal and non-lysosomal 
proteinases vitro. However its effects 1m vivo may be limited by 
restriction of its access to potential sites of action. Evidence for 
inhibition by leupeptin of non-lysosomal proteolytic enzymes in 
intact cells is lacking, though most studies do not eliminate the 
possibility of such action (eg Libby & Goldberg, 1978; Cockle & Dean, 
1982). Indeed Seglen et al. (1979) S Grinde and Seglen (1980) found 
that leupeptin-induced inhibition of proteolysis in hepatocytes was 
slightly additive to that of weak bases, and concluded that the 
additional effect was caused by inhibition of a non-lysosomal pathway 
of protein degradation.
There are two main mechanisms by which leupeptin could enter 
cells: direct plasma—membrane permeation or pinocytosis. If the 
former is the main route of entry, leupeptin will initially be 
located in the cytosol. In order to affect lysosomal enzymes, 
permeation across the lysosomal membrane must then follow. If uptake 
of leupeptin occurs via pinocytosis, the leupeptin will initially be 
located in the vacuolar system, hence permeation across the lysosomal 
membrane will not be required for inhibition of lysosomal enzymes. 
However the effects of the inhibitor may not necessarily be confined 
to the lysosomes if permeation of the intact molecule across the 
lysosomal membrane occurs.
The work described in this chapter attempts to determine whether 
leupeptin is able to permeate lysosomal membranes and so has access
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to both lysosomal and non-lysosomal compartments, whatever its mode 
of uptake. The experiments were performed usincr rat-liver lysosomes 
rather than lysosomes isolated from yolk-sac tissue. This is 
because, although exhaustive attempts have been made in the past to 
isolate intact yolk-sac lysosomes, the majority appeared to rupture 
during homogenization (Williams 6 Lloyd, unpublished observations). 
Even if isolation of intact lysosomes from yolk sacs were possible 
the isolation of a sufficient quantity of protein-loaded lysosomes 
for in vitro studies would prove difficult.
Several different methods have been utilized to demonstrate the 
permeability properties of lysosomes. Traditionally, either the 
ability of an agent to afford osmotic protection to isolated 
lysosomes (eg see Lloyd 1969; 1971), or an assessment of the degree
of vacuolization of lysosomes within intact cells caused by the agent 
(eg Ehrenreich & Cohn, 1969) have been used. Briefly, the rationale 
behind the osmotic protection method is that when lysosomes are 
suspended in an isotonic solution of a permeant molecule, entry of 
this molecule into lysosomes (along the concentration gradient) will 
lead to an osmotic imbalance. Influx of water then causes lysosomal 
expansion and eventual rupture of the membrane. This lysis can be 
detected by measuring the percentage of free, as opposed to latent, 
lysosomal enzyme activity. The vacuolization method is based on the 
fact that when non—permeant molecules enter lysosomes (following 
pinocytic uptake into cells), an osmotic inbalance is created and 
water enters the lysosomes causing swelling. Hence, if vacuolization 
is observed on incubating cells with an agent, that agent must be 
incapable of permeation through the lysosomal membrane.
Both these methods have attendant disadvantages, some of which 
are discussed by Reijngound fi Tager (1977), and by Hales e t ^ al. 
(1984). The osmotic protection method requires careful controls to
167
ensure that the substrate used to measure free enzyme activity cannot 
permeate the lysosomal membrane, or that, if centrifugation is 
employed to separate 'free' from 'latent' enzyme activity, the enzyme 
being assayed does not adsorb to lysed lysosomal membranes. The 
method also has limitations in terms of the solubility, cost, and the 
non-physiological concentration of the agent used. For the 
vacuolization method, only substrates that are taken up by 
pinocytosis and which are not digested by lysosomal enzymes can be 
employed. (This may prevent peptides from being used as vacuolating 
agents.) Quantitation is difficult, and generally only cells or 
tissues that can be conveniently visualized by light microscopy may 
be used.
Some of the conclusions drawn by the early workers using these 
methods are now under review. In the past, movement across the 
lysosomal membrane has been attribted to passive diffusion. The rate 
of permeation of an agent has been correlated with its size, 
hydrophobicity and charge (eg Lloyd, 1973; Reingoud & Taaer, 1977). 
More recent evidence suggests that movement of at least some 
molecules is by specific transport systems (Hales et al. , 1984).
Permeation of several molecules across the lysosomal membrane 
has been monitored using specially-designed techniques. For example, 
cystine transport has been investigated in great detail, in an 
attempt to discover the primary defect in the disease cystinosis. 
Lysosomes were loaded with cystine then the release of this molecule 
monitored. Transport was found to be pH and ATP dependent, and did 
not occur normally in cystinotic cells (for review, see Schneider et 
al., 1984). This suggests the presence of a specific, 
energy-dependent transport system for cystine in the lysosomal 
membrane.
Pepstatin, which is a microbial proteinase inhibitor containing
five amino acid residues, was investigated by introducing it into rat 
liver lysosomes in vivo, as an asialofetuin-pepstatin complex. After
intravenous injection of the complex, pepstatin-loaded lysosomes were 
isolated from the liver and incubated in _ vitro. The time-course of 
release of pepstatin was found to be linear, and 60% of the inhibitor 
initially present was released over 60 minutes (Furuno et al., 1983).
Lysosomal membrane permeation by agents that affect protein 
degradation can be detected by monitoring their effect on the rate of 
intralysosomal proteolysis in isolated lysosomes incubated ill vitro.
A method frequently used is based on one developed by Mego ft McQueen 
(1965 a,b). Liver lysosomes are loaded in vivo with a radiolabelled 
protein (usually ^^I-BSA^^) by means of intravenous injection of the 
protein. The protein is then cleared from the bloodstream, mainly by 
the liver, via pinocytosis. The liver lysosomes are then isolated 
and incubated in an isotonic solution in the presence and absence of 
the proteolytic effector. The labelled protein is degraded within 
the lysosomes and the time-courses of release of low-molecular-weight 
degradation products monitored and compared (Mego & McQueen, 1965 
a,b; Mego et al., 1967; Davies et al., 1971; Reijngoud et al., 1976). 
(When using this method it is important to establish that the 
observed proteolysis occurs only within the lysosomes. Many factors 
are known to affect lysosomal integrity in vitro, therefore ideally, 
optimum conditions of pH, temperature, medium composition etc. to 
maximize lysosomal membrane stability should be used, and lysosomal 
rupture monitored.] The effects of proteolytic inhibitors such as 
ammonia, methylamine (Reijngoud et al., 1976), iodoacetate (Mego S 
McQueen, 1965a), and stimulators such as glutathione (Mego, 1984) and 
cysteine (Mego S McQueen, 1965a) have been investigated using this 
system. (The results of these investigations will be discussed in
Section 7.4).
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The effect of leupeptin on protein degradation within lysosomes 
has also been investigated. Neff et a h  (1979) added leupeptin to a 
suspension of lysosomes (that did not contain any radioabelled 
protein), and measured the rate of production of
fluorescamine-positive material arising from degradation of the 
heterogeneous mixture of proteins present within lysosomes.
Leupeptin did not affect the rate of degradation unless the membranes 
were first lysed by freeze/thaw action, suggesting that leupeptin was 
not able to permeate through membranes. However, Ahlberg 6 Glaumann 
(1985) used leupeptin successfully to inhibit degradation of proteins 
taken up into lysosomes by microautophagy. The lysosomal membrane 
was assummed to be fully permeable to leupeptin in that study.
For the experiments described in this chapter, lysosomes were 
loaded with 125I-BSAf(J using the method of Mego & McQueen (1965a), 
then incubated in the presence of leupeptin. If the rate of release 
of TCA-solubles was lowered compared with controls, leupeptin must 
either be able to enter the lysosomes, or cause lysis of isolated 
lysosomes. These results were compared with the effects of ammonium 
chloride, which is reported to permeate lysosomal membranes (Ohkuma 
& Poole, 1981; Poole fi Ohkuma, 1981; Reijngoud et al., 1976).
The medium composition, [eg presence or absence of ATP and Mg2+ 
(Mego 6 McQueen, 1965a,b; Ohkuma et al.,1982), ionic strength (Mego 
et al., 1967), molarity (Mego et al., 1967; Lloyd, 1973), pH and type 
of buffer (Mego, 1971; Mego et al., 1972)] and temperature of 
incubation (Davis et al., 1971) are all known to affect the rate of 
intralysosomal proteolysis and/or the degree of lysis of the 
lysosomes. Some of these factors were investigated in the work
reported in this chapter.
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In summary, the following were investigated in this chapter:-
4 h Ci) Rat-liver lysosomes loaded with I-BSAfd were incubated either 
in sucrose (0.25M), or in medium containing sucrose (0.2mM), KC1 
(50mM), MgCl2(10mM), ATP (1mM), and HEPES (20mM), buffered at pH 
7.0. The rate of production of TCA-solubles was monitored to 
determine the effect of the more complex ATP-medium on the rate 
of degradation.
ii) The effects of Triton X-100 (0.1%) on the rate of degradation of 
125I-BSAf(l was determined, to assess whether proteolysis could 
occur once the lysosomal contents had been released into the 
medium after lysis of the membrane by the detergent.
125 -iii) The rate of production of TCA-soluble material from I-BSA^d 
loaded lysosomes was monitored in the presence of ammonium 
chloride (20mM) or leupeptin (10ug/ml) to establish whether 
either inhibitor was able to pass into the lysosomes and inhibit 
degradation.
125iv) Leupeptin was added to a suspension of I—BSAfd—loaded 
lysosomes in sucrose (0.25M) to give a final leupeptin 
concentration of 10, 25 or lOOpg/ml. The rates of production 
of TCA-soluble material were then monitored, to determine the 
degree of inhibition at each concentration.
v) The pH of the lysosomal suspension was varied, using a medium 
composed of sucrose (0.25M) and phosphate buffer (30mM). The 
rate of production of TCA-soluble material was thus measured at 
pH 6, 7 and 8. The effects of ammonium chloride (20mM) and 
leupeptin(10pg/ml) were determined at each pH.
vi) An estimate of the amount of lysosomal lysis that occurred 
during each of the above experiments was made by measuring the 
amount of intact 125I-BSAfd that became released into the
incubation medium
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7.2. MATERIALS AND METHODS
I. MATERIALS
Rats Adult male Wistar, weight approximately 250g.
Rats were starved overnight before use to deplete
stored glycogen from the liver.
Equipment
Centrifuge MSE High Speed 18. M.S.E., London, U.K.
All other equipment as described in Chapter 2. Glassware and 
polypropylene vessels were soaked in acid (dilute HCl) before use 
to remove any traces of detergent.
Reagents
125I-BSAfd Prepared as described in Section 2.1a. Used as 
undiluted, dialysed solution.
Leupeptin Portions of a deep frozen stock solution (2mg/ml 
in water) were diluted to final concentrations of 
10, 25 and 100yg/ml with the lysosomal 
suspension.
Ammonium A stock solution (0.2M) in sucrose (0.25M) was
Chloride diluted to a final concentration of 20mM with the 
lysosomal suspension.
Triton X-100 A stock solution (10% v/v) was diluted to 0.1% 
with the lysosomal suspension.
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Suspension Media: 
Sucrose
Buffered sucrose 
ATP medium
0.25M, unbuffered.
0.5M sucrose mixed with an equal volume of 
KH2/Na2H phosphate buffer (60mM) of the 
appropriate pH.
Solutions of HEPES buffer (pH 7.0, 0.2M, 5ml) 
KCM0.25M, 10ml), MgClj (0.5M, 2ml) and sucrose 
(0.5M, 20ml), were mixed together and the total 
volume adjusted to 50ml. Just before use a 
freshly prepared solution of ATP (100mM, 10yl/ml 
medium) was added, and the pH readjusted to 7 if 
necessary. (This resuspension medium is similar 
to that used by Ohkuma e t _ al., 1982.)
All other reagents as described in Chapter 2.
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I I .  METHODS
7.2.1. Preparation of 125I-BSA„-loaded lysosomes
The method used was based on that described by Mego & McQueen 
(1965 a,b). Rats were anaesthetized with ether to allow an 
intravenous injection of 125I-BSAfd (approximately 1ml per animal) 
into the femoral vein. After exactly 30min, during which period the 
125I-BSAfd was cleared from the bloodstream and reached a maximum 
concentration in liver lysosomes (Mego & McQueen 1965a), the animal 
was sacrificed. The liver was flushed with ice-cold sucrose (0.25M, 
about 50ml, introduced via the vena cava), to remove blood from and 
to rapidly cool the organ.
Preparation of the lysosomal-rich fraction was based on the 
method of DeDuve et al.(1955). The liver was removed from the 
animal, chopped roughly with scissors and passed through a sieve.
The resulting pulp was weighed and sucrose solution (0.25M) added to 
give a suspension approximately 40% (w/v). This was homogenized 
using a Teflon-on-glass Potter-Elvehjem-type homogenizer (3-5 passes 
of the pestle over 30secs) and diluted with additional sucrose 
solution to give a 10% w/v suspension. The homogenate was then 
centrifuged at 1100g for 10 min to remove nuclei and unbroken cells, 
and the supernatant carefully decanted into fresh centrifuge tubes. 
This was then centrifuged at 22,500g for 10 minutes to obtain a 
fraction (pellet) enriched in lysosomes. (The fraction would also 
contain a large proportion of mitochondria.) After removing the 
supernatant, the pellets were gently resuspended in approximately 
100ml of the suspension medium (ie. sucrose, buffered sucrose, or 
ATP medium). All material was kept cool (either on ice or in a
cooled centrifuge), and preparation carried out as quickly as
125possible, to minimise degradation of I-BSAfd.
174
12 5 ,7.2.2. Measurement of Rate of Degradation of____I-BSAf^ by
Lysosomes
The lysosomal suspension was measured into 25ml plastic, 
sealable universals, which were incubated at 25°C. The test agent 
(leupeptin, ammonium chloride or Triton X-100) was added at zero time 
and duplicate samples (1ml) of the suspension were removed at t = 0, 
15, 30, 60, 90, 120 and 150 minutes, to assess the amount of 
TCA-soluble radioactive material produced, and hence monitor the 
time-course of 125I-BSAfd degradation. On removal, the samples were 
added to vials containing aqueous TCA solution (20% w/v, 0.5ml) which 
precipitated undegraded 125I-BSAfd and intact proteins. (TCA has been 
shown to release the contents of lysosomes; Mego 6 McQueen, 1965a,b; 
thus it was not necessary to disrupt the lysosomal membrane before 
precipitating the 125I-BSAfd.) The total radioactivity of the samples 
was determined and the TCA-precipitate pelleted by centrifugation at 
10OOg for 20min. The TCA-soluble supernatant was then decanted into 
fresh vials and assayed for radioactivity. The percentage of 
125I—BSAfd that had been degraded at each time point was calculated 
as follows:-
TCA-soluble radioactivity (c.p.m.)
% 125I-BSAfd degraded
Total radioactivity (c.p.m.)
x 100
Both TCA-soluble and total counts were corrected for background 
radioactivity. The time-course of percentage degradation was plotted 
for each experiment.
Samples of the suspension were also removed at t=0 and at
125t=150min, to assess the amount of free, non-sedimentable I-BSAfd 
present in the preparation before and after the 2.5h incubation.
This gives a measure of the fraction of broken lysosomes in the 
preparation initially, and those formed during incubation. The 
samples were centrifuged at about 22,500g for 1h in order to pellet 
the lysosomes (and any lysed membranes). The supernatants and 
pellets were separated, and the pellets resuspended in sucrose (1ml). 
Serum (0.1ml) was added to the supernatants as a carrier protein then 
0.5ml of aqueous TCA (20%,w/v) added to both the supernatants and 
resuspended pellets, to precipitate intact I—BSA^^. The TCA
precipitates were separated by centrifugation (1000g, 10min),
resuspended in water (1ml) and assayed for radioactivity. The 
percentage of TCA précipitable radioactivity was used as a measure of 
lysosomal integrity. (A finding of 100% sedimentable, 
TCA-precipitable radioactivity would indicate complete absence of 
membrane lysis, and no release of intact ^^I-BSAj^.) The percentage 
was calculated as follows
L
% intact lysosomes = _ -------  * 100
L + S
Where: L = TCA-insoluble fraction of the pelleted,
lysosomally-associated radioactivity 
(c.p.m., corrected for background)
S = TCA-insoluble radioactivity associated 
with the supernatant after sedimenting 
the lysosomal pellet (c.p.m., corrected for 
background).
The validity of this method is discussed in Section 7.4.1.
7.3. RESULTS
The control rate of degradation (ie that observed in the absence 
of effectors) and the percentage of TCA-soluble material initially 
present varied between different lysosomal preparations, therefore 
the results could not be combined to give a mean time course of 
125I-BSAfd degradation for each type of experiment. Hence, the 
figures shown are time-courses that were representative for each 
particular type of experiment.
7,3.1, Effect of Composition of Suspension Medium on the Rate
of Intralysosomal 125I-BSAf  ^Degradation 
Optimum conditions for protein degradation within lysosomes 
include an acidic intralysosomal pH. In the past much debate has 
surrounded the mechanism of acidification of lysosomes iji vivo- A 
review by Reijngoud & Tager (1977) favoured a Donnan-type 
equilibrium, with negative lipoproteins within lysosomes maintaining 
a gradient of protons across the lysosomal membranes. However, 
strong evidence now exists for the presence of an Mg2+-ATP-dependent 
proton pump, which actively pumps protons into lysosomes to maintain 
the pH gradient (eg Poole & Ohkuma, 1981; Ohkuma et al., 1982).
The lysosomal suspension medium used by Ohkuma et al. (1982) 
gave good in Vitro acidification of the lysosomes, whereas incubation 
in sucrose buffer alone caused a gradual increase in the
intralysosomal pH. It was therefore decided to examine two different
125resuspension media for their effects on intralysomomal I-BSAfd 
degradation. The ATP medium used was similar to that suggested by 
Ohkuma et al .  (1982). Unbuffered sucrose (0.25M), which is commonly 
used to provide osmotic protection for intact lysosomes (DeDuve at 
a l . ,  1955) was also tested, since this simple medium gave good
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results in the work of Mego & McQueen (1965 a,b).
The time-courses of 125I-BSAfd degradation in lysosomes 
suspended in the two different media are shown in Figs. 7.1 and 7.2. 
The plots for both sucrose and ATP medium were generally slightly 
curved; the rate of degradation slowed after about 90-120min.
Either there was no difference in the time-course of degradation 
(Fig. 7.1) or the rate observed in the ATP-medium was slightly lower 
than for sucrose alone (Fig. 7.2). The percentage of intact 
lysosomes in matched experimental preparations was similar for both 
types of resuspension media/ both before and after the 150min 
incubation period.
7.3.2. Effects of Triton X-100 on the Rate of Degradation of
In order to assess whether leupeptin crosses the lysosomal 
membrane to inhibit proteolysis, it is essential to verify that the 
observed proteolysis occurs only within the isolated lysosomes. (If 
degradation of 125l-BSAfd continued after release of the lysosomal 
contents, any inhibition observed with leupeptin could arise from 
inhibition of extra-lysosomal degradation. Such inhibition would not 
require permeation of leupeptin through the lysosomal membrane.) Mego 
et al. (1967) demonstrated that in the presence of Triton X-100 
(0.2%), or absence of osmotic protectors, the degree of inhibition 
depended on the volume of medium in which lysosomes were resuspended; 
extralysosomal hydrolysis did not occur when lysosomes from 1g liver 
were resuspended in 20ml sucrose solution. This inhibition was 
apparently caused by dilution of the enzyme-substrate mixture on 
release. The results were reported at both pH 5 and pH 7.3. At the 
latter pH, inactivation of the lysosomal cathepsinswould also be 
expected to contribute to the inhibition.
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For the experiments reported in this chapter the 
lysosome-enriched pellet was resuspended in medium to give about a 
15%w/v suspension. The osmotically protective medium was usually 
either unbuffered or buffered to pH 7.0. It was important to check 
that these conditions did not give rise to extra-lysosomal 
proteolysis if the lysosomes became ruptured. Triton X-100 (0.1%) 
was therefore included in the incubation medium. A typical 
time-course of 125I-BSAfd degradation in the presence of the 
detergent is shown in Fig 7.3. No increase in the amount of 
TCA-soluble material over the 150min incubation was observed.
The percentage of intact lysosomes present (as measured via 
non-sedimentable intact 125I-BSAfd) was determined at the beginning 
and end of these experiments. At the start of the experiment, 
immediately after the addition of Triton X—100, about 10 i 1% of the 
lysosomes remained intact. This decreased to 4 ± 1% by the end of 
the 150min incubation period, (see Section 7.4.1 for possible 
explanations).
7.3.3. Effects of Leupeptln (IQyg/ml) and of Ammonium Chloride 
(20mM) on the Rates of Intralysosomal Degradation of
The effects of these inhibitors were examined using a 
lysosome-enriched fraction suspended in either sucrose or ATP medium. 
(Results obtained using buffered sucrose will be described in Section
7.3.5.)
Ammonium chloride is frequently used to inhibit lysosomal 
protein degradation in cells and tissues (eg reviews by Dean et al., 
1984? Seglen, 1983). It is thought to enter lysosomes uncharged then 
become protonated and trapped, causing vacuolization, an increase in 
lysosomal pH, and inhibition of proteolysis (Ohkuma & Poole, 1981?
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Poole fi Ohkuma, 1981). It has also been shown to inhibit degradation 
of 12^l-BSAf(l in isolated lysosomes (Reijngoud et al., 1976). It was 
hoped to use this molecule as a 'positive control' to indicate that 
inhibition of intralysosomal proteolysis in this _in_ vitro system was 
possible.
It was necessary to check whether the added inhibitors affected 
the integrity of the lysosomal membrane. In matched experiments, the 
difference between the initial and final percentage of
re-sedimentable TCA-precipitable radioactivity (taken to indicate the 
fraction of lysosomes ruptured), after incubating lysosomes with 
leupeptin (10yg/ml) or ammonium chloride (20mM) was often less than 
or equal to that of the control (incubated without inhibitor). [The 
differences between control and inhibited lysosomes were similar for 
both sucrose and ATP—containing media.] This suggests that the
inhibitors did not disrupt the lysosomal membrane.
125Fig. 7.4 shows a typical time course of I-BSAfd degradation 
for the lysosomal preparation suspended in sucrose (0.25M) in the 
presence of (a), leupeptin, (10ug/ml); and (b), ammonium chloride 
(2OmM). Leupeptin produced a marked inhibition of degradation but, 
contrary to expectation, the ammonium chloride did not appear to 
strongly inhibit intralysosomal ^2^I-BSAfd degradation.
The results obtained with ammonium chloride for these 
experiments were rather variable. The rate of degradation in the 
presence of ammonium chloride was generally similar to that in the 
matched control. However, occasionally it was observed to be 
slightly inhibited or even stimulated, compared with the control (see 
Figs. 7.5 a, b). (Leupeptin always gave rise to a marked 
inhibition, although the degree of inhibition, compared with the 
control, differed slightly with different preparations of lysosomes.) 
One possible explanation for this variability could be differences in
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the pH of the unbuffered medium, or lack of important cofactors 
necessary for optimal degradative conditions in the various 
preparations. The experiments were therefore repeated using 
lysosomes suspended in the ATP medium, which standardizes such 
conditions. Typical results are shown in Fig. 7.6a (leupeptin 
10yg/ml) and 7.6b (ammonium chloride, 20mM). Again the effect of 
ammonium chloride was variable. Often the rate of degradation of 
125I-BSAfd was greater than that for the control over the first 
60-90min, then decreased to a rate less than the control for the 
remainder of the incubation. Leupeptin consistently inhibited the 
rate of degradation fairly strongly, as in equivalent experiments in 
sucrose medium.
Curvature of the time-course was a feature of experiments that 
included the inhibitors, whether the lysosomes were suspended in 
sucrose or ATP medium. (This was unlikely to be due to increased 
rupture of the lysosomal membrane, which would itself inhibit 
degradation; see above). With leupeptin, the plot was generally 
strongly curved and tended towards a plateau with no further release 
of TCA-solubles after 90-120min. This may be partially attributable 
to a decreased amount of BSA^^ degradation after this period,
noted in Section 7.3.1. However, the marked differences between test 
and control time-courses suggest that the concentration of leupeptin within the 
lysosomes builds up slowly over the incubation period, to produce a 
gradual increase in the degree of inhibition.
7.3.4. Effect of Leupeptin Concentration on Intralysosomal 
Degradation of 125I-BSAfH
The rate of 125I-BSAf(J degradation was monitored in the presence 
of leupeptin at concentrations of 10, 25, and 100yg/ml. Since a 
similar inhibition was observed using either sucrose or ATP medium
181
with leupeptin at 10pg/ml (see section 7.3.3.), the higher 
concentrations of leupeptin were tested using lysosomes suspended 
only in sucrose solution (0.25M). Results are shown in Fig. 7.7.
The time-course of degradation could be considered to show two 
phases. During the first phase the rate of production of 
TCA-soluhles depended on the amount of leupeptin present. During the 
second phase only a small rise in the percentage of TCA-solubles 
occurred, and this was similar for all leupeptin concentrations. The 
first phase (Fig. 7.7) lasted at least 60min and the duration 
appeared to increase as the concentration of leupeptin was decreased.
The pattern of results could be taken to suggest that a maximum 
degree of inhibition was reached at all concentrations of leupeptin, 
when the rate of increase in percentage TCA-solubles fell to 
approximately 1.5 ± 0.5% per hour.
1257.3.5. Effect of pH on the Rate of Degradation of I-BSAf  ^and on 
the Effectiveness of the Inhibitors Leupeptin and 
Ammonium Chloride
In the previous section, it was noted that ammonium chloride did 
not strongly inhibit 125I-BSAfd degradation in isolated lysosomes. 
However, ammonium chloride is known to inhibit intralysosomal 
degradation of exogenous proteins in cells and tissues. This 
suggests that the ammonium chloride was not able to penetrate rapidly 
the lysosomal membrane under the conditions described in Section
7.3.4.
Uptake of weak bases into cells has been investigated by Ohkuma 
a Poole (1978), Poole a Ohkuma (1981), and Solheim a Seglen (1983). 
Ohkuma and Poole demonstrated that uptake of a base depended on the 
concentration of free, unprotonated base in the medium, which in turn 
was dependent on the pH of the medium. It was therefore decided to
182
study the effects of ammonium chloride and of leupeptin on the rate 
of 125i-BSAfd degradation in isolated lysosomes over the pH range 
6•0 -8•0•
The pKa of the ammonium ion is 9.245 (Atkins, 1978). The 
percentage of unprotonated NH3 present at pH 6, 7, and 8 was 
calculated, using the Henderson-Hasselbalch equation, to be 0.06,
0.6, and 5.7% respectively. The pK& of leupeptin was not determined. 
The only ionizable group within the molecule is the guanidinium group 
of the arginal residue. In arginine, the pK of this group is 12.48, 
which means only a minute percentage would be unionized at pH 6-8 
(3x10-5 - 3x 10-3%). However, the pK may not necessarily be the same 
for the guanidinium moiety in the leupeptin molecule because of the 
aldehyde rather than acid group adjacent, and because of the 
different hydration structures of leupeptin (Maeda et al., 1971, see 
Fig. 1.1).
Changes in the pH of the lysosomal suspension medium are 
reported to affect both the stability of the lysosomal membrane and
the rate of intralysosomal protein degradation. These effects are
125discussed more fully in Section 7.4. The rate of I-BSA^ 
degradation wa3 aways monitored both in the presence and absence of 
inhibitor to indicate whether any change in the rate of degradation 
was caused by the inhibitor itself or by the altered medium. The 
percentage of ruptured lysosomes was determined as described 
previously.
Fig. 7.8 shows the time-course of 125I-BSAfd degradation at pH
6.0 in the presence and absence of leupeptin (10pg/ml) or ammonium 
chloride (20mM). Neither inhibitor decreased the rate of 
degradation, suggesting that neither leupeptin nor ammonium chloride 
entered the lysosomes at a detectable rate at this pH.
At pH 7.0, the time courses of degradation were similar to those
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observed previously (Figs 7.4, 7.5, 7.6). Ammonium chloride had 
little effect on the rate of degradation, whereas in the presence of 
leupeptin a marked inhibition occurred, as described in Section
7.3.4.
At pH 8.0, both ammonium chloride (20mM) and leupeptin (10ug/ml) 
inhibited intralysosomal 125I-BSAfd degradation (Fig. 7.10). Both 
inhibitors gave rise to approximately the same degree of inhibition. 
Inhibition was virtually complete after about 60-90min, with little
further increase in the amount of TCA-solubles produced.
125Fig. 7.11 shows the time-course of I-BSAjd degradation at 
each pH in the absence of inhibitors, determined using the same 
lysosomal preparation. During the first hour of incubation, the 
rates of degradation were very similar at each pH. (The duration of 
this close similarity between rates varied slightly for different 
lysosomal preparations, from between 1-2 hours). After this period, 
the rate of hydrolysis decreased at all pH's. The decrease at pH 8 
was most marked, whereas at pH 6 only a slight decrease was observed.
This observation could possibly be explained by an increase in 
the amount of lysosomal lysis at the higher pH's. The percentage of 
resedimentable, TCA-precipitatable radioactivity (ie intact 
125I-BSAfd within lysosomes), was therefore measured at the beginning 
and end of each incubation, and the difference between them (ie 
amount of lysis that occurred during incubation) calculated. For 
tissue incubated in the absence of any inhibitor, the decrease in the 
percentages of resedimentable intact I-BSAfd was 16 ± 4, 15 - 4, 
and 18 ± 2, for pH 6, 7 and 8, respectively. Thus there was no 
marked difference in the degree of lysis at each pH. [This method of 
determining lysis could, however, have been affected by differences 
in affinity of 125I-BSAfd for the ruptured membranes at different 
pH's. Mego et al. (1967) reports that 125I-BSAfd binds to membranes
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1 2 Sat acid pH, thus the percentage resedimentable I-BSAfd at pH 6 may 
be an overestimate of the amount of intact lysosomes.] The decreased 
rate of degradation observed at the higher pH's after 60min could 
not, therefore, be attributed to a greater amount of lysis.
Ifl5
7.4. DISCUSSION
7 .4 .1 . General Features of the Mego & McQueen Method
This method of measuring the permeability of the lysosomal 
membrane towards certain lysosomal effectors offers a number of 
advantages. The method of detecting entry of the effector is 
comparatively direct (c.f. osmotic protection and vacuolization 
methods, which depend on secondary events such as osmotic swelling). 
The method is also convenient in the ease with which permeation is 
detected, and the experimental procedure is relatively simple.
Another advantage is that the concentration of effector can be kept 
low, which is both less expensive and less likely to cause saturation 
of any transport systems. Finally, the concentration of the effector 
can be varied without affecting the osmotic pressue of the medium.
The method does, however, have certain limitations. Since 
^^X-BSAj |^ is the substrate most commonly used for loading the 
lysosomes (due to its exceptionally rapid clearance from the blood 
and comparatively slow degradation by lysosomes) the method is 
confined to studies of inhibitors or stimulators of proteases active 
against 125I-BSAf(i. These proteases have been characterised by 
Kooistra et al. (1982) and Mego (1984). Mego found that 
formaldehyde-denatured albumin, unlike albumin denatured by other 
methods or native albumin, was primarily degraded by
leupeptin-sensitive thiol proteinases. Thus, 125I-BSAfd was suitable 
to use as a substrate to monitor the possible inhibition of 
intra-lysosomal proteolysis by extra-lysosomal leupeptin.
A disadvantage of this method of determining lysosomal 
permeability is that movement of the solute is only monitored in one 
direction, from outside to inside the lysosome. Since permeation 
mechanisms may be partially or totally uni-directional this gives
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only a limited indication of the accessibility of lysosomal and 
non-lysosomal proteases to leupeptin. (If permeation occurred only 
from outside to inside the lysosome, leupeptin taken into the cell by 
pinocytosis may not have access to the cytosol. Conversely, if 
permeation occurred only from inside to outside the lysosome, uptake 
of leupeptin by permeation across the plasma membrane will not lead 
to entry into lysosomes.)
Another possible disadvantage is that many factors other than 
specific inhibitors or stimulators are known to affect the rate of 
protein degradation by isolated lysosomes. For example, prolonged 
incubation or incubation in buffers of certain pH may affect both the 
integrity and internal pH of the lysosomes. These factors must be 
taken into consideration when monitoring the effect of inhibitors or 
stimulators of proteolysis using isolated lysosomes, otherwise such 
effects may be mistakenly assumed to be caused by penetration of the 
inhibitor/stimulator into the lysosomes.
It is therefore important to measure lysosomal integrity, since
125rupture of the lysosomes affects the observed rate of I-BSAfd 
degradation. For the work reported in this chapter, the percentage 
of resedimentable, TCA-precipitable radioactivity was taken to 
indicate the percentage of intact lysosomes. This determination was 
quick and convenient, though some factors must be considered when 
interpreting the data. One problem is the possibility of any 
released ^^I-BSAjd binding to lysed membranes, so becoming 
sedimented and counted as being within intact lysosomes. Mego et a h  
(1967) suggested that such binding only occurs at acid pH. Thus 
binding would not be expected to occur for most of the experiments 
reported in this chapter (although the presence of leupeptin or 
ammonium chloride might affect the degree of binding)•
For experiments in which Triton X-100 was added to the
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4 pCsuspension medium, the percentage of resedimentable I-BSAfd 
decreased during the course of the incubation. This could suggest 
that lysis was not complete immediately after addition of the 
detergent, but progressed during incubation. Alternatively, intact 
^^I_BSAfd may have been adsorbed onto the lysed lysosomal membranes 
at the beginning of the experiment, but gradually became desorbed or 
the membrane became more fragmeted and thus non-pelletable, during 
incubation. (This possibility was suggested by Mego et al., 1967J
The measurement of lysis may also be affected by the inhibition 
of proteolysis within the lysosomes. Disruption of lysosomes in 
which proteolysis is inhibited would result in the release of a 
greater amount of 125I-BSAfd than from non-inhibited lysosomes, 
giving rise to an overestimate of the degree of lysis (Mego, 1971).
In summary, the method developed by Mego 6 McQueen for isolating 
125I-BSAf(J-loaded lysosomes allows the entry of protease effectors 
(inhibitors or stimulators) into lysosomes to be detected. It should 
give meaningful results provided other factors that could interfere 
with the rate of hydrolysis by the lysosomal preparation are 
monitored and taken into consideration when interpreting the data.
7.4.2. Results Obtained Using the Mego & McQueen Method 
7.4.2a. Suspension Media
Many different types of media have been used in the past to 
suspend lysosomes. Factors such as type and concentration of solute; 
type and concentration of ions; type, concentration and pH of 
buffers; as well as energy requirement and temperture of incubation, 
have all been varied to determine their effects on lysosomal 
integrity, intralysosomal pH, and proteolytic capacity.
The solute most often used for suspension media is sucrose, 
since this does not appear to cross the lysosomal membrane (Lloyd,
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1969). It is usually used at a concentration of 0.25M, since this 
has been shown to give good osmotic protection (Lloyd, 1969). 
Concentrations of 0.2M (Mego & McQueen, 1965b) and 0.3M (Marzella et 
al., 1980) have also ben reported to give as good or better 
protection than 0.25M, and Sawant (1964) reported that 0.7M sucrose 
gave better osmotic protection than 0.3M. The total molarity of the 
0.25M sucrose solution is often increased by the addition of other 
solutes such as ions, buffers and thiol agents.
The effects of ions on the stability of the lysosomal membrane 
has been investigated by several workers. Some reviews and reports 
on ion permeability and effects are given by Mego et al. (1967),
Peijngoud & Tager (1977), and Ohkuma et al. (1982). In the latter
- . . 2 +report a permeant anion such as Cl and a divalent cation. Mg were 
found to be important for the activity of the lysosomal ATP-dependent 
proton pump. KC1 and MgCl2 are thus often included in resuspension 
media if ATP is to be added, and where maintenance of the 
intralysosomal pH is important.
Changes in the pH of an incubation medium, brought about by 
buffers, have several effects on lysosomes. Workers have measured 
the effect of pH on the stability of the lysosomal membrane; the data 
are somewhat conflicting, since different reports suggest isolated 
lysosomes are either stable over a range of pH, or are most stable at 
acid pH, or most stable at neutral pH. Thus, Lloyd (1971) noted that 
the permeability of lysosomes towards mannitol was unaffected by 
changes in pH over the range 5-7, and similarly Docherty 6 Hales 
(1979) found lysosomes to be stable for at least 30mm over the pH 
range 5-8 (at 25°C). Sawant et al. (1964) found that lysosomal 
enzyme activity was most latent at neutral pH; the amount of free 
enzyme activity increased at acid pH. Lloyd (1969) also reported 
that a rise in free lysosomal enzyme activity occurred more rapidly
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at pH 5.5# but only at 37°C, not at 25°C (at which temperature the 
lysosomes were stable). Ahlberg S Glaumann (1985) detected a 
decrease in lysosomal integrity after 30min incubation at 37°C at pH
5.5, but not at pH 7. Mego & McQueen (1965b), Mego et al. (1967) and 
Mego (1971) reported that lysosomal integrity decreased markedly on 
incubation at 37°C at pH 8 and 9, and was most stable at acid pH (pH 
5). Likewise, Ahlberg et al. (1982) and Doherty & Hales (1979) also
noted that the type of buffer used could affect the integrity of the
membrane. The conflicting data most probably reflect the use of 
different incubation temperatures, types of buffers, and methods of 
assessing lysosomal integrity.
The pH of the incubation medium may also affect uptake of
effectors into the lysosomes. This is mainly due to changes in the
ionzation of the effector rather than changes in the property of the 
lysosomal membrane (provided that the integrity of the membrane is 
unaltered). Uptake of most amino acids and dipeptides was found to 
be more rapid at pH 7 than at pH 5 or 6 (Lloyd, 1971). It was 
suggested that this was probably due to pH-dependent changes in the 
ionic species of molecule present. Poole & Ohkuma (1981) presented 
evidence that the pH-dependence of uptake of weak bases into the 
lysosomes of macrophages (in situ) was due to changes in the amount 
of free unprotonated base present at different pH. [One report 
suggested that glucose uptake was affected by pH due to the 
ionization of a specific carrier for glucose facilitated-transport in 
the membrane (Docherty S Hales 1979).]
The presence of buffers in the suspension medium affects the 
rate of intralysosomal proteolysis in addition to affecting the 
lysosomal membrane and ionization of effectors. Mego & McQueen 
(1965a,b) found that maximal proteolysis occurred in buffer at pH 5. 
Mego (1971) further characterised the effect of buffers on
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intralysosomal proteolysis. Buffers at pH 4, 7.3 and 8 produced a 
buffer-concentration dependent inhibition of proteolysis that was 
reversible, provided membrane rupture had not occurred, on transfer 
to pH 5. The rate of proteolysis in buffer at pH 5 was no different 
from that in unbuffered sucrose.
Several workers have added ATP (and necessary cofactors) to 
lysosomal suspension media in order to maintain a low intralysosomal 
pH and/or stimulate intralysosomal hydrolysis (eg Mego et al., 1972; 
Okhuma et al., 1982). Other examples of its use are given by Ahlberg 
& Glaumann (1985). This last paper also points out that some workers 
(eg Huisman et al., 1974 a,b) have failed to demonstrate any effect 
of ATP. ATP was shown to enhance degradation of proteins captured by 
microautophagy (Ahlberg & Glaumann, 1985) but had no effect on the 
capture of Percoll by this mechanism.
In the work reported in this chapter, three different types of
media were used to resuspend the lysosome-enriched pellet: sucrose
(0.25H), buffered sucrose (0.25M sucrose containing 30mM phosphate
2+buffer pH 6, 7 or 8) and 'ATP-medium' (containing ATP, Mg , and KC1 
in sucrose solution, buffered to pH 7 with HEPES).
The integrity of the lysosomes was not greatly affected by the 
presence of buffer at pH 6, 7 or 8 on incubation at 25 C, which 
suports the reports of Lloyd (1969, 1971) and Docherty & Hales 
(1979). The rate of intralysosomal hydrolysis was only affected 
after about 60 minutes, at which time the rates of degradation 
decreased at all pH's, the largest decrease occurring at pH 8. 
Initially the rate of degradation was similar to that observed in 
unbuffered sucrose (although a direct comparison, using the same 
lysosomal preparation was not made). This is in marked contrast to 
results reported by Mego (1971) in which intralysosomal degradation 
was inhibited immediately on exposure to buffer. The origin of the
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discrepancy in these observations is not known.
125The ATP medium did not enhance the rate of I-BSAfd 
degradation. One possible explanation for this lack of effect was 
suggested by Ahlberg & Glaumann (1985). The procedure as used in 
this chapter for preparation of the lysosomal-enriched fraction would 
result in a fraction highly contaminated with mitochondria. These 
organelles have a large amount of ATP-ase activity associated with 
them, and hence ATP added to a suspension containing such impurities 
could be consumed by non-lysosomal particles.
7.4.2b. Effect of Ammonium Chloride.
Weak bases are frequently used to inhibit lysosomal protein 
degradation. Their mode of action was suggested by de Duve et^  al. 
(1974), who proposed that they entered lysosomes in the uncharged 
form then became protonated and trapped, leading to an increase in 
intralysosomal pH and osmotic swelling. More recently, Okhuma S 
Poole (1981) and Poole S Okhuma (1981), using macrophages, have been 
able to prove that entry of weak bases into lysosomes does indeed 
cause an increase in pH, and was dependent on the concentration of 
unprotonated base. The increase in intralysosomal pH occurred 
immediately on exposure of the cells to the base, and remained stable 
throughout prolonged incubation, even though the amount of base 
within the cells increased. Uptake of methylamine by hepatocytes has 
been characterised by Solheim & Seglen (1983) who found that two 
mechanisms were in operation, one energy-independent and one energy 
dependent; the latter was probably involved in lysosomal 
accumulation.
The work described above was carried out using intact cells.
Few reports have been made of the effect of bases on isolated 
lysosomes. One such report, by Feijngoud et al. (1976), investigated
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the effect of ammonium chloride and methylamine on intralysosomal 
125I-BSAf(l degradation using a method similar to that described in 
this chapter. A complex buffer at pH 6.2 and 7.5 was included in the 
q#25M sucrose suspension medium, and a range of ammonium chloride 
concentrations from 0-100mM added. At either pH, inhibition of 
proteolysis was observed, the inhibition being greater at pH 7.5 than 
at 6.2. Only the initial 5-10 minutes of the time-course of 
degradation was used to measure the rate (since this declined after 
10-15 minutes), and no measurement of lysosomal integrity was 
reported.
Results reported in the experimental section of this chapter 
were strikingly different. At pH 6 or 7 during the initial 60min of 
incubation with 20mM ammonium chloride (ie over the period monitored 
by Reijngoud et al., 1976), little difference in the rate of 
proteolysis relative to that of the matched control was noted. In 
some experiments there was even a suggestion of slight stimulation 
rather than inhibition. The percentage of free base (NH3) in the 
medium at pH 6 and 7 was about 0.06 and 0.6% respectively, therefore 
the concentration of this permeant species was about 0.01 and 0.1mM, 
respectively. It is possible that these concentrations were too low 
to greatly affect the lysosomes. However, 20mM ammonium chloride 
produces a marked inhibition of intralysosomal proteolysis within 
intact cells when added to the incubation medium at pH 7.3 (eg Grinde 
S Seglen; 1980, Livesey et al., 1980), and an increase in lysosomal 
pH of about 2 units was detected by Poole & Ohkuma (1981) for 
macrophages incubated at pH 7.3. These inconsistencies are difficult 
to explain.
At pH 8, a marked inhibition of proteolysis occurred in the 
presence of ammonium chloride. Hence at this pH, it seems probable 
that sufficient inhibitor was able to pass across the lysosomal
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membrane to increase the intralysosomal pH, thus inhibiting 
proteolysis. The concentration of free base in the medium at this pH 
was about 5.7% (1.2mM). Onset of inhibition was immediate, and the 
degree of inhibition appeared to be constant during the first 90min 
of incubation, when the control rate was linear. Thus, if any 
increase in the intralysosomal ammonium-ion concentration occurred 
over this period, it did not cause an increase in the degree of 
inhibition. This result is compatible with the results of Poole & 
Ohkuma (1981).
Ammonium chloride did not give rise to any increase in the 
degree of lysosomal rupture at any pH. Overall, it appeared to be 
slightly protective to lysosomal integrity (mean percentage lysis 
during incubation for all experimental conditions in the presence of 
ammonium chloride was 13%, compared with 16% for control 
incubations) .
7.4.2e. Effects of Leupeptin.
Uptake of leupeptin into lysosomes has been studied, indirectly, 
by Neff et al. (1979) and by Ahlberg & Glaumann (1985). Neff et al. 
(1979) reported that leupeptin was unable to pass through the 
lysosomal membrane. This was based on the observation that no 
inhibition of degradation of endogenous proteins within isolated 
lysosomes was detected on incubation with leupeptin (10yg/ml) at pH 5 
or 8. Conversely, Ahlberg 6 Glaumann (1985) found that degradation 
of proteins taken into lysosomes by microautophagy was inhibited by 
addition of leupeptin to the suspension medium. They reported that 
membranes were freely permeable to leupeptin, though this statement 
was based on an observation by Seglen et al. (1979) that no delay in 
the leupeptin-induced inhibition of proteolysis was apparent.
It should be noted that Neff et al. measured the effect of
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extralysosoraal leupeptin on the degradation of intralysosomal protein 
substrates, whereas in the work of Ahlberg & Glaumann, both inhibitor 
and substrate were extralysosomal. In view of these conflicting 
reports, a further study of the permeation of leupeptin into 
lysosomes was considered worthwhile.
The "Mego & McQueen method" was very suitable for the
measurement of permeation of leupeptin (See Section 7.4. 1.). Unlike
the methods used by Neff et al., and Ahlberg S Glaumann, the protein
substrate and degradation products were easily measured by gamma
counting, and a large percentage of the protein present was degraded
125over the incubation period. Any changes in the amount of I-BSAf^ 
degraded in the presence of leupeptin were therefore readily 
detectable.
Using this method, it was observed that leupeptin added 
exogenously gave rise to a marked inhibition of intralysosomal 
degradation of 125I-BSAfd. Because the inhibitor did not cause 
lysosomal lysis (mean decrease in percentage of intact lysosomes 
during incubation with leupeptin, under all conditions tested, was 10 
± 4, whereas that for the controls was 16 ± 5), the inhibition must 
have been caused by leupeptin entering the lysosomes and inhibiting 
leupeptin-sensitive proteinases. The rate of proteolysis in the 
presence of leupeptin appeared to be dose-dependent during the 
initial period of incubation (about 60min). However, after this 
period the rate of proteolysis decreased to a common minimum rate at 
all leupeptin concentrations. This suggests that during the initial 
period the concentration of leupeptin in the lysosomes was not 
sufficient to induce maximal inhibition, but inhibition increased at 
a rate proportional to the leupeptin concentration in the medium.
Once maximal inhibition was achieved (ie all leupeptin-sensitive 
enzymes were fully inhibited) the same low rate of degradation
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(presumably mediated by non-leupeptin-sensitive enzymes) was achieved 
at all concentrations of leupeptin. Alternatively, leupeptin could 
reach a steady-state concentration within the lysosomes, either as a 
result of inactivation of the inhibitor or by permeation back out of 
lysosomes such that the rate of influx was equal to the rate of 
efflux. However this would not explain the similarity between the 
rates for diferent concentrations of leupeptin (Fig. 7.7) unless the 
steady-state concentration was greater than the amount required to 
fully inhibit the leupeptin-sensitive enzymes.
The pH of the medium affected the entry of leupeptin into the 
lysosomes. At pH 6, no leupeptin-induced inhibition occurred, 
whereas at pH 7 and 8 a strong inhibition was observed. This 
suggests that entry of leupeptin was dependent either on some 
pH-sensitive change in the leupeptin molecule or on a pH-induced 
change in a transport mechanism in the membrane.
A change in the ionization of leupeptin between pH 6 and 7 was 
not expected, because the guanidinium group of the arginyl residue 
remains charged at either pH (only a slightly greater percentage is 
charged at pH 6). Possibly the structure of leupeptin altered by 
cyclization involving the guanidinyl group (Maeda et a b , 1971) or 
the pH dependence of uptake reflects a change in the ionization of a 
membrane transport component. Alternatively a pH-dependent change in 
the rate of uptake by microautophagy may be possible. Ahlberg s 
Glaumann (1985) reported that degradation of methaemoglobin by 
microautophagy was more rapid at pH 5.5 than at pH 7, but it was not 
made clear whether or not the rate of uptake, as well as of 
degradation, was affected by the lower pH. The rate of degradation 
depended on the type of protein used, which suggests that binding to 
the lysosomal membrane could be important. If microautophagy was the 
main route of entry of leupeptin in lysosomes, the effect of pH on
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uptake of leupeptin could be explained by a difference in affinity of 
leupeptin for the membrane at pH 6 compared with pH 7 and 8 (and/or a 
difference in the rate of microautophagy).
The presence of ATP had no effect on the degree of inhibition 
observed with leupeptin. (Possible reasons for this lack of effect 
were discussed in Section 7.4.2a)
The method used in this chapter to study the permeation of a 
proteinase inhibitor has also been used to study the permeation of a 
stimulator of proteolytic enzymes, glutathione (Mego, 1984). Reduced 
glutathione (glutamyl-cyteinyl-glycine, GSH) acts both by reducing 
disulphide bonds in proteins during degradation (Mego, 1984; Kosistra 
et al., 1982) and as an essential cofactor for thiol proteinases, (eg 
Barrett 1977). Mego (1984) demonstrated that, although GSH was 
capable of stimulating proteolysis in a lysed tritosome extract (its 
effect being saturatable at 10-20mM), it had no effect on the 
degradation of 125I-BSAfd within intact liver lysosomes. Conversely, 
it did stimulate the same process within intact kidney lysosomes, its 
effect being saturable at 2mM. It was suggested that GSH could not 
permeate liver lysosomes, but a saturable system might exist in 
kidney lysosomes to facilitate entry of the tripeptide.
Permeation of another tripeptide, glycyl-glycCy1“^3^ 01"6' was 
investigated by Lloyd (1971), using the osmotic protection method.
It was found to cause lysosomal rupture, which suggested that it was 
able to permeate the membrane. Rupture occurred slowly, the most 
rapid rate occurring at pH 7. It was suggested that the pH effect was 
due to the formation of greater amounts of unprotonated species at pH 
7 than at the other pH's tested (ie 5 and 6). The possibility of 
intralysosomal digestion of the peptide was not discussed.
Degradation of the tripetide could lead to an even greater osmotic
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pressure inside the lysosomes, if the rate of permeation of digestion 
products out of the lysosome was slower than the rate of influx of 
the tripeptide. Slower digestion at pH 7 could thus explain the more
rapid membrane rupture at this pH.
The mechanism of uptake and lysosomal membrane permeability 
towards peptides were investigated by Ehrenreich & Cohn (1969), using 
the vacuolization method. Only the D-isomers of certain peptides 
caused vacuolization of macrophage lysosomes. (The L-isomers of the 
same peptides did not induce vacuolation, presumably because of their 
rapid rate of degradation). The tripeptide (D-Ala) 3 appeared to be 
taken into the macrophage by pinocytosis, and to accumulate within 
lysosomes, indicating that it was not able to permeate either the 
plasma or lysosomal membranes*
The pentapeptide pepstatin has been investigated by Furuno et 
al. (1983) in an attempt to determine the effect of pepstatin on 
proteolysis. In order to load lysosomes with pepstatin it was 
necessary to couple the peptide to a degradable glycoprotein 
(asialofetuin) that was taken up by adsorptive pinocytosis into rat 
liver hepatocyte lysosomes following intravenous injection. The 
glycoprotein was then degraded by lysosomal enzymes, leaving 
lysosomes loaded with free pepstatin. When lysosomes were isolated 
3h after injection of the complex (3mg) and incubated _in vitro at 
37*C in 0.25M sucrose, about 60% of the intralysosomal pepstatin was 
released during the 60min incubation period. The rate of release was 
virtually constant during this period, and was much greater than the 
rate of release of a marker enzyme, 0 -glucuronidase. It was 
suggested that, although pepstatin was thought to be incapable of 
crossing the plasma membrane, it was able to leak out of loaded 
lysosommes because of the non-ionic form in which it existed at the 
low intralysosomal pH.
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In summary, the literature reports on the permeability of 
lysosomal membranes suggest that some, but not all, small peptides 
are able to cross the membrane. Some of the variation in published 
results for leupeptin may have been caused by differences in 
methodology. Results reported in this chapter from Mego 6 McQueen 
style experiments show that leupeptin was able to enter liver 
lysosomes and inhibit intralysosomal proteolysis. The magnitude of 
the induced effects was shown to be dependent on both the leupeptin 
concentration and the pH of the medium, but not on the presence of
ATP.
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Fig. 7 .x Time-Course of 1 2 5 I-BSArJ Degradation Within Isolated Lysosomes 
Suspended in Sucrose and ATP Media
1 2 5 I-BSA -loaded lysosomes were prepared and incubated in fd
sucrose (0.25M) or medium containing ATP as described in
125Section 7.2.1. Appearance of TCA-soluble I-BSAf(J degradation 
products was monitored as described in Section 7.2.2. The graph show 
typical results, in which no difference was observed between the 
1 2 5 I-BSAfd degradation in the two suspension media.rate of
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Fig. 7.2 Time-Course of 1 2 5 I-BSAfJ Degradation Within Isolated Lysosomes 
Suspended in Sucrose and ATP Media
The experimental details were identical to those described for Fig. 7.
The graph shows a typical result in which ATP had a slight inhibiting
1 2 5 I-BSA,. degradation, fdeffect on
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O Triton X-100 (0.1%)
3 Time-Course of 1 2 5 I-BSAf : 1 Degradation by Disrupted Lysosomes
1 2 5 I_BSAfd-loaded lysosomes were prepared and suspended in 
sucrose (0.25M) in the presence and absence of Triton X-100 (0.1%) 
then the production of TCA-soluble material monitored, as described 
in Sections 7.2.1 and7.2.2. The graph shows a typical result.
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Fig. 7 .4a Time-Course of 1 2 5 I-BSArJ Degradation Within Isolated Lysosomes 
Incubated in Sucrose (0.25M) containing Leupeptin
125Production of TCA-soluble radioactivity by I-BSAf<J loaded 
lysosomes suspended in sucrose (0.25M) in the presence and 
absence of leupeptin ( 1 0  ug/ml) was monitored as described in 
Sections 7 .2 . 1  and 7.2.2. The graph shows a typical result.
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Fig. 7.4b Time-Course of
Ammonium chloride (20mM)
l25I_BSAfd Degradation Within Isolated Lysosomes
Incubated in Sucrose (0.25M) containing Ammonium Chloride.
1 2 5 X_BSA ,-loaded lysosomes were prepared and suspended in sucrose fa
(0.25M) in the presence and absence of ammonium chloride (20mM) , the.
the production of TCA-soluble radioactivity monitored. Experimental
details are given in Sections 7 .2.1 and 7.2.2. The graph shows a
typical result in which little difference was observed in the rate
of 1 2 5 i-BSA „ degradation in the presence and absence of ammonium 
fn
chloride.
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Fig. 7.5a Effect of Ammonium Chloride on the Time-Course of 
125I-BSArJ Degradation
Experimental details were identical to those described
for Fig. 6.4b. The graph shows a typical result in which
“ Sj-BSA degradation was slightly inhibited by ammonium fd
chloride.
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Fig. 7.5b Effect of Ammonium Chloride on the Time-Course of 
Degradation
125I-BSA,
Experimental details were identical to those described for
Fig. 7.4b. The graph shows a typical result in which
1 2 5 !_Bsa degradation was slightly stimulated by ammonium fd
chloride.
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Fig. 7.6a Time-Course of 125I-BSArJ Degradation Within Isolated Lysosomes 
Incubated in ATP Medium containing Leupeptin
125Production of TCA-soluble radioactivity by I-BSAfd-loaded 
lysosomes suspended in ATP-medium in the presence and absence 
of leupeptin (10 yg/ml) was monitored as described in Sections
7.2.1 and 7.2.2. The graph shows a typical result.
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125Time-Course of 1 2 I-BSAfJ Degradation Within Isolated Lysosomes 
Incubated in ATP Medium containing Ammonium Chloride
125I-BSA, .-loaded fdProduction of TCA-soluble radioactivity by 
lysosomes suspended in ATP medium in the presence and absence 
of ammonium chloride (20mM) was monitored as described in Sections
7.2.1 and 7.2.2. The graph shows a typical result.
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125Production of TCA-soluble radioactivity by I-BSAf(J-loaded 
lysosomes suspended in sucrose (0.25M) in the presence of various 
concentrations of leupeptin was monitored as described in 
Section 7.2.1 and 7.2.2. The graph shows a typical result.
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Fig. 7.8 Effect of Ammonium Chloride and Leupeptin on Degradation of 
125I-BSAfd Within Lysosomes Incubated at pH 6.0
125I-BSAfd-loaded lysosomes were prepared and suspended in buffered 
sucrose (0.25M, pH 6.0) containing either leupeptin (10 yg/ml) or 
ammonium chloride (20mM). Production of TCA-soluble radioactivity 
was monitored, as described in Sections 7.2.1 and 7.2.2. The graph
shows typical results.
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7.10 Effect of Ammonium Chloride and Leupeptin on Degradation of 
125I_BSAfd within Lysosomes Incubated at pH 8.0
Experimental details were as described for Fig. 7.8 except that 
lysosomes were suspended in sucrose buffer to pH 8.0. The 
graph shows a typical result.
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7.11 Effect of Incubation pH on the Time-Course of____1 BSftfd
Degradation Within Isolated Lysosomes
125I-BSAfd-loaded lysosomes were incubated in sucrose buffered 
to pH 6.0, 7.0 and 8.0 in the absence of leupeptin and ammonium
chloride, as controls for experiments described in Figs. 7.8,
* 1257.9 and 7.10. The time course of I-BSA.. degradation at each fa
r»H -i « chnwn
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INTRODUCTION.
Although many studies have been made of the effects of leupeptin 
on endogenous and exogenous protein degradation (eg Knowles et al., 
1981; Wildenthal et al., 1980; Dean, 1980) comparatively few 
investigators have attempted to correlate directly the observed 
degree of inhibititon of protein degradation with the degree of 
inhibition of intracellular proteinases by leupeptin.
Neff et al. (1979) measured the cathepsin B activity of 
hepatocytes after incubation with leupeptin (10yg/ml) for 4 hours, by 
using the specific substrate carbo~benzoxy-alanyl-arginyl-arginyl- 
4-methoxy-B-napthlylamine. Cathepsin B was inhibited by 25-50%, 
whereas endogenous 'long-lived' protein degradation was inhibited by 
only 20%. No other leupeptin-sensitive cathepsins were assayed in 
this investigation.
Kominami et al;_ (1980) measured the inhibition of cathepsins B 
and L (although a non-specific substrate was used for the assay of 
cathepsin L) in a rat liver lysosome fraction after administration of 
leupeptin to the rat intraperitoneally. Cathepsin B was inhibited 
by 80% and cathepsin L by 40%, but no inhibition of degradation of 
total soluble proteins was detected.
Shaw & Dean (1980) investigated the effects of another
inhibitor, benzyloxycarbonyl-phenylalanyl-alanyl-diazomethane
(Z-Phe-Ala-CHN2 ) on protein degradation and on cathepsin B activity 
in macrophages, using the substrate 
benzyloxycarbonyl-arginyl-arginyl-
2-napthylamide. Cathepsin B was inhibited by 95% after 90min exposure 
to Z-Phe-Ala-CHNj, compared with only about 30% inhibition of protein 
degradation after 24h exposure.
The principal aim of the work described in this chapter was to
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measure the time-course of inhibition of leupeptin-sensitive enzymes 
in rat yolk sacs previously exposed to leupeptin, and to compare 
these results with those for the time-course of inhibition of 
degradation of an exogenous protein (monitored in Chapter 3).
The hydrolytic activity of yolk sacs that had been treated in 
different ways before homogenization was measured using
carbobenzoxy-phenylalanyl-arginy1-aminomethylcoumarin (Z-Phe-Arg-AMC) 
as the substrate. The homogenates were derived from: unincubated 
tissue; unincubated tissue to which known amounts of leupeptin had 
been added; tissue that had been incubated in the absence of 
leupeptin; and tissue that had been incubated in the presence of 
leupeptin.
The substrate chosen for determining enzyme activity, 
2-phe-Arg-AMC, is reported to be an excellent substrate for assay of 
cathepsins L and B (Barrett & Kirschke, 1981), both of which are very 
sensitive to inhibition by leupeptin. A survey of the available 
literature on proteinases (eg Barrett S McDonald, 1980) suggested 
that no other intracellular proteinases were likely to hydrolyse this 
substrate. (Z-Phe-Arg-AMC is also a good substrate for trypsin and 
trypsin-like enzymes, and for tissue and plasma kallilreins.
However, such enzymes are generally extracellular or confined to 
glandular tissue, hence were unlikely to be present within the yolk 
sac.) It is possible that some intracellular leupeptin-sensitive 
enzymes may not be capable of hydrolysing this substrate, in which 
case the total effect of leupeptin on proteinases would be 
underestimated.
Cathepsin B is a cysteine proteinase with a mol. mass of about 
29,000. With synthetic substrates, it shows maximal activity at 
pH 6.0; activity decreases sharply at pH 7.0 due to irreversible 
inactivation. Many substrates (both synthetic peptides and natural
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proteins) are known to be cleaved by cathepsin B, the main 
requirement for such substrates being an arginyl residue in the P1 
position and a phenylalanyl or basic residue at the P2 site. The 
activity of cathepsin B in a cell extract is occasionally seen to 
increase during storage at -20°C (possibly due to inactivation of 
endogenous inhibitors). The kinetic constants for hydrolysis of 
Z-Phe-Arg-AMC by cathepsin B are: = 0.15mM; ltcat/Km = 9900 x 10
sec-1M_1, specific activity = 238 units/pmol.
Cathepsin L is also a cysteine proteinase, with a pH optimum of 
5.0-5.5 (though it is active over a fairly wide range of pH, 
including pH 7). It is a glycoprotein with a mol. mass in the range
21,000 -24,000. It is considered to be the most powerful of the 
lysosomal proteinases, with a higher specific activity against 
protein susbstrates than cathepsin B (Barrett & Kirshke, 1981). It 
is capable of degrading many proteins, but its activity against 
synthetic substrates is limited. z-Phe-Arg-AMC is an exception, 
being a very good substrate. (With this substrate the enzyme shows 
a of 0.007mM; *cat/Km = 3700 x 1°3sec 1 M 1 and a specific 
activity 1200 units/pmol.)
The method of assay used was based on that described by Barrett 
(1980). It was hoped that the experiments described in this chapter 
wovJd allow several factors to be investigated. In summary, these 
were:-
i) The cathepsin B+L activity of homogenates of unincubated 17.5 
day rat yolk sacs.
ii) The effect of incubation of yolk sacs in medium 199 on the 
observed cathepsin B+L activity of the tissue*
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Hi) The amount of leupeptin required to induce a given degree of 
inhibition of the cathepsin B+L activity in an unincubated 
yolk-sac homogenate#
iv) The time-course of inactivation of cathepsin B+L on incubating 
yolk sacs with leupeptin, compared with the time course of 
inhibition of 125I-BSAfd degradation measured in Chapter 3. (In 
particular, it was desirable to try to assess whether the 
incomplete inhibition of 125I-BSAfd degradation observed in 
Chapter 3 was caused by an incomplete inbibition of cathepsins B 
and L or whether it was the result of degradation via 
leupeptin-insensitive proteinases such as cathepsin D.)
v) An attempt was made to quantify the amount of leupeptin 
entering the tissue during incubation with leupeptin by 
comparing the degree of inhibition observed with that obtained 
on adding leupeptin to unincubated yolk-sac homogenates*
Results could then be compared with those obtained in Chapter 5, 
in which the amount of leupeptin extracted from tissue was 
quantified using a trypsin-based assay method.
8 . 2 MATERIALS AND METHODS
I. MATERIALS
Reagents
Reaction buffer
Stopping buffer
Substrate
Reaction Product
A phosphate buffer, pH 6.0, containing EDTA and 
cysteine was used. ^2^0^ (23.93g) Na2 HPO^
(3.41g) and EDTA (0.744g) were dissolved in 
distilled water (500ml) to give concentrations of 
352mM, 48mM and 4mM, respectively. The solution 
was adjusted to pH 6.0 if necessary. Cysteine 
was added freshly as required before use (final 
concentration 0.968 mg/ml, ie 8mM).
Sodium acetate buffer, pH 4.3 (30mM sodium
acetate, 70mM acetic acid) containing sodium 
chloroacetate (100mM).
2 -phe-Arg-AMC. This substrate was prepared as 
stock solution in DMSO (3mg/ml, 4.89mM) for 
storage (-20°C) and diluted in distilled water 
before addition to the assay, to give a 
concentration of 19.6yM (ie 1:250 dilution 
factor).
7 Amino-4-methylcoumarin (AMC) was prepared as a 
50pM stock solution (8.76 mg/1). Gentle warming 
was necessary to dissolve the compound. Before 
use, it was diluted with distilled water to give 
a final concentration of 0.5pM.
All other reagents were as described in Chapter 2
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Equipment
Fluorimeter
Chart Recorder
As described in Chapter 5. Zeroed using
distilled water and full scale (1000 units or 
100%) set using 0.5 pM AMC. The fluorimeter did 
not have a thermostatically-controlled sample 
chamber.
As described in Chapter 5.
All other equipment as given in Chapter 2
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XX,  METHODS
0,2.1 Incubation of Yolk-Sac Tissue and Preparation for Assay 
Yolk sacs were incubated in the presence and absence of 
leupeptin (100pg/ml), using the reduced volume method described in 
Section 2.2b. Incubation was generally over a period of 120min. At 
various periods, yolk sacs (duplicate tissue samples at each time 
point for both leupeptin-treated and control tissues) were removed 
from the incubation flasks, rinsed in three changes of ice-cold 
saline solution (1% w/v), and immediately frozen at -20°C. Yolk 
sacs that had not been incubated were also prepared for assay, by 
rinsing in saline and freezing at the beginning of the experiment.
After freezing yolk-sacs were homogenized in Triton X-100 (0.1% 
v/v; 1ml per yolk sac) using a hand-held glass—on-glass homogenizer. 
Tissue and homogenate were kept on ice whenever possible. The 
homogenates were then centrifuged (1000g, 15min) to remove cell 
debris, and the supernatant fraction used for assay of cathepsin B+L 
activity.
In some experiments, frozen, unincubated yolk sacs were 
homogenized in the presence of leupeptin (0.25—2.Opg) in order to 
assess the amount of leupeptin required to inhibit cathepsin B+L 
activity under the conditions of assay used. In other experiments 
fresh unincubated tissue was homogenized and assayed for enzyme 
activity immediately, with no storage at -20 C.
The protein content of the homogenate supernatant fraction was 
determined using the Folin method as described in Section 2.3., 
except that 20yl of the homogenate supernatant was added to 1.0ml of
0.5M NaOH.
'
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8#2.2 Assay of Z-Phe-Arg-AMC Hydrolysing Activity
The assay procedure was based on that described by Barrett 
(1980). The assay was originally used for cathepsin B but later 
found to be more sensitive for cathepsin L (Barrett 6 Kirschke,
1981). The method suggested the use of a "stopped reaction" carried 
out at a temperature of 40°C over 10 minutes.
The method of Barrett (1980) was assessed for use with yolk-sac 
tissue. In particular, the amount of yolk-sac homogenate protein 
used was varied in an attempt to achieve readily-detectable effects. 
The method was adapted to a continuous rate assay, using a 
fluorimeter connected to a chart recorder. Thus for most 
experiments, the following assay procedure was used.
Reaction buffer (0.825ml, pre-warmed to 37°C in a water bath) 
and homogenate (50yl, stored on ice) were mixed in a cuvette, then 
substrate (0.125 ml, also pre-warmed to 37°C) added. The rate of 
ensuing hydrolysis was monitored, using the fluorimeter and chart 
recorder, for about 5 minutes or until 50% deflection was reached.
The rate of reaction was measured in terms of fluorescence units per 
minute, then the enzyme activity calculated in units of ng AMC 
produced per minute per mg yolk-sac homogenate protein. Since 1000 
florencence units, or full scale deflection, was set using 0.5UM AMC, 
one unit of fluorescence was produced by 0.0875ng AMC in the 1ml 
reaction volume. Hence activity ngAMC/min per mg yolk-sac protein 
could be calculated:-
slope of chart recorder trace (units/min) x 0.0875
ng AMC/min/mg = ------- —
mg protein in 50 yl homogenate
In some preliminary experiments a "stopped-reaction" assay was 
used. The method was similar to that described in detail by Barrett 
(1980). Briefly, a sample of centrifuged homogenate was diluted with
Triton X-100 (0.1%, v/v solution) by a factor of up to 1000. (This 
was necessary to achieve fluorescence readings within the set range). 
This diluted homogenate (0.25ml) was added to the reaction buffer 
(0.125ml) in a small reaction vial, then substrate (0.125ml) added to 
initiate the reaction. After a known reaction period at 37°C, 
(generally about 15 minutes) stopping buffer (0.5ml) was added. The 
fluorescence of the reaction mixture was then measured, after
dilution if necessary.
I
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9 a 3• RESULTS
Before reporting the results obtained it is pertinent to note 
some of the problems encountered with the method. As previously 
mentioned, several different assay conditions were tested in order to 
find a suitable method to use with experimental tissue. The factors 
that were varied included: amount of homogenate protein added; 
storage conditions of intact tissue and homogenate; reaction time; 
and concentration of substrate. Many of these variations caused large 
differences (up to 25-fold) in the apparent activity of cathepsin 
B+L, (ngAMC/min per mg homogenate protein). The results obtained 
during this investigation into optimal reaction conditions are given 
in Section 8.3.2.
The results obtained using experimentally-treated tissue are 
given in Section 8.3.1. In order to standardize these results, the 
same assay conditions were used for each experiment. To permit 
easier comparison of the experiments, the
cathepsin B+L activity measured in yolk sacs that had been incubated 
with or without leupeptin was expressed as a percentage of that 
measured in the same experiment for unincubated tissue. In addition 
to interexperimental variability of the apparent enzyme activity, the 
enzyme activity measured in individual yolk sacs within a single 
experiment, treated and assayed in exactly the same way, differed 
greatly. This difference was particularly marked in unincubated 
tissue or tissue that had been incubated without leupeptin. In order 
to calculate the activity of incubated yolk sacs as a percentage of 
the activity measured in unincubated yolk sacs, it was necessary to 
use the mean enzyme activity of unincubated tissue; at least three 
yolk sacs were assayed to obtain this mean«
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8.3.1. Effect of Incubating Yolk-Sac Tissue in the Presence and 
Absence of Leupeptin on the Residual Cathepsln B+L Activity
Yolk sacs were incubated (0-120 min) in medium with or without 
leupeptin (100 pg/ml). The cathepsin B+L activity of the homogenates 
of these yolk sacs was determined using the continuous rate assay 
described in Section 8.2.2., and expressed as a percentage of that 
measured in unincubated tissue from the same experiment. The results 
from two such experiments are shown in Figs. 8.1 and 8.2. (The 
experiment was repeated a total of five times, with similar results, 
not shown! There were several interesting features of these 
results.
i) The cathepsin B+L activity was greatly decreased in homogenates 
from yolk sacs that were incubated in the presence of leupeptin. 
After 120min exposure to leupeptin, the activity was lowered by 
90-100%. The percentage of residual activity differed slightly 
between experiments, but reached a low, steady-state value in 
all experiments. The decrease in activity occurred very 
rapidly, the majority of activity being lost within the first 
30min exposure to leupeptin; the inhibition of activity was 
maximal by about 60min.
li) The cathepsin B+L activity measured in tissue incubated without 
leupeptin was markedly initially higher than that of unincubated 
tissue: the relative activity rose 200-400%. This apparent 
increase occurred within the first 10min of incubation. The 
activity then tended to decrease, after 120min incubation it was 
usually less than that observed in unincubated tissue, 
iil) The figures illustrate the variability in cathepsin B+L activity 
between yolk sacs removed from incubation after the same period. 
The difference between some 'duplicate' samples was over 100%. 
Variability in the leupeptin-treated tissue was less, probably
because all activity was so strongly depressed.
Fig. 8.3 shows the cathepsin B+L activity in unincubated yolk 
sacs to which known amounts of leupeptin were added, expressed as a 
percentage of unincubated tissue to which no leupeptin was added.
The activity decreased with increasing amounts of leupeptin and was 
virtually totally inhibited by 1.5yg of leupeptin per yolk sac. This 
suggests that only about 1.5yg of leupeptin would be required within 
an average yolk sac to achieve the almost complete inhibition of 
cathepsin B+L activity observed after about 60min incubation in the 
presence of leupeptin (100yg/ml).
8.3.2. Factors Affecting the Measurement of Cathepsin B+L activity 
in Unincubated Yolk Sacs
Preliminary investigations to determine suitable assay 
conditions were made using both the continuous assay and the stopped 
reaction methods. The effects of varying different factors on the 
calculated rate of reaction are discussed briefly below.
8.3.2. a Stopped Reaction Method
i) Homogenate Protein Concentration Duplicate yolk-sac
homogenates were diluted between 10- to 1000-fold. These 
diluted homogenate fractions were assayed for cathepsin B+L 
activity using the stopped reaction method, and the rate of 
reaction expressed as ngAMC/min per mg yolk-sac protein. This 
calculated rate was strongly dependent on the amount of 
homogenate protein present. Surprisingly the rate increased 
non-1inearly, as the amount of homogenate protein decreased (see 
Fig. 8.4). The rate of reaction (ngAMC/min) was similar for all 
concentrations of homogenate protein* 
ii) Substrate Concentration. The concentration of Z-Phe-Arg-AMC in
varied between 6-9ng per ml* Thethe stopped—reaction assay was
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homoqenate was used at dilutions of 1:200 and 1:500 for these 
experiments. At both homogenate dilutions the rate increased 
linearly with substrate concentration, (see Fig. 8.5) indicating 
that the substrate was not at a saturating concentration even 
for the more dilute enzyme concentration.
iii) Reaction period. The reaction period in the stopped reaction 
method was varied from 1 to 30min, to determine whether the 
time-course of reaction was linear. Homogenate supernatant was 
used at a dilution of 1:200, on the standard substrate 
concentration (12ng/ml) was added. Under these conditions, the 
rate of reaction was approximately constant over 30 min 
incubation at 37°C, (results not shown in detail).
iv) Effect of storage of intact tissue on cathepsin B+L activity. 
Homogenates were prepared from tissue that had been frozen at 
-20°C (for 6 days), and from freshly-dissected tissue. These 
freshly prepared homogenates were then assayed together for 
cathepsin B+L activity. Little difference in the activity of 
the homogenates was observed, suggesting that activity did not 
change on storage of intact tissue#
8#3.2«b Continuous Rate Assay
i) Amount of homogenate protein. Initially, the amounts of
reagents used for the continuous rate assay were similar to 
those used for the stopped reaction, except the volume of 
reaction buffer was increased to compensate for the absence of 
stopping buffer. The yolk-sac homogenate was diluted up to 
1:200 before addition. At 200-fold dilution, the reaction was 
too slow to be of use. At 1:5 dilution, the initial rate was 
approximately linear, and rapid enough to allow reasonably short 
assay periods. Additions of more homogenate to the reaction mix 
during assay gave a large increase in the rate of reaction.
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ii) Substrate Concentration. No systematic investigation was made 
on the effect of changing the substrate concentration, but it 
was noted that the rate of reaction increased markedly when 
additional aliguots of substrate were added to the reaction 
mixture.
iii) Effect of storage of tissue homogenate on cathepsin B+L 
activity. Homogenates were prepared from frozen yolk-sac tissue, 
and the cathepsin B+L activity measured (as described in Section
8.2.2.). The homogenates were then stored at -20°C for up to 3 
days, and re-assayed. The rate of reaction was slightly lower 
for the tissue homogenates that had been frozen. This could 
reflect a decrease in cathepsin B+L activity on storage, 
although day-to-day variation in the assay could also explain 
these results. For experimental tissue, all assays were carried 
out on the same day whenever possible, so that the activity 
compared to control, unincubated tissue was not affected by 
day-to-day differences in the assay. Since the rates were 
expressed as a percentage of a control value, the effect of 
storage on the 'absolute' activity of the enzymes were not as 
important, provided the change in activity was proportional in 
all tissues.
iv) Temperature of Assay. In the continuous rate assay, the
initial temperature of the reactants was 37°C. However, the 
fluorimeter sample holder was unthermostatted (temperature about 
25°C), so the temperature of the reaction mixture decreased 
during measurement of reaction rate. This caused a 
corresponding decrease in reaction rate. The curvature of the 
time-course of reaction depended on the initial rate of 
reaction, the higher the initial rate of reaction the more 
linear the time-course, since the period of cooling was less.
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The initial approximately linear portion of the curve was used 
to measure the cathepsin B+L activity of experimental tissue. 
Other factors that may have affected the assay were also 
checked. The fluorescence of AMC was directly proportional to its 
concentration over the range tested, and was not affected by the 
presence of protein (added after the stopping buffer) or Triton 
X-100. The presence of excess AMC in the assay reaction mixture only 
slightly inhibited the rate of reaction; the amount produced during 
the reaction was unlikely to do so.
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8#4 DISCOSSIOW
8.4.1 Cathepsln B+L Activity In the Rat Yolk Sac
The results described in Section 8*3*1 are discussed below* It 
is important to realize that these results indicate only a general 
trend in the cathepsin B+L activity of incubated yolk-sacs. (Further 
investigations into optimum assay conditions and optimum methods of 
tissue preparation are necessary before reliable quantitative data 
can be reported.) Also, several assumptions must be made in order to 
interpret even the trends in the reported results. (These will be 
briefly discussed below.) Notwithstanding these reservations, the
results suggested the following trends.
The cathepsin B+L activity decreased rapidly on incubation of 
the yolk-sac tissue with leupeptin (100 pg/ml). Generally only about 
5% of the activity remained after approximately 60min incubation.
This observation can be compared with results described in Chapter 3. 
In that chapter, 125I-BSAfd degradation was also maximally inhibited 
after 60min, but about 20% of the degradative capacity towards 
125I-BSAfd remained beyond this point. The almost complete and rapid 
inhibition of cathepsin B+L observed in this chapter can also be 
contrasted with those observed by workers using leupeptin in other 
cells or tissues. Thus, Neff et a L  (1979) detected only 25-50% 
inhibition of the cathepsin B activity of hepatocytes after 4h, and 
Tanaka et al. (1981) found that maximal Inhibition, approximately 
55%, occurred only after 10h. However, a stronger effect was 
detected by Kominami et a L  (1980), who found that when leupeptin was 
administered to rats by intraperitoneal injection, maximal inhibition 
of cathepsin B in the lysosomal fraction of the liver occurred after 
1.5h> 80% inhibition was achieved.
Thus it would appear that leupeptin induces a stronger, more 
rapid inhibition of cathepsin B+L in the rat yolk sac compared with
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several other cell types incubated jji vitro, though not necessary 
compared with inhibition of liver proteinases after injection of 
leupeptin in vivo*
The rapid onset of cathepsin inhibition in yolk sacs incubated 
with leupeptin can be compared with that induced by other inhibitors 
in various tissues. For example, Shaw 6 Dean (1980) found that 
Z_phe-Ala-CHN2 gave a 95% inhibition of cathepsin B activity in 
macrophages after 90min exposure. Hashida et al. (1982) found that 
the inhibitor E-64 <N-[N-(L-3-trans-carboxyoxiran-2-carbonyl) 
-L-leucyl]-aqmatine) caused a maximal inhibition (about 75%) of 
cathepsin B 1h after intraperitoneal administration. Several workers 
have reported that pepstatin has little or no effect on proteolysis 
in intact cells (eg Knowles et al., 1981; Tanaka et al^, 1981), 
however, Furuno et al. (1983) found that 1h after a 
pepstatin-asialofetuin complex was administered intraveneously to 
rats, the cathepsin D activity was inhibited by 80%. This difference 
in effect was ascribed to the rate of uptake of pepstatin complex (by 
receptor-mediated pinocytosis) being more rapid than that of free 
pepstatin (which is assumed to enter cells by fluid-phase 
pinocytosis). However, Z-Phe-Ala-CHN2 and E-64 both gave rise to a 
similar time-course of inhibition, even though the former is thought 
to enter cells by pinocytosis and the latter by permeation. Hence it 
is not possible to distinguish between these possible modes of uptake 
of an inhibitor on the basis of the time-course of inhibition alone.
The apparent increase in cathepsin B+L activity of yolk sacs 
which occurred within minutes of incubation in the absence of 
leupeptin was unexpected and difficult to explain. Synthesis of new 
cathepsin is unlikely to have occurred within such a short period, 
and no changes in the proteolytic activity of yolk sacs during 
incubation have been observed previously (eg Knowles et ab, 1981).
[However, the rate-limiting step in the lysosomal degradation of 
endogenous and exogenous proteins is thought to be the delivery of 
the protein to the lysosomes (Williams et al., 1975b), therefore an 
increase in cathepsin activity would not automatically give rise to 
an increase in proteolytic rate.] The stimulation of cathepsin B+L 
observed in yolk sacs was an acute effect only, since the activity 
decreased to below that of unincubated tissue after 120 min. The 
cause of this decreased activity is also unknown.
The observed cathepsin B+L activity in a yolk-sac homogenate can 
only be related to that of the tissue in situ if three important 
assumptions can be made.
First, during the washing of the tissue all leupeptin must be 
removed from extracellular sites. Otherwise, on homogenization it 
would gain access to lysosomal enzymes and give rise to an 
overestimate of the amount of inhibition occurring in the intact 
tissue. (This problem was encountered by Shaw 6 Dean, 1980.) Three 
rinses in saline (1% w/v) were found to release 3H-leupeptin from the 
tissue surface (Section 6.4.5a) therefore it is reasonable to assume 
that any inhibition of cathepsin B+L observed was caused by 
internalized leupeptin.
Second, homogenization of the tissue could bring lysosomal 
proteases into contact with leupeptin from non-lysosomal 
intracellular sites (eg any present in the cytosol or pinosomes).
Such access may be partially or totally prevented in intact tissue. 
Since it was impossible to quantitate the fraction of the total 
leupeptin in such compartments, it had to be assumed that the 
quantity of leupeptin in such compartments was negligible compared 
with the amount present within lysosomes.
Third, it was necessary to assume that any leupeptin that was 
bound to (and thus causing inhibition of) cathepsin B or L within
lysosomes in situ, remained bound during homogenization and assay.
It is possible that the extensive dilution of the lysosomal contents 
(to obtain first a '1 yolk sac per ml' homogenate, and then further 
dilution of the homogenate in the assay reaction mixture) could cause 
dissociation of the enzyme and inhibitor. Moreover, any competition 
between enzyme substrate (Z-Phe-Arg-AMC) and inhibitor (leupeptin) 
would further confuse the interpretation of the observations.
However, the high affinity of leupeptin for cathepsin B and L would 
tend to minimize any such dissociation. (Leupeptin has been reported 
to act as a pseudo-irreversible inhibitor of cathepsin L; Kirschke et 
al., 1977).
It is not possible to compare directly the degree of inhibition 
observed on addition of leupeptin to unincubated yolk sacs during 
homogenization with that observed in yolk sacs that had been 
incubated with leupeptin, because of the apparent different in 
cathepsin B+L activity in incubated and unincubated tissue. However, 
it was possible to demonstrate that approximately 1.5 U9 leupeptin is 
required to fully inhibit the cathepsin B+L activity of (unincubated) 
yolk sacs.
8.4.2. Problems Associated with the Method, and Possible 
Improvements
A number of problems were encountered during development of the 
assay method used in this chapter. Lack of time prevented a search 
for solutions to these problems, but, with hindsight, some could have 
been eliminated or reduced by small changes in the materials and 
methods. For example, the time-course of the reaction could have 
been made more linear if the cuvette-holder had been thermostatted to 
37°C. Some of the variability between the rate of reaction on 
different days may have been reduced if the concentration of
I
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substrate used had been increased to about 5 x Km , since at this 
concentration the substrate is saturating, and small concentration 
differences resulting from error in preparing the substrate solution 
have no effect. (However, this would have produced an extremely rapid 
reaction rate, and would be prohibitively expensive). Variation both 
between individual yolk sacs and between experiments may also have 
been reduced by improving the method of preparing and storing yolk 
sacs. Some cathepsin B activity may have been lost during 
preparation at neutral pH, and ideally both cathepsin B and L should 
be stored at acid pH at -20°C. Cathepsin L retains its activity best 
at -20°C if EDTA and a thiol reagent are present, however cathepsin B 
loses activity more rapidly under these conditions (Kirschke et ah, 
1977). It was hoped that the presence of high concentrations of other 
proteins would stabilize the yolk-sac cathepsins during preparation 
and storage for these experiments.
The reason for the increase in reaction rate with increase in 
dilution of the homogenate was not fully investigated. It could have 
been caused by dissociation of endogenous inhibitors from cathepsin B 
+ L at the higher dilution. Such inhibitors are known to exist in 
the cytosol, and would have access to the lysosomal cathepsins on 
homogenization.
in summary, although the data reported in this chapter are only 
limited and hence qualitative, and their interpretation is impossible 
without a number of assumptions, they suggest that:
i) The observed inhibition of cathepsin B+L is complete within 60 
min incubation with leupeptin (100 pg/ml).
ii) The quantity of leupeptin required to fully inhibit the 
cathepsin contained in a yolk sac could be obtained by
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fluid-phase pinocytosis within 60 min. [Pinocytosis occurs at a 
rate of about 3yl/mg/h, therefore a typical yolk sac would take 
up 15)J 1 of extracellular fluid per hour. For leupeptln at a 
medium concentration of lOOpg/ml, the amount taken up in 60min 
would be 1.5ug, which was sufficient to totally inhibit the 
cathepsin B+L activity of unincubated tissue.]
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• Tissue incubated in the absence of leupeptin 
■ Tissue incubated with leupeptin (100 pg/ml)
.1 Cathepsin B+L Activity of Yolk Sacs Incubated in the Presence 
and Absence of Leupeptin. Relative to Unincubated Tissue
Yolk sacs were incubated with or without leupeptin (100 ug/ml) 
as described in Section 8.3.1. The cathepsin B+L activity of 
this incubated tissue, and of unincubated tissue, was determined 
as described in Section 8.2.2 and the activity of incubated 
tissue expressed as a percentage of that of unincubated tissue. 
The graph shows results from a typical experiment.
■ Tissue incubated with leupeptin (100 pg/ml)
Fig. 8.2 Cathepsin B+L Activity of Yolk Sacs Incubated in the Presence 
and Absence of Leupeptin. Relative to Unincubated Tissue.
Experimental details as described for Fig. 8.1. The graph 
shows results from a typical experiment
5 -75 1-0
Amount of leupeptin added (yg)
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Fig. 8.3 Cathepsin B+L Activity of Yolk Sacs to which Leupeptin 
was Added
Known quantities of leupeptin was added to unincubated yolk sacs, 
which were then homogenized. The residual cathepsin B+L activity wa: 
measured and expressed as a percentage of that detected in 
unincubated tissue in the absence of leupeptin, as described 
in Section 8.2.1.
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Fig. 8.4 Effect of Yolk Sac Homogenate Protein Concentration on the 
Measurement of Cathepsin B+L Activity by the Stopped 
Reaction Method
Unincubated yolk sacs were homogenized then the homogenate 
diluted up to 1000-fold in Triton X-100 (0.1% solution). The 
cathepsin B+L activity was determined as described in 
Section 8.2.2.
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•  Yolk sac homogenate diluted 1:500 
■  Yolk sac homogenate diluted 1:200
Fig. 8.5 Effect of Substrate Concentration on the Rate of Production of AMC 
During the Stopped Reaction Cathepsin B+L Assay
The stopped reaction assay described in Section 8.2.2 was carried out 
using substrate at concentrations between 6 and 9 ng/ml with two 
concentrations of homogenate protein, as described in Section 8.3.2a
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GENERAL DISCUSSION
9 , 1  Aim of Work
The overall aim of the work reported in this thesis was to 
obtain more detailed knowledge of the mode of action of leupeptin as 
an inhibitor of proteolysis in intact mammalian cells and tissues.
The main problems encountered when using leupeptin as an 
inhibitor are the lack'of information on:
i) The site(s) of action of leupeptin. [This depends on its mode 
of entry into cells and on the permeability features of intracellular
membranes.]
ii) The degree of inhibition of proteolysis afforded by leupeptin. 
[This is dictated by the extent to which leupeptin-sensitive enzymes 
are involved in the rate-limiting steps of proteolysis in a given 
cell-type, and by the intracellular concentration of leupeptin (which 
depends on both the rate of entry of leupeptin into cells and on the 
possible rates of inactivation/degradation, or release of 
leupeptin).]
The first problem, ie that of the site(s) of action of 
leupeptin, has been noted by many workers. Tanaka et a h  (1981) 
attempted to relate the effects of leupeptin (and pepstatin) on the 
turnover of endogenous cell proteins with inhibition of lysosomal 
proteolysis, but noted that "the possibility that the inhibitors may 
also act on proteinases in the cytosol to some extent is not 
completely excluded". Knowles et a h  (1981) reported that leupeptin 
caused different degrees of inhibition in the degradation of 
endogenous and exogenous proteins in the rat yolk sac, and state 
that "resolution of these findings reguires information on the 
distribution and eventual intracellular fate of microbial proteinase 
inhibitors". Similar conclusions were reached by other investigators 
(Wildenthal, 1980» Henell 6 Glaumann, 1985» Ward et ah, 1979) using
other tissues and cells.
Dean and co-workers have also stressed the importance of knowinq 
the site of action of inhibitors (eq Dean, 1979; Shaw & Dean, 1980; 
Cockle s Dean, 1982). These authors sugqest that leupeptin probably 
enters cells by permeation (this conclusion being based on the rapid 
action of leupeptin; Dean, 1979) but state that its site of action 
is unclear". Cockle S Dean (1982). The proteinase inhibitors 
pepstatin or Z-Phe-Arg-CHN2 were used by Dean and co-workers because 
they were thought to enter cells by pinocytosis, and were thus 
assumed to be limited to inhibition of lysosomal proteolysis alone 
(Dean, 1979; Shaw & Dean, 1980).
The second problem, a lack of information on the degree of 
inhibition afforded by leupeptin, was noted by Henell & Glaumann 
(1988). They pointed out that, although many workers have assumed 
that leupeptin causes an almost complete cessation of lysosomal 
proteolysis, their results indicated that degradation of cell 
organelles within autophagolysosomes continued in the presence of 
leupeptin.
Hershko & Ciechanover (1982) sum up the use of inhibitors in a 
review of mechanisms of intracellular protein breakdown.
Difficulties in assessing the amount of degradation occurring via 
lysosomes were discussed, and it was noted that "inhibitor studies 
are always subject to uncertainties concerning the specificity of the 
acrent or completeness of its action".
Two models can be proposed to illustrate the possible action(s) 
of leupeptin in yolk sac. In one leupeptin is not able to permeate 
across the plasma membrane (Model A, Fig 9.1); in the other leupeptin 
is able freely to cross the plasma and possibly intracellular
membrane(s) (Model B, Fig. 9.2).
In model A. the only route of uptake of leupeptin is by
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fluid-phase or adsorptive pinocytosis. Pinocytic vesicles containing 
leupeptin fuse with lysosomes, resultinq in delivery of leupeptin to 
lysosomes, and inhibition of lysosomal enzymes. If the lysosomal 
membrane is (like the plasma membrane) impermeable to leupeptin, the 
inhibitor will remain trapped within the vacuolar system. However, if 
the lysosomal (or pinocytic vesicle) membrane is permeable to 
leupeptin, leupeptin will be released into the cytosol, where it 
could inactivate non-lysosomal proteinases. Since pinocytosis is a 
constitutive process in the yolk sac, the rate of fluid-phase 
pinocytosis will be the minimum rate of uptake possible. (The rate 
of uptake via pinocytosis will be greater if leupeptin binds to the 
plasma membrane and is taken up by adsorptive pinocytosis.)
in model B, leupeptin is able to enter the cell by permeation 
across the plasma membrane, and is thus delivered to the cytosol. 
Uptake will also occur via pinocytosis, therefore the total rate of 
uptake by the cell will be the sum of the rates of pinocytosis and of 
permeation. The rate of accumulation of leupeptin by the tissue will 
not equal the total rate of uptake if loss of leupeption from the 
cells by permeation back across the plasma membrane occurs.
Depending on the permeability of the lysosomal membrane towards 
leupeptin, the inhibitor will either permeate directly across the 
lysosomal membrane or be taken up by microautophagy and/or become 
enclosed within autophagic vacuoles (both processes are described by 
Dean, 1984).
Several different methods of detecting leupeptin were developed 
and utilized in the work described in this thesis. Each method 
provided evidence/different aspects of the action of leupeptin as
an inhibitor of proteolysis in yolk-sac tissue. (The advantages, 
limitations and technical problems associated with each method and 
any possible mis-interpretation of results are discussed in detail in
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the relevant experimental chapters, and will not be discussed further 
in this qeneral discussion.) The combined results, giving an overall 
indication of the action of leupeptin in the rat visceral yolk sac, 
are discussed below.
Experiments were designed to investigate two main issues:-
1. What is the mechanism of uptake of leupeptin into yolk-sac 
tissue?
Information on the mode of uptake of leupeptin would provide 
evidence on its initial location and site of action, as 
indicated by Models A and B.
2. What happens to leupeptin once it is inside the cell?
Possible fates include:-
i) Re-release of intact leupeptin from the cell by membrane 
permeation or, possibly, exocytosis.
ii) Inactivation within the cell, in the cytosol and/or 
intralysosomally, for example by oxidation or reduction of the 
essential arginal group.
iii) Degradation within the cvtosol and/or lysosomes, to yield 
products (amino acids) that may be re-utilized by the cell or 
may permeate freely out of the cell.
The guestion of what happens to intracellular leupeptin 
also covers the problem of which intracellular location(s) are 
accessible to leupeptin. This depends on the mode(s) of uptake 
and on the permeability of intracellular membranes towards 
leupeptin.
The interpretation of the results is discussed below.
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9#2 Mechanism of Uptake
The mechanism of uptake of leupeptin was investigated by 
monitorlnq the rate of accumulation of leupeptin, the effect of 
inhibitors of pinocytosis on the accumulation of leupeptin, and the 
saturability of accumulation. These methods have been used by others 
to distinguish between adsorptive and fluid-phase pinocytosis (eg 
PrattenetaU, 1980, Silversteln et al., 1977). Similar methods, eg 
saturability, competition from substrate analogues, and determination 
of the rate of uptake, have been used to characterise membrane
transport systems (Matthews & Burston, 1983).
Some of these methods have been used in the past to characterise 
the uptake of other peptides. For example, the peptide proteinase 
inhibitor Z-Phe-Arq-CHN2 entered cells at about the same rate as 
markers of fluid-phase pinocytosis, therefore uptake was assumed to 
occur by this mechanism (Shaw 6 Dean, 1980). Uptake of (D-Ala>3 and 
of (D-Glu)j was thought to occur via pinocytosis because their entry 
into cells was inhibited by the metabolic inhibitors of pinocytosis, 
parafluorophenylalanine and 2 ,4 ,-dinitrophenol (Ehrenreich fi Cohn, 
1969).]
The main leupeptln-detection methods used to study the mechanism 
of uptake of leupeptin were the fluorogenic enzyme assay (in which 
only active, inhibitory leupeptin was detected), and ^H-monitoring 
(in which active and any inactivated leupeptin, degradation products 
of leupeptin, or cell components containing re-utilized label, were 
detected.) The 125I-BSAfd probe method was also used to suggest the
mechanism of uptake of leupeptin*
The 3H-monitoring method indicated that accumulation of 
leupentin did not become saturated over the concentration range 3-100 
ug/ml. The only mechanisms of uptake that are truly non-saturable 
are fluid-phase pinocytosis and non-mediated passive diffusion,
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suggesting that leupeptin uptake may occur via one of these 
mechanisms. [However, if a saturable transport mechanism 
(carrier-mediated transport or adsorptive pinocytosis) involves a 
transport molecule with a low affinity for leupeptin, saturation 
might not be observed over the limited concentration range tested, 
thus saturable transport mechanisms cannot be entirely ruled-out from 
the available results.]
Both the 3H-monitoring and the fluorogenic enzyme assay results 
indicated that, in yolk-sac tissue, the rate of accumulation of 
leupeptin was similar to that of markers of fluid-phase pinocytosis 
(at least over the first 3h of incubation). This rate was the 
minimum expected, since uptake of leupeptin by permeation or by 
adsorptive pinocytosis would increase the rate of leupeptin uptake 
relative to that for fluid-phase pinocytosis. Hence the observed 
rate of accumulation of leupeptin suggests that the main mechanism of 
uptake is by fluid-phase pinocytosis.
However, the methods used only monitor the net rate of tissue 
accumulation of leupeptin, not the total rate of uptake. The rate of 
uptake will exceed the rate of accumulation if loss of leupeptin 
occurs, either by inactivation (detected by the fluorogenic assay) 
and/or by the release of intact of degraded leupeptin (detected by 
both the fluorogenic and the 3H-monitoring assay). Thus the true 
rate of uptake may be greater than that indicated by using either of 
the above methods.
The mechanism of uptake was further investigated using 
inhibitors of pinocytosis, in order to determine the proportion of 
leupeptin accumulation that could be blocked. The radiotracer assay 
indicated that the pinocytic inhibitors rote^ione(10"5M) and low 
temperatures (4-34°C) prevented association of leupeptin with 
yolk-sac tissue. The fluoroqenic assay method produced similar
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results, indicating that ammonium chloride (20mM) and low temperature 
(4«C) are effective inhibitors of leupeptin accumulation. Similarly, 
the 125i-BSAfd_probe method suggested that entry of leupeptin into 
yolk-sac lysosomes could be partially blocked by ammonium chloride
and by low temperatures.
However, the inhibitors of pinocytosis used may have affected 
uptake processes other than pinocytosis. For example, low 
temperature can also inhibit permeation across membranes (Fox, 1975). 
Alternatively, these inhibitors may have induced a more rapid loss of 
leupeptin from the tissue (eg ammonium chloride was shown to enhance 
the loss of leupeptin activity from yolk sacs, as detected by the 
fluorogenic assay, Section 5.4.2). It is unlikely, however, that all 
three inhibitors tested would each inhibit an alternative route of 
leupeptin uptake to the same extent, or that, for each inhibitor, the 
degree of inhibition of the alternative route would be the same as 
that achieved for pinocytosis. It is also unlikely that all three 
inhibitors caused a rapid loss of leupeptin from tissue. (Even 
ammonium chloride, which enhanced the loss of active leupeptin, did 
not increase the release of leupeptin-derived 3H-label from the 
tissue, thus could not have produced a rapid loss of ^H-leupeptin 
following uptake.)
Considered together, the observations of non-saturability, the 
rate of accumulation being similar to the rate of fluid-phase 
pinocytosis, and tissue-accumulation being inhibited by known 
inhibitors of yolk-sac pinocytosis, all suggest that the major mode 
of uptake of leupeptin is via fluid-phase pinocytosis.
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9,3 Intracellular Fate of Leupeptin
Loss of leupeptin could occur by one or more of the following 
mechanisms: re-release of intact leupeptin, inactivation (possibly 
followed by release of inactivated leupeptin), or degradation 
followed by release of the degradation products.
Three leupeptin assay methods were used to investigate loss of 
leupeptin. The fluorogenic enzyme assay was used to monitor loss of 
active leupeptin from loaded yolk sacs. (The method was sensitive 
to small amounts of leupeptin, and distinguished between active and 
inactive forms.) Liquid scintillation counting was used to monitor 
release of 3H-labelled material from loaded yolk sacs into the 
re-incubation medium. (Although more sensitive than the fluorogenic 
assay, time did not permit a distinction to be made between active, 
inactive and degraded leupeptin by the 3H-monitoring method.) The 
chromogenic enzyme assay was used to characterise inactivation of 
leupeptin by a yolk-sac homogenate, and to monitor any inactivation 
of leupeptin in the medium in the presence and absence of yolk-sac 
tissue.
Results from the chromogenic assay method suggest that little or 
no inactivation of leupeptin occurred in the medium during incubation 
of yolk-sac tissue. However, inactivation of leupeptin was mediated 
by enzyme(s) present in a yolk-sac homogenate, but as the site(s) of 
inactivation were not determined, it was not known if inactivation 
could occur in the intact tissue*
An indirect indication that leupeptin activity was lost from 
intact tissue was given by monitoring uptake of leupeptin via the 
fluorogenic assay. The activity of intracellular leupeptin reached a 
steady state after 3h, when the rate of loss equalled the rate of 
uptake. This observation did not, in itself, allow distinction 
between the possible mechanisms of loss. However, no steady-state
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wag observed when monitoring 3H-lahelled leupeptin uptake via 
Vmonitoring. This suggests that loss of leupeptin was not caused 
by release of leupeptin (either intact, inactivated, or degraded) 
from the tissue, since such a release would have given rise to a 
steadv-state guantlty of 3H-label in the tissue.
Loss of leupeptin was further investigated by re-incubating 
leupeptin-loaded yolk sacs in leupeptin-free medium. Results using 
the fluorogenic assay indicated that 90% of leupeptin activity was 
lost from the tissue within 3h of re-incubation. Such loss was 
greatly enhanced by ammonium chloride <10mM). The rate of loss of 
leupeptin decreased during the re-incubation period, reaching zero 
after 3h in the absence, or 1h in the presence, of ammonium chloride. 
Results using the 3H-monitoring method were very different from 
equivalent results obtained using the fluorogenic assay. Only 28% of 
the 3H-label was released into the re-incubation medium over a 4h 
period, and ammonium chloride had no effect on this process.
Moreover, the rate of release was approximately constant over the
re-incubation period between 1-3h.
The disparity between the results from fluorogenic and 
Vmonitoring methods again suggests that loss of leupeptin activity 
from the tissue was not entirely caused by release of intact 
leupeptin from the yolk sacs. (This conclusion is also supported by 
the lack of detection of active leupeptin released into the 
re-incubation medium by the fluorogenic assay.) Either leupeptin was 
inactivated by yolk-sac tissue and the inactivation product«s) 
retained within the tissue, or membrane-permeable 3H-labelled 
leupeptin degradation products were very rapidly re-utilized within
the tissue, so preventing their release.
Ammonium chloride and other weak bases can affect cells in many 
ways (Dean, 1984, Seglen, 1983) thus their effects cannot immediately
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be attributed to any one action. Several possible actions could each 
explain the increased loss of leupeptin observed usinq the 
fluoroqenic enzynie assay (Section 5.4.2). Some of these were 
subsequently ruled-out by results from the radiometric assay and from 
the lysosomal permeability investigation. Release of 3H-label from 
3H-leupeptin loaded yolk sacs was not enhanced by the presence of 
ammonium chloride. This indicates that neither total degradation of 
leupeptin (with attendant release of membrane-permeable degradation 
products) nor any mechanism of release of active/inactivated 
leupeptin was stimulated by ammonium chloride. Ammonium 
chloride did not affect the release of non-degradable pinocytic 
markers from yolk sacs, which suggests that plasma-membrane 
permeability, cell lysis and the rate of exocvtosis were not 
radically affected, therefore these mechanisms cannot account for the 
increased loss of leupeptin. The lysosomal membrane of liver cells 
was observed to be freely permeable towards leupeptin (Section 7.4.2) 
therefore ammonium chloride is unlikely to act by causing an increase 
in the permeability of lysosomal membranes of yolk sacs so allowing 
inactivation of leupeptin by enzymes to which it was not normally 
exposed.
The most likely explanation is therefore that the increase in 
lvsosomal pH in the presence of ammonium chloride gave rise to an 
increase in the rate of inactivation of leupeptin, which implies that 
the lysosomal system must be at least partially responsible for such 
inactivation. Stimulation of inactivation by raising the pH of the 
lysosomes with a lysosomotropic amine was not expected, and suggests 
that lysosomal enzyme(s) with a relatively high pH optimum were 
involved (as suggested in Section 5.4.2.)
Because loss of leupeptin from tissue clearly occurred, it is 
probable that the observed rate of accumulation of leupeptin (as
/
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monitored by both the fluoroqenic and 3H-monitoring methods) was an
underestimate of the total rate of uptake.
Although 90% of leupeptin activity (as detected by the 
fluoroqenic assay) was lost within 3h of incubation in leupeptin-free 
medium, the results of the 125I-BSAfd_probe assay indicate that those 
leupeptin-sensitive lysosomal enzymes responsible for 125I-BSAf(J 
degradation remained maximally inhibited after 5.5h. This could 
suggest that the 10% of active leupeptin (approximately equal to 0.08 
lig/mg yolk-sac protein) that remained in the tissue after 3h was 
sufficient to maximally inhibit such enzymes. However this 
suggestion is not supported by the results of the cathepsin B+L 
assay, in which it was noted that total inhibition of the cathepsins 
B and L in a homogenate of a single yolk sac was achieved by the 
addition of at least 1.5 M  leupeptin. This is equivalent to about 
0.3 u q  leupeptin per mg yolk-sac protein and is thus much greater 
than the amount remaining within yolk sacs after a 3h re-incubation 
period.
The investigation of the intracellular fate of leupeptin 
included a study of the permeability of the lysosomal membrane 
towards leupeptin, in order to suggest which intracellular 
location«s) were available to leupeptin. A method first developed by 
Meqo & McQueen (1965a,b) was used. Lysosomes isolated from rat liver 
rather than from yolk-sac tissue were used for these experiments. It 
was shown that leupeptin could enter isolated lysosomes freely, but 
no information could be obtained on the movement of leupeptin out of 
lysosomes. [Although it is theoretically possible to load liver 
lysosomes with 3H-labelled leupeptin in vivo, such experiments would 
be prohibitively expensive to conduct.] If the yolk-sac lysosomal 
membrane is freely permeable towards leupeptin, both entry into and 
exit of leupeptin from the lysosome may occur readily, leading to
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leupeptin having access to both lysosomal and non-lysosomal 
compartments of the cell whatever the uptake mechanism by the cell.
9.4 Effectiveness of Leupeptin as an Inhibitor of Proteolysis in 
Intact Cells
The degree of inhibition of proteinase enzymes brought about by 
various concentrations of leupeptin after various periods of exposure 
was investigated to determine both the maximum degree of inhibition 
possible in intact yolk-sac tissue, and the incubation conditions 
necessary to achieve this maximum. The methods used for these 
investigations were the l^l-BSA^-probe, and the cathepsin B+L 
assay.
The 125I-BSAf(1-probe method clearly demonstrated that the degree 
of inhibition of leupeptin-sensitive enzymes reponsible for 
125I-BSAf(1 degradation depended on both the concentration of 
leupeptin in the incubation medium and the period of exposure to the 
inhibitor. Maximal inhibition of 125I-BSAfd degradation was not 
achieved until after 1h of exposure to leupeptin at 100 pg/ml or 3h 
for leupeptin at 50 pg/ml. [Leupeptin at 25 vig/ml did not induce 
maximal inhibition even after a 3h exposure period.] These results 
concur with those of the cathepsin B+L assay for which maximal 
inhibition of cathepsin B+L was observed after about 30-60 min 
incubation with leupeptin at 100 yg/ml.
Using the 125I-BSAf(J probe method, the maximum degree of 
inhibition observed was 80%. This incomplete inhibition of 
125I-BSA^j degradation could have arisen either because 
leupeptin-sensitive enzymes were not totally inhibited by the maximum 
concentration of leupeptin achievable in the yolk sac, or because 20% 
of 125I-BSAfd degradation occurred via leupeptin-insensitive enzymes. 
These two possibilities could not be differentiated by the
I
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125I-BSAfd-probe assay. However, results from the cathepsin B+L assay 
indicated that cathepsins R and L (which are the malor lysosomal 
proteinases sensitive to leupeptln) were totally Inhibited after 
incubation of yolk sacs with leupeptin. Thus the small amount of 
degradation of 125I_BSAfd that continued after incubation 
with leupeptin was probably mediated by
leupeptin-insensitive enzymes. The alternative explanation (ie that 
a maximum steady-state concentration of leupeptin, capable of 
inducing an 80% inhibition of 125I_BSAf(l degradation, occurred after 
1h exposure to leupeptin at 100 yg/ml) could be rejected on the basis 
of results in which uptake of leupeptin was monitored using the 
fluorogenic assay. A steady-state concentration of active leupeptin 
was only observed after 3h incubation with leupeptin at 100 pg/ml; 
the amount of leupeptin in the tissue increased over 1-3h even though 
the degree of inhibition of 125I_BSAfd degradation remained constant.
These results illustrate the importance of an adequate 
pre-incubation period of yolk-sac tissue with leupeptin in order to 
achieve full inhibition of leupeptin-sensitive proteinases. The 
duration of a suitable pre-incubation period would depend on the 
concentration of leupeptin used. The results also demonstrate that 
the major leupeptin-sensitive lysosomal cathepsins, B and L, can be 
fully inhibited by incubating intact tissue with leupeptin, but such 
inhibition may not give rise to total inhibition of lysosomal 
proteolysis. Even though loss of leupeptin activity from the yolk 
sac was shown to occur by the fluorogenic assay, the steady 
concentration of leupeptin in the tissue was sufficient to induce 
maximal inhibition of the enzymes responsible for 125I-BSAfd
degradation, and/or cathepsins B+L.
I
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q#5 Comparison of Results with those in the Literature
Several reports of experiments with leupeptln have postulated 
possible modes of uptake of leupeptin, although the evidence on which 
such suggestions are made is often challengahle. Both pinocytosis 
and permeation have been proposed as the route of entry of leupeptln.
The most frequently suggested mode of leupeptin uptake is 
membrane permeation. The main argument for this is the observed 
rapidity of action of leupeptin. [Unlike results observed in the yolk 
sac, in many cells and tissues there is little or no delay in the 
onset of leupeptin-induced inhibition. For example, Seglen et alU 
(1979), and Grinde & Seglen (1980), indicated that onset of 
inhibition of protein degradation was immediate on addition of 
leupeptin to hepatocvtes cultured _in vitro. ] This rapidity of action 
may be contrasted with that of the peptide proteinase inhibitor 
pepstatin, which takes several hours to achieve inhibition of 
proteolysis in macrophages (Dean, 1979). Dean therefore proposed 
that leupeptin uptake is by membrane permeation, whereas pepstatin 
enters cells by pinocytosis alone (Dean, 1979). However, other 
explanations are possible. For example, leupeptin—sensitive enzymes 
may catalyse the rate-limiting steps of proteolysis, or be 
responsible for a greater proportion of proteolysis, so that 
inhibition by leupeptin is more readily detectable than that by 
pep^statin. Alternatively, leupeptin may inhibit its target enzymes 
more effectively at a lower concentration than pepstatin. It should 
also be noted that several reports suqgest that onset of inhibition 
by leupeptin is not immediate. For example, Tanaka et al. (1979) 
reported that maximal inhibition of cathepsin B-type activity in 
rat-liver cells did not occur until after 10h exposure to leupeptin 
(50 Ug/ml), and Sher et al. (1981) reported that Ca2+-activated 
proteinase activity of muscle was maximally inhibited 24-48h after
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intraperitoneal administration in vivo.
Another indication for a non-pinocytic route of entry for 
leupeptin was made by Cockle A Dean (1982), who noted that leupeptin 
produced similar effects in Swiss 3T3 and human fibroblast cells, but 
pepstatin and Z-Phe-Arg-CHN2 (both of which were thought to enter 
cells by pinocytosis) produced a greater effect on human fibroblasts 
than on 3T3 cells. This difference in degree of inhibition was 
proposed to be caused by differences in the rates of pinocytosis in 
the two cell types, the effect of leupeptin being similar in both 
types because of its non-pinocytic mode of entry. (Again, other 
explanations are possible, for example smaller amounts of leupeptin 
may be required to produce a maximal effect in both cell types, so 
the rate of pinocytosis in each type may be unimportant. Moreover, 
it has been noted by Pratten et al. (1980) that the rates of 
pinocytosis in 3T3 and normal human fibroblasts are very similar.] 
Seglen (1983) noted that intact leupeptin was rapidly 
transferred from liver sinusoids to the bile and suggested that 
leupeptin was thus readily transported across cell membranes.
However, alternative rapid routes of entry into the bile exist, such 
as paracellular diffusion across cell junctions and diacytosis within 
vesicles (Lowe et al., 1985).
A suggestion that uptake of leupeptin may occur via permeation 
was made by Borin et a L  (1981), who stated that leupeptin may be 
useful as an antifertility agent because it was able to permeate, by 
fast transmembrane diffusion, the acrosomal membranes of intact 
spermatozoa and inhibit intracellular acrosin. However,Schill et a L  
(1981) reported evidence that leupeptin was not able to inhibit
acrosin within intact spermatozoa.
To date, the only indication that leupeptin may enter cells by 
pinocytosis was suqqested by Neff et al« (1979) who found that
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leupeptin did not inhibit proteolysis in intact hepatocyte lysosomes. 
They therefore proposed that leupeptin pained entry to lysosomes via 
a pinocvtic mode of uptake or via autophagy.
In view of the growing acceptance in the literature of the 
opinion that leupeptin enters cells by permeation (eg Cockle fi Dean, 
1984; Borin et al. 1981), it was somewhat suprising to find that, in 
yolk-sac tissue, the experimental evidence suggests that the major 
route of uptake of leupeptin was via fluid-phase pinocytosis. It is 
quite possible, however, that in cells that are less pinocytically 
active than yolk-sac epithelial cells (eg muscle), entry by 
permeation would provide a major contribution to uptake. It is also 
possible that the permeability of the plasma membranes of different 
cell types towards leupeptin may differ (West, 1983).
None of the reports that suggest uptake of leupeptin occurs via 
membrane permeation have characterised the mechanism of permeation 
(ie non-mediated, facilitated, or active transport). The size and 
polar nature of leupeptin would be expected to exclude entry by 
passive diffusion across the phospholipid bilayer, though possibly 
the molecule would enter via 'aqueous pores' in the membrane 
(Matthews, 1977), or via protein pores or channels (Alberts et al., 
1983). Non-substrate-specific active transport systems for di- and 
tripeptides are known to exist in the gut. However, those 
characterised to date would not be expected to have any affinity for 
leupeptin (Matthews, 1977). The presence of such general transport 
mechanisms in tissues other than the intestine has not been 
established. Many biologically—active peptides are known to occur in 
mammals some of these have specific transport mechanisms in 
particular tissues to allow their entry and/or exit. Several such 
systems are discussed by Matthews & Payne (1975). Although there is 
no reason for a transport mechanism specific for leupeptin to be
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present in mammalian membranes, it is just possible that leupeptin 
naY utilize a system that normally transports other 
biologically-active peptides. Discussions of peptide transport 
systems are qiven by Matthews and Payne (1975) and in the Ciba 
Foundation Symposia (1972 and 1977).
The intracellular fate of leupeptin has also been discussed by 
several workers. Many reports suggest that leupeptin may be 
inactivated in vivo and in vitro (see Chapter 6 for discussion of 
such reports). The most convincing evidence for leupeptin 
inactivation is provided by Beynon R co-workers, who demonstrated 
leupeptin inactivation by homogenates of many different tissues, and 
who isolated an enzyme from rat liver capable of cleaving the 
Leu-arginal bond of leupeptin. Further evidence of leupeptin 
degradation was reported by Tanaka et a h  (1993) who isolated 
metabolites of leupeptin after intravenous administration to rats. 
Acetyl-Leu-Leu was identified as one such metabolite. The results 
reported in this thesis do not contradict the published data, in that 
leupeptin inactivation also appears to have occurred in the yolk sac. 
However, the indication that leupeptin inactivation products were not 
released from yolk-sac tissue does not concur easily with the 
reported cleavage of leupeptin to form Ac-Leu-Leu and arginal. Only 
if Ac-Leu-Leu cannot be further broken down and if arginal cannot 
utilize amino acid membrane tranpsort systems would these products be 
expected to be retained within the yolk sac, unless rapid metabolism 
and/or re-utilization occurred.
Future Work
Had time permitted, the experiments described in this thesis 
could have been extended in several different directions. The 
possibility of uptake bv permeation could have been investigated
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further by usinq a wider ranqe of leupeptin concentrations and/or bv 
usinq leuneptin analoques as competitive inhibitors of mediated 
transport. It would also have been interestinq to monitor the effect 
of ammonium chloride and low temperature on leupeptin uptake usinq 
the cathepsin R+L assay, to determine whether cathepsins B and L 
could be inhibited by any leupeptin enterinq the tissue in the 
presence of these pinocytic inhibitors. The results could then have 
been compared with the inhibition studies carried out usinq other 
leupeptin detection methods. (However, the cathepsin B+L assav 
method itself would require further modification to obtain more 
reproducible results before future use.)
Many features of the intracellular fate of leupeptin in yolk-sac 
tissue remain unresolved. Future work could include an investiqation 
of the leupeptin metabolites produced in the yolk sac, in order to 
determine why leupeptin inactivation did not lead to release of 
deqradation products. Such an investiqation would require methods 
for separatinq, detectinq and identifyinq any such metabolites (some 
of the methods tested for use are described in Appendix 4). It would 
also be interestinq to further investiqate the location and 
characteristics of enzymes involved in leupeptin
inactivation/deqradatlon. For example, the inactivation of leupeptin 
by isolated lysosomal and cytosolic enzymes could be measured.
(Crude preparations of such enzymes could be obtained from rat liver 
tritosomes and from a particle-free supernatant of a liver 
homoqenate.) Results from such experiments may give a better 
indication of the site of inactivation/degradation of leupeptin.
Also the pH dependence of inactivation/deqradation by a lysosomal 
extract could be measured (usinq the sensitive fluoroqenic assay) to 
indicate whether inactivation occurs more rapidly at neutral pH.
In conclusion the results of these investiqations show that
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fluid phase plnocytosis is a major route of uptake of leupeptin in 
rat yolk-sac tissue, but the possibility of additional mechanisms of 
uptake cannot be ruled out entirely*
Leupeptin appears to be inactivated within yolk sacs, 
however it achieves an intracellular concentration great enough to 
fully inhibit cathepsins B+L and remains sufficiently active to 
inhibit protein degradation 5h after exposure of tissue to inhibitor.
The intracellular location of leupeptin was not fully 
established. It clearly has access to lysosomes via its pinocytic 
route of uptake, and can, in vitro, permeate into the lysosome across 
the lysosomal membrane. However the likelihood of leupeptin 
permeating into the cytosol, either from lysosomes or from the 
extracellular medium, was not determined. Thus it is not possible to 
assess whether leupeptin inhibits only intralysosomal protein 
degradation or whether it is also capable of inhibiting non-lysosomal 
proteinases in vivo. Investigations into these factors are worth 
persuing further, in order to establish whether leupeptin can be used 
to determine the importance of lysosomal and non-lysosomal pathways
of proteolysis in cells.
L leupeptin X inactivated leupeptin
E enzyme K inhibited enzyme
P protein
Fig. 9.1 Possible Intracellular Fate of Leupeptin MODEL Plasma Membrane 
Impermeable Towards Leupeptin
Uptake of leupeptin would occur via pinocytosis, leading to delivery of 
leupeptin to lysosomes. Leupeptin would then inhibit lysosomal enzymes and 
may become inactivated within lysosomes. It is also possible that intact 
leupeptin may permeate out of lysosomes to inhibit cytosolic protéinases
(or become inactivated itself).
Inhibition of non- 
lysosomal protéinases
Inactivation of leupeptin 
in the cytosol
Inactivation of leupeptin 
within lysosomes
Permeation of leupeptin 
into lysosomes from the 
cytosol
1 lysosome A autophagosome
L leupeptin K inactivated leupeptin
E enzymes E inhibited enzyme
P undegraded protein
Fig. 9.2 Possible Intracellular Fates of Leupeptin MODEL B: Plasma Membrane
Permeable Towards Leupeptin
Uptake of leupeptin would occur via both membrane permeation and pinocytosis, 
leading to delivery of leupeptin to the cytosol and lysosomes. Leupeptin may 
also enter lysosomes from the cytosol via direct permeation, microautophage 
uptake or by fusion with autophagosomes, pinosomes by permeation. Leupeptin 
may inhibit both lysosomal and non-lysosomal proteinases, and may become 
inactivated itself at either location.
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GENERAL DISCUSSION: POST-SCRIPT
After the experimental work and the majority of the writing of 
this thesis had been completed, a paper by Dennis 6 Aronson (1985) 
was published which reports in detail the uptake, subcellular 
distribution and metabolism of 3H-leupeptin by perfused rat liver and 
by rat liver in vivo. 3H-leupeptin was detected both by 
3H-monitoring and by a papain-inhibition assay. [The latter was 
similar, in principle, to the chromogenic method used in this thesis. 
Active leupeptin was detected over the concentration range 0.09-0.23 
liM (0.04-0.1pg/ml)] . Ion-exchange chromatography and paper 
electrophoresis were used to separate putative inactivation products* 
that could be detected (but not identified) by 3H-monitoring.
The main results reported by Dennis & Aronson (1985) are 
summarised below, 
i) Uptake of Leupeptin
Uptake of 3H-leupeptin was measured in terms of the percentage 
of administered leupeptin that entered the liver plus bile during the 
experimental period. Over a 2h period, 35-50% of the leupeptin added 
to a perfusate was removed by the liver. About 49% of this 
radioactivity passed into the bile. At low concentrations (below 
0.02mM) the rate of removal of leupeptin from the perfusate was 
greater during the initial 15min of perfusion. (This phenomenon was 
not observed for higher concentrations of leupeptin.) Uptake was not 
saturable over the range 0.001-0.4mM (0.44-176 yg/ml).
The uptake of leupeptin into the liver plus bile by a perfused 
liver was lowered by 25% in the presence of a mixture of eight amino 
acids (present at 500-1000 times the concentration of leupeptin), and 
slightly lowered (about 10%) by the tripeptide Leu-Arg-Leu (present 
at 140 times the concentration of leupeptin). Similarly, 
chemically-reduced leupeptin, ie. leupeptin alcohol, present at 200
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tines the concentration of leupeptin, diminished uptake by about 50%. 
Uptake into the liver plus bile was also inhibited by low 
temperatures and by the lysosomotropic weak base chloroquine. (The 
rate of uptake decreased linearly between 35 and 25°C; at 21°C only 
5% of the added radioactivity entered the liver plus bile. 
Chloroquine, 0.2mM, inhibited total uptake by about 40%, but 
secretion into the bile was unchanged.) 
ii) Subcellular Location of Leupeptin
The distribution of radioactivity in subcellular fractions of 
rat livers was measured at various time-intervals after injection of 
3H-leupeptin into rats _iii vivo. The radioactivity in the heavy and 
light (ML) mitochondrial fraction increased from 15% (immediately 
after injection) to 49% after 90min; over the same time period, 
radioactivity in the supernatant decreased from 66% to 29%. (When 
^H-leupeptin was added to a liver homogenate prior to fractionation, 
75% of the radioactivity remained in the supernatant and only 4% 
became associated with the ML fraction.] When livers were treated 
with chloroquine (0.2mM) for 30min prior to perfusion with 
^H-leupeptin, uptake into the ML fraction was inhibited by 75% and 
the percentage of radioactivity in the supernatant increased .
Although leupeptin appeared to accumulate within the 
mitochondrial fraction in vivo, radioactivity did not become 
associated with a mitochondrial fraction incubated _in vitro, 
ui) Metabolism of 3H-Leupeptin
Metabolism of 3H-leupeptin was assessed by measuring both its 
specific activity (in terms of % inhibition of papain per cpm), and 
the molecular nature of the radioactivity within a perfused liver.
The radioactivity in the bile was shown to be intact leupeptin. 
However, 40% of the radioactivity in the liver itself was 
non-inhibitory, and was found to differ in characteristics from
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3H-leupeptin on lon-exchange and paper chromatography.
Although the exact uptake mechanism(s) of leupeptin was not 
determined the results were taken to suggest that uptake of leupeptin 
occurred mainly by direct diffusion across the plasma-membrane, 
although some leupeptin may enter the tissue by a more specific 
process. Pinocytosis was dismissed as a route of entry because 
fluid-phase pinocytosis would only account for about 2% of the volume 
of perfusate whose contained substrate entered the liver over a 2h 
period, and also because radioactivity became associated with the 
cytosolic fraction before the ML fraction. Inhibition of uptake by 
chloroquine and low temperature could indicate an energy requirement 
for uptake, although the latter inhibitor may have acted by 
decreasing membrane fluidity. Nearly 50% of the leupeptin that 
entered the tissue appears, intact, in the bile. This osbervation is 
not compatible with release of lysosomal contents (unless the 
leupeptin stimulated exocytosis) hence release by membrane permeation 
was considered more likely.
On comparing the results of Dennis & Aronson (1985) with those 
reported in this thesis some similarities are observed. However, a 
few results are very different. [Several experiments are peculiar to 
only one of the studies so do not permit a comparison of data.]
Similarities include the observation that uptake of leupeptin 
was inhibited by weak bases (ammonium chloride or chloroquine) and by 
low temperatures but was not saturable up to a concentration of 
200|jg/ml.
Divergent results include the rates of uptake of leupeptin. In 
the perfused liver, a greater percentage of 3H-leupeptin entered the 
liver than could be accounted for by fluid-phase pinocytosis alone, 
whereas in yolk sacs the rate of accumulation of 3H-leupeptin 
occurred at the same rate as fluid-phase pinocytosis. Another
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difference between results was that, in the report of Dennis & 
Aronson, 3H-leupeptin did not become associated with liver lysosomes 
incubated in vitro. However, in the "Mego 6 McQueen" type experiments 
described in this thesis, it was observed that leupeptin was able to 
cross the membrane of isolated rat-liver lysosomes. Also, release of 
leupeptin from the liver into the bile was apparently greater than 
the release of leupeptin from yolk-sac tissue. (This might be 
expected for any low-molecular-weight substrate because exocytosis is 
known to occur in the liver.)
Several results of Dennis S Aronson (1985) had no equivalent in 
the work reported in this thesis, and the information provided by 
them will be discussed here.
i) In the perfused liver, large excesses of amino-acids or 
leupeptin analogues inhibited the uptake of 3H-leupeptin. It was 
suggested that this competitive inhibition could indicate that some 
uptake occurred by a specific process or by different transport 
mechanisms in different liver cell types. The main uptake mechanism 
was proposed to be direct permeation, because uptake of 3H-leupeptin 
alone was not saturable.
No control experiments to monitor the effects of the competitive 
inhibitors on the tissue itself were reported, and the concentration 
dependence of competition was not determined. Additional experiments 
may enable a more precise interpretation of these initial 
observations. It would also be interesting to carry out equivalent 
experiments in rat yolk-sac tissue to measure any inhibition of 
uptake of leupeptin by its analogues.
ii) The subcellular distribution of 3H—leupeptin that had 
entered the liver was determined in the experiments of Dennis S 
Aronson. (Unfortunately, this type of experiment was not possible in 
yolk-sac tissue because of difficulties in obtaining intact
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subcellular orqanelles.)
Immediately after administration _iii vivo, very little of the 
radioactivity in the liver was associated with lysosomes (most was 
located in the cytosol), but, 90min after administration, the 
distribution had changed so that a qreater percentage of the 
radioactivity was located in the lysosomes, rather than in the 
cytosol. The change in distribution was taken to sugqest that 
leupeptin first entered the cytosol then accumulated in the 
lysosomes. This implies that uptake of leupeptin occurred by direct 
permeation across the plasma membrane into the cytosol, followed by 
entry into and accumulation within lysosomes. Chloroquine inhibited 
both uptake and accumulation within lysosomes.
It was suggested that this may be because a 
low intralysosomal pH and/or active proton pump was necessary for 
leupeptin accumulation and/or uptake. Thus some leupeptin 
accumulation must be energy—dependent (although the report suggested 
that the most prominent route of entry was probably permeation 
throuqh membrane pores).
However, an alternative explanation, other than uptake occurring entirely 
by membrane permeation, can be put forward; the results of Dennis &
Aronson are compatible with at least a fraction of the leupeptin 
entering the tissue by pinocytosis (possibly adsorptive pinocytosis).
Thus chloroquine (which inhibits pinocytosis) could inhibit uptake of 
leupeptin into lysosomes, as observed. (Any remaining uptake could 
occur by permeation directly into the cytosol.) The observation that 
leupeptin accumulates in lysosomes within 30min could also be 
attributed to a pinocytic mode of entry, as substrates taken up by 
pinocytosis are thought to reach lysosomes within about 10-15min.
The greater proportion of leupeptin in the cytosolic fraction at 
early time-points could be explained either by a proportion of uptake
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occurring rapidly via direct membrane permeation, or by free 
3H-leupeptin arising either from extracellular sites (by failure to 
be displaced by the flushing procedure) or possibly from lysed 
lysosomes. These possible alternative explanations are not 
discussed by Dennis 6 Aronson.
j j j) Dennis & Aronson measured uptake of leupeptin in terms
of the amount of radioactivity that accumulated in the liver tissue 
and in the bile. [The possibility of loss of leupeptin from the 
tissue back into the perfusion medium was not discussed, although 
back-diffusion would be expected if passive diffusion was the main 
route of entry. (Loss of leupeptin from yolk sacs back into the 
incubation medium was considered in the experiments described in this 
thesis, but no route of release equivalent to biliary secretion 
exists in yolk-sac tissue.)]
In perfused liver, leupeptin appeared in the bile in an 
inhibitory form a short time (within 15min) after addition to the 
perfusate. Moreover, the amount of leupeptin in the bile increased 
steadilv over the 2h perfusion period, about 50% of the radioactivity 
cleared from the perfusate was located in the bile after this period. 
The presence of 0.2mM chloroquine (which inhibited total uptake the 
liver plus bile by about 40%) did not affect the amount of leupeptin 
secreted into the bile.
All 3H-leupeptin in the bile was assumed to have entered that 
compartment via an intracellular route through the liver tissue, and 
thus contributed to the total uptake by the tissue. However, it is 
possible that leupeptin may enter the bile via a paracellular route, 
by diffusion across the tight junctions between cells in the liver. 
This paracellular route has been investigated using markers such as 
sucrose (mol. mass 342) and inulin (mol. mass 5000) and can occur for 
much larger molecules such as horseradish peroxidase; Lowe et al»>
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1985. (Substrates entering the bile via this route first appear 
within about 5min of addition to the perfusate.) Thus it appears 
likely that leupeptin (mol. mass approx 435) could also diffuse 
across tight junctions. Whatever the route by which intact leupeptin 
rapidly reaches the bile canaliculi in quantity, there appears to be 
a distinct possibility that intact leupeptin in this compartment will 
not be flushed from the liver and may mistakenly be assumed to be 
present in the cytosolic compartment when interpreting the results of 
subcellular fractionation experiments.
In conclusion, although the results of Dennis & Aronson (1985) 
were taken to suggest that the major route of uptake was via direct 
permeation of the plasma membrane, the data do not preclude other 
modes of uptake. In particular, uptake by pinocytosis (adsorptive) 
may be of more importance than originally assumed. The main 
arguments against a pinocytic mode of uptake were the rapid rate of 
clearance of leupeptin, and its subcellular distribution in liver 
tissue. However, as argued above, direct permeation across the plasma 
membrane may not be as great as proposed and a subcellular 
distribution similar to that observed could occur if pinocytosis was 
the main route of uptake by hepatocytes. Indeed, several of the 
reported results, such as those observed with chloroquine and at low 
temperatures, are equally compatible with a pinocytic mode of uptake.
It is possible that several different modes of entry contribute 
towards the uptake of leupeptin by liver tissue. These could include 
passive diffusion, mediated diffusion, and adsorptive pinocytosis. 
Different routes may be absent or be dominant in the different cell 
types, found in liver and yolk-sac tissue, so that there may be real 
differences between different tissues.
Dennis, P A. & Aronson, N.N. Jr. (I985). Arch. Biochem. Biophys. 240, 768-776.
GENERAL DISCUSSION: POST SCRIPT II
NOMENCLATURE OP PROTEIN-DEGRADING ENZYMES.
Until fairly recently there has been widespread confusion over 
the nomenclature of proteolytic enzymes; this confusion is reflected 
in some of the terms used in this thesis. Recent publications 
(Barrett, 1980; Barrett & McDonald, 1985; Barrett & McDonald, 1986) 
have clarified the definitions and the following nomenclature and 
classifications are now accepted.
i) Peptidase; any hydrolase that cleaves peptide bonds. The 
substrate may have any number of amino acid residues and range 
in size from a small peptide to a protein. The term "peptidase” 
replaces the older term "protease".
ii) Exopeptidase; a hydrolase that cleaves peptide bonds at or 
near the ends of a polypeptide chain. Exopeptidases require the 
substrate to have a free carboxyl- or amino-terminal residue.
iii) Endopeptidase; a hydrolase that can cleave bonds distant 
from the ends of a polypeptide chain. [Some endopeptidases are 
also capable of cleaving bonds at the ends of a polypeptide 
chain, but these do not require free carboxyl- or amino-terminal 
residues.] An older expression, having the same meaning as 
"endopeptidase" is "proteinase".
Endoproteinases may be further classified according to 
their catalytic mechanism. The first three groups, now named 
after the active-site amino-acid residue most important for 
their mechanism of catalysis, are known as serine, cysteine 
(formerly "thiol") and aspartic (formerly "acid" or "aspartate") 
endopeptidases. A fourth group is the metallo-endopeptidases, 
which contain a metal ion as an integral part of the active 
site. [A fifth group of endopeptidases exists in which the
mechanism of catalysis is unknown.]
In order to conform with these definitions, the following
modifications are required to the text of this thesis.
i) On pages 1 and 2 the terms "endopeptidase" and "exopeptidase" 
were defined as peptide hydrolases that act only on "peptides". 
This definition is not accurate: "peptidases" can act on both 
peptides and proteins.
ii) Also on pages 1 and 2 (and others e.g. pages 4, 89) the terms 
"endoproteinase" and "exoproteinase" were used. This 
nomenclature is not accepted; the terms "endopeptidase" and 
"exopeptidase" should have been used.
iii) The classification "thiol" was used (e.g. on pages 2, 4, 8,
185); the more recent nomenclature "cyteine" is to be preferred. 
Likewise, "aspartate" <p2) is better replaced with "aspartic".
iv) Throughout the thesis the term "proteinase" was used as a general
term for all peptide bond hydrolases and should therefore have 
been replaced by the term "peptidase". However, as used in this 
thesis the term "proteinase" does in fact imply "endopeptidase", 
because endopeptidases generally initiate (and hence control) 
the total hydrolysis of proteins and because most peptidase 
inhibitors inhibit only endopeptidases. Thus the term 
"proteinase" (meaning endopeptidase), though an 'old-fashioned' 
word, is in fact correct in the context of this thesis, and was 
not altered in the final draft.
Barrett, A.J. (1980). In: Protein Degradation in Health and Disease, 
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Appendix 1.1
0010 DIM C£30
0020 REM KEW 125-IPVP PROGRAM,MODIFIED NOV. , 1974 
0027 REM FURTHER MODIFIED DECEMBER 1980 BY LEN 
0030 DIMH(30),I(30),K(30),L(30),R(30)
0060 PRINT "NON-DIGESTIBLE PROG. ENTERED"
0070 % "EXPERIMENT CODE ="»
0080 INPUT Z£
0090 PRINT "BACKGROUND IN CPM=")
0100 INPUT A
0110 PRINT "COUNTING TIME FOR EACH ML OF MEDIUM, SECS=";
0120 INPUT C
0130 PRINT "COUNTING TIME FOR EACH ML OF YS SOLUTION, SECS="; 
0140 INPUT D
0150 PRINT "NO. OF POINTS IN PLOT=";
0160 INPUT G
0165 PRINT "NAME OF DATA FILE:“;
0167 INPUT F1£
0170 PRINT "NAME OF REGRESSION FILE:";
0174 INPUT F2£
0176 FILES l-BSA ,F1£,University of Keele,,F2£
0180 PRINT "NAME OFfRESULTS FILE:";
0184 INPUT F3£
0186 FILES Keele,,F3£
0190 FOR X=1 TO G
0200 INPUT 5I-BSAf(J, H (X ) , I (X) ,K(X) ,L(X ) ,
0210 NEXT X
0220 FOR X=1 TO G
0230 LET M=(I(X)*60/C)-A
0240 LET Q=((K(X)*60/D)-A)*5
0250 LET N=M+Q/20
0260 LET R(X)=(Q*1000)/(N*L(X))
0265
0266
0270 % University of Keele,,H(X),",",R(X)
0280 NEXT X
0310 PRINT Keele,, " "
0315 % Keele,,"THIS IS EXPT CODED ";Z£
0320 PRINT Keele ** w
0330 % Keele,,"INCUBATION TIME";" PROTEIN IN Y.S. ";" UPTAKE 
0332 % Keele,,"(HOURS)"
0340 PRINT Keele,,
0350 FOR X=1 TO G
0360 % Keele,,H(X),L(X),R(X)
0370 NEXT X 
0380 STOP
Appendix 1.2
0020 REM PROTEIN PROGRAM , REVISED OUTPUT ,NOV. 1974 
0030 DIM E(12),H(12),I(12),J(12),K(12),L(12),S<12) 
0040 DIM C£30 
0045 DIM V£30
0060 PRINT "PROTEIN PROGRAM ENTERED"
0070 PRINT "EXPERIMENT CODE »";
0080 INPUT V£
0090 PRINT "BACKGROUND IN CPM=";
0100 INPUT A
0110 PRINT "PERCENT SOLUBLES IN PREP=">
0120 INPUT B
0130 PRINT "COUNTING TIME MEDIUM TOTALS,SECS = ”>
0140 INPUT C
0150 PRINT "COUNTING TIME MEDIUM SOLUBLES, SECS = " ; 
0160 INPUT Z
0170 PRINT "YS COUNTING TIME, SECS=";
0180 INPUT D
0190 PRINT "CORRECTION FACTOR FOR MEDIUM TOTALS="; 
0200 INPUT Y
0210 PRINT "CORRECTION FACTOR FOR MEDIUM SOLUBLES="; 
0220 INPUT R
0230 PRINT "NO. OF POINTS IN PLOT=";
0240 INPUT G
0264 PRINT "NAME OF DATA FILE:";
0265 INPUT F1£
0266 PRINT "NAME OF REGRESSION FILE:";
0267 INPUT F2£
0269 FILES 125I-BSA,F1£,University of Keele,,F2£
0270 PRINT "NAME OFfRESULTS FILE:";
0272 INPUT F3£
0275 FILES Keele,,F3£
0277 FOR X=1 TO G 
0280 INPUT 
0290 NEXT X 
0300 FOR X=1 TO G 
0310 LET M=(I(X)*60/C-A)*Y 
0320 LET N=(J(X)*60/Z-A)*R 
0330 LET O=N-(M*B/100)
0340 LET Q=( (K(X ) *60/D )-A )*5 
0350 LET P=(M-N)+0/2 
0360 LET F=((10*0)+Q)* 1000 
0370 LET E(X)=(Q*1000)/(L(X)*P)
0380 LET S(X)=F/(L(X)*P)
1—BSA , H(X),I(X),J(X),K(X),L(X), rd
0385
0387 % Keele,,
0390 % University of Keele, ,H(X),'
0400 NEXT X
0405 % Keele,,
0410 % Keele,,"GOOD MORNING 1 THIS
0430 PRINT Keele,, m »
0435
0440 PRINT Keele,, M M
0445 % Keele,,
0450 PRINT Keele,, " INCUBATION
UPTAKE"
0460 PRINT Keele,, "TIME (HOURS)
0465 % Keele,,
0470 FOR X=1 TO G
0480 % Keele,,H(X),L(X),E(X),S(X)
0490 NEXT X
0500 STOP
PER MG YS
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Appendix 1.3
DIMENSION COUNTS(100),CPM(100),T(100),SIGC(10 1 )
DIMENSION FNAME(20)
DATA SPACES/4H / .FSTOP/4HSTOP/
1 WRITE(2f*)"INPUT DATA FILENAME"
READ(1,110)(FNAME(I),I=1,20)
110 FORMAT(20A4)
CALL CONECT(0,3)
IF (FNAME(1).EQ.FSTOP)GOTO 50 
IF (FNAME(1).EQ.SPACES)GOTO 4 
CALL CONECT(FNAME,3)
GOTO 6
4 CALL CONECT(4H* ,3)
6 READ(3,*)N,WEIGHT,ITIME,IBACK 
SIGC( 1 )=0.0 
C READ THE COUNTS
DO 10 1=1,N 
10 READ(3,*)COUNTS(I)
C CORRECT COUNTS FOR TIME,BG,CF
DO 20 1=1,N
CPM( I ) = ( ( COUNTS ( I ) *60.0/FLOAT ( ITIME ) )-FLOAT ( IBACK) ) * 1.2065 
20 SIGC(1+1)=SIGC(I)+CPM(I)
C CCALCULATE TOTAL COUNTS
WRITE(6,105)(FNAME(I),1=1,20)
105 FORMAT(1H1,12H DATA FROM ,20A4//)
WRITE(6,115)
115 FORMAT ( 1X, 3HNO. , 3X, 6HCOUNTS, 7X, 3HCPM, 9X, 4HSIGC, 7X, 5HTOTAL/) 
DO 30 1=1,N
T(I) = ((10* 0+CPM(I)+SIGC(I))/WEIGHT)
WRITE(4,100)1.COUNTS(I),CPM(I),SIGC(I),T(I)
30 WRITE(6,100) I.COUNTS(I),CPM(I),SIGC(I),T(I)
100 FORMAT(1X,I3,4(3X,F9•0))
GOTO 1 
50 STOP 
END
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APPENDIX 2
Preparation of Yolk-Sac Tissue for Assay of Active Leupeptin
Efficient extraction of leupeptin from tissue was important for 
the quantitative estimation of the amount of leupeptin that had 
accumulated within tissue during incubation. Several different 
methods of tissue disruption were tested for their suitability. 
(Suitable methods were defined as those that were quick and 
effective, and that gave a high recovery of leupeptin). Tissue 
disruption was assessed qualitatively by observing the amount of 
tissue debris remaining at the end of the disruption procedure. The 
percentage recovery of leupeptin was estimated by adding a known 
amount of leupeptin to intact, unincubated tissue then disrupting the 
tissue and assaying its leupeptin content using the fluor* metric 
method described in Section 5.2.1.
The following methods of tissue disruption were tested, 
i) Homogenization The precise methods of homogenization used for 
each experiment are given in the relevant chapters. Greatest tissue 
disruption was achieved using a hand-held
qround-glass-on-ground-glass tissue homogenizer, particularly when 
tissue was homogenized from the deep-frozen (-20°C) state.
Homogenization using a Teflon-on-glass, Potter-Elvehjem type 
homogenizer did not disrupt tissue efficiently; best results using 
this homogenizer were obtained when at least three yolk sacs were 
homogenized together
[Recovery of leupeptin from homogenized tissue that was either 
assayed directly or treated with TCA (which precipitated cell 
proteins leaving leupeptin in the soluble fraction) is discussed in 
Sections 4.3.4 and 5.3.21.
Leupeptin was stable on storage at -20°C in a yolk-sac
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homogenate or the TCA - soluble fraction of a homogenate.
11} Grinding Under Liquid Nitrogen Yolk sacs were immersed in liquid 
nitrogen in a stoneware mortar. Once frozen, the tissue was ground 
with a pestle (also at liquid nitrogen temperature) then the nitrogen 
allowed to evaporate. The powdery, frozen residue was quickly 
transferred to a small vial, and distilled water added.
The method was not considered suitable for general use because 
quantitative transfer of tissue from mortar to vial was difficult, 
and fairly large quantities of liquid nitrogen were required, 
iii) Collagenase Disintegration Collagenase (Sigma Types IV or V) 
was used at concentrations of 1,5 and 10mg/ml in Trfs buffer (0.1M, pH 
7.5) containing calcium chloride (10mM>. Yolk sacs were placed singly 
in small vials and finely chopped with scissors. Collagenase solution 
(0.5ml) was added and the vials incubated at 37°C, with occasional 
vortexing. Tissue became fully disrupted within 12h at all 
concentrations of collagenase tested*
The method was convienient in that it was less labour intensive 
than homogenization or grinding. However, leupeptin was inactivated 
during incubation with collagenase solution (only about 10% of the 
added leupeptin remained after 6h incubation with collagenase. Type 
IV, at 37°C) therefore the method could not be used to disrupt tissue
containing leupeptin prior to assay.
iv) Digestion in Sodium Hydroxide Yolk sacs were digested in sodium 
hydroxide solution (1M, 0.5ml per yolk sac) at 37°C. Digestion to a 
clear solution took approximately 1h. However, leupeptin lost 
activity rapidly when incubated with sodium hydroxide, therefore the 
method was unsuitable for use in preparing leupeptin - containing
tissue for assay.
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APPENDIX 3
P r e p a r a t io n  of Yolk-Sac Tissue f o r  Assay of 3H- and 14C- 
R a d io a c t iv i t y
14
It was necessary to disrupt yolk-sac tissue prior to assay of C 
3H-radioactivity, both to improve counting efficiency and to enable 
samples to be removed for assay of protein content. The method of 
disruption used should give a homogeneous susupension or solution 
with a high counting efficiency, so that counts are reproducible both 
between tissue samples and over time. Several methods were tested for 
their suitability, by comparing the observed counts in a 'spike of 
radioactivity added to both unincubated tissue and water.
i) Neutralised Sodiu» Hydroxide Tissue was first digested in sodium 
hydroxide (0.5M, 2ml/yolk sac) for 4h at 37°C, then the solution 
neutralised with an equal molar quantity of nitric acid and the 
volume made up to 5ml with distilled water. Duplicate samples (0.5ml) 
were mixed with scintillation fluid, allowed to stand overnight, then 
assayed for radioactivity.
This method was found to give poor reproducibility between 
tissue samples. Some vials contained a precipitate that reduced the 
counting efficiency relative to other spiked tissue and to water.
ii) Commercial Tissue Solubiliser Tissue solubilizer (NCS, 1ml/yolk 
sac) was added to the tissue and the tissue digested overnight at 
37°C. A sample (0.5ml) of the digest was mixed with scintillation 
fluid (4ml), allowed to stand overnight, then counted.
The method was not suitable for use with experimental tissue 
because the digest could not be used in the protein assay.
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lii) Collagenase Collagenase solution (Worthington Type CLS III 
1mg/ml dissolved in Tris buffer, 0.1M pH 7,5, containing calcium 
chloride, 10mM) was added to the tissue (0.5ml/yolk sac) and 
incubated overnight at 37°C. A sample (0.4ml) of the resulting cell 
suspension was mixed with scintillation fluid (4ml), allowed to stand 
overnight, then counted.
The method gave good counting efficiency relative to water (mean 
97%) but was not ideal because of the relatively high cost of 
collagenase, long period of time required for disruption, and 
additional calculations required to determine the protein content of 
the tissue alone.
iv) Sodium Hydroxide Tissue was digested in a small volume of sodium 
hydroxide (1M, 1ml/yolk sac) over a period of 2h at 37°C. A sample 
(0.5ml) of the digest was mixed with scintillation fluid (4ml), and 
either counted immediately or allowed to stand for a period of 2h — 9 
days before counting.
Immediately after addition of scintillation fluid, the number of 
counts observed from spikes of ^C- sucrose and in a yolk-sac
digest was greater than in water (counting efficiency relative to 
water was about 110%), probably because of chemiluminesence. However, 
the number of counts observed in the digest when  ^C- surcrose was 
used as the spike decreased markedly over the 9 day monitoring 
period, the relative counting efficiency falling to 50% on standing 
overnight and 30% after 5-9 days. A less marked drop occurred when 
3H2o was used as the spike, the realative counting efficiency falling 
from 115% to 105%. Because chemiluminesence and loss of observed 
counts occurred the method was not considered suitable for the 
preparation of experimental tissue for assay.
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t ) Homogenization Yolk sacs were homogenized (from frozen) in 
distilled water (1ml/yolk sac) in a hand-held ground-glass 
homogenizer. Duplicate samples (0.4ml) were mixed with scintillation 
fluid (4ml) and allowed to stand overnight before counting, (except 
when reproducibility of counts over time was investigated, when 
samples were counted immediately then at intervals over 9 days).
This method was used for all experimental tissues. The method 
gave good reproducibility over time for both 14C and 3H counts, and 
counting efficiency was high and fairly reproducible. The protein 
content of the homogenate was readily determined.
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APPENDIX 4
Analysis of Leupeptln Degradation Products
The separation and possible identification of leupeptin 
degradation products was desirable for several reasons, one of the 
most important being in the characterisation of material released 
from leupeptin-loaded yolk-sac tissue. If the material released was 
found to be mainly intact leupeptin, this would suggest that 
leupeptin is capable of permeating out of the cell across the plasma 
membrane. If, however, it was found that mainly degradation products of 
leupeptin were released, it may have been possible to calculate the 
total uptake of leupeptin (rather than simple tissue-accumulation) by 
estimating the amount of degradation products in the incubation 
medium and adding this to the amount of material detected in the 
tissue after each period of incubation. The metnod of separation used 
need not identify the degradation products produced, but would 
ideally be quick and simple (similar, for example, to the addition of 
TCA to precipitate, and thus separate, an intact protein from its 
degradation products). It would also need to be both quantitative 
and reliable for small quantities of material (such as those present 
in re—incubation medium or in incubation medium containing a high 
concentration of intact leupeptin, but only small quantities of 
degradation product).
If a method were found to identify inactivation and/or 
degradation products, metabolism of leupeptin within tissue could 
have been monitored. This, in turn, may have provided an explanation 
for the observed loss of active leupeptin, but not 3H-radioactivity 
derived from leupeptin, from yolk-sac tissue.
Several potential methods of separating leupeptin from its 
putative degradation products were tested. (3H-leupeptin was used
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for all experiments because any degradation product(s) could be 
readily detected by beta-counting]. Experimental details, together 
with the basis of separation and results for each method are given 
below.
i) Paper Chromatography
Paper chromatography separates materials mainly on the basis of 
their relative affinity (ie partition) between a mobile solvent 
phase and a stationary water phase (that is absorbed to the paper). 
Adsorption of the material itself to the paper may also contribute to 
separation.
Two solvent systems were tested for use in the separation of 
leupeptin from putative degradation products. These were:
a) A mixture of butanol: glacial acetic acid: water (volume ratio 
12:3:5), which is reported to give good separation of amino 
acids. The Rf value of leucine in this system is reported to be
0.79 (Browning, 1973).
b) A mixture of propan—1—ol : water (volume ratio 7:3), which was 
used by Kando et al. (1969) to demonstrate the purity of 
leupeptin. Leupeptin has an Rf value of 0.9-0.95 in this system. 
3H- leupeptin stock solution and re-incuhation medium containing
material released from 3H-leupeptin-loaded yolk sacs were loaded onto 
sheets of filter paper (Whatman No. 1) as small spots. The paper was 
placed in tanks containing one of the above solvent systems (approx. 
200ml) and developed for 4h. The chomatographs were dryed and cut 
into horizontal strips 1cm wide, which were placed in scintillation 
vials, scintillation fluid was added and the vials counted for 
beta—radioactivity (after having stood overnight).
Results were similar for both solvent systems. All radioactivity 
travelled with the solvent front (ie Rf value 1.0). No secondary
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peaks were detected for leupeptin-derived radioactivity released from 
yolk sacs, suggesting either that the method was not capable of 
separating degradation products from leupeptin, or that no such 
products were present, or that the method was not sufficiently 
sensitive to detect the small amount of degradation product loaded 
onto the paper.
ii) Cation-Exchange Chromatography
Cation-exchange resins contain acidic, negatively-charged groups 
that bind positively charged ions or molecules, but allow 
negatively-charged material to remain free in solution. Bound 
material may be removed from the resin by displacement with other 
ions, provided the displacement ions have a greater affinity for the 
resin. It was hoped that leupeptin could be separated from at least 
some of its degradation products on the basis of charge differences 
related to the structures which are given over the page.
Intact
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in the absence of any other strongly binding cations intact leupeptin 
should bind to the cation-exchange resin, but only 50% of leupeptin 
degradation products should bind. The proportion of radioactivity 
bound to the resin should therefore provide an indication of the 
amount of degraded leupeptin in the sample.
The ion-exchange resin used was Dowex 50W x 4, which contains 
the functional group -SC>3 (a strong acid). It was prepared for use 
by first washing with methanol (to remove organic impurities), then 
with hydrochloric acid (followed by distilled water) to remove any 
positive ions that were bound, then with sodium hydroxide (followed 
by water) to ensure all functional groups were present as SC>3Na) . 
After addition of the sample, un-bound material can be removed with 
distilled water and bound material with hydrochloric acid or excess 
sodium hydroxide.
Two methods of mixing sample with resin and measuring the 
proportion of bound radioactivity were tested.
a) Batch Method; Dowex 50W x 4, suspended in distilled water 
(0.1ml), was mixed with 3H- leupetin stock solution and allowed 
to stand approximately 5min. The supernatant was then removed and 
the Dowex washed with distilled water (2 x 0.5ml). The 
supernatant, washings and Dowex were all counted for 
radioactivity. In some experiments, a portion of the Dowex was 
washed with hydrochloric acid before counting.
b) Column Method: Dowex 50W x 4 slurry in distilled water was used 
to pack a small column (approximately 0.7cm diameter by 2cm 
length). 3H-leupeptin stock solution was loaded onto the column 
and eluted first with water (about 15ml) then with sodium 
hydroxide (1.0M, about 13ml). Eluant fractions were collected and 
counted for radioactitivty. Fractions containing sodium hydroxide 
were neutralised with hydrochloric acid before addition of
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scintillation fluid.
The results obtained using the batch method (a) indicated that 
most radioactivity was detected in the supernatant and wash 
fractions; only about 2% of the radioactivity loaded was detected in 
the resin itself. However, when a portion of Dowex resin was washed 
with hydrochloric acid, the washings contained a greater number of 
counts than the unwashed Dowex, suggesting that not all 
3H-radioactivity bound to the resin was detected. (This was verified 
by counting a "spike" of intact 3H-leupeptin of known radioactivity 
in the presence of Dowex; only 33% of the radioactivity was detected). 
It was therefore decided to try method (b). Only about 8% of the 
loaded radioactivity was eluted with distilled water, indicating 
that most leupeptin remained associated with the resin. Sodium 
hydroxide released 70-80% of the loaded radioactivity from the 
column. However, the method was not considered suitable for general 
use because of the large dilution of sample necessary during elution 
(the small number of counts present in re-incubation medium would not 
be detectable after such dilution). Also, problems were encountered 
when assaying the radioactivity in samples containing alkali because 
of guenching and chemiluminescence.
iii) Paper Electrophoresis
In addition to the effects of applied voltage, the migration 
rates of compounds during paper electrophoresis depend mainly on the 
net charge on compounds. (The latter in turn may depend on the pH of 
the electrophoresis medium, and on the type of buffer used) It was 
hoped that the difference in charge between leupeptin and its 
potential degradation products (discussed in the previous section) 
would provide a basis for separation. Leupeptin degradation would be 
detected by the appearance of negatively-charged fragments that
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migrated towards the anode.
Strips of Whatman No. 1 paper were wetted with buffer (M, pH) 
and stretched across the apparatus. The current was switched on for 
approx. 15min, then (with the current off) either leupeptin stock 
solution or incubation medium that may contain degradation products 
released from yolk sacs was loaded across the width of the centre of 
the strip. The paper was then run at 400v and 17mA for 10min, then 
the paper removed, dried, and cut into strips 1cm wide for 10cm 
either side of the loading band. The strips were placed in vials, 
scintillation fluid added, and the vials counted for radioactivity 
(after having stood overnight).
Typical results are shown in Figs. IVa and IVb. Leupeptin stock 
solution gave a single peak that had migrated only a very short 
distance towards the cathode. Medium containing leupeptin that had 
been incubated with yolk sacs gave two peaks, one in a similar 
position to that of stock leupeptin, the other almost out of the 
monitored range nearest the anode. (The peaks were located in these 
positions even when the period of electrophoresis was increased) The 
radioactive moiety that gave rise to the second peak was clearly 
negatively charged, suggesting that it may have been a fragment of 
leupeptin containing the acyl group. Appropriate markers (such as 
labelled acetic acid, N-acety1-Leucine) would be required for 
positive identification.
Paper electophoresis thus seemed to be a potential method of 
separating leupeptin degradation products from intact leupeptin, 
however further work would be required before it could be used as a 
reliable quantitative test. For example, complete recovery of all 
radioactivity after electrophoresis should be ensured. It was 
expected that, if negatively-charged degradation products had been 
generated, positively-charged fragments would also be produced,
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however none was detected.
The positively charged degradation products may have had a 
similar mobility to intact leupeptin (in which case quantification of 
the proportion of intact leupentin and degradation products may be 
difficult). Ideally, the separation of the possible degradation 
products would have been established using labelled markers.
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Fig. iva Paper Electrophoresis of 3H-Leupeptin Stock Solution 
Experimental details as given in Appendix 4
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Fig. ivb Paper E le c t r o p h o r e s is  of Incubation Medium Containing 
3H-Leupeptin
3
Yolk sacs were incubated in medium containing H-leupeptin 
for approximately 5h, then a sample of the incubation medium
described in Appendix 4.used for paper electrophoresis, as
